0001144204-15-064837.txt : 20151112 0001144204-15-064837.hdr.sgml : 20151112 20151112171540 ACCESSION NUMBER: 0001144204-15-064837 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20150930 FILED AS OF DATE: 20151112 DATE AS OF CHANGE: 20151112 FILER: COMPANY DATA: COMPANY CONFORMED NAME: INTERLEUKIN GENETICS INC CENTRAL INDEX KEY: 0001037649 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 943123681 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-32715 FILM NUMBER: 151225892 BUSINESS ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 BUSINESS PHONE: 1-781-398-0700 MAIL ADDRESS: STREET 1: 135 BEAVER ST CITY: WATHAM STATE: MA ZIP: 02452 FORMER COMPANY: FORMER CONFORMED NAME: MEDICAL SCIENCE SYSTEMS INC DATE OF NAME CHANGE: 19971003 10-Q 1 v424036_10q.htm 10-Q

  

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 10-Q

 

xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2015

 

¨TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission File Number: 001-32715

 

INTERLEUKIN GENETICS, INC.

(Exact name of registrant in its charter)

 

Delaware   94-3123681
(State or other jurisdiction of
incorporation or organization)		   (I.R.S. Employer
Identification No.)
     
135 Beaver Street, Waltham, MA   02452
(Address of principal executive offices)   (Zip Code)

Registrant’s Telephone Number: (781) 398-0700

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES x   NO ¨

 

Indicate by check mark whether each registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). YES x  NO ¨

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

 

Large accelerated filer ¨ Accelerated filer ¨
   
Non-Accelerated filer ¨ (Do not check if a smaller reporting company)  Smaller reporting company x

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ¨   NO x

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

 

Class   Outstanding at November 11, 2015
Common Stock, par value $0.001 per share   172,887,221

 

 

 

 

INTERLEUKIN GENETICS, INC.

 

FORM 10-Q

FOR THE QUARTER ENDED September 30, 2015

 

Table of Contents

 

  Page
PART I—FINANCIAL INFORMATION  
Item 1. Financial Statements  
Condensed Balance Sheets as of September 30, 2015 (Unaudited) and December 31, 2014 3
Condensed Statements of Operations (Unaudited) 4
Condensed Statements of Stockholders’ Equity  (Unaudited) 5
Condensed Statements of Cash Flows (Unaudited) 6
Notes to Condensed Financial Statements (Unaudited) 7
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations 20
Item 3. Quantitative and Qualitative Disclosures About Market Risk 25
Item 4. Controls and Procedures 25
PART II—OTHER INFORMATION  
Item 1. Legal Proceedings 25
Item 1A. Risk Factors 25
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 26
Item 3. Defaults Upon Senior Securities 26
Item 4. Mine Safety Disclosures 26
Item 5. Other Information 26
Item 6. Exhibits 26

 

Smaller Reporting Company – Scaled Disclosure

 

Pursuant to Item 10(f) of Regulation S-K promulgated under the Securities Act of 1933, as amended, as indicated herein, we have elected to comply with the scaled disclosure requirements applicable to “smaller reporting companies.”

 

 2 

 

 

PART I —FINANCIAL INFORMATION

 

Item 1. Financial Statements

 

INTERLEUKIN GENETICS, INC.

 

CONDENSED BALANCE SHEETS

 

   September 30,   December 31, 
   2015   2014 
   (Unaudited)     
ASSETS          
Current assets:          
Cash and cash equivalents  $6,270,644   $11,466,807 
Accounts receivable from related party   40,603    23,544 
Trade accounts receivable   5,305    14,013 
Inventory   159,093    171,575 
Prepaid expenses   531,628    504,719 
Total current assets   7,007,273    12,180,658 
Fixed assets, net   658,899    773,779 
Intangible assets, net   137,523    195,765 
Other assets   99,135    116,919 
Total assets  $7,902,830   $13,267,121 
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT)          
Current liabilities:          
Accounts payable  $576,210   $513,927 
Accrued expenses   455,299    343,225 
Deferred revenue   2,925,725    3,154,498 
Total current liabilities   3,957,234    4,011,650 
Long Term Debt   4,790,891    4,738,614 
           
Total Liabilities   8,748,125    8,750,264 
           
Commitments and contingencies (Note 6)          
           
Stockholders’ equity:          
Common stock, $0.001 par value — 450,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 172,841,047 and 172,683,342 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively    172,843    172,686 
Additional paid-in capital   126,107,664    125,434,483 
Accumulated deficit   (127,125,802)   (121,090,312)
Total stockholders’ equity (deficit)   (845,295)   4,516,857 
Total liabilities and stockholders’ equity (deficit)  $7,902,830   $13,267,121 

 

The accompanying notes are an integral part of these financial statements.

 

 3 

 

 

INTERLEUKIN GENETICS, INC.

 

CONDENSED STATEMENTS OF OPERATIONS

 

(Unaudited)

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2015   2014   2015   2014 
Revenue:                    
Genetic testing  $248,873   $439,400   $921,610   $1,342,947 
Other   47,125    32,751    153,651    145,365 
Total revenue   295,998    472,151    1,075,261    1,488,312 
Cost of revenue   323,136    358,578    985,732    1,115,095 
Gross profit   (27,138)   113,573    89,529    373,217 
Operating expenses:                    
Research and development   411,902    242,142    978,970    666,839 
Selling, general and administrative   1,413,702    1,305,583    4,631,718    4,338,245 
Amortization of intangibles   19,414    23,525    58,242    70,575 
Total operating expenses   1,845,018    1,571,250    5,668,930    5,075,659 
Loss from operations   (1,872,156)   (1,457,677)   (5,579,401)   (4,702,442)
Other income (expense):                    
Interest income   —    911    222    4,511 
Interest expense   (153,354)   —    (456,311)   — 
Total other income (expense)   (153,354)   911    (456,089)   4,511 
Loss before income taxes   (2,025,510)   (1,456,766)   (6,035,490)   (4,697,931)
Benefit for income taxes   —    —    —    — 
Net loss  $(2,025,510)  $(1,456,766)  $(6,035,490)  $(4,697,931)
                     
Basic and diluted net loss per common share  $(0.01)  $(0.01)  $(0.03)  $(0.04)
Weighted average common shares outstanding, basic and diluted   172,841,047    122,548,292    172,788,286    122,515,671 

 

The accompanying notes are an integral part of these financial statements.

 

 4 

 

 

INTERLEUKIN GENETICS, INC.

 

CONDENSED STATEMENTS OF STOCKHOLDERS’ EQUITY

 

(Unaudited)

 

   Common Stock             
   Shares   Amount   Additional
Paid-in
Capital		   Accumulated
Deficit		   Total 
Balance as of December 31, 2013   122,448,707   $122,449   $119,885,371   $(114,754,598)  $5,253,222 
                          
Net loss   —    —    —    (4,697,931)   (4,697,931)
Common stock issued:                         
Employee stock purchase plan   99,585    101    27,456    —    27,557 
Stock-based compensation expense   —    —    354,441    —    354,441 
Balance as of September 30, 2014   122,548,292   $122,550   $120,267,268   $(119,452,529)  $937,289 
Balance as of December 31, 2014   172,683,342   $172,686   $125,434,483   $(121,090,312)  $4,516,857 
                          
Net loss   —    —    —    (6,035,490)   (6,035,490)
Common stock issued:                         
Private Placement             (7,100)        (7,100)
Horizon Warrant             11,848         11,848 
Employee stock purchase plan   157,705    157    16,642    —    16,799 
Stock-based compensation expense   —    —    651,791    —    651,791 
Balance as of September 30, 2015   172,841,047   $172,843   $126,107,664   $(127,125,802)  $(845,295)

 

The accompanying notes are an integral part of these financial statements.

 

 5 

 

 

INTERLEUKIN GENETICS, INC.

 

CONDENSED STATEMENTS OF CASH FLOWS

 

(Unaudited)

 

   For the Nine Months Ended September 30, 
   2015   2014 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(6,035,490)  $(4,697,931)
Adjustments to reconcile loss to net cash used in operating activities:          
Depreciation and amortization   214,180    190,012 
Amortization of loan issuance costs and FV of warrants   81,908    — 
Stock-based compensation expense   651,791    354,441 
Changes in operating assets and liabilities:          
Accounts receivable   8,708    (5,926)
Receivable from related party   (17,059)   499,987 
Inventory   12,482    23,248 
Prepaid expenses and other current assets   (26,909)   115,005 
Accounts payable   62,283    (537,561)
Accrued expenses   112,074    (62,224)
Deferred revenue   (228,773)   (752,212)
Net cash used in operating activities   (5,164,805)   (4,873,161)
CASH FLOWS FROM INVESTING ACTIVITIES:          
Capital additions   (41,057)   (92,278)
Net cash used in investing activities   (41,057)   (92,278)
CASH FLOWS FROM FINANCING ACTIVITIES:          
Private placement offering costs   (7,100)   — 
Proceeds from employee stock purchase plan   16,799    27,557 
Net cash provided by financing activities   9,699    27,557 
Net (decrease) in cash and cash equivalents   (5,196,163)   (4,937,882)
Cash and cash equivalents, beginning of period   11,466,807    7,542,281 
Cash and cash equivalents, end of period  $6,270,644   $2,604,399 
           
Supplemental disclosures of cash flow information:          
Cash paid for interest  $352,500    — 

 

The accompanying notes are an integral part of these financial statements.

 

 6 

 

 

INTERLEUKIN GENETICS, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

SEPTEMBER 30, 2015

(UNAUDITED)

 

Note 1—Basis of Presentation

 

Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company’s principal operations and markets are located in the United States.

 

The accompanying condensed financial statements include the accounts of the Company as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014.

 

The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire 2015 fiscal year.

 

For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3 to our condensed financial statements contained herein.

 

Note 2—Liquidity

 

The Company has experienced net operating losses since its inception through September 30, 2015. The Company had net losses of $6.3 million for the year ended December 31, 2014, and $6.04 million for the nine months ended September 30, 2015, contributing to an accumulated deficit of $127.1 million as of September 30, 2015.

 

On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 shares of common stock at a price of $0.2745 per share for gross proceeds of $12,000,000. The 2013 Investors also received warrants to purchase up to an aggregate of 32,786,885 shares of common stock an exercise price of $0.2745 per share (the “2013 Warrants”). The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.

 

On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 shares of common stock at a price of $0.1003 per share for gross proceeds of approximately $5.025 million. The 2014 Investors also received warrants to purchase up to an aggregate of 50,099,700 shares of common stock an exercise price of $0.1003 per share (the “2014 Warrants”). The 2014 Warrants are all currently exercisable and have a term of seven years.

 

On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $5.0 million. The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. At September 30, 2015, the rate was 9.0% per annum. The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (10) years.

 

 7 

 

 

 The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The financial statements do not include any adjustments that might result from the outcome of this uncertain realization. The Company expects to incur additional losses in 2015 and, accordingly, is dependent on financings and potential revenue to fund its operations and support the market adoption of the PerioPredict® test. The timing of any revenues that the Company may receive from the PerioPredict® test is uncertain at this time, and is contingent upon a number of factors, including the Company’s ability to consummate arrangements with partners to promote the PerioPredict® test, the Company and its partners’ ability to develop insurance plans that provide for use and reimbursement of the PerioPredict® test, or other possible arrangements, and to develop a viable market for such plans, and the timing of utilization of the PerioPredict® test pursuant to such plans. The Company expects to have the cash resources necessary to fund its operations into the second half of 2016.

 

The ability of the Company to realize the carrying value of its fixed assets and intangible assets is dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.

 

Note 3—Summary of Significant Accounting Policies

 

Management Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.

 

Revenue Recognition

 

Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $2.9 million and $3.2 million, respectively. Included in deferred revenue at September 30, 2015 is $2.7 million for test kits that are still outstanding one year or longer after initial kit sale, of which $0.3 million was sold directly to consumers (credit card payments) and $2.4 million was sold to distributors for the promotional bundle. Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs).

 

The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $39,000 and $167,000, respectively, of breakage revenue related to unredeemed genetic test kits sold in the first, second and third quarters of 2012, compared to breakage revenue included in genetic test revenue in the three and nine months ended September 30, 2014 of $86,000 and $242,000, respectively, related to unredeemed genetic test kits sold in the first, second and third quarters of 2011. The Company expects to continue to recognize breakage revenue on a quarterly basis based on the historical analysis.

 

 8 

 

 

Sales Commission

 

On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company accounts for sales commissions due to Amway Global under the Merchant Network and Channel Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. The cost of commissions was $70,000 and $59,000 for the three months ended September 30, 2015 and 2014, respectively, and $239,000 and $160,000 for the nine months ended September 30, 2015 and 2014, respectively.

 

Accounts Receivable

 

Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date. No accounts receivable reserve is required at September 30, 2015 as all accounts receivable are expected to be collected.

 

Inventory

 

Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict® genetic tests kits to dental offices. The agreement with the fulfillment provider requires them to purchase and fulfill all materials related to the PerioPredict® test and Body Key™ genetic test kits, with the Company’s approval. The Company reimburses the fulfillment provider for materials and pays fulfillment charges when the product is shipped. During the nine months ended September 30, 2015, the Company made a onetime purchase of $33,000 of inventory related to its PerioPredict® test from our fulfillment provider, which is held at our fulfillment center. The balance of our inventory is related to our Inherent Health® brand and is stored at a separate facility. When a kit is sold, the corresponding cost of the kit is recorded as deferred cost of goods sold and removed from inventory. Any kit components remaining at the fulfillment center are reflected in inventory with a corresponding offset to accounts payable.

 

Inventory consisted of the following:

 

   September 30, 2015   December 31, 2014 
         
Raw materials  $142,351   $163,239 
Finished goods   16,742    8,336 
Total inventory, net  $159,093   $171,575 

 

Stock-Based Compensation

 

The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation. The standard addresses all forms of share-based payment (SBP) awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. We expense SBP awards within compensation cost for SBP transactions measured at fair value. Compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the effective date shall be recognized as the requisite service is rendered on or after the effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated under the Black-Scholes option pricing model. Common stock purchased pursuant to our employee stock purchase plan will be expensed based upon the fair market value in excess of purchase price.

 

Income Taxes

 

The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.

 

 9 

 

 

Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.

 

As a result of the Company’s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $14.3 million into common stock of the Company prior to an additional investment by an unrelated investor.

 

The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.

 

Research and Development

 

Research and development costs are expensed as incurred.

 

Basic and Diluted Net Loss per Common Share

 

The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:

 

   As of September 30, 
   2015   2014 
Options outstanding   22,258,659    4,810,675 
Warrants outstanding   88,301,079    37,269,125 
Total   110,559,738    42,079,800 

 

Fair Value of Financial Instruments

 

The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.

 

 10 

 

 

Cash and Cash Equivalents

 

The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.

 

Fixed Assets

 

Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.

 

Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $19,500 in the Projects in Progress account, all of which is laboratory equipment.

 

Segment Reporting

 

As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.

 

Recent Accounting Pronouncements

 

FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.

 

In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts.  Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet.  Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements.

 

FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers.

 

In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps:

 

·Identify the contract(s) with a customer.
·Identify the performance obligations in the contract.
·Determine the transaction price.
·Allocate the transaction price to the performance obligations in the contract.
·Recognize revenue when (or as) the entity satisfies a performance obligation.

 

The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application.

 

 11 

 

 

In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements.

 

FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.

 

In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance.  The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation.  ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.

 

Note 4—Related Party Transactions

 

Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations.

 

On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to the Company’s e-commerce site. The Company paid Amway Global $70,000 and $59,000 in commissions for the three months ended September 30, 2015 and 2014, respectively, and $239,000 and $160,000 in commissions for the nine months ended September 30, 2015 and 2014, respectively, representing a percentage of net sales to their customers. The Company expenses commissions owed to Amway Global in the month of sale to the customer.

 

Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs). Of the $3.3 million in orders, $1.5 million was received for the 2013 program and $1.8 million for the 2014 program. As a component of the 2013 promotional program, and not reflective of actual product expiry, the kits were required to be redeemed by December 31, 2013. In February 2014, the Company removed the redemption date requirement for the 2013 promotional program, for which ABG paid the Company $519,000 as a retrospective increase in the product purchase price. All cash received related to the 2013 promotional program, including the $519,000, will be treated as deferred revenue until specific kits are returned for processing or the breakage analysis determines the probability of eventual redemption is remote. In October 2014, the Company received $250,000 as a retrospective increase in the product purchase price for unsold kits as consideration for extending the required redemption date of the 2014 promotional program to December 31, 2017. All cash received for these kits will be treated as deferred revenue until specific kits are returned for processing or on the final allowed redemption date of December 31, 2017.

 

On September 21, 2012, the Company entered into a License Agreement with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least 60 days prior to the anniversary date. During the three and nine months ended September 30, 2015, $39,000 and $143,000, respectively, was earned, compared to $31,000 and $129,000 in the same periods in 2014

 

 12 

 

 

In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the year ended December 31, 2014 or the nine months ended September 30, 2015 under the PSA.

 

For the three months ended September 30, 2015 and 2014, approximately 45% and 48%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 14% and 30%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program. For the nine months ended September 30, 2015 and 2014, approximately 49% and 41%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 15% and 35%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program.

 

On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company. Pursuant to this agreement, as amended, affiliates of RHSC have agreed to reimburse the Company a fixed price for each PerioPredict® genetic test that the Company processes for a customer of affiliates of RHSC. In addition, if during the term of the agreement the Company offers the PerioPredict® test to any other person or party for a lower price, such lower price shall then be applicable to tests processed for a customer of such affiliates of RHSC for the remainder of the term of the agreement. RHSC and its affiliates will continue to receive the preferred pricing (or any lower market price during the term) only for so long as affiliates of RHSC continue to: (a) work to develop and to offer dental benefit plans that provide for use of the PerioPredict test and reimbursement of the test at the agreed upon price(each such plan, hereinafter referred to as a “Reimbursed Dental Plan”) for which a significant portion of employees of RHSC’s affiliates’ customers are eligible; and (b) exercise their commercially-reasonable best efforts to maximize the number of customers that offer a Reimbursed Dental Plan. In addition, under the terms of the amended agreement, the Company is no longer obligated to make the PerioPredict® test available solely to RHSC affiliates and not to any other third party or person. This amended agreement has a term of three years beginning February 25, 2013, unless terminated earlier (1) upon the mutual written agreement of us and RHSC, (2) if either party becomes the subject of bankruptcy, insolvency, liquidation or other similar proceedings, or (3) in the event of an uncured breach of the amended agreement by either party.

 

The timing of any revenues that the Company may receive under the amended agreement with RHSC is dependent upon the timing of the offering of Reimbursed Dental Plans and the subsequent adoption of such Reimbursed Dental Plans by RHSC customers, the timing of which is very uncertain at this time and is dependent on a viable market developing for such plans. RHSC has informed us that it has presented the scientific data underlying Reimbursed Dental Plans to a number of customers and will make available Reimbursed Dental Plans as an alternative to a customer’s current plan for any customer that expresses an interest in such a plan. The Company may never receive significant revenues under this agreement.

 

Note 5—Debt Instruments

 

Venture Loan and Security Agreement

 

On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $5.0 million. The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. At September 30, 2015, the rate was 9.0% per annum. The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (10) years.

 

 13 

 

 

Additionally, $89,000 in cash fees paid to the Lender and $261,000, the intrinsic value of the Lender Warrants, were recorded as a discount on the loan and amortized over the term of the loan. The final non-principal payment of $225,000 will be accrued as additional interest expense, using the effective interest method, over the term of the loan. As of September 30, 2015, the unamortized discount associated with the loan was $280,000. Cash interest expense for the three and nine months ending September 30, 2015 was $115,000 and $341,000, respectively. Non-cash interest expense for the three and nine months ending September 30, 2015 was $38,000 and $115,000, respectively.

 

Note 6—Commitments and contingencies

 

Operating Lease

 

The Company leases its office and laboratory space under a non-cancelable operating lease which was originally scheduled to expire on March 31, 2014. In May 2010, the Company completed a sublease of 6,011 square feet of underutilized office and laboratory space and on March 31, 2014, the sublease expired. On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies; and, c) set an initial base rent with an escalation of 2.06% of base rent in year two and another 2.06% in year three.

 

Rent expense, net of the benefit of the sublease in 2014, was $96,000 and $80,000 for the three months ended September 30, 2015 and 2014, respectively, and $268,000 and $230,000 for the nine months ended September 30, 2015 and 2014, respectively.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows.

 

Employment Agreements

 

On April 6, 2015 the Company entered into an Executive Employment Agreement (the “Agreement”), pursuant to which Mark B. Carbeau was appointed as the Company’s Chief Executive Officer and a member of the Company’s Board of Directors. Effective upon Mr. Carbeau’s appointment, Dr. Kenneth S. Kornman resigned as Chief Executive Officer and remained as the Company’s President and Chief Scientific Officer.

 

Pursuant to the Agreement, Mr. Carbeau will receive an initial annual base salary of $365,000 per year and is eligible to receive an annual target bonus of 35% of his base salary, with a stretch bonus opportunity of 150% of the target bonus. Under the terms of the Agreement, Mr. Carbeau has been granted options to purchase up to 14,245,227 shares of Interleukin’s common stock (the “Options”) at an exercise price of $0.1525 per share (the closing price of the common stock on April 6, 2015). The Options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.

 

The Agreement provides that if Mr. Carbeau’s employment with the Company is terminated for any reason other than Cause (as defined in the Agreement) and on execution of a release of claims agreement, he will be entitled to (i) severance payments equal to 12 months of base salary and (ii) continuation of medical benefits for up to 12 months. In addition to the above, if termination is within one year following a Change of Control event and is for any reason other than Cause, all outstanding unvested equity awards held by Mr. Carbeau will immediately vest and be exercisable.

 

On November 12, 2008, the Company entered into an employment agreement with Dr. Kornman, its President and Chief Scientific Officer, for a three-year term, commencing on March 31, 2009, the date his previous employment agreement expired. Effective March 31, 2012, this agreement was extended through November 30, 2012, and was extended again on November 20, 2012 through November 30, 2015. Under this agreement, Dr. Kornman received an initial annual salary of $360,000 and is eligible to receive salary increases and/or annual bonuses solely at the discretion of the Board of Directors. Under the agreement, Dr. Kornman is entitled to participate in employee benefit plans that the Company provides or may establish for the benefit of its executive management generally. In addition, while Dr. Kornman remains employed by the Company, it will reimburse him $3,296 annually for payment of life insurance premiums.

 

 14 

 

 

The agreement is terminable immediately by the Company with cause or upon thirty days prior written notice without cause. The agreement is terminable by Dr. Kornman upon thirty days prior written notice. If the Company terminates Dr. Kornman without cause or Dr. Kornman terminates his employment with good reason, then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) twelve months. If the Company terminates Dr. Kornman in connection with a Cessation of the Company’s Business (as defined in the agreement), then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) three months. The agreement also includes non-compete and non-solicitation provisions for a period of twelve months following the termination of Dr. Kornman’s employment.

 

In April 2010, Dr. Kornman was issued an option to purchase 30,000 shares of the Company’s common stock at an exercise price of $0.745 per share. The option vests as to 20% of the shares on each of the first five anniversaries of the date of grant.

 

In May 2011, Dr. Kornman was issued an option to purchase 100,000 shares of the Company’s common stock, exercisable at $0.46 per share. The option vests as to 25% of the shares on each of the first four anniversaries of the date of grant.

 

In December 2012, Dr. Kornman was issued an option to purchase 300,000 shares of the Company’s common stock, exercisable at $0.34 per share. The option vests as to 25%, 33% and 42% of the shares on each of the first three anniversaries of the date of grant.

 

In October 2013, Dr. Kornman was issued an option to purchase 2,250,000 shares of the Company’s common stock, at an exercise price of $0.3799 per share. The option vests as to 25% of the shares on the first anniversary of the grant date, and as to 2.08% of the remaining shares at the end of each month thereafter beginning on October 31, 2014.

 

In January 2015, Dr. Kornman was granted an option to purchase 2,030,000 shares of the Company’s common stock. This option has an exercise price of $0.26 per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.

 

On December 26, 2012, the Company entered into an employment agreement with Scott Snyder for the position of Chief Marketing Officer beginning on January 2, 2013. The agreement provides for a minimum annual base salary of $265,000. He is eligible for a bonus of up to 30% of his base salary, based on factors such as evaluation of individual performance, the Company’s financial performance, economic conditions generally, and the policy terms applicable to such bonus. Mr. Snyder is entitled to a maximum of $34,000 in expense reimbursement in calendar year 2013, and an additional $16,000 for the six months ending June 30, 2014, for travel and housing expenses from his residence to Interleukin’s offices. On July 23, 2013, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement and increase the aggregate amount of travel and lodging expenses that may be reimbursed to an aggregate of $60,000. On August 4, 2014, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement again and increase the aggregate amount of reimbursable travel and lodging expenses through December 2014 to $80,000. On January 9, 2015, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement again to increase the amount of reimbursable travel and lodging expenses to include $40,000 for calendar year 2015. Upon hire, Mr. Snyder was granted an option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.29 per share. The option vests in three installments of 50,000, 66,000 and 84,000 shares on each of the first three anniversaries of the grant date.

 

In October 2013, Mr. Snyder was issued an option to purchase 675,000 shares of the Company’s common stock, at an exercise price of $0.3799 per share. The option vests as to 25% of the shares on the first anniversary of the grant date, and as to 2.08% of the remaining shares at the end of each month thereafter beginning on October 31, 2014

 

In January 2015, Mr. Snyder was granted an option to purchase 660,000 shares of the Company’s common stock at an exercise price of $0.26 per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.

 

Mr. Snyder’s employment with the Company terminated effective November 13, 2015. The Company will pay Mr. Snyder any compensation that is earned but unpaid prior to termination, and an amount equal to six months of his base salary in effect at the time of the termination with such payment made in equal installments on the Company’s regularly-scheduled payment dates. Per Mr. Snyder’s employment agreement, 84,000 unvested shares related to the 200,000 shares granted on January 2, 2013 will become fully vested.

 

 15 

 

 

Note 7—Capital Stock

 

Authorized Preferred and Common Stock

 

As of September 30, 2015, the Company has 6,000,000 shares of preferred stock, par value $0.001 authorized and 450,000,000 shares of common stock, par value $0.001 authorized. On July 21, 2015, the Company’s shareholders’ approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. As of September 30, 2015 the Company had 172,841,047 shares of common stock outstanding and the following shares of common stock are reserved for issuance:

 

   Reserved
for issuance		   Strike
Price		   Expiry
            
Shares reserved under outstanding stock options and options available for grant   52,311,279         
Shares reserved for future issuance under the Employee Stock Purchase Plan   346,247         
Warrants to purchase common stock associated with December 2014 private placement   50,189,431   $0.1003   December 23, 2021
Warrants to purchase common stock associated with December 2014 venture loan and security agreement   2,492,523   $0.1003   December 23, 2024
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors   100,000   $0.2500   September 8, 2024
Outstanding warrants issued in June 2012   437,158   $0.2745   June 29, 2017
Outstanding warrants issued in May 2013, vesting May 2013   20,655,737   $0.2745   May 17, 2020
Outstanding warrants issued in May 2013, vesting August 2013   14,426,230   $0.2745   August 9, 2020
Total common shares reserved for issuance at September 30, 2015   140,958,605         
Total common shares issued and outstanding at September 30, 2015   172,841,047         
Total common shares outstanding and reserved for issuance at September 30, 2015   313,799,652         

 

On May 17, 2013, the Company entered into the 2013 Purchase Agreement with the 2013 Investors, pursuant to which the Company sold securities to the 2013 Investors in the May 2013 Private Placement. In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share for gross proceeds of $12,000,000. The 2013 Investors also received the 2013 Warrants to purchase up to an aggregate of 32,786,885 shares of common stock an exercise price of $0.2745 per share. The 2013 Warrants were immediately exercisable as to 63% of the shares issuable thereunder. The remaining 37% of the shares issuable under the 2013 Warrants were to become exercisable upon an increase in the number of authorized shares of common stock. On August 9, 2013, the Company’s shareholders’ approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000 shares, which provided for adequate authorized shares for all potential common stock equivalents issued pursuant to the May 2013 Private Placement. The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.

 

For its services in this transaction, the placement agent received cash compensation in the amount of approximately $780,000 and the placement agent and an affiliate received warrants to purchase an aggregate of 2,295,082 shares of common stock, at an exercise price of $0.2745 per share (the “2013 Placement Agent Warrants”). The 2013 Placement Agent Warrants became exercisable on August 9, 2013, following shareholder approval of an increase in the Company’s authorized shares of common stock and expire August 9, 2020. The cash compensation and the fair value of the warrants were recorded as issuance costs resulting in a reduction to shareholders’ equity.

 

 16 

 

 

In September, 2014, the Company issued warrants to the Company’s financial consultant, Danforth Advisors, to purchase up to 100,000 shares of common stock at a price of $0.25 per share. The warrants have a ten year term and vest on a monthly basis over two years, provided that, if the Company terminates the agreement without cause before the one year anniversary, 50% of the warrants immediately vest, and the remaining 50% of the warrants immediately vest if the Company terminates the agreement without cause after the extension of the agreement after one year. The warrant will also become exercisable in full upon a change of control of the Company if the agreement is still in effect. The fair value of the warrants at issuance was recorded as equity totaling $24,000 and will be amortized to consulting fees over the remaining service requirement. The non-cash compensation expense for the three and nine months ended September 30, 2015 was $3,000 and $9,000 respectively.

 

On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of 50,099,700 shares of common stock at a price of $0.1003 per share for gross proceeds of approximately $5.025 million. The 2014 Investors also received 2014 Warrants to purchase up to an aggregate of 50,099,700 shares of common stock at an exercise price of $0.1003 per share. The 2014 Warrants are all currently exercisable and have a term of seven years.

 

For services related to this transaction, the placement agent and legal counsel received an aggregate of $218,000 in cash fees and the placement agent and an affiliate received warrants to purchase an aggregate of 89,731 shares of common stock (the “2014 Placement Agent Warrants”). The cash fees and the fair value of the 2014 Placement Agent Warrants were recorded as equity issuance costs resulting in a reduction to shareholders’ equity.

 

The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model:

 

   December 23, 2014 
Risk-free interest rate   1.98%
Expected life      7 years 
Expected volatility   138.4%
Dividend yield   0%

 

On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $5.2 million, and the fair value of the 2014 Placement Agent Warrants was $9,000.

 

Registration Rights Agreement

 

In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015.

 

Venture Loan and Security Agreement

 

On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $5.0 million. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates Lender Warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share. The Lender Warrants have a term of ten (10) years.

 

The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model:

 

  

December 23, 2014

 
Risk-free interest rate   2.17%
Expected life   10 years 
Expected volatility   121.6%
Dividend yield   0%

 

 17 

 

 

The fair value of the Lender Warrants at issuance was $261,000. Cash interest paid during the three and nine months ended September 30, 2015 totaled $115,000 and $353,000, respectively. Non-cash interest related to debt discounts recorded during the three and nine months ended September 30, 2015 totaled was $38,000 and $115,000, respectively, with a remaining debt discount balance of $280,000.

 

Note 8—Stock-Based Compensation Arrangements

 

Total stock-based compensation is as follows:

 

   Three Months Ended September 30,   Nine Months Ended September 30, 
   2015   2014   2015   2014 
Stock option grants beginning of period  $251,374   $108,363   $491,197   $348,545 
Stock-based arrangements during the period:                    
Stock option grants   92    —    157,463    1,166 
Restricted stock issued:                    
Employee stock purchase plan   1,088    1,279    3,129    4,730 
   $252,554   $109,642   $651,789   $354,441 

 

Stock option and restricted stock grants

 

The following table details stock option activity:

 

  

Nine Months Ended

September 30, 2015

  

Nine Months Ended

September 30, 2014

 
   Shares   Weighted Avg
Exercise
Price		   Shares   Weighted Avg
Exercise
Price		 
Outstanding, beginning of period   4,523,900   $0.39    5,884,050   $0.43 
Stock options granted   17,793,027    0.17    137,000    0.35 
Stock options exercised   —    0.00    —    0.00 
Restricted stock exercised   —    0.00    —    0.00 
Canceled/Expired   (58,268)   0.28    (1,210,375)   0.43 
Outstanding, end of period   22,258,659   $0.22    4,810,675   $0.43 
Exercisable, end of period   3,067,959   $0.34    723,925   $0.71 

 

At September 30, 2015, there was approximately $2,700,000 of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company’s stock plans.

 

Restricted Stock Awards

 

At September 30, 2015 and 2014, there were no outstanding restricted stock awards.

 

Stock Option Grants

 

On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 additional shares of our common stock pursuant to awards granted under the 2013 Plan. Additionally, the 2013 plan allows for the issuance of up to a maximum of 2,435,500 additional shares of our common stock, pursuant to the cancellation, forfeiture, or expiry, of awards granted under the 2004 Plan and terminated on or after the 2013 plan approval on August 9, 2013. During the nine month period ended September 30, 2015, the Company granted 6,170,748 stock options under the 2013 Plan. On July 21, 2015, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available for issuance thereunder by 30,000,000 shares. At September 30, 2015, the Company had an aggregate of 30,052,620 shares of common stock available for grant under the 2013 Plan.

 

 18 

 

 

Pursuant to his Employment Agreement on April 6, 2015, Mr. Carbeau was granted options to purchase up to 14,245,227 shares of Interleukin’s common stock at an exercise price of $0.1525 per share (the closing price of the common stock on April 6, 2015). Of those options, 2,622,948 were granted under the 2013 Plan and 11,622,279 were granted outside of the 2013 Plan. The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.

 

It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance.

 

Employee Stock Purchase Plan

 

Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85% of the fair market value of the Company’s common stock on either the first day or the last day of a calendar quarter, whichever is lower. During the nine months ended September 30, 2015 and 2014, employees purchased 157,705 and 99,585 shares, respectively, of common stock at a weighted-average purchase price of $0.10 and $0.28, respectively, while the weighted-average market value was $0.12 and $0.32 per share, respectively, resulting in compensation expense of $3,129 and $4,730, respectively.

 

Note 9—Industry Risk and Concentration

 

The Company develops genetic risk assessment tests and performs research for its own benefit. As of September 30, 2015, the Company sells five genetic risk assessment tests. Commercial success of the Company’s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners.

 

Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated.

 

During the three months ended September 30, 2015 and 2014, approximately 45% and 48%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 14% and 30%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program. During the nine months ended September 30, 2015 and 2014, approximately 49% and 41%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 15% and 35%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program.

 

Note 10—Subsequent Events

 

On November 13, 2015, the employment of Mr. Scott Snyder, formerly Chief Marketing Officer, terminated. Details of this event are disclosed in Note 6.

 

 

 19 

 

  

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

The following discussion of our financial condition and results of operations should be read in conjunction with the unaudited condensed financial statements and the notes thereto included elsewhere in this document.

 

General Overview and Trends

 

Interleukin Genetics, Inc. is a personalized health company that develops specific, health area focused, unique genetic tests. Our overall mission is to provide test products that can help individuals improve or maintain their health through preventive or treatment measures. Our vision is to use the science of applied genetics to empower individuals and physicians to better understand the actions and steps necessary to guide the best lifestyle and treatment options. We believe that Interleukin Genetics’ tests can help individuals and their healthcare providers more effectively prevent common, chronic diseases associated with systemic inflammation and their complications, and thereby positively impact an individual’s wellness while reducing health care costs.

 

During the three months ended September 30, 2015, we continued to focus our resources primarily on commercializing our PerioPredict® test, as well as on the sales of our Inherent Health® brand of genetic tests and related programs.

 

The clinical utility of the PerioPredict® test is supported by the large validation study conducted by the University of Michigan and referred to as the Michigan Personalized Prevention Study, or MPPS. The objective of the MPPS is to improve dental care by identifying and using certain risk factors to set preventative treatment regimens. On August 6, 2012, we announced that we had received top line results from the MPPS, and on June 10, 2013, we announced the publication of the MPPS results in the Journal of Dental Research. The study examined data from 5,117 patients monitored for 16 consecutive years. These results indicate that in Low Risk patients (those with none of three risk factors: smoking, diabetes, and PerioPredict®) there was no significant difference between two dental preventive visits per year and one preventive visit per year in the percentage of patients who had tooth extractions over the 16 year monitoring period; 13.8% versus 16.4%, respectively. In addition, these results indicate that in High Risk patients (those with any one of the three risk factors, with PerioPredict® being the most common of the three), two preventive visits per year significantly reduced the percentage of patients who had extractions over a 16 year monitoring period compared to one preventive visit per year; 16.9% vs. 22.1%. There was also a positive relationship between number of risk factors and the percentage of patients with extractions. For patients with two or three risk factors, and smoking plus PerioPredict® positive represented approximately 67% of those patients, two cleanings annually did not appear to be sufficient to control risk for tooth loss.

 

There is also increasing evidence that the PerioPredict® test enables the identification of patients who may be at higher risk for increased systemic inflammation, which is implicated in a variety of chronic diseases, such as diabetes and coronary artery disease, as well as periodontitis. Such high-risk patients may be responsive to greater preventive dental care in managing these chronic conditions. We believe that significant improvement in patient care and reduced medical expenses can be achieved by stratifying patient risk for these chronic inflammatory conditions through PerioPredict® testing, combined with cost-effective dental intervention; for example, one to two additional annual cleanings.

 

We believe the use of the PerioPredict® test to identify patients who may be responsive to a cost-effective dental intervention is a compelling value proposition, and are engaged in discussions with a number of relevant parties with an interest in reducing costs and improving patient care, including medical and dental insurers, large and small employers and benefits brokers and consultants, regarding implementing PerioPredict® testing, both directly and through our partner, Employee Benefit Consulting Group LLC (EBCG), with whom we entered a collaboration agreement on March 30, 2015 to help expand knowledge and potential coverage for PerioPredict®. We believe this collaboration will help us leverage genetic testing as part of an approach to more effective overall healthcare management.  Under the terms of this strategic collaboration, we will work together with EBCG to build awareness of PerioPredict® as a tool for personalizing patient care among insurance carriers, benefit plans and employer groups, and to potentially incorporate the test in the design of risk-based benefit plans.

 

 20 

 

 

On February 25, 2013, we entered into a Preferred Participation Agreement with RHSC, for itself and on behalf of certain of its affiliates and subsidiaries, which was amended and restated on November 1, 2013. Pursuant to this agreement, affiliates of RHSC have agreed to reimburse us a fixed price for each PerioPredict® genetic test that we process for a customer of affiliates of RHSC. The timing of any revenues that we may receive under the Amended and Restated Preferred Participation Agreement (the “Preferred Participation Agreement”) with RHSC is dependent upon the timing of the offering of dental benefit plans that provide for use of the PerioPredict® test and reimbursement of the test (each such plan, hereinafter referred to as a “Reimbursed Dental Plan”), which timing is very uncertain at this time and is dependent on a viable market developing for such plans.

 

On April 11, 2014, we announced the pre-print online publication of our research study titled “Association of interleukin-1 gene variations with moderate to severe chronic periodontitis in multiple ethnicities” in the Journal of Periodontal Research. The study results from multiple ethnic groups further validated the association between periodontitis and the interleukin-1 beta (IL1B) composite genotype pattern, a specific genetic profile that can be elucidated by our PerioPredict® genetic risk test. In addition, the study results demonstrated that detection of the IL1B variations tested provided added value in the prediction of moderate to severe periodontitis above and beyond the risk attributable to smoking and diabetes alone.

 

On April 22, 2014, we announced receipt of conditional approval from the New York State Department of Health to offer, process and report the results of the PerioPredict® test for periodontal disease.  The State of New York is the only U.S. state that requires an independent regulatory review process including technical validation with clinical utility for laboratory developed tests run within a CLIA certified laboratory. Conditional status will be removed on successful completion of a future additional review, the timing of which is determined solely by the State of New York. As a result of New York State approval the PerioPredict® test is now available to dental providers and their patients in all 50 U.S. states.

 

The PerioPredict® test is solely available through Interleukin Genetics. The web site for the PerioPredict® test is www.PerioPredict.com. We will continue to engage in discussions that may lead to increased adoption of our PerioPredict® test but the timing of any such adoption is uncertain at this time, and may never occur.

 

Our Inherent Health® brand of genetic tests includes the first-of-its-kind test for weight management that identifies an individual’s genetic tendencies for weight gain related to either fat or carbohydrates in the diet. The Inherent Health® brand also offers customers a full suite of affordable, easy-to-use and meaningful genetic tests in heart health, bone health and nutritional needs. In addition, we launched additional products under the name Wellness Select that allows our e-commerce customers to purchase any combination of our Inherent Health® genetic tests at a discounted price.

 

A recently published paper in the Journal of the American College of Cardiology (Tsimikas et al. 2014) extends the scientific evidence supporting the value of Interleukin Genetics’ proprietary Heart Health test to improve the identification of individuals with a prior diagnosis of cardiovascular disease who are at increased risk for a future cardiovascular disease event. This test has the potential to change a physician’s clinical actions to better manage cardiovascular disease risk. We believe this test may be most appropriately applied in the future to guide use of drugs currently in development by others that directly address the biological mechanisms identified by our test.

 

We market our Inherent Health® brand of genetic assessment tests primarily through our commercial relationships with Alticor Inc. affiliated companies. Alticor is a related party. On October 26, 2009, we entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor. Pursuant to this agreement, Amway Global sells our Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. In the three months ended September 30, 2015 and 2014, revenues from this agreement accounted for approximately 45% and 48% of our revenues, respectively. In the nine months ended September 30, 2015 and 2014, revenues from this agreement accounted for approximately 49% and 41% of our revenues, respectively.

 

Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway is now selling to their Individual Business Owners (IBOs). Of the $3.3 million in orders $1.8 million was received in 2013 for the 2014 program and $1.5 million for the 2013 program. All cash for the orders and royalties was received by December 31, 2013. The 2013 program was amended by ABG so that it would not expire at December 31, 2013. Rather than having all program kits expire at December 31, 2013, cash received from the orders will remain in deferred revenue until the tests are returned and processed. For the three months ended September 30, 2015 and 2014, approximately 14% and 30%, respectively, of our revenue came from sales through ABG’s promotional product bundle program. For the nine months ended September 30, 2015 and 2014, approximately 15% and 35%, respectively, of our revenue came from sales through ABG’s promotional product bundle program.

 

 21 

 

 

On September 21, 2012, we entered into a License Agreement with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to this License Agreement, we granted ABGI and its affiliates a non-exclusive license to use the technology related to our Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa. ABGI, or a laboratory designated by ABGI, is responsible for processing the tests, and we receive a royalty for each test sold. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. During the three and nine months ended September 30, 2015, royalties of $39,000 and $143,000, respectively, were received and recorded as Other Revenue in the Condensed Statement of Operations.

 

Our research and development efforts, and related expenses, are focused on expanding the evidence supporting our existing tests, primarily our PerioPredict® test. This is different than in prior years, when our research and development focus was concentrated on bringing new tests to market.

 

We recognize revenue from genetic testing services when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. During the fourth quarter of 2013, we concluded that sufficient historical customer genetic test redemption patterns existed to determine the period of time after which the likelihood of test redemption was remote for Inherent Health® tests purchased. Based on our analysis of the redemption data, we estimate that period of time to be three years after the sale of a genetic test kit. Prior to making this determination, revenue was recognized only on test kits returned and processed. Beginning in the fourth quarter of 2013, we began to recognize breakage revenue related to genetic tests kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. We analyzed redemption patterns from 2009 through 2013. Included in genetic test revenue in the three and nine months ended September 30, 2015, is $39,000 and $167,000, respectively, of breakage revenue related to unredeemed genetic test kits from the first, second and third quarters of 2012, compared to $86,000 and $242,000 in the same periods in 2014 related to unredeemed genetic test kits from the first, second and third quarters of 2011. We will continue to recognize breakage revenue and the corresponding deferred cost of goods as well as analyze the data on a quarterly basis based on the historical analysis.

 

In the genetic test business, competition is in flux and the markets and customer base are not well established. Adoption of new technologies requires substantial market development and customer education. Historically, we have focused on our relationship with our primary customer, Alticor, a significant direct marketing company, in order to assist us in developing the market for our products, primarily the Inherent Health® line of tests, and educating our potential customers. Our challenge in the remainder of 2015 and beyond will be to develop the market for our other personalized health products, in particular our PerioPredict® test. We continue to allocate considerable resources to commercialization of our PerioPredict® and Inherent Health® brands of genetic tests. Due to the early stage of these initiatives, we cannot predict with certainty fluctuations we may experience in our genetic test revenues or whether revenues derived from the Preferred Participation Agreement with RHSC, from our arrangements with Alticor-affiliated entities or from our discussions with other potential partners and customers will ever be material, or if material, will be sustained in future periods.

 

Results of Operations

 

Three Months Ended September 30, 2015 and 2014

 

Total revenue was $296,000 for the three months ended September 30, 2015 compared to $472,000 for the three months ended September 30, 2014. The change in total revenue is largely attributable to a decrease in the number of kits returned for processing related to our sales through ABG’s promotional product bundle program.

 

During the three months ended September 30, 2015, 45% of our sales revenue came through our Merchant Network and Channel Partner Agreement with Amway Global compared to 48% during the three months ended September 30, 2014. During the same periods, 14% and 30%, respectively, of our revenue came from sales through ABG’s promotional product bundle program.

 

Cost of revenue for the three months ended September, 30 2015 was $323,000, or 109.2% of revenue, compared to $359,000, or 76.0% of revenue, for the three months ended September 30, 2014. The increase in the cost of revenue as a percentage of revenue in the three months ended September 30, 2015 is primarily attributable to the fixed laboratory costs being applied to a lower volume of genetic tests being processed in the period.

 

 22 

 

 

Research and development expenses were $412,000 for the three months ended September 30, 2015, compared to $242,000 for the three months ended September 30, 2014. The increase of $169,000 or 70.1%, in research and development expenses is primarily attributable to increased compensation due to annual salary increases for existing staff, and to compensation and other expenses related to Dr. Kornman moving back into R&D from G&A in April 2015.

 

Selling, general and administrative expenses were $1.4 million for the three months ended September 30, 2015, compared to $1.3 million for the three months ended September 30, 2014. The increase of $100,000, or 8.3%, is primarily attributable to compensation and other employee expenses as well as higher consulting costs.

 

Interest expense was $153,000 for the three months ended September 30, 2015, as compared to interest income of $911 for the three months ended September 30, 2014. The interest expense for the three months ended September 30, 2015 was related to our venture loan and security agreement with Horizon Technology Finance Corporation (“Horizon”) entered into on December 23, 2014.

 

Nine Months Ended September 30, 2015 and 2014

 

Total revenue was $1.1 million for the nine months ended September 30, 2015 compared to $1.5 million for the nine months ended September 30, 2014. The change in total revenue is largely attributable to a decrease in the number of kits returned for processing related to our sales through ABG’s promotional product bundle program.

 

During the nine months ended September 30, 2015, 49% of our sales revenue came through our Merchant Network and Channel Partner Agreement with Amway Global compared to 41% during the nine months ended September 30, 2014. During the same periods, 15% and 35%, respectively, of our revenue came from sales through ABG’s promotional product bundle program.

 

Cost of revenue for the nine months ended September 30, 2015 was $986,000, or 91.7% of revenue, compared to $1.1 million, or 74.9% of revenue, for the nine months ended September 30, 2014. The increase in the cost of revenue as a percentage of revenue in the nine months ended September 30, 2015 is primarily attributable to the fixed laboratory costs being applied to a lower volume of genetic tests being processed in the period.

 

Research and development expenses were $979,000 for the nine months ended September 30, 2015, compared to $667,000 for the nine months ended September 30, 2014. The increase of $312,000 or 46.8%, in research and development expenses is primarily attributable to increased compensation due to annual salary increases for existing staff, and to compensation and other expenses related to Dr. Kornman being moved into R&D from G&A in April 2015.

 

Selling, general and administrative expenses were $4.6 million for the nine months ended September 30, 2015, compared to $4.3 million for the nine months ended September 30, 2014. The increase of $300,000, or 7.0%, is primarily attributable to increased compensation expenses based primarily on employee annual performance reviews, expenses related to recruiting our new Chief Executive Officer, higher consulting costs and higher patent related costs.

 

Interest expense (net) was $456,000 for the nine months ended September 30, 2015, as compared to interest income of $4,500 for the nine months ended September 30, 2014. The interest expense for the nine months ended September 30, 2015 was related to our venture loan and security agreement with Horizon entered into on December 23, 2014.

 

Liquidity and Capital Resources

 

As of September 30, 2015, we had cash and cash equivalents of $6.3 million.

 

Cash used in operations was $5.2 million for the nine months ended September 30, 2015 compared to $4.9 million for the nine months ended September 30, 2014. Cash used in operations is primarily impacted by operating results and changes in working capital, particularly the timing of the collection of related party receivables, inventory levels, receipt of orders and the timing of payments to suppliers.

 

Cash used in investing activities was $41,000 for the nine months ended September 30, 2015, compared to $92,000 for the nine months ended September 30, 2014. Half of the $41,000 in 2015 relates to the purchase of new IT equipment while the other half relates to the purchase of new lab equipment. The majority of the $92,000 in 2014 relates to the addition of new laboratory equipment and software.

 

 23 

 

 

Cash provided by financing activities was $10,000 for the nine months ended September 30, 2015 compared to $28,000 for the nine months ended September 30, 2014. The Company received $17,000 from stock purchases through the employee stock purchase plan during the nine months ended September 30, 2015 compared to 28,000 for the nine months ended September 30, 2014. The $17,000 received through the employee stock purchase plan for the nine months ended September 30, 2015 was offset in part by $7,000 in additional fees related to the December 2014 Private Placement.

 

The amount of cash we generate from operations is currently not sufficient to continue to fund operations and grow our business. We expect that our current and anticipated financial resources will be adequate to maintain our current and planned operations into the second half of 2016. If we are unable to obtain funding from our current or new investors, we may have to end our operations and seek protection under bankruptcy laws. We will need significant additional capital to fund our continued operations, to facilitate the continued commercial launch of our PerioPredict® genetic test, for continued research and development efforts, for obtaining and protecting patents and for administrative expenses. We believe our success depends on our ability to have sufficient capital and liquidity to fund operations at least until we begin to receive significant revenues from the processing of the PerioPredict® genetic test. The timing of any revenues that we may receive under the Preferred Participation Agreement with RHSC or any other agreements we may enter into with other partners is dependent upon the market adoption of the PerioPredict® test, which timing is uncertain. We do not expect to receive any significant revenues for the PerioPredict® test until 2016, at the earliest, and the timing of any such revenues may be substantially later. We may never receive significant revenues for the PerioPredict® test or any of our other genetic tests.

 

Until such time, if ever, that we generate revenues sufficient to fund operations, we may fund our operations by issuing common stock, debt or other securities in one or more public or private offerings, as market conditions permit, or through the incurrence of debt from commercial lenders, but additional funding may not be available on favorable terms, or at all. We currently trade on the OTCQB®. As a result, our access to capital through the public markets may be more limited. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring debt, making capital expenditures or declaring dividends. There can be no assurance that additional funds will be available when we need them on terms that are acceptable to us, or at all. If adequate funds are not available to us on a timely basis, we may be required to delay, limit, reduce or cease activities or operations or enter into licenses or other arrangements with third parties on terms that may be unfavorable to us or sell, license or relinquish rights to develop or commercialize our products, technologies or intellectual property, or seek protection under U.S. bankruptcy laws. However, no assurance can be given at this time as to whether we will be able to achieve these objectives. The financial statements do not include any adjustment relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our financial statements. The preparation of these financial statements and related disclosures in conformity with accounting principles generally accepted in the United States of America requires us to (i) make judgments, assumptions and estimates that affect the reported amounts of assets, liabilities, revenue and expenses; and (ii) disclose contingent assets and liabilities. A critical accounting estimate is an assumption that could have a material effect on our financial statements if another, also reasonable, amount were used or a change in the estimates is reasonably likely from period to period. We base our accounting estimates on historical experience and other factors that we consider reasonable under the circumstances. However, actual results may differ from these estimates. To the extent there are material differences between our estimates and the actual results, our future financial condition and results of operations will be affected. Our most critical accounting policies and estimates upon which our financial condition depends, and which involve the most complex or subjective decisions or assessments are set forth in Note 3 to our financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2014. There have been no significant changes in our accounting policies or changes from the methodology applied by management for critical accounting estimates previously disclosed in our most recent Annual Report on Form 10-K.

 

Recent Accounting Pronouncements

 

Please see the discussion of “Recent Accounting Pronouncements” in Note 3, “Summary of Significant Accounting Policies” contained in the Notes to Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3, “Summary of Significant Accounting Policies” contained in the Notes to Unaudited Condensed Financial Statements included in this Quarterly Report on Form 10-Q.

 

 24 

 

 

Item 3.   Quantitative and Qualitative Disclosures about Market Risk

 

As a smaller reporting company, we have elected scaled disclosure reporting obligations and therefore are not required to provide the information required by this Item 3.

 

Item 4.   Controls and Procedures

 

(a) Evaluation of Disclosure Controls and Procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15(d)-15(e)) as of the end of the period covered by this Quarterly Report on Form 10-Q, have concluded that, based on such evaluation, our disclosure controls and procedures were adequate and effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

(b) Changes in Internal Control Over Financial Reporting. No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15(d)-15(f)) occurred during the quarter ended September 30, 2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

PART II—OTHER INFORMATION

 

Item 1.   Legal Proceedings

 

Not applicable.

 

Item 1A.   Risk Factors

 

There have been no material changes to the risk factors included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2014, except for the addition of the following risk factor:

 

If the U.S. Food and Drug Administration (“FDA”) requires us to obtain premarket clearance or approval for our genetic tests, our business would be materially and adversely affected.

 

Our genetic tests are provided as laboratory developed tests (“LDTs”), performed in our CLIA-certified clinical laboratory operating in Waltham, Massachusetts. Although the FDA believes that tests such as ours fall within its jurisdiction as medical devices, it has historically exercised enforcement discretion with respect to most LDTs, meaning that such tests have not been subject to FDA regulatory requirements. However, FDA officials have stated that direct-to-consumer (“DTC”) genetic tests that make medical claims will no longer be subject to such enforcement discretion. In July 2010, the FDA sent Interleukin a letter regarding the LDTs that it sold at that time consistent with this change in its position. However, the FDA has not stated what specific requirements will apply to LDTs sold DTC, and we received no feedback from the FDA regarding the plan we submitted in response to its July 2010 letter. In addition, in March 2011, the FDA convened an advisory panel to make recommendations regarding oversight of DTC genetic tests. Following the meeting, the Director of the Office of In Vitro Diagnostics (“OIVD”), stated that the FDA would likely need to take a case-by-case approach with respect to which types of genetic tests could be offered DTC. On November 4, 2015, we received a letter from the FDA stating that certain of our genetic tests “appear to meet the definition of devices” as defined in the Federal Food Drug and Cosmetic Act and requested that we provide information regarding the basis for our determination that these tests that appear to be offered under a DTC model do not require FDA clearance. We believe that our genetic tests do not require FDA clearance and we intend to provide a response to the FDA’s letter and engage the FDA in dialog on this matter.

 

There can be no assurance, however, that the FDA will not require us to obtain clearance through its 510(k) premarket notification process or obtain approval through its premarket approval (“PMA”), process, either as a condition of continuing to market our tests or bringing future tests to market. Obtaining FDA clearance or approval could be lengthy, costly and burdensome. In addition, depending upon the FDA’s response to the information we provide, we may be required to stop selling our tests or revise our tests or promotional materials significantly, which would materially and adversely affect our business.

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I – Item 2, contains or incorporates a number of forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Exchange Act. Any or all of our forward-looking statements in this Quarterly Report on Form 10-Q may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. Many factors mentioned in our discussion in this Quarterly Report on Form 10-Q will be important in determining future results. Consequently, no forward-looking statement can be guaranteed. Actual future results may vary materially.

 

Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. There are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, many of which are beyond our control, including the factors set forth under “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2014. In addition, the forward-looking statements contained herein represent our estimates and expectations only as of the date of this filing and should not be relied upon as representing our estimates and expectations as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.

 

 25 

 

 

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds.

 

Not applicable.

 

Item 3.     Defaults Upon Senior Securities.

 

Not applicable.

 

Item 4.     Mine Safety Disclosures

 

Not applicable.

 

Item 5.     Other Information.

 

As stated in Notes 6 and 10, on November 12, 2015, the Company notified Scott Snyder, its Chief Marketing Officer, that his employment would be terminated effective as of November 13, 2015.

 

Item 6.     Exhibits.

 

Exhibit
Number		   Exhibit
3.1   Restated Certificate of Incorporation of the Company, as filed with the Delaware Secretary of State on October 23, 2013 (incorporated herein by reference to Exhibit 3.1 of the Company’s Quarterly Report on Form 10-Q filed November 14, 2013 (File No. 001-32715)
3.2   Certificate of Amendment to the Restated Certificate of Incorporation filed with the Delaware Secretary of State on July 21, 2015 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed on July 23, 2015 (File No. 001-32715).
10.1   2013 Employee, Director and Consultant Equity Incentive Plan, as amended (incorporated herein by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed on July 23, 2015 (File No. 001-32715).
31.1*   Certification by Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2*   Certification by Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*   Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101*   The following materials from Interleukin Genetics Inc.’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, formatted in XBRL (eXtensible Business Reporting Language): (i) the Condensed Balance Sheets, (ii) the Condensed Statements of Operations, (iii) the Condensed Statements of Stockholders’ Deficit, (iv) the Condensed Statements of Cash Flows, and (v) Notes to Condensed Financial Statements.

  

 

*Filed herewith.

 

 26 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  Interleukin Genetics, Inc.
     
Date: November 12, 2015 By: /s/ mark B. Carbeau
   

Mark B. Carbeau

Chief Executive Officer

(Principal Executive Officer)

     
Date: November 12, 2015 By: /s/ Stephen DiPalma
   

Stephen DiPalma

Interim Chief Financial Officer

(Principal Financial Officer)

 

 27 

 

 EX-31.1 2 v424036_ex31-1.htm EXHIBIT 31.1

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO
SECTION 302 OF
SARBANES-OXLEY ACT OF 2002

 

I, Mark B. Carbeau certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Interleukin Genetics, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2015 /s/ MARK B. CARBEAU
  Mark B. Carbeau
  Chief Executive Officer
   

 

 

 EX-31.2 3 v424036_ex31-2.htm EXHIBIT 31.2

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO
SECTION 302 OF
SARBANES-OXLEY ACT OF 2002

 

I, Stephen DiPalma certify that:

 

1.I have reviewed this quarterly report on Form 10-Q of Interleukin Genetics, Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

 

a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c)evaluated the effectiveness of the registrant’s disclosure controls and procedures, and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: November 12, 2015 /s/ STEPHEN DIPALMA
  Stephen DiPalma
  Interim Chief Financial Officer (Principal Financial and Accounting Officer)
   

 

 

 

 EX-32.1 4 v424036_ex32-1.htm EXHIBIT 32.1

 

EXHIBIT 32.1

 

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS (A) AND (B) OF SECTION 1350, CHAPTER 63 OF TITLE 18,
UNITED STATES CODE)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18 United States Code), each of the undersigned officers of Interleukin Genetics, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

 

The Quarterly Report of Form 10-Q for the quarter ended September 30, 2015 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13 (a) or 15 (d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: November 12, 2015 /s/ MARK B. CARBEAU
 

Mark B. Carbeau 

Chief Executive Officer 

   
Date: November 12, 2015 /s/ STEPHEN DIPALMA
 

Stephen DiPalma 

Interim Chief Financial Officer (Principal Financial and Accounting Officer) 

  

 

 

 EX-101.INS 5 iliu-20150930.xml XBRL INSTANCE DOCUMENT 0001037649 2014-01-01 2014-09-30 0001037649 2014-01-01 2014-12-31 0001037649 2015-01-01 2015-09-30 0001037649 2014-07-01 2014-09-30 0001037649 2015-07-01 2015-09-30 0001037649 2014-09-30 0001037649 2015-09-30 0001037649 2013-10-01 2013-10-31 0001037649 2014-10-01 2014-10-31 0001037649 2015-11-11 0001037649 2014-12-31 0001037649 2013-12-31 0001037649 us-gaap:CommonStockMember 2013-12-31 0001037649 us-gaap:AdditionalPaidInCapitalMember 2013-12-31 0001037649 us-gaap:RetainedEarningsMember 2013-12-31 0001037649 us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2014-01-01 2014-09-30 0001037649 us-gaap:RetainedEarningsMember 2014-01-01 2014-09-30 0001037649 us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2015-01-01 2015-09-30 0001037649 us-gaap:RetainedEarningsMember 2015-01-01 2015-09-30 0001037649 us-gaap:CommonStockMember 2014-09-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2014-09-30 0001037649 us-gaap:RetainedEarningsMember 2014-09-30 0001037649 us-gaap:CommonStockMember 2015-09-30 0001037649 us-gaap:AdditionalPaidInCapitalMember 2015-09-30 0001037649 us-gaap:RetainedEarningsMember 2015-09-30 0001037649 us-gaap:CommonStockMember iliu:May2013PrivatePlacementMember 2013-05-01 2013-05-17 0001037649 us-gaap:CommonStockMember iliu:May2013PrivatePlacementMember 2013-05-17 0001037649 us-gaap:CommonStockMember 2013-05-01 2013-05-17 0001037649 iliu:Warrants2013Member 2013-05-17 0001037649 iliu:PlacementAgentWarrants2014Member 2014-12-23 0001037649 iliu:December2014PrivatePlacementMember 2014-12-01 2014-12-23 0001037649 iliu:December2014PrivatePlacementMember 2014-12-23 0001037649 iliu:VentureLoanMember 2014-12-01 2014-12-23 0001037649 iliu:VentureLoanMember 2015-09-30 0001037649 iliu:VentureLoanMember 2014-12-23 0001037649 iliu:KitsComponentsMember 2015-09-30 0001037649 iliu:CustomerPaymentMember 2015-09-30 0001037649 iliu:DistributorsMember 2015-09-30 0001037649 iliu:GeneticTestRevenueMember 2015-07-01 2015-09-30 0001037649 iliu:GeneticTestRevenueMember 2015-01-01 2015-09-30 0001037649 iliu:GeneticTestRevenueMember 2014-07-01 2014-09-30 0001037649 iliu:GeneticTestRevenueMember 2014-01-01 2014-09-30 0001037649 iliu:FulfillmentCenterMember 2015-01-01 2015-09-30 0001037649 us-gaap:StockOptionMember 2015-01-01 2015-09-30 0001037649 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001037649 us-gaap:StockOptionMember 2014-01-01 2014-09-30 0001037649 us-gaap:WarrantMember 2014-01-01 2014-09-30 0001037649 iliu:AmwayGlobalMember 2015-07-01 2015-09-30 0001037649 iliu:AmwayGlobalMember 2014-07-01 2014-09-30 0001037649 iliu:AmwayGlobalMember 2015-01-01 2015-09-30 0001037649 iliu:AmwayGlobalMember 2014-01-01 2014-09-30 0001037649 iliu:AccessBusinessGroupInternationalLlcMember 2015-07-01 2015-09-30 0001037649 iliu:AccessBusinessGroupInternationalLlcMember 2015-01-01 2015-09-30 0001037649 iliu:AccessBusinessGroupInternationalLlcMember 2014-07-01 2014-09-30 0001037649 iliu:AccessBusinessGroupInternationalLlcMember 2014-01-01 2014-09-30 0001037649 iliu:AmwayGlobalMember us-gaap:SalesMember 2015-07-01 2015-09-30 0001037649 iliu:AmwayGlobalMember us-gaap:SalesMember 2014-07-01 2014-09-30 0001037649 iliu:AbgMember us-gaap:SalesMember 2015-07-01 2015-09-30 0001037649 iliu:AbgMember us-gaap:SalesMember 2014-07-01 2014-09-30 0001037649 iliu:AmwayGlobalMember us-gaap:SalesMember 2015-01-01 2015-09-30 0001037649 iliu:AmwayGlobalMember us-gaap:SalesMember 2014-01-01 2014-09-30 0001037649 iliu:AbgMember us-gaap:SalesMember 2015-01-01 2015-09-30 0001037649 iliu:AbgMember us-gaap:SalesMember 2014-01-01 2014-09-30 0001037649 iliu:VentureLoanMember 2015-07-01 2015-09-30 0001037649 iliu:VentureLoanMember 2015-01-01 2015-09-30 0001037649 us-gaap:ChiefExecutiveOfficerMember 2015-04-01 2015-04-06 0001037649 us-gaap:ChiefExecutiveOfficerMember 2015-04-06 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2010-04-01 2010-04-30 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2010-04-30 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2011-05-01 2011-05-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2011-05-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2012-12-01 2012-12-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2012-12-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember iliu:FirstAnniversariesMember 2012-12-01 2012-12-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember iliu:SecondAnniversariesMember 2012-12-01 2012-12-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember iliu:ThirdAnniversariesMember 2012-12-01 2012-12-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2013-10-01 2013-10-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember iliu:FirstAnniversariesMember 2013-10-01 2013-10-31 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2015-01-01 2015-01-31 0001037649 iliu:ChiefMarketingOfficerMember 2012-12-01 2012-12-31 0001037649 iliu:ChiefMarketingOfficerMember 2014-01-01 2014-09-30 0001037649 iliu:ChiefMarketingOfficerMember 2013-07-01 2013-07-31 0001037649 iliu:ChiefMarketingOfficerMember 2014-01-01 2014-12-31 0001037649 iliu:ChiefMarketingOfficerMember 2015-01-01 2015-09-30 0001037649 iliu:ChiefMarketingOfficerMember 2013-01-01 2013-01-02 0001037649 iliu:ChiefMarketingOfficerMember iliu:FirstAnniversariesMember 2013-01-01 2013-01-02 0001037649 iliu:ChiefMarketingOfficerMember iliu:SecondAnniversariesMember 2013-01-01 2013-01-02 0001037649 iliu:ChiefMarketingOfficerMember iliu:ThirdAnniversariesMember 2013-01-01 2013-01-02 0001037649 iliu:ChiefMarketingOfficerMember 2015-01-01 2015-01-31 0001037649 us-gaap:EmployeeStockOptionMember 2015-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2015-09-30 0001037649 us-gaap:PrivatePlacementMember 2015-09-30 0001037649 us-gaap:WarrantMember 2015-09-30 0001037649 iliu:WarrantThreeMember 2015-09-30 0001037649 iliu:WarrantFourMember 2015-09-30 0001037649 iliu:WarrantFiveMember 2015-09-30 0001037649 us-gaap:PrivatePlacementMember 2015-01-01 2015-09-30 0001037649 us-gaap:WarrantMember 2015-01-01 2015-09-30 0001037649 iliu:WarrantThreeMember 2015-01-01 2015-09-30 0001037649 iliu:WarrantFourMember 2015-01-01 2015-09-30 0001037649 iliu:WarrantFiveMember 2015-01-01 2015-09-30 0001037649 iliu:ConsultingMemberMember 2015-09-30 0001037649 iliu:ConsultingMemberMember 2015-01-01 2015-09-30 0001037649 iliu:Warrants2013Member 2013-05-17 0001037649 iliu:Warrants2013Member 2013-05-01 2013-05-17 0001037649 iliu:May2013PrivatePlacementMember us-gaap:MinimumMember 2013-08-09 0001037649 iliu:PlacementAgentWarrantsMember 2015-01-01 2015-09-30 0001037649 iliu:PlacementAgentWarrantsMember 2015-09-30 0001037649 iliu:FinancialConsultantMember 2014-09-30 0001037649 iliu:FinancialConsultantMember 2014-09-01 2014-09-30 0001037649 us-gaap:InvestorMember 2014-12-01 2014-12-23 0001037649 us-gaap:InvestorMember 2014-12-23 0001037649 iliu:PlacementAgentWarrants2014Member 2014-12-01 2014-12-23 0001037649 iliu:OptionOutstandingMember 2015-07-01 2015-09-30 0001037649 iliu:StockGrantsMember 2015-07-01 2015-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2015-07-01 2015-09-30 0001037649 iliu:OptionOutstandingMember 2014-07-01 2014-09-30 0001037649 iliu:StockGrantsMember 2014-07-01 2014-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2014-07-01 2014-09-30 0001037649 iliu:OptionOutstandingMember 2015-01-01 2015-09-30 0001037649 iliu:StockGrantsMember 2015-01-01 2015-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2015-01-01 2015-09-30 0001037649 iliu:OptionOutstandingMember 2014-01-01 2014-09-30 0001037649 iliu:StockGrantsMember 2014-01-01 2014-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2014-01-01 2014-09-30 0001037649 iliu:TwoThousandThirteenPlanMember 2013-08-09 0001037649 iliu:TwoThousandFourPlanMember 2013-08-09 0001037649 iliu:TwoThousandThirteenPlanMember 2015-01-01 2015-09-30 0001037649 iliu:TwoThousandThirteenPlanMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001037649 iliu:TwoThousandThirteenPlanMember 2015-07-02 2015-07-21 0001037649 iliu:EmploymentAgreementMember 2015-04-01 2015-04-06 0001037649 iliu:EmploymentAgreementMember iliu:TwoThousandThirteenPlanMember 2015-04-01 2015-04-06 0001037649 iliu:EmploymentAgreementMember iliu:OutsideOf2013PlanMember 2015-04-01 2015-04-06 0001037649 iliu:EmployeeStockPurchasePlanMember 2015-01-01 2015-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2015-01-01 2015-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember us-gaap:CommonStockMember 2014-01-01 2014-09-30 0001037649 iliu:EmployeeStockPurchasePlanMember 2014-01-01 2014-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AmwayGlobalMember 2015-07-01 2015-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AmwayGlobalMember 2014-07-01 2014-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AbgsPromotionalProductBundleProgramMember 2015-07-01 2015-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AbgsPromotionalProductBundleProgramMember 2014-07-01 2014-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AmwayGlobalMember 2015-01-01 2015-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AmwayGlobalMember 2014-01-01 2014-09-30 0001037649 us-gaap:SalesRevenueNetMember iliu:AbgsPromotionalProductBundleProgramMember 2015-01-01 2015-09-30 0001037649 us-gaap:CommonStockMember 2014-12-31 0001037649 us-gaap:AdditionalPaidInCapitalMember 2014-12-31 0001037649 us-gaap:RetainedEarningsMember 2014-12-31 0001037649 iliu:AbgMember iliu:TwoZeroOneThreeProgramMember 2013-12-31 0001037649 iliu:AbgMember iliu:TwoZeroOneFourProgramMember 2013-12-31 0001037649 iliu:AbgMember 2015-01-01 2015-09-30 0001037649 iliu:PresidentAndChiefScientificOfficerMember 2015-01-01 2015-09-30 0001037649 iliu:ChiefMarketingOfficerMember iliu:FirstAnniversariesMember 2013-10-01 2013-10-31 0001037649 iliu:ChiefMarketingOfficerMember 2013-10-01 2013-10-31 0001037649 iliu:May2013PrivatePlacementMember us-gaap:MaximumMember 2013-08-09 0001037649 iliu:PlacementAgentWarrants2014Member 2015-01-01 2015-09-30 0001037649 iliu:LenderWarrantsMember 2015-01-01 2015-09-30 0001037649 iliu:LenderWarrantsMember 2014-12-01 2014-12-23 0001037649 iliu:Warrants2014Member 2014-12-31 0001037649 iliu:PlacementAgentWarrantsMember 2014-12-31 0001037649 us-gaap:SubsequentEventMember 2015-11-01 2015-11-13 0001037649 iliu:EmploymentAgreementMember 2015-01-01 2015-09-30 0001037649 iliu:Warrants2013Member 2013-05-01 2013-05-17 0001037649 iliu:PlacementAgentWarrants2014Member 2014-12-01 2014-12-23 0001037649 us-gaap:SalesRevenueNetMember iliu:AbgsPromotionalProductBundleProgramMember 2014-01-01 2014-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure 6270644 11466807 40603 23544 5305 14013 159093 171575 531628 504719 7007273 12180658 658899 773779 137523 195765 99135 116919 7902830 13267121 576210 513927 455299 343225 2925725 3154498 3957234 4011650 126107664 125434483 -127125802 -121090312 -845295 4516857 7902830 13267121 4790891 8748125 8750264 172843 172686 4738614 248873 439400 47125 32751 295998 472151 323136 358578 -27138 113573 411902 242142 1413702 1305583 19414 23525 1845018 1571250 -1872156 -1457677 0 911 153354 0 -153354 911 -2025510 -1456766 0 0 -2025510 -1456766 -0.01 -0.01 172841047 122548292 921610 1342947 153651 145365 1075261 1488312 985732 1115095 89529 373217 978970 666839 4631718 4338245 58242 70575 5668930 5075659 -5579401 -4702442 222 4511 456311 0 -456089 4511 -6035490 -4697931 0 0 -6035490 -4697931 -0.03 -0.04 172788286 122515671 5253222 122449 119885371 -114754598 122448707 0 0 -4697931 0 0 -6035490 27557 101 27456 0 99585 7100 7100 16799 157 16642 0 157705 354441 651791 0 354441 0 0 651791 0 937289 122550 120267268 -119452529 172843 126107664 -127125802 122548292 172841047 11848 11848 214180 190012 651791 354441 17059 -499987 -12482 -23248 26909 -115005 62283 -537561 112074 -62224 -228773 -752212 -5164805 -4873161 41057 92278 -41057 -92278 7100 0 16799 27557 9699 27557 -5196163 -4937882 7542281 2604399 81908 -8708 5926 0 352500 0 43715847 0.2745 12000000 32786885 0.2745 50099700 0.1003 5025000 50099700 0.1003 5000000 0.090 2492523 0.1003 2900000 3200000 2700000 300000 2400000 39000 167000 86000 242000 70000 59000 239000 160000 0.02 33000 142351 163239 16742 8336 14300000 110559738 42079800 22258659 88301079 4810675 37269125 70000 59000 239000 160000 P60D 39000 143000 31000 129000 0.45 0.48 0.14 0.3 0.49 0.41 0.15 0.35 0.090 89000 261000 225000 280000 115000 341000 38000 115000 0.0206 0.0206 96000 80000 268000 230000 365000 0.35 1.5 14245227 0.1525 0.25 0.02083 30000 0.745 0.2 100000 0.46 0.25 300000 0.34 0.25 0.33 0.42 2250000 0.3799 0.25 0.0208 2030000 0.26 265000 0.3 34000 16000 60000 80000 40000 200000 0.29 50000 66000 84000 660000 0.26 6000000 0.001 450000000 0.001 172841047 140958605 52311279 346247 50189431 2492523 437158 20655737 14426230 172841047 313799652 0.1003 0.1003 0.2745 0.2745 0.2745 2021-12-23 2024-12-23 2017-06-29 2020-05-17 2020-08-09 100000 0.2500 2024-09-08 32786885 0.2745 12000000 0.63 0.37 150000000 780000 2295082 0.2745 3000 9000 100000 0.25 0.5 24000 89731 50099700 0.1003 5025000 50099700 0.1003 218000 0.0198 1.384 0 261000 251374 92 1088 108363 0 1279 491197 157463 3129 348545 1166 4730 4523900 17793027 0.17 0.39 0.22 22258659 0.34 3067959 5884050 137000 0.35 0.43 0.43 4810675 0 0 0 0 58268 1210375 0.00 0.00 0.00 0.00 0.28 0.43 723925 0.71 2700000 8860000 2435500 6170748 30052620 30000000 14245227 0.1525 2622948 11622279 0.85 157705 99585 0.10 0.28 0.12 0.32 3129 4730 0.45 0.48 0.14 0.3 0.49 0.41 0.15 10-Q false 2015-09-30 2015 Q3 INTERLEUKIN GENETICS INC 0001037649 --12-31 Smaller Reporting Company ILIU 172887221 0.001 172841047 172683342 172683342 172683342 172686 125434483 -121090312 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="center"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note&#160;1&#151;Basis of Presentation</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Interleukin Genetics, Inc. (&#8220;the Company&#8221;) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company&#8217;s principal operations and markets are located in the United States.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The accompanying condensed financial statements include the accounts of the Company as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2014. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire 2015 fiscal year.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">For information regarding our critical accounting policies and estimates, please refer to &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations &#150; Critical Accounting Policies and Estimates&#8221; contained in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3 to our condensed financial statements contained herein.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt"> Note&#160;2&#151;Liquidity</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">The Company has experienced net operating losses since its inception through September 30, 2015. The Company had net losses of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.3</font> million for the year ended December 31, 2014, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">6.04</font> million for the nine months ended September 30, 2015, contributing to an accumulated deficit of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">127.1</font> million as of September 30, 2015.</div> <font style="FONT-SIZE: 10pt"><font style="FONT-SIZE: 10pt"></font></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify">&#160;</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the &#8220;2013 Purchase Agreement&#8221;) with various accredited investors (the &#8220;2013 Investors&#8221;), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the &#8220;May 2013 Private Placement&#8221;). In the May 2013 Private Placement, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43,715,847</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2745</font> per share for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000,000</font>. The 2013 Investors also received warrants to purchase up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 32,786,885</font> shares of common stock an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2745</font> per share (the &#8220;2013 Warrants&#8221;). The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 23, 2014, the Company entered into a Securities Purchase Agreement (the &#8220;2014 Purchase Agreement&#8221;) with various accredited investors (the &#8220;2014 Investors&#8221;), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the &#8220;December 2014 Private Placement&#8221;) an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,099,700</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share for gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.025</font> million. The 2014 Investors also received warrants to purchase up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,099,700</font> shares of common stock an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share (the &#8220;2014 Warrants&#8221;). The 2014 Warrants are all currently exercisable and have a term of seven years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the &#8220;Loan Agreement&#8221;) with Horizon Technology Finance Corporation (the &#8220;Lender&#8221;) under which the Company has borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.</font> At September 30, 2015, the rate was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9.0</font>% per annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable.</font> The Company&#8217;s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,492,523</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (10) years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;<font style="COLOR: black">The Company&#8217;s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.&#160;</font> The financial statements do not include any adjustments that might result from the outcome of this uncertain realization.&#160;<font style="COLOR: black">The Company expects to incur additional losses in 2015 and, accordingly, is dependent on financings and potential revenue to fund its operations&#160;</font> and support the market adoption of the PerioPredict<sup style="font-style:normal">&#174;&#160;</sup> test. The timing of any revenues that the Company may receive from the PerioPredict<sup style="font-style:normal">&#174;&#160;</sup> test is uncertain at this time, and is contingent upon a number of factors, including the Company&#8217;s ability to consummate arrangements with partners to promote the PerioPredict<sup style="font-style:normal">&#174;&#160;</sup> test, the Company and its partners&#8217; ability to develop insurance plans that provide for use and reimbursement of the PerioPredict<sup style="font-style:normal">&#174;</sup> test, or other possible arrangements, and to develop a viable market for such plans, and the timing of utilization of the PerioPredict<sup style="font-style:normal">&#174;</sup> test pursuant to such plans.&#160;<font style="COLOR: black">The Company expects to have the cash resources necessary to fund its operations into the second half of 2016.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The ability of the Company to realize the carrying value of its fixed assets and intangible assets is dependent on management&#8217;s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 6300000 The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable. P10Y <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Note&#160;3&#151;Summary of Significant Accounting Policies</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Management Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company&#8217;s most critical accounting policies are more fully discussed in these notes to the financial statements.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.9</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million, respectively. Included in deferred revenue at September 30, 2015 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.7</font> million for test kits that are still outstanding one year or longer after initial kit sale, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million was sold directly to consumers (credit card payments) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.4</font> million was sold to distributors for the promotional bundle. Beginning in September 2012 and again in 2013, Access Business Group LLC (&#8220;ABG&#8221;), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,000</font>, respectively, of breakage revenue related to unredeemed genetic test kits sold in the first, second and third quarters of 2012, compared to breakage revenue included in genetic test revenue in the three and nine months ended September 30, 2014 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">86,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">242,000</font>, respectively, related to unredeemed genetic test kits sold in the first, second and third quarters of 2011. The Company expects to continue to recognize breakage revenue on a quarterly basis based on the historical analysis.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Sales Commission</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (&#8220;Amway Global&#8221;), a subsidiary of Alticor Inc. (&#8220;Alticor&#8221;). Pursuant to this Agreement, Amway Global sells the Company&#8217;s Inherent Health<sup style="font-style:normal">&#174;</sup> brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company accounts for sales commissions due to Amway Global under the Merchant Network and Channel Partner Agreement in accordance with SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. The cost of commissions was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">59,000</font> for the three months ended September 30, 2015 and 2014, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">239,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font> for the nine months ended September 30, 2015 and 2014, respectively.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Accounts Receivable</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>% cash discount if payment is made by bank wire transfer within 10&#160;days of the invoice date. No accounts receivable reserve is required at September 30, 2015 as all accounts receivable are expected to be collected.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict<sup style="font-style:normal">&#174;</sup> genetic tests kits to dental offices. The agreement with the fulfillment provider requires them to purchase and fulfill all materials related to the PerioPredict<sup style="font-style:normal">&#174;</sup> test and Body Key&#153; genetic test kits, with the Company&#8217;s approval. The Company reimburses the fulfillment provider for materials and pays fulfillment charges when the product is shipped. During the nine months ended September 30, 2015, the Company made a onetime purchase of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,000</font> of inventory related to its PerioPredict<sup style="font-style:normal">&#174;</sup> test from our fulfillment provider, which is held at our fulfillment center. The balance of our inventory is related to our Inherent Health<sup style="font-style:normal">&#174;</sup> brand and is stored at a separate facility. When a kit is sold, the corresponding cost of the kit is recorded as deferred cost of goods sold and removed from inventory. Any kit components remaining at the fulfillment center are reflected in inventory with a corresponding offset to accounts payable.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>142,351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,336</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>159,093</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>171,575 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Stock-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, <i>Compensation &#150; Stock Compensation</i>. The standard addresses all forms of share-based payment (SBP) awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. We expense SBP awards within compensation cost for SBP transactions measured at fair value. Compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the effective date shall be recognized as the requisite service is rendered on or after the effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated under the Black-Scholes option pricing model. Common stock purchased pursuant to our employee stock purchase plan will be expensed based upon the fair market value in excess of purchase price.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Income Taxes</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company accounts for income taxes in accordance with FASB ASC 740, <i>Income Taxes</i>, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Significant management judgment is required in determining the Company&#8217;s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management&#8217;s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Company&#8217;s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company&#8217;s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company&#8217;s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder&#8217;s conversion of debt of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.3</font> million into common stock of the Company prior to an additional investment by an unrelated investor.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Research and Development</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Basic and Diluted Net Loss per Common Share</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company applies the provisions of FASB ASC 260, <i>Earnings per Share</i>, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>As&#160;of&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>22,258,659</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,810,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrants outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>88,301,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>37,269,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>110,559,738</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>42,079,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fair Value of Financial Instruments</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Cash and Cash Equivalents</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Fixed Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,500</font> in the Projects in Progress account, all of which is laboratory equipment.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Segment Reporting</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company&#8217;s principal operations and markets are located in the United States.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Recent Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts.&#160; Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet.&#160; Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively.&#160;All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.55in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.55in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Identify the contract(s) with a customer.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Identify the performance obligations in the contract.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Determine the transaction price.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Allocate the transaction price to the performance obligations in the contract.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Recognize revenue when (or as) the entity satisfies a performance obligation.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance.&#160; The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation.&#160; ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Management Estimates</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company&#8217;s most critical accounting policies are more fully discussed in these notes to the financial statements.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Sales Commission</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (&#8220;Amway Global&#8221;), a subsidiary of Alticor Inc. (&#8220;Alticor&#8221;). Pursuant to this Agreement, Amway Global sells the Company&#8217;s Inherent Health<sup style="font-style:normal">&#174;</sup> brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company accounts for sales commissions due to Amway Global under the Merchant Network and Channel Partner Agreement in accordance with SEC Staff Accounting Bulletin (&#8220;SAB&#8221;) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. The cost of commissions was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">59,000</font> for the three months ended September 30, 2015 and 2014, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">239,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font> for the nine months ended September 30, 2015 and 2014, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Accounts Receivable</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2</font>% cash discount if payment is made by bank wire transfer within 10&#160;days of the invoice date. No accounts receivable reserve is required at September 30, 2015 as all accounts receivable are expected to be collected.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> Inventory</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict<sup style="font-style:normal">&#174;</sup> genetic tests kits to dental offices. The agreement with the fulfillment provider requires them to purchase and fulfill all materials related to the PerioPredict<sup style="font-style:normal">&#174;</sup> test and Body Key&#153; genetic test kits, with the Company&#8217;s approval. The Company reimburses the fulfillment provider for materials and pays fulfillment charges when the product is shipped. During the nine months ended September 30, 2015, the Company made a onetime purchase of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">33,000</font> of inventory related to its PerioPredict<sup style="font-style:normal">&#174;</sup> test from our fulfillment provider, which is held at our fulfillment center. The balance of our inventory is related to our Inherent Health<sup style="font-style:normal">&#174;</sup> brand and is stored at a separate facility. When a kit is sold, the corresponding cost of the kit is recorded as deferred cost of goods sold and removed from inventory. Any kit components remaining at the fulfillment center are reflected in inventory with a corresponding offset to accounts payable.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Inventory consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>142,351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,336</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>159,093</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>171,575 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Stock-Based Compensation</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, <i>Compensation &#150; Stock Compensation</i>. The standard addresses all forms of share-based payment (SBP) awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. We expense SBP awards within compensation cost for SBP transactions measured at fair value. Compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the effective date shall be recognized as the requisite service is rendered on or after the effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated under the Black-Scholes option pricing model. Common stock purchased pursuant to our employee stock purchase plan will be expensed based upon the fair market value in excess of purchase price.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Research and Development</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Research and development costs are expensed as incurred.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Basic and Diluted Net Loss per Common Share</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company applies the provisions of FASB ASC 260, <i>Earnings per Share</i>, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>As&#160;of&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>22,258,659</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,810,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrants outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>88,301,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>37,269,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>110,559,738</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>42,079,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Fair Value of Financial Instruments</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Cash and Cash Equivalents</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Fixed Assets</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">19,500</font> in the Projects in Progress account, all of which is laboratory equipment.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Segment Reporting</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company&#8217;s principal operations and markets are located in the United States.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Recent Accounting Pronouncements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts.&#160; Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet.&#160; Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively.&#160;All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.55in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.55in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Identify the contract(s) with a customer.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Identify the performance obligations in the contract.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Determine the transaction price.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Allocate the transaction price to the performance obligations in the contract.</font></div> </td> </tr> </table> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; LINE-HEIGHT: 115%; WIDTH: 100%; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" border="0" cellspacing="0" cellpadding="0" width="100%"> <tr> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"></td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; WIDTH: 0.25in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top" width="24"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-FAMILY: Symbol; FONT-SIZE: 10pt"> &#8901;</font></div> </td> <td style="PADDING-BOTTOM: 0in; PADDING-LEFT: 0in; PADDING-RIGHT: 0in; PADDING-TOP: 0in" valign="top"> <div style="CLEAR:both;MARGIN: 0in 0in 0pt; FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 12pt"> <font style="FONT-SIZE: 10pt">Recognize revenue when (or as) the entity satisfies a performance obligation.</font></div> </td> </tr> </table> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -0.25in; MARGIN: 0in 0in 0pt 0.5in"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements&#151;Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance.&#160; The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation.&#160; ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Inventory consisted of the following:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 88%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>September&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;31,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Raw materials</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>142,351</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>163,239</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Finished goods</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>16,742</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>8,336</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="63%"> <div>Total inventory, net</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>159,093</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>171,575 <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160; <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.75in; WIDTH: 80%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>As&#160;of&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Options outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>22,258,659</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,810,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Warrants outstanding</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>88,301,079</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>37,269,125</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="57%"> <div>Total</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>110,559,738</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>42,079,800</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Note&#160;4&#151;Related Party Transactions</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> &#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (&#8220;Amway Global&#8221;), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company&#8217;s Inherent Health<sup style="font-style:normal">&#174;</sup> brand of genetic tests through its e-commerce website via a hyperlink to the Company&#8217;s e-commerce site. The Company paid Amway Global $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">70,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">59,000</font> in commissions for the three months ended September 30, 2015 and 2014, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">239,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">160,000</font> in commissions for the nine months ended September 30, 2015 and 2014, respectively, representing a percentage of net sales to their customers. The Company expenses commissions owed to Amway Global in the month of sale to the customer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Beginning in September 2012 and again in 2013, Access Business Group LLC (&#8220;ABG&#8221;), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs). Of the $3.3 million in orders, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.5</font> million was received for the 2013 program and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">1.8</font> million for the 2014 program. As a component of the 2013 promotional program, and not reflective of actual product expiry, the kits were required to be redeemed by December 31, 2013. In February 2014, the Company removed the redemption date requirement for the 2013 promotional program, for which ABG paid the Company $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">519,000</font> as a retrospective increase in the product purchase price. All cash received related to the 2013 promotional program, including the $519,000, will be treated as deferred revenue until specific kits are returned for processing or the breakage analysis determines the probability of eventual redemption is remote. In October 2014, the Company received $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> as a retrospective increase in the product purchase price for unsold kits as consideration for extending the required redemption date of the 2014 promotional program to December 31, 2017. All cash received for these kits will be treated as deferred revenue until specific kits are returned for processing or on the final allowed redemption date of December 31, 2017.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On September 21, 2012, the Company entered into a License Agreement with Access Business Group International LLC (&#8220;ABGI&#8221;), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin&#8217;s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the &#8220;Territories&#8221;). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60</font> days prior to the anniversary date. During the three and nine months ended September 30, 2015, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">143,000</font>, respectively, was earned, compared to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">31,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">129,000</font> in the same periods in 2014</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the &#8220;PSA&#8221;) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. <font style="COLOR: black">No fees were earned in the year ended December 31, 2014 or the nine months ended September 30, 2015 under the PSA.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">For the three months ended September 30, 2015 and 2014, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 45</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48</font>%, respectively, of the Company&#8217;s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>%, respectively, of the Company&#8217;s revenue came from sales through ABG&#8217;s promotional product bundle program. For the nine months ended September 30, 2015 and 2014, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 49</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 41</font>%, respectively, of the Company&#8217;s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>%, respectively, of the Company&#8217;s revenue came from sales through ABG&#8217;s promotional product bundle program.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (&#8220;RHSC&#8221;), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (&#8220;DDMI&#8221;), a stockholder of the Company.<b><i>&#160;</i></b> Pursuant to this agreement, as amended, affiliates of RHSC have agreed to reimburse the Company a fixed price for each PerioPredict<sup style="font-style:normal">&#174;</sup>&#160;genetic test that the Company processes for a customer of affiliates of RHSC. In addition, if during the term of the agreement the Company offers the PerioPredict<sup style="font-style:normal">&#174;</sup>&#160;test to any other person or party for a lower price, such lower price shall then be applicable to tests processed for a customer of such affiliates of RHSC for the remainder of the term of the agreement. RHSC and its affiliates will continue to receive the preferred pricing (or any lower market price during the term) only for so long as affiliates of RHSC continue to: (a) work to develop and to offer dental benefit plans that provide for use of the PerioPredict test and reimbursement of the test at the agreed upon price(each such plan, hereinafter referred to as a &#8220;Reimbursed Dental Plan&#8221;) for which a significant portion of employees of RHSC&#8217;s affiliates&#8217; customers are eligible; and (b) exercise their commercially-reasonable best efforts to maximize the number of customers that offer a Reimbursed Dental Plan. In addition, under the terms of the amended agreement, the Company is no longer obligated to make the PerioPredict<sup style="font-style:normal">&#174;</sup>&#160;test available solely to RHSC affiliates and not to any other third party or person. This amended agreement has a term of three years beginning February 25, 2013,&#160;<font style="COLOR: black">unless terminated earlier&#160;</font> (1) upon the mutual written agreement of us and RHSC, (2) if either party becomes the subject of bankruptcy, insolvency, liquidation or other similar proceedings, or (3) in the event of an uncured breach of the amended agreement by either party<font style="COLOR: black">.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The timing of any revenues that the Company may receive under the amended agreement with RHSC is dependent upon the timing of the offering of Reimbursed Dental Plans and the subsequent adoption of such Reimbursed Dental Plans by RHSC customers, the timing of which is very uncertain at this time and is dependent on a viable market developing for such plans. RHSC has informed us that it has presented the scientific data underlying Reimbursed Dental Plans to a number of customers and will make available Reimbursed Dental Plans as an alternative to a customer&#8217;s current plan for any customer that expresses an interest in such a plan.&#160;The Company may never receive significant revenues under this agreement.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 250000 1500000 1800000 519000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -10.1pt; MARGIN: 0in 0in 0pt 10.1pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note 5&#151;Debt Instruments</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: -10.1pt; MARGIN: 0in 0in 0pt 10.1pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Venture Loan and Security Agreement</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the &#8220;Lender&#8221;) under which the Company borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.</font> At September 30, 2015, the rate was <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 9.0</font>% per annum. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable.</font> The Company&#8217;s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,492,523</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">10</font>) years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Additionally, $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">89,000</font> in cash fees paid to the Lender and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">261,000</font>, the intrinsic value of the Lender Warrants, were recorded as a discount on the loan and amortized over the term of the loan. The final non-principal payment of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">225,000</font> will be accrued as additional interest expense, using the effective interest method, over the term of the loan. As of September 30, 2015, the unamortized discount associated with the loan was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">280,000</font>. Cash interest expense for the three and nine months ending September 30, 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">341,000</font>, respectively. Non-cash interest expense for the three and nine months ending September 30, 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font>, respectively.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">Note&#160;6&#151;Commitments and contingencies</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <b><font style="FONT-SIZE: 10pt">&#160;</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Operating Lease</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company leases its office and laboratory space under a non-cancelable operating lease which was originally scheduled to expire on March 31, 2014. In May 2010, the Company completed a sublease of 6,011 square feet of underutilized office and laboratory space and on March 31, 2014, the sublease expired. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies</font>; and, c) set an initial base rent with an escalation of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.06</font>% of base rent in year two and another <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.06</font>% in year three.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Rent expense, net of the benefit of the sublease in 2014, was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">96,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font> for the three months ended September 30, 2015 and 2014, respectively, and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">268,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">230,000</font> for the nine months ended September 30, 2015 and 2014, respectively.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Off-Balance Sheet Arrangements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Employment Agreements</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On April 6, 2015 the Company entered into an Executive Employment Agreement (the &#8220;Agreement&#8221;), pursuant to which Mark B. Carbeau was appointed as the Company&#8217;s Chief Executive Officer and a member of the Company&#8217;s Board of Directors. Effective upon Mr. Carbeau&#8217;s appointment, Dr. Kenneth S. Kornman resigned as Chief Executive Officer and remained as the Company&#8217;s President and Chief Scientific Officer.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to the Agreement, Mr. Carbeau will receive an initial annual base salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">365,000</font> per year and is eligible to receive an annual target bonus of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 35</font>% of his base salary, with a stretch bonus opportunity of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150</font>% of the target bonus. Under the terms of the Agreement, Mr. Carbeau has been granted options to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,245,227</font> shares of Interleukin&#8217;s common stock (the &#8220;Options&#8221;) at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1525</font> per share (the closing price of the common stock on April 6, 2015). The Options will vest as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of the shares on April 6, 2016, and as to an additional <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.083</font>% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Agreement provides that if Mr. Carbeau&#8217;s employment with the Company is terminated for any reason other than Cause (as defined in the Agreement) and on execution of a release of claims agreement, he will be entitled to (i) severance payments equal to 12 months of base salary and (ii) continuation of medical benefits for up to 12 months. In addition to the above, if termination is within one year following a Change of Control event and is for any reason other than Cause, all outstanding unvested equity awards held by Mr. Carbeau will immediately vest and be exercisable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On November&#160;12, 2008, the Company entered into an employment agreement with Dr.&#160;Kornman, its President and Chief Scientific Officer, for a three-year term, commencing on March&#160;31, 2009, the date his previous employment agreement expired. Effective March 31, 2012, this agreement was extended through November 30, 2012, and was extended again on November 20, 2012 through November 30, 2015. Under this agreement, Dr.&#160;Kornman received an initial annual salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">360,000</font> and is eligible to receive salary increases and/or annual bonuses solely at the discretion of the Board of Directors. Under the agreement, Dr.&#160;Kornman is entitled to participate in employee benefit plans that the Company provides or may establish for the benefit of its executive management generally. In addition, while Dr.&#160;Kornman remains employed by the Company, it will reimburse him $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,296</font> annually for payment of life insurance premiums.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The agreement is terminable immediately by the Company with cause or upon thirty days prior written notice without cause. The agreement is terminable by Dr.&#160;Kornman upon thirty days prior written notice. If the Company terminates Dr.&#160;Kornman without cause or Dr.&#160;Kornman terminates his employment with good reason, then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) twelve months. If the Company terminates Dr.&#160;Kornman in connection with a Cessation of the Company&#8217;s Business (as defined in the agreement), then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) three months. The agreement also includes non-compete and non-solicitation provisions for a period of twelve months following the termination of Dr. Kornman&#8217;s employment.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In April 2010, Dr. Kornman was issued an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.745</font> per share. The option vests as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 20</font>% of the shares on each of the first five anniversaries of the date of grant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In May 2011, Dr. Kornman was issued an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of the Company&#8217;s common stock, exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.46</font> per share. The option vests as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of the shares on each of the first four anniversaries of the date of grant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In December 2012, Dr. Kornman was issued an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000</font> shares of the Company&#8217;s common stock, exercisable at $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.34</font> per share. The option vests as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>%, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 33</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 42</font>% of the shares on each of the first three anniversaries of the date of grant.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In October 2013, Dr. Kornman was issued an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,250,000</font> shares of the Company&#8217;s common stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3799</font> per share. The option vests as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of the shares on the first anniversary of the grant date, and as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.08</font>% of the remaining shares at the end of each month thereafter beginning on October 31, 2014.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2015, Dr. Kornman was granted an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,030,000</font> shares of the Company&#8217;s common stock. This option has an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.26</font> per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 26, 2012, the Company entered into an employment agreement with Scott Snyder for the position of Chief Marketing Officer beginning on January 2, 2013. The agreement provides for a minimum annual base salary of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">265,000</font>. He is eligible for a bonus of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>% of his base salary, based on factors such as evaluation of individual performance, the Company&#8217;s financial performance, economic conditions generally, and the policy terms applicable to such bonus. Mr. Snyder is entitled to a maximum of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">34,000</font> in expense reimbursement in calendar year 2013, and an additional $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">16,000</font> for the six months ending June 30, 2014, for travel and housing expenses from his residence to Interleukin&#8217;s offices. On July 23, 2013, the Compensation Committee agreed to amend Mr. Snyder&#8217;s employment agreement and increase the aggregate amount of travel and lodging expenses that may be reimbursed to an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">60,000</font>. On August 4, 2014, the Compensation Committee agreed to amend Mr. Snyder&#8217;s employment agreement again and increase the aggregate amount of reimbursable travel and lodging expenses through December 2014 to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">80,000</font>. On January 9, 2015, the Compensation Committee agreed to amend Mr. Snyder&#8217;s employment agreement again to increase the amount of reimbursable travel and lodging expenses to include $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">40,000</font> for calendar year 2015. Upon hire, Mr. Snyder was granted an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 200,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.29</font> per share. The option vests in three installments of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,000</font>, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 66,000</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 84,000</font> shares on each of the first three anniversaries of the grant date.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In October 2013, Mr. Snyder was issued an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 675,000</font></font> shares of the Company&#8217;s common stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3799</font> per share. The option vests as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 25</font>% of the shares on the first anniversary of the grant date, and as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2.08</font>% of the remaining shares at the end of each month thereafter beginning on October 31, 2014</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In January 2015, Mr. Snyder was granted an option to purchase <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 660,000</font> shares of the Company&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.26</font> per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Mr. Snyder&#8217;s employment with the Company terminated effective November 13, 2015. The Company will pay Mr. Snyder any compensation that is earned but unpaid prior to termination, and an amount equal to six months of his base salary in effect at the time of the termination with such payment made in equal installments on the Company&#8217;s regularly-scheduled payment dates. Per Mr. Snyder&#8217;s employment agreement, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 84,000</font> unvested shares related to the 200,000 shares granted on January 2, 2013 will become fully vested.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies 360000 3296 0.25 0.0208 300000000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> Note&#160;7&#151;Capital Stock</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><strong><font style="FONT-SIZE: 10pt"> &#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Authorized Preferred and Common Stock</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of September 30, 2015, the Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font> shares of preferred stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> authorized and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000,000</font> shares of common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> authorized. On July 21, 2015, the Company&#8217;s shareholders&#8217; approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000,000</font>. As of September 30, 2015 the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 172,841,047</font> shares of common stock outstanding and the following shares of common stock are reserved for issuance:</font></div> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Strike</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>for&#160;issuance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Expiry</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Shares reserved under outstanding stock options and options available for grant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>52,311,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Shares reserved for future issuance under the Employee Stock Purchase Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>346,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with December 2014 private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,189,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.1003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>December 23, 2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with December 2014 venture loan and security agreement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,492,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.1003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>December 23, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>September 8, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in June 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>437,158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>June 29, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in May 2013, vesting May 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,655,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>May 17, 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in May 2013, vesting August 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,426,230</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>August 9, 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares reserved for issuance at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>140,958,605</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares issued and outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>172,841,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares outstanding and reserved for issuance at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>313,799,652</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On May 17, 2013, the Company entered into the 2013 Purchase Agreement with the 2013 Investors, pursuant to which the Company sold securities to the 2013 Investors in the May 2013 Private Placement. In the May 2013 Private Placement, the Company sold an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 43,715,847</font> shares of its common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2745</font> per share for gross proceeds of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">12,000,000</font>. The 2013 Investors also received the 2013 Warrants to purchase up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 32,786,885</font> shares of common stock an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2745</font> per share. The 2013 Warrants were immediately exercisable as to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 63</font>% of the shares issuable thereunder. The remaining <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 37</font>% of the shares issuable under the 2013 Warrants were to become exercisable upon an increase in the number of authorized shares of common stock. On August 9, 2013, the Company&#8217;s shareholders&#8217; approved an amendment to the Company&#8217;s Certificate of Incorporation to increase the number of authorized shares of common stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 150,000,000</font> to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000,000</font> shares, which provided for adequate authorized shares for all potential common stock equivalents issued pursuant to the May 2013 Private Placement. The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">For its services in this transaction, the placement agent received cash compensation in the amount of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">780,000</font> and the placement agent and an affiliate received warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,295,082</font> shares of common stock, at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.2745</font> per share (the &#8220;2013 Placement Agent Warrants&#8221;). The 2013 Placement Agent Warrants became exercisable on August 9, 2013, following shareholder approval of an increase in the Company&#8217;s authorized shares of common stock and expire August 9, 2020. The cash compensation and the fair value of the warrants were recorded as issuance costs resulting in a reduction to shareholders&#8217; equity.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt"> </font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="COLOR: black; FONT-SIZE: 10pt">In September, 2014,&#160;</font> <font style="FONT-SIZE: 10pt">the Company&#160;<font style="COLOR: black">issued warrants to&#160;</font> the Company&#8217;s&#160;<font style="COLOR: black">financial consultant, Danforth Advisors, to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 100,000</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.25</font> per share. The warrants have a ten year term and vest on a monthly basis over two years, provided that,</font>&#160;<font style="COLOR: black">if the Company terminates the agreement without cause before the one year anniversary, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50</font>% of the warrants immediately vest, and the remaining 50% of the warrants immediately vest if the Company terminates the agreement without cause after the extension of the agreement after one year. The warrant will also become exercisable in full upon a change of control of the Company if the agreement is still in effect. The fair value of the warrants at issuance was recorded as equity totaling $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">24,000</font> and will be amortized to consulting fees over the remaining service requirement. The non-cash compensation expense for the three and nine months ended September 30, 2015 was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font> respectively.</font></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,099,700</font> shares of common stock at a price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share for gross proceeds of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.025</font> million. The 2014 Investors also received 2014 Warrants to purchase up to an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 50,099,700</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share. The 2014 Warrants are all currently exercisable and have a term of seven years.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">For services related to this transaction, the placement agent and legal counsel received an aggregate of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">218,000</font> in cash fees and the placement agent and an affiliate received warrants to purchase an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 89,731</font> shares of common stock (the &#8220;2014 Placement Agent Warrants&#8221;). The cash fees and the fair value of the 2014 Placement Agent Warrants were recorded as equity issuance costs resulting in a reduction to shareholders&#8217; equity.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>138.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.2</font> million, and the fair value of the 2014 Placement Agent Warrants was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">9,000</font>.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Registration Rights Agreement</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Venture Loan and Security Agreement</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the &#8220;Lender&#8221;) under which the Company has borrowed $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">5.0</font> million. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates Lender Warrants to purchase a total of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,492,523</font> shares of common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1003</font> per share. The Lender Warrants have a term of ten (10) years.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> </table> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The fair value of the Lender Warrants at issuance was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">261,000</font>. Cash interest paid during the three and nine months ended September 30, 2015 totaled $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">353,000</font>, respectively. Non-cash interest related to debt discounts recorded during the three and nine months ended September 30, 2015 totaled was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">38,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">115,000</font>, respectively, with a remaining debt discount balance of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">280,000</font>.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>1.98</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>7&#160;years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>138.4</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 2px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model: <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>December&#160;23,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Risk-free interest rate</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected life</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>10 years</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Expected volatility</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>121.6</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="86%"> <div>Dividend yield</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="2%"> <div>%</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> P7Y 0.0217 1.216 0 P10Y 5200000 9000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">Note&#160;8&#151;Stock-Based Compensation Arrangements</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <strong><font style="FONT-SIZE: 10pt">&#160;</font></strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Total stock-based compensation is as&#160;follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock option grants beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>251,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>108,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>491,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>348,545</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock-based arrangements during the period:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock option grants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>157,463</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock issued:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Employee stock purchase plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,088</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>252,554</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>109,642</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>651,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>354,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">Stock option and restricted stock grants</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The following table details stock option activity:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>Nine&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>Nine&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>September&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>September&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted&#160;Avg</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted&#160;Avg</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Outstanding, beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,523,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5,884,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,793,027</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>137,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Restricted stock exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Canceled/Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(58,268)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(1,210,375)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Outstanding, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>22,258,659</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,810,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Exercisable, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>3,067,959</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>0.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>723,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35.3pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35.3pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; At September 30, 2015, there was approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2,700,000</font> of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company&#8217;s stock plans.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Restricted Stock Awards</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">At September 30, 2015 and 2014, there were no outstanding restricted stock awards.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Stock Option Grants</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">On August 9, 2013, the Company&#8217;s shareholders&#8217; approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the &#8220;2013 Plan&#8221;). The 2013 Plan allows for the issuance of up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 8,860,000</font> additional shares of our common stock pursuant to awards granted under the 2013 Plan. Additionally, the 2013 plan allows for the issuance of up to a maximum of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,435,500</font> additional shares of our common stock, pursuant to the cancellation, forfeiture, or expiry, of awards granted under the 2004 Plan and terminated on or after the 2013 plan approval on August 9, 2013. During the nine month period ended September 30, 2015, the Company granted <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,170,748</font> stock options under the 2013 Plan. On July 21, 2015, the Company&#8217;s stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available for issuance thereunder by <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,000,000</font> shares. At September 30, 2015, the Company had an aggregate of <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30,052,620</font> shares of common stock available for grant under the 2013 Plan.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Pursuant to his Employment Agreement on April 6, 2015, Mr. Carbeau was granted options to purchase up to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14,245,227</font> shares of Interleukin&#8217;s common stock at an exercise price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.1525</font> per share (the closing price of the common stock on April 6, 2015). Of those options, <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 2,622,948</font> were granted under the 2013 Plan and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 11,622,279</font> were granted outside of the 2013 Plan. <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">It is the Company&#8217;s policy to grant stock options with an exercise price equal to the fair market value of the Company&#8217;s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company&#8217;s stock options have been granted in connection with the employee&#8217;s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 35pt; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Employee Stock Purchase Plan</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Purchases made under the Company&#8217;s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 85</font>% of the fair market value of the Company&#8217;s common stock on either the first day or the last day of a calendar quarter, whichever is lower. During the nine months ended September 30, 2015 and 2014, employees purchased <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 157,705</font> and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 99,585</font> shares, respectively, of common stock at a weighted-average purchase price of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.10</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.28</font>, respectively, while the weighted-average market value was $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.12</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.32</font> per share, respectively, resulting in compensation expense of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3,129</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">4,730</font>, respectively.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Total stock-based compensation is as&#160;follows:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Three&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="23%" colspan="5"> <div>Nine&#160;Months&#160;Ended&#160;September&#160;30,</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock option grants beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>251,374</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>108,363</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>491,197</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>348,545</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock-based arrangements during the period:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Stock option grants</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>92</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>157,463</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,166</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Restricted stock issued:</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 20px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>Employee stock purchase plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,088</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>1,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>3,129</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>4,730</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="51%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>252,554</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>109,642</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>651,789</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>354,441</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">The following table details stock option activity:</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="BORDER-BOTTOM: 0px solid; BORDER-LEFT: 0px solid; MARGIN: 0in 0in 0in 0.5in; WIDTH: 85%; BORDER-COLLAPSE: collapse; OVERFLOW: visible; BORDER-TOP: 0px solid; BORDER-RIGHT: 0px solid" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>Nine&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>Nine&#160;Months&#160;Ended</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>September&#160;30,&#160;2015</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="21%" colspan="5"> <div>September&#160;30,&#160;2014</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted&#160;Avg</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Weighted&#160;Avg</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Exercise</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Shares</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="10%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Outstanding, beginning of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,523,900</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.39</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>5,884,050</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options granted</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>17,793,027</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.17</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>137,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.35</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Stock options exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Restricted stock exercised</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>&#151;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.00</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 10px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Canceled/Expired</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(58,268)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.28</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>(1,210,375)</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Outstanding, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>22,258,659</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.22</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>4,810,675</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="9%"> <div>0.43</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="40%"> <div>Exercisable, end of period</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>3,067,959</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>0.34</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>723,925</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 3px double; FONT-WEIGHT: 400" width="9%"> <div>0.71</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt"> Note&#160;9&#151;Industry Risk and Concentration</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company develops genetic risk assessment tests and performs research for its own benefit. As of September 30, 2015, the Company sells five genetic risk assessment tests. Commercial success of the Company&#8217;s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">During the three months ended September 30, 2015 and 2014, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 45</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 48</font>%, respectively, of the Company&#8217;s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 14</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 30</font>%, respectively, of the Company&#8217;s revenue came from sales through ABG&#8217;s promotional product bundle program. During the nine months ended September 30, 2015 and 2014, approximately <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 49</font>% and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 41</font>%, respectively, of the Company&#8217;s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 15</font>% and 35%, respectively, of the Company&#8217;s revenue came from sales through ABG&#8217;s promotional product bundle program.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;size: 8.5in 11.0in"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><b><font style="FONT-SIZE: 10pt">Note&#160;10&#151;Subsequent Events</font></b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;CLEAR: both"> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">On November 13, 2015, the employment of Mr. Scott Snyder, formerly Chief Marketing Officer</font></font></font>, terminated. Details of this event are disclosed in Note 6.</font></div> </div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>Revenue Recognition</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.9</font> million and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">3.2</font> million, respectively. Included in deferred revenue at September 30, 2015 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.7</font> million for test kits that are still outstanding one year or longer after initial kit sale, of which $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.3</font> million was sold directly to consumers (credit card payments) and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">2.4</font> million was sold to distributors for the promotional bundle. Beginning in September 2012 and again in 2013, Access Business Group LLC (&#8220;ABG&#8221;), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs).</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">39,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">167,000</font>, respectively, of breakage revenue related to unredeemed genetic test kits sold in the first, second and third quarters of 2012, compared to breakage revenue included in genetic test revenue in the three and nine months ended September 30, 2014 of $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">86,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">242,000</font>, respectively, related to unredeemed genetic test kits sold in the first, second and third quarters of 2011. The Company expects to continue to recognize breakage revenue on a quarterly basis based on the historical analysis.</font></div> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 84000 The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date. 19500 7 years 7 years 300000000 675000 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt">Income Taxes</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt" align="justify"><i><font style="FONT-SIZE: 10pt"> &#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> </font>The Company accounts for income taxes in accordance with FASB ASC 740, <i>Income Taxes</i>, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">Significant management judgment is required in determining the Company&#8217;s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management&#8217;s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">As a result of the Company&#8217;s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company&#8217;s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company&#8217;s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder&#8217;s conversion of debt of approximately $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">14.3</font> million into common stock of the Company prior to an additional investment by an unrelated investor.</font></div> <font style="FONT-SIZE: 10pt">&#160;</font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> 0.35 252554 109642 651789 354441 <div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"></font> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt"> <font style="FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font>As of September 30, 2015, the Company has <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 6,000,000</font> shares of preferred stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> authorized and <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 450,000,000</font> shares of common stock, par value $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">0.001</font> authorized. On July 21, 2015, the Company&#8217;s shareholders&#8217; approved an amendment to the Company&#8217;s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 300,000,000</font> to 450,000,000. As of September 30, 2015 the Company had <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> 172,841,047</font> shares of common stock outstanding and the following shares of common stock are reserved for issuance:</font></div> <i><font style="FONT-SIZE: 10pt">&#160;</font></i></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt; TEXT-INDENT: 0in; WIDTH: 100%"> <table style="MARGIN: 0in; WIDTH: 100%; BORDER-COLLAPSE: collapse; OVERFLOW: visible" cellspacing="0" cellpadding="0"> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Reserved</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Strike</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>for&#160;issuance</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="11%" colspan="2"> <div>Price</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="white-space:nowrap; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 700" width="15%"> <div>Expiry</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="11%" colspan="2"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Shares reserved under outstanding stock options and options available for grant</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>52,311,279</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Shares reserved for future issuance under the Employee Stock Purchase Plan</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>346,247</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with December 2014 private placement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>50,189,431</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.1003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>December 23, 2021</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with December 2014 venture loan and security agreement</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>2,492,523</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.1003</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>December 23, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>100,000</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2500</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>September 8, 2024</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in June 2012</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>437,158</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>June 29, 2017</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in May 2013, vesting May 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>20,655,737</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>May 17, 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Outstanding warrants issued in May 2013, vesting August 2013</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>14,426,230</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>$</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>0.2745</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; PADDING-LEFT: 26px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>August 9, 2020</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares reserved for issuance at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 400" width="10%"> <div>140,958,605</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares issued and outstanding at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>172,841,047</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #ffffff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> <tr style="HEIGHT: 12px"> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="59%"> <div>Total common shares outstanding and reserved for issuance at September 30, 2015</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; PADDING-RIGHT: 4px; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; BORDER-TOP: #000000 1px solid; FONT-WEIGHT: 700" width="10%"> <div>313,799,652</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: right; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="10%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: center; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: bottom; FONT-WEIGHT: 400" width="15%"> <div>&#160;</div> </td> <td style="TEXT-ALIGN: left; FONT-STYLE: normal; FONT-FAMILY: times new roman; BACKGROUND: #cceeff; COLOR: #000000; FONT-SIZE: 10pt; VERTICAL-ALIGN: middle; FONT-WEIGHT: 400" width="1%"> <div>&#160;</div> </td> </tr> </table> </div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> EX-101.SCH 6 iliu-20150930.xsd XBRL TAXONOMY EXTENSION SCHEMA 101 - Document - Document And Entity Information link:presentationLink link:definitionLink link:calculationLink 102 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:definitionLink link:calculationLink 103 - Statement - CONDENSED BALANCE SHEETS [Parenthetical] link:presentationLink link:definitionLink link:calculationLink 104 - Statement - CONDENSED STATEMENTS OF OPERATIONS link:presentationLink link:definitionLink link:calculationLink 105 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY link:presentationLink link:definitionLink link:calculationLink 106 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:definitionLink link:calculationLink 107 - Disclosure - Basis of Presentation link:presentationLink link:definitionLink link:calculationLink 108 - Disclosure - Liquidity link:presentationLink link:definitionLink link:calculationLink 109 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:definitionLink link:calculationLink 110 - Disclosure - Related Party Transactions link:presentationLink link:definitionLink link:calculationLink 111 - Disclosure - Debt Instruments link:presentationLink link:definitionLink link:calculationLink 112 - Disclosure - Commitments and contingencies link:presentationLink link:definitionLink link:calculationLink 113 - Disclosure - Capital Stock link:presentationLink link:definitionLink link:calculationLink 114 - Disclosure - Stock-Based Compensation Arrangements link:presentationLink link:definitionLink link:calculationLink 115 - Disclosure - Industry Risk and Concentration link:presentationLink link:definitionLink link:calculationLink 116 - Disclosure - Subsequent Events link:presentationLink link:definitionLink link:calculationLink 117 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:definitionLink link:calculationLink 118 - Disclosure - Summary of Significant Accounting Policies (Tables) link:presentationLink link:definitionLink link:calculationLink 119 - Disclosure - Capital Stock (Tables) link:presentationLink link:definitionLink link:calculationLink 120 - Disclosure - Stock-Based Compensation Arrangements (Tables) link:presentationLink link:definitionLink link:calculationLink 121 - Statement - Liquidity - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 122 - Disclosure - Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) link:presentationLink link:definitionLink link:calculationLink 123 - Disclosure - Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) link:presentationLink link:definitionLink link:calculationLink 124 - Disclosure - Summary of Significant Accounting Policies- Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 125 - Disclosure - Related Party Transactions - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 126 - Disclosure - Debt Instruments - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 127 - Disclosure - Commitments and contingencies - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 128 - Disclosure - Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail) link:presentationLink link:definitionLink link:calculationLink 129 - Disclosure - Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail) link:presentationLink link:definitionLink link:calculationLink 130 - Disclosure - Capital Stock - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 131 - Disclosure - Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) link:presentationLink link:definitionLink link:calculationLink 132 - Disclosure - Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) link:presentationLink link:definitionLink link:calculationLink 133 - Disclosure - Stock-Based Compensation Arrangements - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink 134 - Disclosure - Industry Risk and Concentration - Additional Information (Detail) link:presentationLink link:definitionLink link:calculationLink EX-101.CAL 7 iliu-20150930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 iliu-20150930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 iliu-20150930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE EX-101.PRE 10 iliu-20150930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0````(`-V3;$>0&ZUDM`$``(L6```3````6T-O;G1E;G1?5'EP97-= M+GAM;,V8RV[",!!%?P5E6Q%CIZ4/`9O2;8O4_H";3(A%'%NV"?#WM0-4;916 MT!)I-GEPQW-O,LY9,'G;:;"#K2PK.XT*Y_0#(38M0'(;*PV55W)E)'?^UBR) MYNF*+X&PT6A,4E4YJ-S0A1[1;/)2@S$B@\'C7@B]IQ'7NA0I=T)5I*ZR5M>A MRG.10J;2M?1+8N>MXM2[%````*P(```L```!?.0Q(OW[CMB`PD.MQ-*O>X^NO`ZIK`XTHO8<4M?' M5$Q^#*G*_=ITJK$"2+8CCVG!D4*>-BP>-9?20D0[8$NP+,L5R*V.V:SGVL7. MU49V[M,41Y26M#;3"&>6X9MY6&3I//B)]!=C;IK>TI;MR5/0!_ZS#0//>997 M'L=V+YRO+0O]C^AY%.!)T:'B1?4C9@,2[2F]@OIZ`(4QOCLEFI2"(S>C@KN_ MV/P"4$L#!!0````(`-V3;$=+^1`9A`$``(,5```:````>&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'/%V$MN@S`0QO&K1!R@9L9Y*\FJFVS;7L`B$T`)#]FN MVMR^E$5%'QYU$>G;@`!I_-_PD^5=&_+MDUQ=K+LV5'4?9N_-M0W;X?T^JV+L MM\:$HI+&A8>NEW;X>NY\X^+PZ$O3N^+B2C&^O\)50B,9CQ1@_#`L/G6R__6;X[G^M"'KOBM9$V_E%AOA;(3#J( MTT$,";+I(`L)FJ>#YI"@13IH`0E:IH.6D*!5.F@%"5JG@]:0H$TZ:`,)HER1 M,<C-&; M%;T9HSC-&;ZOH;3%Z6T5OB]';*GI;T%F)=EB"T=LJ>EN,WG:B=ZBW4HT=QP(``.`)```0````9&]C4')O<',O87!P+GAM;+U6 M46_:,!#^*U:>-FDT%-`V(1HI#:E`HX!(UCU.QG'`(K%3VT%EOW[GI+#0!DIX M&"^YG+_OSO?=V6'`5;L_ER*C4C.JT$N:<-4'YYVUUCKKV[8B:YIB=0,0#JNQ MD"G6\"I7MHAC1NA0D#RE7-N==ONK35\TY1&-6MDAJ.4,3!8WRQ)&L&:".X^, M2*%$K)'_0F@RL-\""@9$#BC))=,[IUUBJJX"$Q"<4`]R.3%.%"U1_YP%QA-I MAOG.+M\FC&_4SRP40ZQIE76\4$9?8TDC2'H4_>`L,*,=U)D8KK?&?$6C*O;] MXEZ+)RJ5J?2V<].&WT&"O;^,37'$^&J.F53.8*O[6TJTD*]MVNIKNQ0)8IJN MGD+8G[+0$BMJS#MKBR7#7%M(L3_PVK'*M*6WL)-,:>G\$G*CUI1J-;`/SL*L M8JLVZSG=7H$`ZQAI'RIS7F4[JMMX0J83JF;Q'$O]GZ0H:MH+T>U9E>KW(9#+ M(^1S#>.(QKQ,!IC4/0-G3.,$!5J037UM9J4% M2L%>S95%89]FF\B5L.=5+6?,HQR>.[1@:E/LQ!. MK/"LTK??KN!\_U@7]"G$2SCGGYL+U&F?'R?40FX$!N`AV_ZP-B^CT[F"T[V" MTVLXS$6!%TWT&RF:#SAJ7=)*-]=K(>'VC+Z@L5+Y)9S[!,,C(&L!4X!2<0'G M75^;ST[W]@K.B3DXRZF?@[.'N'LT!^^^E&^^B_;Q_SGG+U!+`P04````"`#= MDVQ'X8#HO#X!``!I`P``$0```&1O8U!R;W!S+V-O&ULS9--3\,P#(;_ M"NJ]2[,QA**N!T".%K?X:7H\6[GZP23@D`-&@P&0D>49-6KV1K; MF)(,^JJ,CFL><&ZE6BF0=^U0]CL5.R-X'8YRD'W[]/=/#RE#LJYR'U1?U33- MJ)FDNC@P)>_SIY=T-KDR`;D1$%5!,6P=S+)3Y[?)_#EH$Z8+ML6VL9Z&:ITOX;H\'+BRM;6M\?4C^CL555?4$L#!!0` M```(`-V3;$>97)PC$`8``)PG```3````>&PO=&AE;64O=&AE;64Q+GAM;.U: M6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?A1%8C6QY9)&$?[]'-A#+ ME@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@V2_;UKNW+][@5S(D$4$P M&:>O\,`*I4Q>M5II`,,X?+&A`T%116F]?(+3E'S/X%/F7/ MZ3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1TDB`@LE]E`6Z2?:CTQ4( M,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP'`3@4;N>PIWT;+^D00FT MHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG`J-6T_3:W?=TXZ)QJW0>`V^\4^'PZZ) MQJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@`%AP=M;,T@.67BGZ=90:V1V[ MW4%<\%CN.8D1_L;%!-9ITAF6-$9RG9`%#@`WQ-%,4'RO0;:*X,*2TER0UL\I MM5`:")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']IJP&G[;N;SY/\<^CDGZ>3 MUTU"SG"\+`GQ^R-;88C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZY!$XM4D-,A,_")V&F&I0 M'`*D"3&6H8;XM,:L$>`3?;>^",C?C8CWJV^:/5>A6$G:A/@01AKBG'/F<]%L M^P>E1M'V5;SOX%^9PU M"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:CFED)O816:I^JAS0^J!XR M"@7QN1X^Y7IX"C>6QKQ0KH)[`?_1VC?"J_B"P#E_+GW/I>^Y]#VATK\>WZV22$KYI9 M+2,6D$N!LT$DN/R+RO`JQ`GH9%LE"0AMNZ5/U2I77Y:^Y*+@\ M6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KTL@ M'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K34I!OP_GIQ7@:XCG9!+E] MF%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'>7M?F&>5QE`T%&ULK"0L M1K=@N-?Q+!3@9&`MH`>#KU$"\E)58#%;Q@,KD*)\3(Q%Z'#GEUQ?X]&2X]NF M9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^:CVT%4[/_EFMR)\,$4X6 M"Q)(8Y07IDJB\QE3ON>;G*YZ(G;ZEW?!8/+]<,E'#^4[YU_T74.N M?O;=X_INDSM(3)QYQ1$!=$4"(Y4U#VT%SU& M\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83+$.D?L%]BHJ`$:MBOKJO M3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'?!^2!F.,6_0T7X\48JVF ML:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5`Y3_;U`UH]@TT')$%7C&9 MMC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%`````@`W9-L1QNGL#Q:`@``=`L` M``T```!X;"]S='EL97,N>&ULS59=:]LP%/TK0AVCA1';Z9JVJVT8A M17"N5/G-\ZITCAFJ1J+$7*_D0C*D]%067E5*C++*!#'JC7U_XC%$.(Q#7K,I M4Q5(1S,__YXFZ(G]N%"P@211)!O_V]/5W2L]O!;(]0NKD]#<1AB93"DD_U!+3V;%GJS7'! ML1-I_79X%Q(M@_'56H`==-Y$R`S++G,`5U`<4IPK'2!),3>C$J61+I023!L9 M087@B!K*541K:-H44_ID/L3?^09WDP/G8^[8A\"H6)GZ(%JS+P-[J-XZF^-> MIQT?Q`N:O$N@HU%9TN5W2@K.L!/KH*EH9[OH@RWT<8A6K&`N)'G1_J804@U@ M"<$"2T72=>2O1.4,-ZJM8*_)MRD\=,OOJ>GXI]:KT27XT<=S<'(+/=0LP7)J M_QSWEW1YO?O*[-<)!S(_MFH.D'"$PS%]\V2E34Y7VOO4U%&DW9RJM,O;_U3F MM3UKK3%NM,4.!4E-J")\)0&9A\R#D4TW.E;?$C5GUO3=T*XJE.@G\$8639;A M'-54/9*%4'8Q@KW]T\@/)IW7K*.(8&__PAFIV:U5T+^SXW]02P,$%`````@` MW9-L1RHE:(ZM`P``]@L```\```!X;"]W;W)K8F]O:RYX;6R-EFUSVC@0@/^* MQI_N9BX'EH&D3.F,`\Z%:0J9V-/[>"-L$321)2K)2=-??RL3VC7H?/F$W_:1 MM'JT[$<[?='F::/U$_E>2V6G9A;MG-M/!P-;[GC-[)]ZSQ6\VVI3,P>WYG&@ MMUM1\H4NFYHK-Z##X61@N&1.:&5W8F^C-YI]#\WN#6>5W7'N:GF`U4RHZ--' M.]T*R;]R8P%,V'Z_8C6?1=]E1"2S+JN$X]4L&L&M?N&=!Z;97S="^IOQ+@?X! M8:43S[Q@FUDTC`AKG+X1TG&S8([_972S%^H16!'9"F-=[I?;?ED+)6KQP\\; M[NQ.O]QJ(WYHY9C,2Z.E;*/\BS8(1K`_G\`?`[,8LF0P`^"RLV M0@KW.HO::\G]2@8G2VG3_^N*J#8YQRTFJ:I(IAQ0R%(=-@]2X^<`'R^K=F`S M%7!AEE5\2!4&S=>K1;;*LP6Y3N_2U3PC^6V6%3DB4$2@[R>0?^Z9X7@J"0(E M?:"\2(OL2[8"R/J&K.^SA[18(M`(@4;O!^7%>O[Y=HU`8P0:OQ\T3_-; M_9BY>%0"Z@+SNI2E;D`7!/J`0!_.00^^?/"*P&:"8X5AROH#!?4$2S;$E@W/ M*0N^<2"H=:;5MA/;,32DJ*YKX=HPPD#W$DX@'%FN2L$[("QJ'#*5[06<79([ M73[A0"QF'#"S#;B`380\P&R@4MIV!TEJ(!^/&(75C`-N+E750!9>R8.P3^UR MYEJ5L#9S=G"QG''`SKS96/ZM\54@>SY-*A8R#AC9ZT=\B5%8SCA@9S_J"J.P MM''`VLX.D=^@HDIN?\<$;&L)-GD8A;6F`:U/ M2\5)]C$*2TX#DO=6#G*!45AR&I#\Q,RT<3O?#/#J#[*TML$H+#G]?\FO)8.? MO-QI<)W4&J.P[31@>Q=UIBG^[\6V)P';>P].$F,4MCT)V=Z+PK8GV/8D9'LO M"MN>=+J+@.V]E3?!MB?8]F3TUI7]:L2@%Q6*5[Y-M>TPT.>5OG>%G\,?T6CL M"Y6__P+]["SR32?TEXV4:M:W9@7SL5C_]"U!+`P04````"`#=DVQ' M(69[1AZC*AKPRCS_J&K-_1U+1;N]#?^AX*^^%4!T@S\#H MNY8U:7A)&X^1V]X_P-T)1DJB%;]+TG'KVU/)GRE]5XV?U[T?J!Q(12Y"A<#R M]20G4E4JDB3_[8-^,I71_AZB?]?#E>F?,2-F]`O0&-!I1\:0A[0S@: MS-0!DYD>USS@)LQ689D#B`Q+)O9P&V`@;+A-0AI+8?3A&Q01A)8Y8Y@/$R M9.-`-C;$V2F)@4PD*[;*UD%L;7\T.U43R8I1P,!AJ-+Q&2&9G:Q>T_0+$J9) MM%V!@BYJ12[/,)YS?81(-6[#`8NA3[&",X3YEHT`J*>]BA M?991.+W#O0M]-,(4V;%WO.$.2%?I3WF> MM?A.?F%V+QONG:F0M5X7YANE@LA<@A>94R'OX+%1D9M0GZE*UMQ*IB%H.URR MXTV?_P=02P,$%`````@`W9-L1X3\BS30`P``+Q```!@```!X;"]W;W)K$3%>ZR82Y7\X/T\?R:PO=?.]/7C?)3^J\M0^KPY==WY* MT_;UX*NB_5R?_2G\LJ^;JNA"L7E+VW/CB]T05)4I"F'2JCB>5IOU\.UKLUG7 M[UUY//FO3=*^5U71_+?U97UY7L'J^N';\>W0]1_2S3J]Q>V.E3^UQ_J4-'[_ MO/H"3SF:7C(H_C[Z2TO>D][\2UU_[PM_[IY7HO?@2__:]544X?'AZ;(>_R>M[V]75-6255,6/\7D\#<_+^(L34Q@?@%,`W@)`_3)`3@$R"DA' M9T.[?BNZ8K-NZDO2GHM^M.$IR)N^DE!ST@ZU-6-WA9:UX>O'!M4Z_>CKF20X M2+8S":?(9PI]DZ0A/VL"KR;&XA>D\>9QO+S&JS%>TG@[MVC'1HR2TR`Q:(51 MBM/E5`>@C''"/C:D(D.*&G+S1'HTI$@B)8R0G"JG*I2:F+[K14=>-/62L5XT MR:*ET*P5*@(E0#ZV8B(KAEB1@K5B:!:=B8SOEYG,@K8+9IV-W%CJ!E@W=M8Q M8/BQS&.959*ZU=T#T@(CL]DG_Z4:R?23.U7%J-?`?-=9FV9L'T`8@=4>Q) M=M%L)\V8*:FTQCN+ M8Z:32N*2#11BL@)%J^+1"A2:F*&V>&;S2"B=@07[,\2@!4I:%1%K M.KX`9:BSRD$\=M/Y)1)J@6:!)XQIBY2V\5%IU&SG&LUI\GN:^TX@X@=2RJH% MAT.,L8@4BXH_'N*,=A8=/PYYK#-NB:/XO(J4B8HG&LY.HFA`6&/XM1%)M9)* MN07',XQ)BY2TBN<:4H)^`@S;@G:"74EYK`61"0FXP%E,7*3$U3S?D)+TDU,! MN3S?<(YF,$XOV`4P9BY2YFK@YQ5%*;O=7B?6[$3+;[BL\E(UP$``"P%```8````>&PO=V]R:W-H965T&ULC93+CILP&(5?!?$`L0$[B2*"U*$:M8M*HUFT:R>8@,;&C.V$ MZ=O7%Z`.(NVPP!?..?]G,,X'(=]40ZF./CCKU#%NM.X/`*AS0SE1&]'3SCRI MA>1$FZ&\`-5+2BIGX@RD$&X!)VT7%[F;>Y%%+JZ:M1U]D9&Z&TOC;83H,C![*M:3CO5BBZ2M#[&7Y)#B:W""7ZV=%!!/[+L)R'>[.![ M=8RA1:",GK5-(*:YT9(R9H-,X?S*WK*]&DR*48(M43^[&3@Y%+&V*2(^72I']=9F7*S-X*G.;@ M9G-&2>HD3Z%D55'>*?`L`:;^*D0Z02`/D880V7V)O8?PDLY)X`;"9$U5/E8] M9,D6+%G(@NZK8,^2!540AOY:4Y:A,H-+Y4,FM&!"(1->94)!I627[E$"T6Z5 M::'<[K,,I?]GP@LF'#)M5YGPIYGP)YA`L+%[&PO=V]R:W-H965T&ULC9A-_/ZSCN7@YE772/S;D\F7]>F[8N>O/8 MOL7=N2V+_=6HKF)*2!+7Q?&TVFZN;=_;[:9Y[ZOCJ?S>1MU[71?MOVE9-9>G M%:QN#3^.;X=^:(BWF_ANMS_6Y:D[-J>H+5^?5M]@O:-L0*[$7\?RTCF_HV'P MSTWS]7_:"Z_EU:#&!R^-%5W_8Q>WKN^J6\FJZ@N M?HW?Q]/U^S+^([DUPPVH-:!W@WL_N`&S!NS3X/][X-:`+^U!6`,1]!"/VJ\S MEQ=]L=VTS27JSL6PGF!M\'9P8CQ'W=5;.P;$S%UG6C^V0F[BC\&/1>@523U$ M84CN(G`G8M,_.@BZ\GN@CCG%.LA<0FAT#+-.=A-.)H?);L-DXUPQQSXA\_;\ M9L]'>^[:@S]$.<[$B)Q&$5PIR3`L(\SBP6!G1>G0S425<=1]5)+R(,6(*J\S"A MA$0G(7?!RJ!X:%3WG"8"#>F%>=B M2@NJ46TNQS@-0=THV<>1IG`3^CH8Z$Z-^GBJR6UC%6GN"#XC&<^*(84A'K,/5"8]:?9Q$+U0'-6)TL*"P@K M`W!+`XF>]BFX:?H!U)`_\(,X(+F0B43W=^Z30DA32N"YQB>YV26<+\@V(()C M"]PZ02[Q$*9C:*E M9DO>T<)Z@;KU`GZ>I)3,[KMY))]'=A/(M)JP-J!N;1!6JO9EC,)LW.S[F$^B M<;.O9#Z)QLV^E?GD\KB%]0%UZP,9[`1ME;JI^H$\ADE`6YF+L/P+QC!L]P7C M"]2%]0%UZP.%UP?42_N2*@Z$HPLX\U%*!5=4X[5LZ%4J116Z67=?O)K,+<-8 MQL[%35VV;]PCH#I#V']6Z\=/MTO]V< MB[?RSZ)].YZZZ+GI^Z:^W@V]-DU?FK&31Z/A4!;[^T-5OO;#3SF(&Z_>QH>^ M.=]N$N_7F=O_`%!+`P04````"`#=DVQ'2S#!+P`$```4$@``&````'AL+W=O M7ZGEQ MJNOK4QQ7KR>3I]67XFHN]I=C4>9I;2_+M[BZEB8]M$%Y%E-"9)RGY\MBO6KO M?2W7J^*]SLX7\[6,JO<\3\M_-R8K;L\+6`PWOIW?3G5S(UZOXGO`#M`^@]`.C#`-8' ML'L`?1S`^P!^#V#R88#H`\1G!=WVLN/>=FZ7UNEZ51:WJ+JFS7R")PLOFR0V M5?;NQSJ!5?S1Y.DAM(5L/`C%(%L/PC#(SH-P#++W(.(.B2T- ME`L=N/"."W7CI5]"=5PZR*6%""H8I13#;5T<4,JYQF`[#P8Z2013@"'W+G() MP)7@0B?3'%G`D;D22K!*&^Z2XE(KS5#V6Q=( ML%2[2<3^8;%15F)@Q3I6PNW?C/[+H"O2C==H5Z0S4*J$4&A+7!000)OB9^)" MHHV1:.M&&:F`D7(8:;3U6^54T%K,69M)4"5QJZ!L-XE3A0G..3Z7DLFY-)6H M[QN>:)21#AAIEQ%%&6FW;TS1<,+TC+2_8(7`:?DP0J6B$EV7>^V+C>96ZJB> MI@@DX-@X[2=)ADZ.'O,Y?)Y0IQ_CQ2`L!@_TN^]HCYD6<`^(*7C?5!^'2WC? M50_Z?S0<0J,".JWB\(L%S9-Q"!T#V+20@^L9DI'F;T:IT#+`]0S-\5*NCG,! M,AD12`\(S5Q'I\3.Q]GIQVRKT*FZ]Z!+H$`T83!GKHJ0J>LC6N!/4(0$&.-S MBH6>`W+&$W1=8"F)U;U0S(>^XG[AM702LG]<;YS;W7UZ/P;7?N88,H3.`IZU MC,B&J_5+!62$]SAL?#RA+X!G#.CBWH"GY9!P]*'N'L#&7XI##:>NAH^\LE!/ MPZ72N%'YL'#=]H,.N/>@\WH,PWM@KIV,?+B0L$?L")SMA6_["M:&N7$L!*L0-+:23JV\RU=!!/-4XK]`9J.L,.L'&NZ&N,RP3^R81JMU`C/EJ MEW"&X78^CDH@RLX1?,_$?+E65MT3,D-!:6A,U#,F=`UL*0\)`.&AX<;.[OJ: MOIF_TO+M?*FBEZ*V&_5V5WTLBMK8A.2+37PRZ>%^D9ECW9RJIF+WT:*[J(OK M\`WF_B%H_1]02P,$%`````@`W9-L1_J"Q/'P`P``]1```!@```!X;"]W;W)K MTTG3H*&0P9(9_;MUQQ"N[R.VMJ;$,A?Y;]L\T%E^ M==M->QVJLM'?NJB_UG71_;/357M[B6E\O_"]/)V'\4*RW21KW*&L==.7;1-U M^O@2O]+G'-0HF11_E?K66]^CT?Q;V_X83_XXO,1D]*`KO1_&%(4YO.M<5]68 MR8S\88:'^_9_]M*M?8?RMZG;?5W^5A.!NW)(X.^EA_M=+S7P M,>&^K?KI,]I?^Z&M[R%Q5!>_YF/93,?;_(N$).M,;)S$"9UXVM(I\;R1PCF65$4:^/S!I! M<"K]LMR6F>W`6,`R*V>9%9H6_GD"2IQZ1E19*82WHD6T3*U\,+-(]<05B``_ MU/6#B2+]?J@]$I7$NNN1(UO'E%*9#+`$KB6;+ZEWC^\6S;+)@67@-V3+(#6Z M`#^IZP?SRKL8NT6T3!$(11Y,D:VCE).@7>0"D-H$3!\XLLDF`#(O5'(D>^*I MY"+@QJ#<=603,/76OELT]]J!2"]8S MA(22`X10E;I8I9BK#Z9)HA6A@F76)D&ND))E,J5!B[="=L$:M2E+:0"FJ7(K M0VBD?E(OHKM?0U`O;W*L4P`RX+X%%[6`4$N]A-@!";.$=:&6J#/1@&A+TX`4 M+AT!4`K_HQD`;=?_O"G>B[)E`:L.+AH!H9%Z=^D.$/*$5'XR(AE(S@.>'>"" M$1@RY'^\@HT\)1[Y8?_#CXM%0"^&U/]X!8YO>"6H\&,(*YE*998%<`A<-@)Z MW:3^!PB@%TG*A,C\[P-2\,"-O-2#MR]9Y=^!>E<-XG53=:Z.TU==A_M MVVLSS)W>>G7MY%^G?M>YOC,=_MR/?Z39;B[%2?]9=*>RZ:.W=C"][M28'MMV MT,8;^6*F_JR+PWI2Z>,P?I7CFLQ=^7PRM)?[GPSK/QW;?P%02P,$%`````@` MW9-L1P7.@HB?`0``L0,``!@```!X;"]W;W)K&<,V=\*2#B!QVM,-70I/HNM=*+"J9"NO M$0JT%:B)@79/[S:[0Q$0$?!7P&3/8A*\'Q&?0_*[V=,L6``)M0L*W"\GN`F\TH::#EHW1/./V">83K(%BC MM/%+ZM$Z5`N%$L5?TRIT7*?TYS:;:5\3\IF0?R*PU"C:_,D=KTJ#$[$##V>W MV7FX"2)>F=BH9M+TWJCUU5.UR?.2G8+0C$F4PP5F13"O_F6+G%[2\S-Z_CU] MN]"WR>'VPN'V>X%B$2B20/&_$1/F<(DI/C5A9WNJP'3QZEA2XZA=VM*UNM[. MNSR>R0>\*@?>P1]N.J$M.:+S)QN/H45TX$UD5]>4]/[]K(F$UH7PQL&PO=V]R M:W-H965T&ULA5/+;MLP$/P5@A\0RK2=%(8L($X1M(<"00[M MF996$A&2JY"4E?Y]^;`4.PB:B[B[FIF=Y:.^V''F*M[ MT,+=X``F_&G1:N%#:COF!@NB222M&"^*6Z:%-+0J4^W)5B6.7DD#3Y:X46MA M_QY`X;2G*SH7GF77^UA@5QK/Z8YHVN#\*!P^H_LC& M]\%L04D#K1B5?\;I!YQ'V$;!&I5+7U*/SJ.>*91H\997:=(ZY3]\IGU.X&<" M7PC?BF0\-THVOPLOJM+B1-P@XMFM=@%NHTA0)BZIV3Q],.I"]52M^+9DIRAT MQF3*X0JS(%A0_[0%I]=T?D'G7]/7,WV=':ZO'-Y^+;"9!3998/._$3/F<(VY M^]"$7>RI!MNEJ^-(C:/Q>4N7ZG([[WDZDW=X50ZB@U_"=M(X!SF![*\TNH?4$L#!!0````(`-V3;$>8 MFE*@HP$``+$#```8````>&PO=V]R:W-H965T&ULA5/;;IPP M$/T5RQ\0LT#:=,4B95-5[4.E*`_MLQ<&L&)[J&V6]._K"Y#=*&I>\,QPSIDS MOE0SFF<[`#CRHJ2V!SHX-^X9L\T`BML;'$'[/QT:Q9U/3<_L:("WD:0DR[/L M$U-<:%I7L?9HZ@HG)X6&1T/LI!0W?X\@<3[0'5T+3Z(?7"BPNF(;KQ4*M!6H MB8'N0.]W^V,9$!'P2\!L+V(2O)\0GT/RHSW0+%@`"8T+"MPO9W@`*8.0;_QG MT7QM&8B7\:K^+4[KW9^XA0>4OT7K!F\VHZ2%CD_2/>'\'981;H-@@]+&+VDF MZU"M%$H4?TFKT'&=TY^R6&CO$_*%D&^$NRP:3XVBS:_<\;HR.!,[\G!VN[V' MFR#BE8F-:B9-[XU:7SW7N_RN8N<@M&`2Y7B%V1#,J[_;(J?7]/R"GG],+U9Z MD1P65PZ_?"Q0K@)E$BC_-V+"'*\P1?:F";O84P6FCU?'D@8G[=*6;M7M=M[G M\4Q>X74U\AY^`P=H@-O(KNYI63P[V=+)'0NA)]];-*52HG# M<7T@VRNM_P%02P,$%`````@`W9-L1^_OQONB`0``L0,``!D```!X;"]W;W)K M&ULC5/+;MLP$/P5@A\0ZN&T@2$+B!,4[:%`D$-[ MIJ651(3D*B1EI7]?/B3%+H*V%W%W-3,[RTZ"#<^.>,=L, MH+B]P1&T_].A4=SYU/3,C@9X&TE*LB++/C'%A:9U%6M/IJYP#+$3DIQ M\^L($N<#S>E:>!;]X$*!U17;>*U0H*U`30QT!WJ?[X^[@(B`'P)F>Q&3X/V$ M^!*2;^V!9L$"2&A<4.!^.<,#2!F$?./71?.]92!>QJOZESBM=W_B%AY0_A2M M&[S9C)(6.CY)]XSS5UA&N`V"#4H;OZ29K$.U4BA1_"VM0L=U3G_*NX7V,:%8 M",5&N,NB\=0HVGSDCM>5P9G8D8>SR_<>;H*(5R8VJIDTO3=J??5L7,0 M6C")G%!+_Y-+U=ZF1R65P[_0V"W"NR2P.YO(R;,\1I3 M_M&$7>RI`M/'JV-)@Y-V:4NWZG8[[XMX)N_PNAIY#]^YZ86VY(3.GVP\A@[1 M@3>1W=Q2,OCWLR42.A?"SSXVZ4JEQ.&X/I#ME=:_`5!+`P04````"`#=DVQ' M6O)WKJ(!``"Q`P``&0```'AL+W=OP)$W);4]T-ZY8<^8K7M0W-[@`-K_:=$H[GQJ.F8'`[R))"59 MGF6W3'&A:57&VI.I2AR=%!J>#+&C4MS\/8+$Z4`W="D\BZYWH<"JDJV\1BC0 M5J`F!MH#O=_LCT5`1,!O`9.]B$GP?D)\"NL^=XR$"_C1?TQ3NO=G[B%!Y1_1.-Z;S:CI(&6C](]X_0#YA%V0;!&:>.7 MU*-UJ!8*)8J_I57HN$[I3WXWTSXGY#,A7PG?LF@\-8HVOW/'J]+@1.S`P]EM M]AYN@HA7)C:JF32]-VI]]5QMMD7)SD%HQB3*\0JS(IA7_[1%3J_I^04]_YJ^ M7>C;Y'![Y7#WM4"Q"!1)H/C?B`ESO,;GBU;&DQE&[M*5K=;V= M]WD\DW=X50Z\@U_<=$);0XOHP)O(;G:4]/[]K(F$UH7PSLP-C+,H@$``+$#```9````>&PO=V]R M:W-H965TU#I2@/ M[;,7!K!B>ZAMEO3OZPN0W2IJ7O#,<,Z9,[Y4,YH7.P`X\JJDM@%AB=#[*04 M-W^.('$^T)RNA6?1#RX46%VQC=<*!=H*U,1`=Z`/^?Y8!D0$_!0PVXN8!.\G MQ)>0?&\/-`L60$+C@@+WRQD>0O.3=,\X?X-EA-L@V*"T\4N:R3I4*X42Q5_3*G1P< MA!9,HARO,!N">?5W6Q3TFEY!,@F4_QLQ88[7 MF,__-&$7>ZK`]/'J6-+@I%W:TJVZW&ULC5/; M3N,P$/T5RQ^`TS0LJ$HC459H]V$EQ`,\N\DDL;`]P78:^'M\:4*+JMU]B6#3$CDIQ\[$#B=.6KNA<>!)=[T*!525;>(U0 MH*U`30RT6WJWVNR*@(B`9P&3/8E)\+Y'?`W)[V9+LV`!)-0N*'"_'.`>I`Q" MOO';4?.K92">QK/Z0YS6N]]S"_F\VHZ2!EH_2/>'T"XXC7`?!&J6- M7U*/UJ&:*90H_IY6H>,ZI3_Y3+M,R(^$?"'<9M%X:A1M_N2.5Z7!B=B!A[-; M;3S'ZS.%_]"]F@2()%'\;,6%VYYCO+MG)GBHP7;PZEM0X:I>V=*DNM_,N MCV?R!:_*@7?PAYM.:$OVZ/S)QF-H$1UX$]G5-26]?S]+(J%U(;SQL4E7*B4. MA_F!+*^T^@102P,$%`````@`W9-L1YI^082B`0``L0,``!D```!X;"]W;W)K M&ULA5/;;J,P$/T5RQ]0$T+V$A&DIJM5^[!2U8?= M9P<&L&I[6-N$]N_K"]!D56U?\,QPSIDSOI03FF?;`SCRHJ2V!]H[-^P9LW4/ MBML;'$#[/RT:Q9U/30.!WHABZ%)]'U+A185;*5UP@%V@K4Q$![H+>;_;$(B`CX+6"R%S$)WD^( MSR%Y:`XT"Q9`0NV"`O?+&>Y`RB#D&_^=-=];!N)EO*C_C--Z]R=NX0[E']&X MWIO-*&F@Y:-T3SC=PSS"+@C6*&W\DGJT#M5"H43QE[0*'=GY!SS^G;Q?Z-CG<7CDL/A8 MW3]-V,6>*C!=O#J6U#AJE[9TK:ZW\S:/9_(.K\J!=_"+FTYH2T[H_,G&8V@1 M'7@3V70)-5M7W!,\,Y M9\[X4DYHWFP/X,B'DMKN:._1=>[4&!5R19>(Q1H M*U`3`^V./JRV^R(@(N"7@,E>Q"1X/R*^A>2IV=$L6``)M0L*W"\G.("40<@W M?C]K?K8,Q,MX5O\1I_7NC]S"`>5OT;C>F\TH::#EHW2O./V$\PB;(%BCM/%+ MZM$Z5#.%$L4_TBIT7*?T9SW3OB;D9T*^$.ZS:#PUBC8?N>-5:7`B=N#A[%9; M#S=!Q"L3&]5,FMX;M;YZJE;%;B,293]%69!,*_^98N<7M/S"WK^/7T] MT]?)X?K*X=WW`L4L4"2!XG\C)LS^&G/_3Q-VL:<*3!>OCB4UCMJE+5VJR^U\ MR..9?,*KS)!):%\(['YMTI5+B M<)@?R/)*J[]02P,$%`````@`W9-L1Q]<`5.D`0``L0,``!D```!X;"]W;W)K M&ULA5/;;IPP$/T5RQ\0`\NVS8I%RJ:JVH=*41[: M9R\,8,5FJ&V6]._K"Q"H(N4%SPSGG#GC2S&A?C$=@"6O2O;F3#MKAQ-CINI` M<7.'`_3N3X-:<>M2W3(S:.!U("G)LB3YQ!07/2V+4'O298&CE:*')TW,J!37 M?R\@<3K3E"Z%9]%VUA=86;"55PL%O1'8$PW-F3ZDITON$0'P2\!D-C'QWJ^( M+S[Y49]IXBV`A,IZ!>Z6&SR"E%[(-?XS:[ZU],1MO*A_"],Z]U=NX!'E;U'; MSIE-**FAX:.TSSA]AWF$HQ>L4)KP)=5H+*J%0HGBKW$5?5BG^">[GVGO$[*9 MD*V$+TDP'AL%FU^YY66A<2)FX/[LTI.#:R_BE(D):CI.[XP:5[V5:7Y?L)L7 MFC&1GFWHV';?=C\K%`O@CD42#?":3[$2/F MLL?\[Y)M]E2!;L/5,:3"L;=Q2]?J>CL?LG`F;_"R&'@+/[EN16_(%:T[V7`, M#:(%9R*Y.U+2N?>S)A(:Z\//+M;Q2L7$XK`\D/65EO\`4$L#!!0````(`-V3 M;$?*&5SK6P(``.H(```9````>&PO=V]R:W-H965TU%I=5>M-=.X@2T@*GMA.W;US:!92Q'X2;8 MYLSYQF0&4PR,?XB*4NE]MDTGMGXE9?\ M4W(T06T31&&8!2VI.[\LS-H;+PMVD4W=T3?NB4O;$OYO1QLV;'WD3POO];F2 M>B$HBV"..]8M[43-.H_3T]9_0<\[A+7$*'[7=!"+L:>3WS/VH2<_CUL_U#G0 MAAZDMB#JGOB:"OK/E3'V6EL@U][TA/ MY-+(=S;\H+<]I-KPP!IA?KW#14C63B&^UY+/\5IWYCJ,=]+D%N8.B&X!T1R0 MAR;Q$632_$8D*0O.!D_T1/]YZ%G)N391SIXP;GSY$1#X,CQ;AT>/P>`J/QPSC)3W:/#9()H-D-$C`%A.XQ5&S@YKT M,22U("DPR)P0J,&/(9D%R8!![H1`S8K'A2T(7AIDH1,"-2MJ(K<@^<(@=C-R MP%A1.!N+L0$&L1,"-1?/J M?*R_1.8L^Y*714_.]!?AY[H3WIY)=2*:X^O$F*0JB_!)/=5*?7C,DX:>I!YB M->;C43Q.).NG+XOY\Z;\#U!+`P04````"`#=DVQ'MD9<$+$!```5!```&0`` M`'AL+W=OQS9#]^_@!!$8C92^XW5155],VQ2C5F^X`#/K@3.A# MU!G3[S'650>WF!,JHK+PN6=5%G(P MC`IX5D@/G!/U[PA,CH;$"VT[XQ*X+/#"JRD'H:D42$%SB.Z3_7'G$![P M2F'4JQ@Y[R9'C$TPM>(>59-H_435H(_E,B1`G'V&EPJ]C M>',73[3KA'0BI!<$'`IYF[^((66AY(AT3]SLDKV%*R=BE9'V:BIT;XUJFSV7 MR5U2X+,3FC"!&PO=V]R M:W-H965TI# M^^S`<%%MS-HFM']?7X#&*%+Z@L?C<\X#]Q_F$F?XM#$!H+0"%71H'HX0R/0*D1TH7_CYH_)0WQ,I[4G^QNM?L3D?#( MZ7M3J%J;#0-40$EZJE[Y\`SC%C9&,.=4VB_*>ZDXFR@!8N33C4UKQ\&M)/%( MNTZ(1D(T$[:A->X*69M_B")9*OB`9$?,V:WV&BZ,B%9&TJH)MWMM5.KL.5MM M-RD^&Z$1XRA'#S,CL%:_6B(*?'IT08]NT^\G^MHYO/<)%T5B3^`71Y$L!))?N/0PN^6!X8OV8B`J M>XLDRGG?*M==)9VI()_1%1-*]&)*]WDMB-+SA5H$^&=_E>U M?DKF"852F3#1L7"WRTT4[Z:W8GZPLF]02P,$%`````@`W9-L1ZRUZF:Q`0`` M%@0``!D```!X;"]W;W)K&ULA53+;J,P%/T5RQ]0 M$T+2F8@@-:U&TT6EJHN9M0,7L.H'M4WH_/WX`12J2-E@^_J\KFR3#TJ_FQ;` MHD_!I3GBUMKN0(@I6Q#4W*D.I-NIE1;4NJ5NB.DTT"J0!"=IDNR)H$SB(@^U M5UWDJK><27C5R/1"4/WO!%P-1[S!4^&--:WU!5+D9.953(`T3$FDH3[BA\WA MM/.(`/C#8#"+.?+9STJ]^\5S=<2)CP`<2NL5J!LN\`B<>R%G_#%J?EEZXG(^ MJ?\*W;KT9VK@4?&_K+*M"YM@5$%->V[?U/`;QA9"PE)Q$[ZH[(U58J)@).AG M')D,XQ!W]NE(NTY(1T(Z$WXD(7@T"C&?J*5%KM6`3$?]V6T.#JZ]B%-&)JCI MV+T+:ESU4FQ^;G-R\4(C)E).*\R,($[]JD6*U_1T04]OT[<3?1L3;I?N679; M()L$LBB0K5K,UBU&S&F-V=TVV7TSV:T$]E=-UIC[;R9D<7`"=!/NIT&EZJ6- MYS97YR?P$&X*^8(7>4<;>*&Z8=*@L[+N^H2SKI6RX$(D=RY%ZQ[IO.!06S^] M=W,=[VU<6-5-KW#^%13_`5!+`P04````"`#=DVQ'A5M)UA$$```1%```&0`` M`'AL+W=OY<`>[ MW2G567G*,Z?0^\?9-S;?<-5`6L2_)WTM1^^=)OC7//_9//R]>YQY30PZT=NJ M<1'7+V\ZTDG2>*J9?_5.WSD;P_'[F_=UFVX=_FMVE[+*TYO)S$GCW]WK*6M?K]TG4O9F9@/H#6`P M4-ZG!KPWX(,!\S\U\'L#_]U`?&H@>@-ARQ#T!H$M@^P-I"V#Z@W4NT'0MK=K M1]O,I[B*EXLBOSKE.6ZV.)O7\*)Q4GMVRM9;T>V1NIUEO?JV9*%:N&^-HQX# M+6:%,:$)\S3&"*.;-7)C0FS&B%IC`\:M$S%F`S,<*2`'1I((8\"8#<*8$,]C MA#"69#WIY&7:R08Y$=,5X;>*\*Z_'&7+IQWX-P=^Y\!'#GP:P:72L1NEZ#\RS(0H)48B()"82'4\XX@$_!`$61,PC3$W4(RHR_?Q^ MB&)0:,'#*`^:CU1B-QX,8A8\0'G0T&'&';GJ05WMA&M3))HT""9\HH MHQXT[(4PE%:;@50&4-8#%Z(P!479"^Q2D!5-;`IZ=OU(,Z*@Y2!4K9D%%%@C\] M%R,,`HNS$Z@B`2G2YJ@`JDBX6Y%`%0G2HHTKD%\0"5!!@IINXPK4E]0/5)$0 M6AQO&&331D[5R,=J5!9EX52,_&XQJ==+L[Q0?\3%X=35CJO>57E:7M_L<_S2M0]USXXZW@T/B=Y7S5O9-+.[L>H>JOQ\NX`;;@&7_P-02P,$%`````@`W9-L M1R:U5434`0``T`0``!D```!X;"]W;W)K&ULC93= M;ILP',5?Q>(!:K`A)!%!:JFF[6)2U8OMV@DFH-J8VD[HWG[^@!1':-T-_N"< MX]_?&!>CD&^JI52##\YZ=8A:K8<]A.K44D[4@QAH;]XT0G*BS5">H1HD);4S M<091'&\@)UT?E86;>Y%E(2Z:=3U]D4!=."?RSQ-E8CQ$231/O';G5ML)6!;P MYJL[3GO5B1Y(VARBQV1?95;A!+\Z.JI%'UCVHQ!O=O"C/D2Q1:",GK1-(*:Y MTHHR9H/,PN]3YN>2UKCLS^G?7+6&_D@4K03[W=6Z-;!Q!&K:D`O3KV+\3J<2 M'.%),.6>X'116O#9$@%./GS;]:X=_9MM/-G6#6@RH)LA2?]IP),!WQF@)W-U M/1--RD**$:B!V(^=[(U`Y(?0`.`O(0,O=E>$WO-$F*<):LR:I`ML$( M[[[&2>]PT@!G&ZZ3>9PT6"=/T9JJ6JJV&/_'UF1W+%G`LEO=FFS)DNWB'5[= MFD"6)UE^_ZGAXO`-Y$Q_$GGN>@6.0IMS[`Y=(X2F)BQ^,&FMN5YN`T8;;;NY M+=W_<7Z@Q3#?'[=+K/P+4$L#!!0````(`-V3;$?WMVKU*0(``'H&```9```` M>&PO=V]R:W-H965T^\)$2`CZ9N^=XI MA>AVKLN+DC28O]".M/+.E;(&"WED-Y=WC."+)C6UBR",W`97K9-G.O;*\HS> M15VUY)4!?F\:S/X=24W[O>,Y8^"MNI5"!=P\I6I(RRO:`D:N>^?@[4X> M5!"-^%V1GEM[H,R?*7U7AY^7O0.5!U*30B@)+)<'.9&Z5DHR\]]!])E3$>W] MJ/Y=EROMGS$G)UK_J2ZBE&ZA`R[DBN^U>*/]#S+4$"K!@M9<7T%QYX(V(\4! M#?XP:]7JM3=W$CC0U@EH(*"),.59)_@#P7\2`EVI<:;K^H8%SC-&>\`[K)ZV MMY-PID2D,N!:C9EVRC.)P MVU&R<)3,'`7;`NFB)^E7>^+!A04U&C:[,H!,M4GB0T^^!:MMF2']&$6IAY:- M<:U/NB'LID<=!P6]M\)\;E-T&J<'I$;"(GY48U:/BJ=,GG7X1GYA=JM:#LY4 MR(&CI\.54D&D1?@BK9;R1S`=:G(5:ANK&LQH-`=!NW'23[^;_#]02P,$%``` M``@`W9-L1]YX2CH:`P``J`T``!D```!X;"]W;W)K&ULE5==CZ(P%/TKA!\PT/)MU&1&Q^P^;#*9A]UG1JN2`>K2.L[^^VUIP;:A M@#X(U'///??07MOE#3>?Y(P0=;ZKLB8K]TSI9>%Y9']&54Z>\`75[)&H=!;D2Y=[CX#XP_ M^_8=VVY3/Y'3M`&EW^* M`STSM;[K'-`QOY;T'=]^(%E#Q`GWN"3MM[._$HJK+L1UJOQ;7(NZO=[$+ZDO MPX8#H`R`?4"?9S@@D`'!/2`<#0AE0#@W0R0#HKD98AD0&P&>,*NU>IO3?+UL M\,TAEYQ/0+!@\(:3,&:'M&R->(/,;,)&O]8PB);>%R>2&-AB7E1,E`Y!MBH$ M]`B/"1A4`5T]`U15#"78J(@H&]0P2?(Z3;+32*+I2H*NDD#X&6A^QM,$84<0 M"H)0(0A]76,BW!*06N3(?/X9PFUGXG8J+H`ZSJH[,G1'6N&)GB@2PB,E46*3 MLU%1468K3D7!P`9[56$@GE=:;)06:Z49"T!@MCHFFTZ2&$D2E`9(9%)GI2_:H+]`W5$!_VA>)D?,@L1LS"K1K,EL`U%M` M.H,"&LY`^+`S@:DB&'%&;A,DIELA]GW"*%!H\I1=986:4WL`(,X>7VLJ-D'] M:'_(>(9\5VJ,OX#%!@R,;\'B51PA[O3KY24_H5]YS]7]02P,$%`````@`W9-L M1V!&_$`V`P``APX``!D```!X;"]W;W)K&ULE5?; M;J,P$/T5Q`<4;,"$B$1J<^GNPTI5'[;/-'$25,!9[#3=OU\;'(I'SL;)0P!S MYLRP\S-K/_B!4N%]U57#9_Y!B.,T"/CF0.N"/[`C;>2;'6OK0LC'=A_P M8TN+;6=45P$.0Q+41=GX\[P;>VGG.3N)JFSH2^OQ4UT7[=\G6K'SS$?^9>"U MW!^$&@CF>3#8;YL0%JR\FOE<77_VU;+KKN7^3(FUF-\#: M``\&@Q^[0:0-(E>#6!O$WP;Q?PT2;9"X>B#:@+AZ2+5!"@R"/KO=W"P+4,?6]E,N9X?+T<\YCK,\^%1$&H,[S-,8@S(K9C'& M)!,;9&70#(A`!FF-%/MF%'@<:1):HS`P-L1RC$BL4E8W2=:W29[-:!WD1A>Y M43\QD4&`;Q/$%X*X)X@-@LB,LL>L3$Q\VTD"G"0&06(ZZ4V>>DQSF3CYN^V' M`#_$\$-N$Z0@G>F]Z9R`""8&06I3NIB,E*:&T!%J.48EV174:HS"T378>@Q# MQ"VY&9"6&=(FMPE0"+*K>OY]Z44(!(&,3@2K*M9=Q@"1T`9:`A"RKGP`PC;0 M&H`B!UD8RC(:`7$H,00[`;J[%2#8"Y!1Z,1:IPL-ZM?2U16W-&'HVOHU8"B. MKBU@$X:4QB%T66(M4FL-$C7/W(4#-L1,OH1 M<2G:#`K.[A6,0Q`%#AV*U@01*VAI@E)K9:\`R%K9:P!RD05[$3;J/G6H>XQ! MC/7!-VWUWON'>AIT:T>^TAM'A#/6(U1X:C"_0=(DLXRLT7?7XL]O17T>[+AGOO3,B=>[?-WC$FJ(P\?)`9.LA3X?!0T9U0MZF\;_MS4O\@ MV/%R[!O.GO-_4$L#!!0````(`-V3;$?U#%9^]@(``,\+```9````>&PO=V]R M:W-H965T^*ME) M-'5'G_J`G]J6]'^7M&'G10C#R\)SO3\(M1!5933%;>N6=KQF7=#3W2)\@/>/ ML%`0C?A5TS,W[@,E_H6Q5_7P8[L(@=)`&[H1*@61ES>ZHDVC,DGF/V/2#TX5 M:-Y?LG_3Y4KY+X33%6M^UUMQD&I!&&SICIP:\I_@O83W*HG,''"=K1\V1/:.R]6W"F5I&;VI M1",&:$7<1#R:"%S< MUAE?=,9#1V.KH]GM!,DE03(D2*P$3B^SH8P!TVE,C!$&P`=[-&'@MA+L*,%6 MR_'M!*G3B_1_>Y$Y"C(S`42^(I>94:1LA/K<)LH=HMPJU6GZ@%G:F!FO1N&0 M%%8UL9?$QB0^S&H&9GT-S#HCT/4#:!E"#OP[A`<*M=CH&4R MN==D5M!T&5DZ\#ON^BO<=4FN&\'\J_\`/$K*#2H(\2=)>)1DXN)DYH:XW@4M M0\EC?Y<*DRJ_VJ3BNO)!461,,2WM]WI^Y,&&G3HQC`;3ZC2C/B`U!3GK:S6[ MZNGH(TU5'LF>_B3]ONYX\,*$G+'T0+1C3%`I$-S))ASD=#T]-'0GU&VFNC/, MF\.#8,?+^#S-\-4_4$L#!!0````(`-V3;$```9````>&PO M=V]R:W-H965T_&%"9DY!&B@ M!#I]Z'DV9"&9VG%J&]+S[8^OJ2761.X+N?"3M/*N_I*=V2'-?N8;8XK)[R3> MY1?335'LSQTG?]Z8),K/TKW9E?]Y2;,D*LJ/V:N3[S,3K6NC)':$ZWI.$FUW MT_FL_NY;-I^E;T6\W9EOV21_2Y(H^^_2Q.GA8@K3[HOOV]=-47WAS&?.T6Z] M3+J;_P/FC]BND)GYLS2'OO9]4BW]*TY_5A]OUQ=2MUF!B\UQ4 M+J+RY=TL3!Q7GLK(OUJG?V)6AOWWG?>;.MUR^4]1;A9I_.]V76S*U;K3R=J\ M1&]Q\3T]+$V;@ZX[^O70_"=P6S.[@6@- MQ-$`U*<&LC607`/5&BBN@6X---?`:PT\KH'?&OA<@Z`U"+@&86L0<@VJ/6]V MSF6;'#<;V";==@-[OZ';<)#<,P7=E@-[SZ';=*"[[C0GOJZ7JZB(YK,L/4SR M?52I")Q7?%;Y*9U/\MIAUM1A63)Y^>W[7`1JYKQ7GEI&U,PE9K2-66#&LS%7 MF/%MS#5F`AMS@YG0QGQ!3.C:F"5FP,;<8D;8F#O,2!OS%3$VXKY/:&M2JY-. M'DX[>41._FRF4YX6^Y$1W9&1S9$1*%W%\"`[#ZKQ()$'.YVM>.AX)Y*%`Y$2%33I>+Y![!KX->L"0Y!P\GZS%[ZU%TCULPGSU<1AE M@^XQY(,U*XZGAT%/PUD%)*L`9076`X,9P8@2DB@A\B"M4<+14<`E8:JFW//! M$0<`HB\`HP4&!%V'0.NP2LRJA9K=DQZSX(&J&HOA08DW[/W2=+HEH) M&IT%SY;]"OIJ*?O"_4DD*I;@G5:H)7@,8;DEE"*K#MH]PY2O.+(*5%M%0%KAV.2HF`)AR,3YB.$P+/"M;^NFRA;NYF3J"2UIATT7JM_?6J MA;K^.M3EKA'G<7N^I)4F\8QB;7-7+71L<_9F2"G.GDHZ[TC!T"$"!9Q`'V[= M<-7:3SJ"A,^ZPK2T)2[MP';"OLC^A.`-W?\M$2;5X/U?'P./>33HN"'1N`&A M+=1*]L<--;3P1X0%W,-*U4DBX1$L'SX1#>F/%@U)F[9$35N`O9"#7LJ:FS+5 M)QERZ@%#G):KJ#@IU+8%I^4J>L.CQM_P*"H`2C"NK1)4_#BAJ`0H)`&"T[B5 MHBFK\2G30E.:DS*J(,5,F5:0PA7$6BZM(#6^@A2M((4K2-M2OE3!WZ1,*TBA MXF!U)>V2E+4[.F5-.ZU&,ZU]TECH?@^5W$E#TR+2>/:U3AH+W2\B4$)I(5B/ M\&@=:?S<@#2*]B9XH?NWY>X9:-8S6TW;J4;M5%@%<8$@X7/$3']X,HFKTGJ? MN"`01WDUK4F-:E*Z]D#>:(G7=.;6:.:6UB=T"P+12^?T?I;91Z]F%66OVUT^ M>4J+(DWJ7V->TK0PI2OWK%S'QD3KXX?8O!356[]:8/,;9_.A2/?=3[;'WXWG M_P-02P,$%`````@`W9-L1YY((G4J`P``LPX``!D```!X;"]W;W)K&ULG5?;;MLP#/T5PQ]02Y3D2Y$&:#L,V\.`H@_;LYLHB5'; MRBREZ?Y^ENVD%A<@7/,0VPIY#DWJB.'B:+I7N]/:1>]-W=J[>.?<_C9)[&JG MF]+>F+UN^U\VIFM*US]VV\3N.UVN!Z>F3H"Q-&G*JHV7BV'MJ5LNS,'55:N? MNL@>FJ;L_CSHVASO8AZ?%IZK[<[YA62Y2,Y^ZZK1K:U,&W5Z5-/^JZ]D@]\^\)](/3.\[O M3^A?A]?MPW\IK7XT]:]J[79]M"R.UGI3'FKW;([?]/0.R@.N3&V'[VAUL,XT M)YVR`TP.<'80@T,R$@UA?BE=N5QTYAC9?>F+QV][ M\\Z#],B1'="Z\>W[0&V_^K840BR2-P\TV8PN#W,;?K9(>O2+%!"'[A!0R.L` MX@0@QQA%`*#"&-5(,MJT8XR2%2I/F;I.)1&5#*C2BU1R3I5!+CF3V74JA:A4 M0)5=I%(S*L%%5A2I@NM4*:)*`ZK\.D"&`#)"!;)9K(KQO)""L%ERQ)0'3$7( MY%7FJ?(9%;OAC(GK1`4B*N9$DH5$H\U#:$-X&\X0BX]X!D&H'><8@A.2/QE- MFY+Y#X$*,!50LC]9G=(/!)EQ+&DN".E'1H0B(E<_5*F0*E!.,8['R0*TR)4!@&?*"$FTQBQ9D M`7V&"7T(BQ$897M/5O]WN@!6+7#"!D=&A!(`EBP$DI6$LQVP%H'27V'>8*7( MN*)083F")%5`A@=,1M$!8-V"HE0@-")(%K!D(9"L(IR[@"4+%,G"7++`4J4R M0=DQ6+1`:K&0?Z8&6-U`Z;*AD2*T68&5+0)E4_XB"2Q806FS(FBS4D(*@E!P M@54K2(U6P"=J(/[Y]TQIM:&1PB=>,ALJ&MUMA]G)1BMS:-TX4YQ7S_/9/0Q# MR8?Y&PO M=V]R:W-H965T99&+FV95 M35\E4#?.B?QWH$RT^PA%?>"MNI;:!F"1PR'O7'%:JTK40-++/GI&NP-*+:1# M_*YHJT9S8,T?A7BWBY_G?11;#Y31D[84Q`QW^D(9LTQ&^>^#]%/3)H[G/?OW M;KO&_I$H^B+8G^JL2^,VCL"97LB-Z3?1_J"//:PLX4DPU3W!Z::TX'U*!#CY M<&-5=V/KWFSB1]IT`GXDX"'!Z4`GU-G\1C0I8*D)TB=R\1S MN9HG2'N"Q!&D'D$V3[`*'*P\@K7_G1SFX&,V\R)9())Y!-M)D3$&8SPOL@Y$ MUF.1+)X4\3$+?M@F$-EX!'A2Q,4"ER@.RL(>VZ_5!4*!"806 M5(8/RM(%.CC4P0N*PP-AM&0_X5%#R8+Z"$`+#B1*0YUT08D$H+!&X*C7<2JO M74M7X"1NM7:M;H@.U\8S[GKE)[S(&W*EOXB\5K4"1Z%-Q^W:XT4(38V+^,D< M[-)<;,."T8NVT[692]?JW4*+IK^YANNS^`]02P,$%`````@`W9-L1X`?1EZU M!0``SR```!D```!X;"]W;W)K&ULG5K;9,?2>3]H MR#_F^>_FP\/SW3!J.&3;[*EJ7*3URWLVR[;;QE,]\K^]T\\Q&T/W_8?W13O= MFOYC6F:S?/O/YKE:UVRCX>`Y>TG?MM6O_+C*^CGHQN%3OBW;_X.GM[+*=Q\F MP\$N_=.];O;MZ['[QD:]F=\`>@,X&9S&\1O(WD!^&JBS!JHW4%P#W1MH+B73 M&QBN0=P;Q%Q*MC>P7(.D-TB(P:B+7QO]>5JEDW&1'P?E(6TT(6YK>-$XJ3T/ MRM9;T6VJ.OYE??5](HT9C]X;1ST&6LS4Q8@D\6'N78RV/L@"N3DA1C5)+U,8 M8A;@F$,D?$/,7(SV$IUC-^"=#,)XYW(1L;Q,986<:!_D`5!XXLNK)C]637;Q ME:X#;2X[4!\.5.=`(08DLK9;KPZS;S'1342#TZ$68520C"9D-")#5E5W9+0S MC(G:/Q]N<0X7)&0((>-&67GY&&<$?>RRE][0QJS0 MLE"K,"K(V!+&UF5LO.MMG5%$#%:)2,7>]68C5P1IK)0*+K-/"/O$W;XQ"6W< MT4](:'V@A0M*6*$7$>'2%`(.&>%=RQ[$64P^=$6AW.44@LX!G5XQ>'=P#[JT MA7FPU1E8F#=0WBCSQ]8;XQ[4[P0-VK\7E@C'V0F2LD%G1"P9+DZ'1'_*"'1* M<(X905.[T!=3Z8-P<[;XDB'#@]&T+0R:LF*XB.F4XZNG3).9L(PIV^^E>D%S MCW"3#T3ZL@N(R)0ANG;*0!4+6+&DZ&D20UOJ89&)*&)L2J`J`USJ>7/1%%SU M@$I``VD\(A).*.7TJ77"E"U9ZSRU`!9(-,C)AYF%&M(J"&#$"_R*YQ0_88`UX M#A>F1#,+6+0=&7T#)%3LR;5BE[3$D&Z^`/`>7U,9H9T*O"!(FEBD0*JP7E5( M@561)#%K,)I9)'"RF(1O9#%),XN4:&))8"SYG;%H:I&*D3&E^MXBTMPB43/G MY):P"T/VJ#17[U$J7GFN!^IL9A(W+K15[U#+,"K,ANI68MTF/L7,I$5'5J!' M6)Z!A0G1JD'BEL7;)Z/(<+WX^@647AQ@6\(5,1)V1A5)@.33P* M5314,ZJG@T"6,VV:"E+7WPOZ7<^A,DEEI<&TM--:31N4TKM0XT)R"&TC0]LS52FE7^ M<3"(LZI4CAJUW8$Z9*[5=R+XY=8K4J._-IAK5.+7#8.QK(G1(E\CW5I.K&E_ MKJ_NSS55H\:GL;>I6VE7C1J8RM=4C!H=M):A9T/;V[H869P>^Z_^6C< M*CIFMBB&:M%@F7E3W<*@[AP2'5G&?4)#]6@D0R?W1H9UX@(7YX!A4E2\AE%L MWQM7NS:)I;<"6YR!A0E1A1O-V.[&53COUK/Y\M`$J]M;Y2Z,VYO71^'7H4;. MD\Y=5KRVS\G+P5/^MJ^Z!V&GJZ=G\3^@>5)*KD_%[5QXKB_$[;)[TO[I?C(^ MI*_97VGQNMF7@\>\JO)=^S#U)<^KK"8>W=0KM,[2Y].';?92-6_C)EC=\_;N M0Y4?/GX^"%*^C?P(``'T(```9````>&PO M=V]R:W-H965TY)$Q%7PV=2OGX5&I MTRR*Y/;(&BJ?^(FU^LF>BX8J/12'2)X$H[M.U-01C.,D:FC5AF71S;V(LN!G M55Q&!/#<-%?\6K.:7>0C"Z\1K=3@J,Q&5133H=E7#6EGQ-A!L/P^?P6R= M&Z(#_E3L(IW[P.2^X?S-#'[MYF%L4F`UVRKC0/7E@RU971LC'?B]][R%-$+W M_NK^HZM69[^ADBUY_;?:J:-.-@Z#'=O3^>4GZTL@QG#+:]G]!MNS5+RY M2L*@H9_V6K7=]6*?9'$O\PM@+X"#8(CC%Z!>@&X"_*T`]P+\:`32"\@D0F1K M[SJWHHJ6A>"70)ZH^3N!F<:%,='.@>S-^` M3`S(=]VQD@49=0>@%/NP)1EU)T,)\F$K%\,Y`'GJP]8NAG!&,+E?7#(I+AD5 MA^X;I!.#]('NI$ZB.?1VQD5B;U-<`I`4^WNW'F$@2>Y7E$TJRD85X?L&^<0@ M?V`YY>-_0N9=3",(IMXULG(A!*!_(;D03E$\*2IR-M>&B4-WK,E@R\^MLMO% M,#N><\5T MUO&3[N]1?PL,@YKME;E-3>/M\6@'BI^NA_WPQ5'^!U!+`P04````"`#=DVQ' MECE=!?`"``#""P``&0```'AL+W=OL_PZ<")DK2*WY7],:U;T_!OS+VI@8_#EL?*`9: MT[U0+DKY>J<%K6OE24;^.SK]C*D,]>_)^[<^78G_6G):L/I/=1!G20M\[T"/ MY;46O]CM.QUS(,KAGM6\?WK[*Q>LF4Q\KRD_AG?5]N_;\".74NTV?)+R3CF1GCW>>^N&Y9*9<3G[ MGN.49,&[$!.$4`)>NT'4D24)`P#(0L8"(`90X@8@6",9Q MB@%RDA>&$,<`K`"*+*#(`$J=0)$6Q[TV;L5=B-B"B#6(T+W\NW@1PJVX"Y%8 M$(D!`9T0B1;B"TE0Y-S!PI!!!`&.R3)0:@&E!A!R`J5:)(0022+BW,-"%X8) M!-$:(@@L)%4_-2;L9!I%0RPL(Z5WF`QA+&\>6L,$K2(!H<$4KG"![+30HSJ1 MCFDA_7QM<.I2%98JQ"MPL(V#'U4)"$<>;$2"L5-66#*\9HGM,@K#%54"AHLW M]([D/HA=/B%942D@609Q2^Z#V&431H^JQ;Q%1EW<(/=.%I9LU9FQ2RB,'U6+ M&2@V@=RRPI*M`K++*4P>E8KI3B7FX0S==\I4Q7:O$FBM44.[4]\R7 MLUKIK&36IZ;]V1VT[H-?55EW=ZM#WQ]OP[![.>@J[VZ:HZZ';_9-6^7]<-N^ MAMVQU?EN#*K*$*(H#JN\J%>;]?CL6[M9-V]]6=3Z6QMT;U65M[_O==F<[E9B M=7[PO7@]].9!N%F'E[A=4>FZ*YHZ:/7^;O6/N'W"U$!&Q(]"GSKKD.1#Y=W_:#+TC`-RO_-I'\U3:#]^#U-WZ31'.8.@#D`+@%"?AB`9R83Y0GE$-R)Q@1XI"-7U5&*62DQ2$=<)$C:[R=+935D&Z?6BWZ?6.(4$ MJ0`\E#*FE'U4=M-IC51&ZZ[`HZ@B8DJ&S))BWI.S.RD(/70$U['-F?HP<'.* MQ>X4W)Z"^%-(UPQNA6U0H9*$MT4--GSLU#V*9'`4[4(T')!#T:/_#&`,3SX$,AV,H$L71E`O`LP,.Q M,^BJ8PG.T['`>PB0'@(>^Q!(7A>YN"Y\7P9B>@#7>)_`WG33-/8[:@#O#D", M[][W'F;0O#"CB)YKR&S9R%@D42(]W`N\EP#I)>"QHT#*YR%=/`_@=R1N-B1R!V)<'W$6P2Z&M0P:H^EA_\[3U.S>?@5 MN=EPL=F0FPU]S(:VV4"B4CYF0VXV)&8#CUT6^3D7%Q]TD6^-Z'/417+6%<.Z MAB1C8J'UL_28O^JO>?M:U%WPW/3#+]SQY^B^:7H]\$4W`^]!Y[O+3:GWO?F8 M&,'I?<)TTS?'\^N1RSN:S1]02P,$%`````@`W9-L1Y:ETP@7`@``?08``!D` M``!X;"]W;W)K&ULC57;CILP$/T5BP]8@P-D-R)( MFTO5/E1:[4/[["23@-;&U';"]N]K&T(`>9N\Q/9PSIF9$SQDC9`?J@#0Z).S M2BV#0NMZ@;':%\"I>A(U5.;)44A.M3G*$U:U!'IP),XP"<,4G0ML`SC/<\PXEATJ5HD(2CLO@-5IL M4XMP@%\E-&JP1[;VG1`?]O#CL`Q"6P(PV&NK0,UR@34P9H5,XC^=YBVE)0[W M5_5OKEM3_8XJ6`OVNSSHPA0;!N@`1WIF^ETTWZ%K(;&">\&4^T7[L]*"7RD! MXO2S7*1.]Y#&99_ABA3H,<9C5$),\ M^R";(23J$=@4X*V"!.,,9$`GO@3K(2)Y\=9P5V3[A!T98>9>US9CC->U[1A#)@WAP>7B($]NK"FT%^=*MZ]+'^TGYRNQ MEW,27T6+=>2);\RD;0?C33[/:GJ"GU2>RDJAG=!F)+C[>Q1"@RDZ?#+>%N9; MT!\8'+7=SJWI[7AL#UK4UV'??W'R?U!+`P04````"`#=DVQ'U.T^#+LY``"D M$`$`%````'AL+W-H87)E9%-T&UL[7W9;N3(E?:UYRD"C3(L`516 M[IEJVPVHM%3+727)DKH;1F,NF)E,B2XFF>8BE8RY\,U<_??3&."?5YB'J$?Q MD\Q98F60J515=7L3,)Y6)_>8G?\'?[XFV6EK<%?+.(%O6G5]&Z(P;=0/2[O5']X5EVUQ&] M7O-#/1Y[$#^\B=-(G);1JOCWU@^N']91_6&ON_?[^F\'\/:"OCA)PIOZTV68 M%%XSNH^+*(\SI--"'(6E]YZ:]K_]XA<;YW82%_,P$7^(PER=>MORGX; MW_W]H/Z+7,;+Z"8NRCR$9L["E3?8T[/KX\LWQ]]^ M/U>K,,'GE]$ZR\LXO1&'V6H=IMZ+UWFXP,=7#ZM9EGC3?W/Z;=M4L]4*N.ZJ MS.;O`G%%_"_.J[(HPQ1;]&9^?G9T?'9U?"1>';PY.#L\%E=?'Q]?7\'F^?;J M2.R\V/76-YH#H_`6&+81,BR*J"R^]!Z'Q:V`@8@Y_A']J8KOP@3>]QCC8#[' M_5Z(/)I'\-(LB<0RSU;P[P1HNQ#K,"\;J1:)T/_6(V!Z![TV+-!%'JW#>"&B M]R"@"E]T7&)Y743L9CJ)E!+TL@,1`R,K[WB63-9+Z MBV\R8/+K*%^)HVCFD8";>=/^.7)[7**T*9BM0*X#DT?I'%X6.V=9&8EQG8-1 M)7U9K,-Y]-LO0.<447X7??&5\/8J;J';+%E$>?'7O_PW<6OYX+,T;[B"-]R+ M;J?;[2%W"N#L*H)M-!QU@VZ7_D=C''3-OUD_B;`J;[,\_C.R32E`$H.VF,'B M*RU$W\&^D[_*O1<`]8MU-"_CNRAY^+7H3?K!=-@+NL,)?8#_'D\'P6#85QW% M18'+BD\S(Q,^OE./;Q:+&+4>K!INH[TXA9V^CF$5&SBL6E6\EQ?1,I['+:M? M-"Z#V)$?>>*)O[)8CN;QU%9:Q>(/%R'R]&U4QJ`I_AW6]X5XV6)GN*RA>6+S M:QY+;/4Z+^Q6KV;;*(.KZX/KX[?'9S#C\Q-Q?G%\>7!]>GZV02T,MC:J/*5Q MR4+$VUJOHQ3)+,JH*!M&2P*R>?E;Q-)A!@9IMFQ[_#K/"A")>;;TF?%\'>4A M:6PE$[WA7H(H"?,Y*[@%=)%D:Q1-/BV2!!H*!,BI",T2?#]6&NI%+ENUGJO<,J*$[GV2H2.[*E76_BH,\B MX*Q2OMGZ6#;0,N+&OAI'/8O`O([4NV7XWI_=*R`MK**`%S>^=Q:!>H(VO>_# M`AB/%C).*A12J7Q3`+5`S_#&PATE=D#*+;(D"7-^2+]Z(_\^BF]NL:'P#LA] M$SEM.+LR$#.O=^R#W]P@JMQ->W5]?OC-U^=OCHXOKWXECG__[>GU']JW+RU" MB_P@32A^>$N:P'-B+)E_(67^(;M?=.VC0X/KKX6)V_.O]^@^ZQW3B[/WRI]>?9:'!Q>GWYW>GUZ M?.7;X(L_5H6T7(,D9P3^GHK M3Z3=6;M\B@M8=^#8UB7=LMEK.]N&VH\M_.G9=\=7CRV\DHZA%)R/#R4&=[5X MXE!.3L_`;GUD*&I#KM6&A&4&SPY[HL7WW\_F4;20AD/T!-&HYP3FU5T,%J*8 M/8AEG`*C;9X7?@AF^CR/H.E=01[%EB!"*]H`&C:ZB=,4>P:^7A-"]82O(^2I MMN^NJO4Z(6+"&B_B8@[[N2(5O^2FEDEV#_/0$&$S2D)H$^ M+/36M,'/\YLPE1L\$(?`;%D2+XQPL+_%MDYX16#D5_!CQ-+IAX,9&J;SLJZ< M6SQIPE-+"!Y*>IJ`W=O[ZE_\/6U6!8G_]R__L*D.Z M(&M9>0,%4::`]4#R9`(_@L'F-[BBL"P%FB/D3]]&85+>BE68OP-&PBG#8R1] MH=P*@<..Y[!`Y6V(3)K"1\D:&EX`2RZJ,`')MD*VC>A[!*5+^!]V&N>J@_(V MSZH;9&_T+="&%S!"E#OA.JIPW"M@8.2#CKBVI_C?Z'&`B1JOC=D.RR2[PE'# MWSEJA3E)/>Y8?)O&^"]:)=DDXE[4*&]?<,-2E!]+O:2%65+H,*D6$36E\3)8 M*8OZ("?QEVV!`?IUR7-&:D1,K131[Q5[AA%ZAFT-8AL\C\8!WX+9#+LV2I'" M(/E9@-C#!<+@3/(%Z:[[&!9%SHR8@FD,#I-RNY('?(Z#:28J3OX`>`K\?+,/ MXY4UO%RAN!UQ0#W#G\E#@$T]@$<@TJS4A(;^%'VMK<\DRK"W'"6,G%;#")NG M@N/"14^BLIEN1%$0R54:5@N:W&;&",3];3R_#11%LC5XI2P:5F$*;@N^A1C0 M,HGF) MW83$I.!M`M_D,6%8#FN!=I@KS`S%XPIW0@`:';4O+CO,&Z@)BX1%T M7!6%XND#D+\/4OH;G0+ZATT>>N=2SAY>.3=R[\-_B4,UL@,SL@M[9,=J9*`A M"/,%<2R--IC8)RXG]4`J;(!3)5)M%J9F!,AL<=KQ4(L8]C;,W+-67V<<`P*) ME:Q/VOP-'8$=DV"Q8@X=.Y$I< M*%ORX`8T"5FF._@M,!XVU/"PW;*J0+Z&YF.6[VA`9WGAMG*J?L:/ M`S1@T?,I<=E)##K#!`EO;G"CER1EAH-@TAL%T^%$=#O]R7`$"Z.C#X-^ M,)F.@^ETI![">NG]T!\HQ'_#HET9>FQ>LN%G6;+A1RR96:?AQZV3H0A-HVFQ M/+ICS&=_/Y@`E;N=7K<[$*-.MS]J^/W))/\._HT*X0WZZBBKY!H\-!">WFF@ MM\)9KJ/Y;9HEV&E[@)IO\F)T-#O8_@*]#:;-VR_X<*L4'.Y$UO$Z%RC-(8/RGLT M9HL*Z)B3N2F'*WU+&CXB'/&\2D!9D0G=$?LV76,20F0@D;<(\P`%5S[L+='& MV!F.=ODSL#W6X8/65:"62^GY+N-EBZA[P03-$I@@^\USENBH='IY5K/ZO>H3N0"3B9984.8/0>I#OJE)0Z0FC-7;R4 MQ!-\QDYC&=FKAY1@7#9?L.6^0NG&0U:A^W@#*X_]%?0T[XO`B&A!<*B^^('<)WD7'T.%Z`HFO-NX:D M5PA::UXJNU+?]Q&"#T7KN)2\ M(5=610,65H"09RR(D'%?NF<\`=6V@QXE[=989'+1_)6F&"PV;'. M$0Z#_\?;>\%NLU[`(E*X1=8Z^XZ0"1,\J!LW2\+`F3$%53+@301"[V^CE-$0 M?(`8:146:"=$",>C38)K"6H98SP*YY%ML76'"BXG2S!:L!1``);@RWG$\DWJ M9MK(E(Z5($RD9!L-*$1L=H:L6R!C+#I@OW(GU`)TO-!6#?>EAZY7QBA4=`]1*7;)!FAJGS`&;/0E7=>4M^MRJ)6?E=5?DAO<[^V+0Z<-_T>\;P'^'CM+0 M?`'+"DOR#O,15`-J[%*EZ`[>H>BN2EC*/YLMM$)IN(I@8\#$OB7?P'L0^'W8 MV)['H2`1WD5)?)MEVAZ$/5)F(,E0'>;SN"#'`?,IY$Y?1"RQH$7,]2CD`'B# MD@DI1Z3%(&XGM(-IGUI@E>[):G0=EM!&RG`K+B]SC'2X<97!(4MQ:6T:4ZM_ M)B9H:`EW;K_;W==HBX:>U"Z2;*OP/B!$O()M!0:[[7_5:,6.&U"XFQO76&^UT`YLVLIO4.T\$_('6+\1@GU"(WGA"_YV.Z3_](0$4 MZ!>?S\N,W.)Q0+3:Z!:_C1!>P'QQ<*VR_!T-!B/3:82)*7D)*M/RD$F['JSN MPP?R>#N!6+R)]D,.`,#4O8/##J$8*+-BG@12_U_D`!9@#5T#$O^ MP##.A051@--4F$$$;F<%*+3"`Z=/4Y39\/G7'&@"VWC"\,V(Z=?7=.2?FU*G M8V9XSB]5^HO1.^E@X%MDI,D(`'YBS`P6K7=9/-9'E`=;66@&4U5%)82#JF2 M)7B61&$96<_9AUBOT7.']NG\Q07":F#$L7,U&!"G\#\:MJ>/B5^&]P+7.(\Q M'/I"]&"7#D8]_&L\"(`%$3^*BUO42B"+"O@YF`S[8AH,!F/!&7YZ8I3NCI\B M!^\/\*])+QA-1J[\5'Q,H=Y',J2:HG\G!U>OQ,'5H9CTI@$UJ[_Z\%\29W9^ M/>5$P6M,%'2,>LMF_F.UN*$_8BMDA^Z1E-I*-;KQ75@8"HWLS#@O<==+3`QH MK;1JA]\V&=9(']RM,HB(J`S-&[5ICGP4WH1Q"GNAH4&?K#`1@=*V!.:JC%Y@D(@P&&K1`%P2@*S=&2']BAY1RS`1)) M6]F>4=.H89&89WR'VS@]J#?#]RPG>45F#[#.>5S@EL$&X[0!\61P02Z(K:GO M'`7=1"R%/R'A,1N4L"PL!0HXF2I^GP9F/ MF.S!:V,WX^U(!K+W">N^ MR5*4X>+T\A"Q(YK'8-H7V3THQ^(V7JNQ,47NB2))O(K+.NO:P(B4`PH1(=XH MRSP&GP,/KL2=""R2)1ARH']?DNINCM])BC;FG0N.I12[%G7BW#J_P?`,BJ+[ M,+?\X),J1T<1W50WPD*FN%X);Q5<,LKI8OX4<$R26,GKBV@&NQN!2+7C.*Q@ MT[C7G>Y$NSO37<5K,)EJ+HUB!Y)E*C70A^>WI^=GS:3>TVQWI[^[<["KY1$Y MW^''8A3U+)G&99RPH`MEZ.*YDQ MDWO?-4E#%?V6.Z1Q@[`LW6;)>+-B3!P%4LB)MGS$AK=L!OH^+V0+^'V#D@!# MHC.HN:9W<73/5J'M6:.'4=PJETLF4RF[!\TTFAZK,IR5=$P:@3:M;(BJ2CSA M-GP7(59JDC`8B>#?*62('["_UVD<-KJ'2A[66E?>(_M?>`*:+#48%@*\\*?V M_-`5+NDX!-D9A!>1HX>6.,@B-#$U7]:'?Z]R+P:3H#_>#WK]D324>_#A M"&SCR6`JT!N>[`?3;M>>52`JPD#"NS!.R'*1,L=*]PG(MJNA"<97(TE%(JIP M`6DT\_+*9(\IS]&\VYJ`&S2=O65Y53MP:LL!:RBV](7-GI=[!-ZD(2EYM@O( MV*\-T6K!RE-G+S&9RY,F3#)L^E42@C=Q-0=Q(O%+?++*%E'B,H_*]91.:MN\ MV=]8(/*$GJM+RQBVMP'3;9$_BX`S[R(5Q861W\8WMU)M"\4J[HC,-]!:L,&N M9J\:-F5:FK"#;!I,VW>VC;UA8B$[M(7QACJB-3.:MJ3AR0S=HA7[*PMZ9A"% M."7%6?!./#H]1%I5.>DILI[0#G'B1'ED81@H`0()03@G23<= MG6Z8!:-#"#7N)22T"$=@(]]LIJJ(,$R6Q'?2GR`X#$.1:&:1P.^(-YA#1QI, MIA.O#,UX')%L6+,_HQKNQM5]+76,A.V"3&.OH?1#<>^HN#=VCF8V$9-8T<>T M*0^&W%D)_`=6P)5DKI*Q*E>3)2_F*7">=_9'BM1""_#W34ZAYG-<4S-,'4MH MZ(W'SVMIA#PEY2@SB(4#B0_8N"@^YK+8@E03UA(3J@2]%YP+N:WF,6$2L$_V M@Q&":ILP^R:8'MY/,=A\8Q*U'&"K.1+_CYOL_I-FMTM-_2V1?*\[$'M"'RJ% M/U?KRIQ@T`]VKJI9F:V!B-/!:&_0W?U27,'48-\\J*U=/_V`-0C$J3K^A*>% M"_++#V`.B92K^!V-1YZEQV&=91TU-..MR$`#T9FLW]JYJID5@I33GLES:U0$ MAY-$%M#('!M0]KUR_]$[B106J]-F>.LH]P3L!)GOHR%O-H/<:=/H%'8+,[X` M/S#7.TV5G`'MWC2-^RB/7&D0&J<%G,7\)E+^+$87403L*E/4F:_V.X-:OXJ6 M\F?WQ%K3D'12E(P)6[EGTE[L("N`ELK1"VMJ0H%L&M'.*#U]%5S!!A:"0]*_28G M%!]:N=^%=<")`ST:\T`>9D[6&5DZJYP-&9H0^@-V@][@5@@/S2)I7U,0+,], M90A0->#JZ/%I-9*M=9QT@7\KAR"Z5\LLYR[=!DKZBF'M35"T)X1WC6HR[8R6X MAGO=?9!63NQ>`?K2@M31#I(Z,O%WZ,L<6@:$VJN8\6[2=@CYQ9,FC# M'`:P$W5N.H%E\9DF8`1\UD#_M,OKIN>J)2LR!Q<]DL=GV3G5@?#--`%#(999 M+?9T0?6MXD*',6Q2H:&L6T`P0&=Y$O?),S&%M)98/K"<? MXA03UD!GJD:(H#O%KHI`*9)T_+>E\<$<:I+,E,14C?&71QK\T$LB<@'5?0Q M,BV%'Q/>XT"8@U:M(IQXTFVZ@S!'(D&1.;-"S&)PC=0O2Q:3\)N>A4DSCF+: MQS5)SX*<3?,HG*-5&!,2YW9MV0B9WX:V3:0O1XE)G'=&\&-<1FS/+XAC*9,>,#OTM]7AX@\_NF>@C-7> M[X[VAMW=7]/1,LXBQ$:^=0*%X0R#^R#PN/P='^H3BYB)F\KC9^HTJ#(\ M-^8[8BZ:W*@<%60(Q6Y?:>MY2P0=&0FBY[ M7VZ<35SH61,E0?E*.-A.`E5&8_TT9L.DG=%U',Z"OAH%:9-!NX4H)=G#9POT M%K*DX6-;SQY9QB<0S72LR3,9U<%0D@14G\GM.)26*"ZCEP5]*?T[3&=Z$-=& M_WE9S^UO?ES"\_##CQN:O*)3A&\)J^]WNP,?#%$X`B49S/(L7!"N5L+JS#$H M$INTC2*ZXZI8RR7L8QVAAP:=/*MEN,)#M93T(T5L0`$TJSB(Y'W5O%$CFO_0 M5.)2<'S>C-$:$(85]+5'G-T:7@U-'E<(>V,.CB7QF9MCEFW$3"^LW.Z/]'3:3[N?/F M7FE)`4+)('VPM?L,!V`&C#P(`QQ^0(BVGF!I& MMJ88*/13%TVA5&6TM,HP(3:J9=-T!CJ9QCW#Q87%Q%LKKU^EZS+_4^*NDV5F M0;8A>3R9/"\RJ](%)X,J!F4[DNEM':>,<9%TJK4FPCDE18B=TU?GZ+>=\[YU M!J\.HP#KOQ"]S@C^-Q6CGEP3KI6)/&NM`">A]3=R[1O:?Y''F(VK1!@A'R'# M^J)FS4XW+EJ=)R._5U_RW6`H"JT):)TU%*Z&D6TA>MA[X/,E%:7C)[))S'4J M(A.QY5.:5M#&JJ-"#._S@0,XD^S(:+-0HRUL`\MS7.7@MP?B$L_SAWS$%(02 M$'-)1TG4J=#K*,_C$HQ5.H\J"DE@/&"WZD`;&N62I$ND3DKJE5%P@;0F^@,[N'G*NZ:#'_^SS MSZA4!S_D/3%U0$= M;=Y\EIP6&;_EK&:.$SK@$`TD]B>&&YZ6EP(RAL/E%#G$8\%FUK[J@/4EEE$D M8798EM08S1N+6#PEW&48"TAA0F46-QB M0"4&3J)97J'*[X^VJ`MQD:MHP@4=AX[7[('4)/UEE(:P342,QH7%_:V#`L-TLH4 M/0Y=0P=G&/DE#T1E7.%P<&/5K%<=9K-[UUQU%"5E"/^?RHS!$-\"PX+1EUJE MM(Z.WIYJ0\L40*[E5W;,H5L%Z\H3UC`0A;[+DS3Q2C*N3'E"O*PAL0&A#B6? M+:FE"%);.#E[PO)"[<4LD*`D>+]0ATBQ]\-C,80>TR`*VAY4"TA4YL1LK9ITJ9* M*V)!Z\`3TXZT!!T*-6DFYU)SR-?D$S4^MQ"H MC_*>1Q]^K/>S51F/)]8&(87I5/SXJ:I]/%?Z>*[T\8]0Z8.\D1=]L#.PYM$3 MZG[TNL+4M<8D@1=B*EW4,5NRLE'1G[++VNOQOP=#?CZ8VC\_Z>**QUX^=&ZY M^"B)-/[PX^:[,TQ).TI;<^0O!6@Y)1)T,GH%=$;)N'S4J10>[-]R0CEG!9H< M?6K9N#`J[@%+C_=$+:I$1I7>KS'](TLEQ&@*[YDH>=>5BZHHXH(Q)NX)&&,< M='L]46`&?(2&-6$@-%!YL&BQ<4K21G2'$2B+@WOAT2XZCJ4[V4IX7W%M$G/+ M$X4PM(_XQM`K0+&#.YN\+W0=L-[*+I]K5X<1O/P_]D/=T6,?SB^37XO9KG/: M0H(S%M54BHY*/K(7')^LP`F,9"0_D,%FRS?P5B$@T\%YIS?P.]4&6%/OSO*S MV8'X\'Q>K9&A^YWNF/_?)8D,3@3BHXB21M:A'&=%&?.#Q4,F?2'V^:"RW/?] M\53"B1*Z6B[W5/WQ*\KC.C`5%0KO[!V>!X4O:IE?]A.U7F>Q2D:K MP\*'MW&TM+H_I]V>RT,UJTB9Q?7O7F48H\4<04K(RS!'YU@'H9OK<7!) M'QX'HQ9'\/";*`5N`[\4_LSR=$78/IJN/-1-0^/H7/.4,,P:+U1\@%NY,GZ! M;,8'+RU,Q1IZ#5TSL)8,LN%9$H0S)&3_0@S&4O&-P,-'P"?H#T=!OX^5)WJC M_DC@_W6Z4S[F8]980BC*NUEZ](L,9VB`2!?[=;Q4Y5CPQM!",<2;*!!$W:&# M$,O8`D_T.':54'>P)W+%E=*8)V&\*NQXSZVQ!G7F#E!U)]Z5X2OS$\+6L$*9MGA4>VT:JLVB21VW63F..C:73-F<9RH-XZ5A1 M<>$%;DWF3RBXD#_VBR9&GB72PI8^[2-D#KC(L16^JBBFAC`"Q]C">TK_NHT2 M,BP]KHM7.%^6_W<*M*::N%3U@VVU2ORB8GM M]E(@JQ830L9H*5(Y4`GG9'.[9H(*NA$`?$O11+.N44UG;JMR4Y:B>D*PI>R-P:[H8&6)=I%E(NCPZ8 MG$\MTK!$%L>D%-H(H]WI[?(F<-P_LT`PRIW^K@#?.KF+C"#K[B.(R,NY(4RUEK2#X=T&5T4HU=7U` MDR6L5?W(7FE+:]6(1"::6>N:(>'F_W5=@85245^0J!+5D7HJ1"\M_&X'2R7W MNY;WV7MB2[VN:FHX1OOH-'72!_M/'IAJ;C#$Y@8#,<1J.2;Q@X(L3VH33[+J M5B?[^\J,PV9_%Z8.!_DW:_&J>E:6X2A]0 M-:E<=EU\`JT:TN=O"81'WE$6MG4;C#4Y^T!\Z)NMS*!XQ&.%AT):K..^LHX1 M&9+Y)O0?J?:D%SF4SJ1>R/Z^D.0?2W=SJ`*G[J*B$26G_.B:CB>CK5:TUN;F M!1V/K>4T7SYJPMM1)FWD&,MNT%1RGJQ$%'36"!76M5Z7K)BGS^YT+>^R+H\XIXTB/%(/K/"2XCB5/>$1X9`K.!6U MG%LB81[=5'10:<]@8JJE!1^/NP`JM!/>,L^8A]KNHZ**2!L??AS6./GPH]O* M@;GNU@1W&=BTK@`8ZSKU?*>N?8\N_V+?I&L_M2_"O>2QX%G"/'['628ZY?:" M3@TFJ("]%>?V?89A461X$#9:J("Q7<;>+WT/ M!.Q-]X/A`*MZ21B\%GWJ]SZYWSL9]DI4V*M082\C8@T:WSJ0X4<,Q,GI&U)\ M!+,\_93-HQ!CKYCPM`!K!&\+4/H:Q]/'\\"FK:D(Z0U#0_4'7M"Z?[\OVY:W?SKVF#L]K9F^^<+H'6G`?RV=T1XUM/>GV M:EL(-#7FM""K*&T[T`$0"10HD+O_A"M.\$'+Y25&.[K7B7RV.TGPU_:+1/XF M=XV,!P(XM6?);5N>GW!BCE7-6!ZELDY]\9B,!`NIM+3&'0BR=BP#Y;'IR$&] M&M%$@?I!?Q],I6E?#?;42DAM"N5(UKRWA)*#KZ.D"0DAJ;F;IN'SDJA;\]9%K6#QVW/X*EA/[E*>58;L=OU&@$'JE>Q;2(DH2#7F=_*GZ)M@H7IJ+R'Q.97JI_OHEUM_1$B,P7<:CMZQ;1& MYC#9J-.73'4)[E6AJM!<&(#9O\>T&Y2#;I^'Q).'7UII9V* MM8^=`@>,C"^B>4(7LQA7LQ['!U?S'SHGJ^$&)B^M97MYT^^`+5J7-[WN)H'3 M[W7&S0+GNE%H\)PL%K*J<+`(4;DV.K=F-&C(K5$I.,VWJK^BVG=.G5\[(/]1 M'WV<'SS]\.-VK5\3H/J6L8?CAL3KLSC=^-P4J3-_75G.*WNH]N'(3-UFC%0? M]8+!9(C'<[K38#!&-VRXWPMZ^^A8#(;38`1RR;ZSWLE7L,K\<9-?-O:]WQA/.&! MIX+N;MQ_''.H,S)_2/"`L0KG'Y8_UWBC-=`!]GZP+QW7P;X`ZQPQH!'_,!PX MPF@C+Z/]ZB]G^ZB%EAT6+E\<< M]A0[X`7VQ]-=M("G8@?6MM<%GASM\JB=B3N7<=L5&,E-[5N%&.6>IXZS5'E3!#JX!K`3_P7.ZDWB6O M4&W#0&?!J'Q$Z=^(8P[TGU+=0=2R!%JY5W#\;]KI/S@M9\8[915LMX$!](-]/`33HS]1/IV6*GW-*9&&,3#*XF+HT`4:.4"9ZOTC MBYTX"<>-=8?KW;CH&,/6W.&",Z731:UK3+Z4:VY?!T&Y&61Z+O&XNZPX1:J` M8N,R+(G9#=*OZHBO8S0R^>19(),$_YCE_HUKS(O.,,S=/&HA&D*X%+R4@Y5M MX!G7!:=NN\&'6EJR$U<-'QI7(4[K%_WH@[-(N)=9;A>%Z6Q&<=6_"@X&&.S7 MIL'&%C`/T+DM20,=F*TZBQ@%,(N'T](LJSD@K//2=$0J>=(="?"11X36]+HL MAN$OQ$,&?5O+UNVGTW0!0@:&@(:ED@ZF"*E7IP#>8N?!K>OQ40;6_H MQM>T5S8/GT)F?!I)AI?B7+=&I3@)`[!9R1PJHMU.16/-E5Y%N6>;:`H55^%F7!T%/`JO]@?@CNP^'5*P9O\#Y M<^>*$C2`G.K_HE>#!TCQ,5;7362P$.O2W47^71@K'4XL8QM]=TA2U,S`7E@FFW!@4,3.'MP%"(A2YGTIG;+'4XRR>A%4ZEU%+NU*<+@H@T45YTG'7!K.IXE[[M7 MB>9X>!L+_U)$N"..C!?Q^<^A^K=+ZM."QW>-7F']A78!Y;W[!`'6Z^*]DO6N MG(3'@2U1K"AOQOFS=@H$92FN$'%I2WSX^%LVQ8[Z:[?>B'5L_5C=/+(=#9J^ M?+X\\_GRS,]Z>:9?*8EG>FF,N^VX]?D2SN=+.*/G2SB?+^'\Y[V$T[,/2-30 MP5&JJ[*E7J]_]@];DNQO?;=G?3WT59^7^K:5[5:DX<-_XGM#MZ.)N5ST^9K1 M?_)K1K<-^FTIWMJ">HXB^KEO,_6!N;F^W'3;#6&^>+X;]?ENU.>[49_O1GV^ M&_7Y;E09<'R^&[5]R9[O1FT:]O/=J)_M;E0?Q;3DW)&1<]M"F>IN:;L#E M2UNWW+W6%\\7Z#Y?H/MWCS1TY-01OT/GXOF8Y,[T,)SBO7ORFJ](3XE.G?.71K`\>1TS\I.W<,"SD& MG'.BQD"19(8\5153RLF M^5Q`\KF`Y',!R><"DC]+`4E/=;54Q&*F^^$M->6=.G7CR!RYL;#7+D/$)J^VT+>#E$[P/'6]-VV_GCQ2 M?6[K880M(7D#?L3INF*W/:P%ZBE`_^7?IGY??>GK=;1:6&3#.M9;^.PKY'7P ML]+^<]8R^[AZ86TF#\L5YSL,,Q$*1;1'6?)IIQ.XB]83!W'A&)+/I<=^UM)C M'C?)$N]DS3MER="[!<[%)^!Z#@=Y3_L;'X.$[VCI[I>9>.CH MJMO^V%.^QHR3OT[".%YYF_+WM(O^1>_MC=WIB_POC+EOP_#!(-&LX:PAX^_"G.\LITN9,=_6:P+%S/.USY_UVN='5^E"'HN]QF.QK0OR?%^TRMI[ MVGW1K3=$>TX:GJM`MB'P[M0"[=]DZ0VG"N/:/;J>.C^)N?:*$S0O0%8@V'U3 MAQN_V@>=XAFA>K>SCB'F\&2MM'<;A.S&LNIMHNXJM,P41QZQ&C_5L,"U"SC3T2%/&8J_35I)E61*+[QSYV$&?UDOB/#9JGPOD= MRC'DXP'6T#.!]"A4+35RHS)!/9]=/ M,"D?XXE-U.1*)//6`B9?&<&K3Y>8G#]2[@LG\<>3$$WBN2FKVQ<:>"*PI#J+ M38KCQ*K`<$CE45I7X4)IV>L,",2YDIDE$^KOOY8IS=>DAF362RO.J*H(R1>] M>:C2/\-ZXS2E)YH(]M3.Z0+;^RKA+=T&T=@6TG.D[ M[5S=>&WR_ST99E>IV:31Y(81:$]NU0AH/-YN[:W:1W40O`LV&#[#4=/6&DX; M?VVTDH:]IE\/N$*I)N/K/*O6;)8Q,6%*;Y)Y^VYS+,$WL'!8P.,$:^XJD\3K M\M7K]N84OG2.5=/81-C8P*-D[@V;ICWH-OW::R3RH/'7VB"D^0C2+5QM.[MM M",1-#QYMNF99?]+&K[6U<>=J`_ZB86/HA\><:!XTRG9X"YPA/-#*L9CSUEA, M0X/GF+WUJ)OQ;6I.2!U)A>;KC7BQ%Z=[W\3@^*B.&D6!/-K,U05E64K2O9]` M\[/LKJ/+FWH,LNB0=!/OG>N2#G0TK@A@1Z6:-QHD%;P/^I%+!%K%I>EK M<8`7WE0SSK?F]?+X[]RZ9V>RU>4W8!=GT/"!SA^E/+Q:UY1*%R"F@N@#Y2-B M/AE8R>&N?:M]Y!_)8[GKW.1#5R,YOTQ^+6:[3I6,'A=6*[#>`[011:4Z9Z). MT!"L;F55K,("K2[J-)`9TU:YAG$`BUUK+ZN]TQOXG>JJ:4V]VY2E1WWW(,A)!4_I3K(_8!KC]7W68.&//5W8W-2E MTQ1&UCPQ8EV=W:;89*WFXE<;RWL=<,[C912O9E5>,!'QS*:B'"B5-QCW/-6G M+"[X`%,+&\TVK\],K<^L:7WH/^([F07"`/0FXPZOH?:(VF\T._J-ADL3(<%R M.,'"?"#8U+V'\08[J:4));^V:F,P>,+@KF_C?-N&AXV.9=M]YFVMO`W?TV7E MEI<+;/$J2RN^((9YZ(INN&[[UN4PJ6I\G"CA*LCG!\QA2?QTA;M/86#ZG7E-].N`"/ACB8NE&\M?Y<2OWFT M('#G#(<]QHHM+$ARDQF0I)=NE0VM!37>-*TY'_[7DZC#*FU MR-.]SL2KB'A@\^N6W?OHERCM!OYF=I-D/RX;UJ"6WK)&:VUWCEZ(E[*!9F3S MLBF7K1G+_?@,NVW:^X0DN]8@"1_^+I_`Y9V?JI2;"MNXJSASG"\1_" M+$#]14XF;O0W^H/@WW[Q"\RB;9W;SY'+VCI%Y+"I'**'EWWN[.A6*%#>Z6KF M^SU.8V-.]"-X]T^:J]R.9]@K[I%30?%@H;8V\;L*?-_^/C?1F[0V03E?[38# M)0#S,#R'5;5Q@N=3ZN0?62J_($OYRK_,ZVP3@ MQG30#?L61B4OQ5.WVVV,C37G('HJJ+/O&[Q.@F+K0Y.FZ#6**:,-YJ=*8OP# M)C'6GS:J0LR8],%!3(IL,$*=]?L$!(C8I+O?#+C8\9%UK@I*%!P)7H>2&Y[T ME50QH5:TWH`25?VDU9YL,V?M8*03$-_XY@7,XSQ720`,!K9&P[<()V/0.4[) M;-^TO;=H11K_CPK*VAV%K8%&Y]YH*;*MS#)YJ)/')M1^ MQN#)PE._`+:P@?Z73JS>1Z$?3.%,0BKO,:R>WK3MM2TSL-M>VR9#HFW[-PYE MBT3GCEUN)?7OJXI6Z!=NTG;["\_EN&[B3@ZG7?S M2SHKM\&_:@#_&N[77DM\[D,0L!F MDDC03XDQ2;0]WA)M?P+8WGCA\4\(FS4AOYZCKPL_R7+_=)]P2&Y6WR1D*@C` MO9UY',B+]BB\DMJ^.^,J_N<4*PKQQH>0<3S4/Y1?9(R$L>1=UNJI6;Q&&QT47WNJYU& M:5K[:2.`KIAG+Y11DLV->*\;WZO!EO6N,ODHM0469V,298-+-WA$X;5Q=(UM MO?35@U:OP.\4AOND;=;8PI83[@XW3QCU$7`NSN33!_K8;+M15W#"."[X$2;RJTD42;<@;>5D4Y5?_ M!U!+`0(4`Q0````(`-V3;$>0&ZUDM`$``(L6```3``````````````"``0`` M``!;0V]N=&5N=%]4>7!E&UL4$L!`A0#%`````@`W9-L1TAU!>[%```` M*P(```L``````````````(`!Y0$``%]R96QS+RYR96QS4$L!`A0#%`````@` MW9-L1TOY$!F$`0``@Q4``!H``````````````(`!TP(``'AL+U]R96QS+W=O M&PO=&AE;64O=&AE;64Q+GAM;%!+`0(4`Q0````(`-V3;$<;I[`\ M6@(``'0+```-``````````````"``3(/``!X;"]S='EL97,N>&UL4$L!`A0# M%`````@`W9-L1RHE:(ZM`P``]@L```\``````````````(`!MQ$``'AL+W=O M&PO=V]R:W-H M965T&UL4$L!`A0#%`````@`W9-L1Z*SR4C7`0``+`4``!@` M`````````````(`!(!P``'AL+W=O``!X;"]W M;W)K&PO=V]R:W-H965T&UL M4$L!`A0#%`````@`W9-L1_J"Q/'P`P``]1```!@``````````````(`!.R<` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`W9-L M1YB:4J"C`0``L0,``!@``````````````(`!#2\``'AL+W=O8P``!X;"]W;W)K&UL4$L!`A0#%``` M``@`W9-L1UKR=ZZB`0``L0,``!D``````````````(`!OS(``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`W9-L1YI^082B M`0``L0,``!D``````````````(`!2#@``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`W9-L1\H97.M;`@``Z@@``!D````` M`````````(`!U#T``'AL+W=O&PO=V]R M:W-H965T&UL M4$L!`A0#%`````@`W9-L1ZRUZF:Q`0``%@0``!D``````````````(`!2T0` M`'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@` MW9-L1_>W:O4I`@``>@8``!D``````````````(`!ADP``'AL+W=O&PO=V]R:W-H965T&UL4$L!`A0#%`````@`W9-L1_4,5G[V`@`` MSPL``!D``````````````(`!I%4``'AL+W=O&PO=V]R:W-H965T> M2")U*@,``+,.```9``````````````"``3I>``!X;"]W;W)K&UL4$L!`A0#%`````@`W9-L1V=;@[@@`@``2@<``!D````````` M`````(`!FV$``'AL+W=O&PO=V]R:W-H M965T"%*^C?P(``'T(```9 M``````````````"``=YI``!X;"]W;W)K&UL4$L! M`A0#%`````@`W9-L1Y8Y707P`@``P@L``!D``````````````(`!E&P``'AL M+W=O&PO=V]R:W-H965T6I=,(%P(``'T&```9``````````````"` M`8YS``!X;"]W;W)K&UL4$L!`A0#%`````@`W9-L M1]3M/@R[.0``I!`!`!0``````````````(`!W'4``'AL+W-H87)E9%-T&UL4$L%!@`````K`"L`GPL``,FO```````` ` end XML 12 R33.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 9 Months Ended
Apr. 06, 2015
Jul. 21, 2015
Oct. 31, 2013
Sep. 30, 2015
Sep. 30, 2014
Aug. 09, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Share-based Awards Other than Options       $ 2,700,000    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross     675,000      
Granted,Weighted Avg.Exercise Price       $ 0.17 $ 0.35  
Employment Agreement [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 14,245,227          
Granted,Weighted Avg.Exercise Price $ 0.1525          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights       The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.    
Common Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock Issued During Period, Shares, Employee Stock Purchase Plans       157,705 99,585  
Employee Stock Purchase Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock purchase price       85.00%    
Weighted-average purchase price       $ 0.10 $ 0.28  
Weighted-average fair value       $ 0.12 $ 0.32  
Compensation expense       $ 3,129 $ 4,730  
Employee Stock Purchase Plan [Member] | Common Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Stock Issued During Period, Shares, Employee Stock Purchase Plans       157,705 99,585  
2013 Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Payment Award, Number of Shares Authorized           8,860,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross   30,000,000   6,170,748    
2013 Plan [Member] | Employment Agreement [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 2,622,948          
2013 Plan [Member] | Common Stock [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross       30,052,620    
2004 Plan [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Payment Award, Number of Shares Authorized           2,435,500
Outside of 2013 Plan [Member] | Employment Agreement [Member]            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 11,622,279          
XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 R25.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transactions - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Oct. 31, 2014
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2013
Business Acquisition [Line Items]            
Prior Period Notice       60 days    
Business Combination, Consideration Transferred $ 250,000          
Amway Global [Member]            
Business Acquisition [Line Items]            
Commissions paid   $ 70,000 $ 59,000 $ 239,000 $ 160,000  
Amway Global [Member] | Sales [Member]            
Business Acquisition [Line Items]            
Concentration Risk, Percentage   45.00% 48.00% 49.00% 41.00%  
Access Business Group International Llc [Member]            
Business Acquisition [Line Items]            
Proceeds from License Fees Received   $ 39,000 $ 31,000 $ 143,000 $ 129,000  
ABG [Member]            
Business Acquisition [Line Items]            
Purchase Order Placed       $ 519,000    
ABG [Member] | Sales [Member]            
Business Acquisition [Line Items]            
Concentration Risk, Percentage   14.00% 30.00% 15.00% 35.00%  
ABG [Member] | 2014 Program [Member]            
Business Acquisition [Line Items]            
Purchase Order Received           $ 1,800,000
ABG [Member] | 2013 Program [Member]            
Business Acquisition [Line Items]            
Purchase Order Received           $ 1,500,000
XML 15 R9.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2015
Significant Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Note 3—Summary of Significant Accounting Policies
 
Management Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
 
Revenue Recognition
 
Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $2.9 million and $3.2 million, respectively. Included in deferred revenue at September 30, 2015 is $2.7 million for test kits that are still outstanding one year or longer after initial kit sale, of which $0.3 million was sold directly to consumers (credit card payments) and $2.4 million was sold to distributors for the promotional bundle. Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs).
 
The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $39,000 and $167,000, respectively, of breakage revenue related to unredeemed genetic test kits sold in the first, second and third quarters of 2012, compared to breakage revenue included in genetic test revenue in the three and nine months ended September 30, 2014 of $86,000 and $242,000, respectively, related to unredeemed genetic test kits sold in the first, second and third quarters of 2011. The Company expects to continue to recognize breakage revenue on a quarterly basis based on the historical analysis.
 
Sales Commission
 
On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company accounts for sales commissions due to Amway Global under the Merchant Network and Channel Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. The cost of commissions was $70,000 and $59,000 for the three months ended September 30, 2015 and 2014, respectively, and $239,000 and $160,000 for the nine months ended September 30, 2015 and 2014, respectively.
 
Accounts Receivable
 
Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date. No accounts receivable reserve is required at September 30, 2015 as all accounts receivable are expected to be collected.
 
Inventory
 
Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict® genetic tests kits to dental offices. The agreement with the fulfillment provider requires them to purchase and fulfill all materials related to the PerioPredict® test and Body Key™ genetic test kits, with the Company’s approval. The Company reimburses the fulfillment provider for materials and pays fulfillment charges when the product is shipped. During the nine months ended September 30, 2015, the Company made a onetime purchase of $33,000 of inventory related to its PerioPredict® test from our fulfillment provider, which is held at our fulfillment center. The balance of our inventory is related to our Inherent Health® brand and is stored at a separate facility. When a kit is sold, the corresponding cost of the kit is recorded as deferred cost of goods sold and removed from inventory. Any kit components remaining at the fulfillment center are reflected in inventory with a corresponding offset to accounts payable.
 
Inventory consisted of the following:
 
 
 
September 30, 2015
 
December 31, 2014
 
 
 
 
 
 
 
Raw materials
 
$
142,351
 
$
163,239
 
Finished goods
 
 
16,742
 
 
8,336
 
Total inventory, net
 
$
159,093
 
$
171,575
 
 
Stock-Based Compensation
 
The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation. The standard addresses all forms of share-based payment (SBP) awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. We expense SBP awards within compensation cost for SBP transactions measured at fair value. Compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the effective date shall be recognized as the requisite service is rendered on or after the effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated under the Black-Scholes option pricing model. Common stock purchased pursuant to our employee stock purchase plan will be expensed based upon the fair market value in excess of purchase price.
 
Income Taxes
 
The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.
 
Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.
 
As a result of the Company’s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $14.3 million into common stock of the Company prior to an additional investment by an unrelated investor.
 
The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.
 
Research and Development
 
Research and development costs are expensed as incurred.
 
Basic and Diluted Net Loss per Common Share
 
The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:
 
 
 
As of September 30,
 
 
 
2015
 
2014
 
Options outstanding
 
 
22,258,659
 
 
4,810,675
 
Warrants outstanding
 
 
88,301,079
 
 
37,269,125
 
Total
 
 
110,559,738
 
 
42,079,800
 
 
Fair Value of Financial Instruments
 
The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
 
Cash and Cash Equivalents
 
The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.
 
Fixed Assets
 
Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.
 
Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $19,500 in the Projects in Progress account, all of which is laboratory equipment.
 
Segment Reporting
 
As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
 
Recent Accounting Pronouncements
 
FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.
 
In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts.  Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet.  Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements.
 
FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers.
 
In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps:
 
⋅
Identify the contract(s) with a customer.
⋅
Identify the performance obligations in the contract.
⋅
Determine the transaction price.
⋅
Allocate the transaction price to the performance obligations in the contract.
⋅
Recognize revenue when (or as) the entity satisfies a performance obligation.
 
The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application.
 
In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements.
 
FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.
 
In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance.  The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation.  ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.
XML 16 R29.htm IDEA: XBRL DOCUMENT v3.3.0.814
Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail)
 1 Months Ended
Dec. 23, 2014
2014 Placement Agent Warrants [Member]  
Stockholders Equity [Line Items]  
Risk-free interest rate 1.98%
Expected life 7 years
Expected volatility 138.40%
Dividend Yield 0.00%
Lender Warrants [Member]  
Stockholders Equity [Line Items]  
Risk-free interest rate 2.17%
Expected life 10 years
Expected volatility 121.60%
Dividend Yield 0.00%
XML 17 R28.htm IDEA: XBRL DOCUMENT v3.3.0.814
Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail)
 9 Months Ended
Sep. 30, 2015
$ / shares
shares
Reserved for issuance 140,958,605
Total common shares issued and outstanding at September 30, 2015 172,841,047
Total common shares outstanding and reserved for issuance at September 30, 2015 313,799,652
Warrants with common stock additional purchase rights associated with December 2014 private placement [Member]  
Reserved for issuance 50,189,431
Strike Price | $ / shares $ 0.1003
Expiry Dec. 23, 2021
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors [Member]  
Reserved for issuance 100,000
Strike Price | $ / shares $ 0.2500
Expiry Sep. 08, 2024
Shares reserved under outstanding stock options and options available for grant [Member]  
Reserved for issuance 52,311,279
Rights Associated With Employee Stock Purchase Plan [Member]  
Reserved for issuance 346,247
Warrants to purchase common stock associated with December 2014 venture loan and security agreement [Member]  
Reserved for issuance 2,492,523
Strike Price | $ / shares $ 0.1003
Expiry Dec. 23, 2024
Warrant Two [Member]  
Reserved for issuance 437,158
Strike Price | $ / shares $ 0.2745
Expiry Jun. 29, 2017
Warrant Three [Member]  
Reserved for issuance 20,655,737
Strike Price | $ / shares $ 0.2745
Expiry May 17, 2020
Warrant Four [Member]  
Reserved for issuance 14,426,230
Strike Price | $ / shares $ 0.2745
Expiry Aug. 09, 2020
XML 18 R30.htm IDEA: XBRL DOCUMENT v3.3.0.814
Capital Stock - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 23, 2014
Sep. 30, 2014
May. 17, 2013
Sep. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Aug. 09, 2013
Stockholders Equity [Line Items]                
Convertible preferred stock, par value       $ 0.001 $ 0.001      
Convertible preferred stock, shares authorized       6,000,000 6,000,000      
Common stock, shares authorized       450,000,000 450,000,000   300,000,000  
Common stock, par value       $ 0.001 $ 0.001   $ 0.001  
Common stock, shares outstanding       172,841,047 172,841,047   172,683,342  
Allocated Share-based Compensation Expense       $ 3,000 $ 9,000      
Common Stock Shares Issued       172,841,047 172,841,047   172,683,342  
Common Stock Par Or Stated Value Per Share       $ 0.001 $ 0.001   $ 0.001  
Interest Paid         $ 352,500 $ 0    
May 2013 Private Placement [Member] | Minimum [Member]                
Stockholders Equity [Line Items]                
Common stock, shares authorized               150,000,000
May 2013 Private Placement [Member] | Maximum [Member]                
Stockholders Equity [Line Items]                
Common stock, shares authorized               300,000,000
Venture Loan [Member]                
Stockholders Equity [Line Items]                
Warrants exercise price per share $ 0.1003              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,492,523              
Warrants and Rights Outstanding $ 261,000              
Proceeds from Issuance of Long-term Debt 5,000,000              
Interest Paid       $ 115,000 341,000      
Paid-in-Kind Interest       38,000 115,000      
Debt Instrument, Unamortized Discount       $ 280,000 280,000      
Investor [Member]                
Stockholders Equity [Line Items]                
Sale of Stock, Consideration Received on Transaction $ 5,025,000              
Sale of Stock, Number of Shares Issued in Transaction 50,099,700              
Warrants exercise price per share $ 0.1003              
Sale of Stock, Price Per Share $ 0.1003              
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 50,099,700              
Danforth Advisors [Member]                
Stockholders Equity [Line Items]                
Common stock, par value   $ 0.25       $ 0.25    
Warrants Fair Value Disclosure   $ 24,000       $ 24,000    
Common Stock Shares Issued   100,000       100,000    
Common Stock Par Or Stated Value Per Share   $ 0.25       $ 0.25    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage   50.00%            
Common Stock [Member]                
Stockholders Equity [Line Items]                
Sale of Stock, Consideration Received on Transaction     $ 12,000,000          
Common Stock [Member] | May 2013 Private Placement [Member]                
Stockholders Equity [Line Items]                
Sale of Stock, Consideration Received on Transaction     $ 12,000,000          
Sale of Stock, Number of Shares Issued in Transaction     43,715,847          
Sale of Stock, Price Per Share     $ 0.2745          
Warrants 2013 [Member]                
Stockholders Equity [Line Items]                
Percentage Of Warrants Exercisable     63.00%          
Percentage Of Warrants Exercisable After Shareholder Approval     37.00%          
Warrants exercise price per share     $ 0.2745          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights     32,786,885          
Warrants 2014 [Member]                
Stockholders Equity [Line Items]                
Warrants and Rights Outstanding             $ 5,200,000  
Placement Agent Warrants [Member]                
Stockholders Equity [Line Items]                
Allocated Share-based Compensation Expense         $ 780,000      
Warrants To Purchase Of Common Stock         2,295,082      
Warrants exercise price per share       $ 0.2745 $ 0.2745      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights       89,731 89,731      
Warrants and Rights Outstanding             $ 9,000  
Payments for Underwriting Expense         $ 218,000      
XML 19 R31.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Share-based Compensation $ 252,554 $ 109,642 $ 651,789 $ 354,441
Stock option grants beginning of period [Member]        
Share-based Compensation 251,374 108,363 491,197 348,545
Stock option grants [Member]        
Share-based Compensation 92 0 157,463 1,166
Employee Stock Purchase Plan [Member]        
Share-based Compensation $ 1,088 $ 1,279 $ 3,129 $ 4,730
XML 20 R8.htm IDEA: XBRL DOCUMENT v3.3.0.814
Liquidity
 9 Months Ended
Sep. 30, 2015
Going Concern [Abstract]  
Liquidity
Note 2—Liquidity
 
The Company has experienced net operating losses since its inception through September 30, 2015. The Company had net losses of $6.3 million for the year ended December 31, 2014, and $6.04 million for the nine months ended September 30, 2015, contributing to an accumulated deficit of $127.1 million as of September 30, 2015.
 
On May 17, 2013, the Company entered into a Common Stock Purchase Agreement (the “2013 Purchase Agreement”) with various accredited investors (the “2013 Investors”), pursuant to which the Company sold securities to the 2013 Investors in a private placement transaction (the “May 2013 Private Placement”). In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 shares of common stock at a price of $0.2745 per share for gross proceeds of $12,000,000. The 2013 Investors also received warrants to purchase up to an aggregate of 32,786,885 shares of common stock an exercise price of $0.2745 per share (the “2013 Warrants”). The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.
 
On December 23, 2014, the Company entered into a Securities Purchase Agreement (the “2014 Purchase Agreement”) with various accredited investors (the “2014 Investors”), pursuant to which the Company sold to the 2014 Investors in a private placement transaction (the “December 2014 Private Placement”) an aggregate of 50,099,700 shares of common stock at a price of $0.1003 per share for gross proceeds of approximately $5.025 million. The 2014 Investors also received warrants to purchase up to an aggregate of 50,099,700 shares of common stock an exercise price of $0.1003 per share (the “2014 Warrants”). The 2014 Warrants are all currently exercisable and have a term of seven years.
 
On December 23, 2014, the Company entered into a Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $5.0 million. The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. At September 30, 2015, the rate was 9.0% per annum. The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (10) years.
 
 The Company’s financial statements have been prepared assuming that it will continue as a going concern which contemplates the realization of assets and satisfaction of liabilities in the normal course of business.  The financial statements do not include any adjustments that might result from the outcome of this uncertain realization. The Company expects to incur additional losses in 2015 and, accordingly, is dependent on financings and potential revenue to fund its operations  and support the market adoption of the PerioPredict®  test. The timing of any revenues that the Company may receive from the PerioPredict®  test is uncertain at this time, and is contingent upon a number of factors, including the Company’s ability to consummate arrangements with partners to promote the PerioPredict®  test, the Company and its partners’ ability to develop insurance plans that provide for use and reimbursement of the PerioPredict® test, or other possible arrangements, and to develop a viable market for such plans, and the timing of utilization of the PerioPredict® test pursuant to such plans. The Company expects to have the cash resources necessary to fund its operations into the second half of 2016.
 
The ability of the Company to realize the carrying value of its fixed assets and intangible assets is dependent on management’s ability to successfully execute on its plan. The Company needs to generate additional funds in order to meet its financial obligations. If it is unsuccessful in doing so, the Company may not be able to realize the carrying value of its fixed assets and intangible assets.
XML 21 R32.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) - $ / shares
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Shares    
Outstanding, beginning of period 4,523,900 5,884,050
Stock options granted 17,793,027 137,000
Stock options exercised 0 0
Restricted stock exercised 0 0
Canceled/Expired (58,268) (1,210,375)
Outstanding, end of period 22,258,659 4,810,675
Exercisable, end of period 3,067,959 723,925
Weighted Avg. Exercise Price    
Outstanding, beginning of period $ 0.39 $ 0.43
Stock options granted 0.17 0.35
Stock options exercised 0.00 0.00
Restricted stock exercised 0.00 0.00
Canceled/Expired 0.28 0.43
Outstanding, end of period 0.22 0.43
Exercisable, end of period $ 0.34 $ 0.71
XML 22 R2.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED BALANCE SHEETS - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Current assets:    
Cash and cash equivalents $ 6,270,644 $ 11,466,807
Accounts receivable from related party 40,603 23,544
Trade accounts receivable 5,305 14,013
Inventory 159,093 171,575
Prepaid expenses 531,628 504,719
Total current assets 7,007,273 12,180,658
Fixed assets, net 658,899 773,779
Intangible assets, net 137,523 195,765
Other assets 99,135 116,919
Total assets 7,902,830 13,267,121
Current liabilities:    
Accounts payable 576,210 513,927
Accrued expenses 455,299 343,225
Deferred revenue 2,925,725 3,154,498
Total current liabilities 3,957,234 4,011,650
Long Term Debt 4,790,891 4,738,614
Total Liabilities $ 8,748,125 $ 8,750,264
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Common stock, $0.001 par value - 450,000,000 and 300,000,000 shares authorized at September 30, 2015 and December 31, 2014, respectively; 172,841,047 and 172,683,342 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively $ 172,843 $ 172,686
Additional paid-in capital 126,107,664 125,434,483
Accumulated deficit (127,125,802) (121,090,312)
Total stockholders’ equity (deficit) (845,295) 4,516,857
Total liabilities and stockholders’ equity (deficit) $ 7,902,830 $ 13,267,121
XML 23 R6.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (6,035,490) $ (4,697,931)
Adjustments to reconcile loss to net cash used in operating activities:    
Depreciation and amortization 214,180 190,012
Amortization of loan issuance costs and FV of warrants 81,908 0
Stock-based compensation expense 651,791 354,441
Changes in operating assets and liabilities:    
Accounts receivable 8,708 (5,926)
Receivable from related party (17,059) 499,987
Inventory 12,482 23,248
Prepaid expenses and other current assets (26,909) 115,005
Accounts payable 62,283 (537,561)
Accrued expenses 112,074 (62,224)
Deferred revenue (228,773) (752,212)
Net cash used in operating activities (5,164,805) (4,873,161)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital additions (41,057) (92,278)
Net cash used in investing activities (41,057) (92,278)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Private placement offering costs (7,100) 0
Proceeds from employee stock purchase plan 16,799 27,557
Net cash provided by financing activities 9,699 27,557
Net (decrease) in cash and cash equivalents (5,196,163) (4,937,882)
Cash and cash equivalents, beginning of period 11,466,807 7,542,281
Cash and cash equivalents, end of period 6,270,644 2,604,399
Supplemental disclosures of cash flow information:    
Cash paid for interest $ 352,500 $ 0
XML 24 R22.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) - USD ($)
Sep. 30, 2015
Dec. 31, 2014
Inventory Disclosure [Line Items]    
Raw materials $ 142,351 $ 163,239
Finished goods 16,742 8,336
Total inventory, net $ 159,093 $ 171,575
XML 25 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies- Additional Information (Detail) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Significant Accounting Policies [Line Items]          
Deferred revenue $ 2,900,000   $ 2,900,000   $ 3,200,000
Sales commissions 70,000 $ 59,000 $ 239,000 $ 160,000  
Percentage of cash discount offered to customers     2.00%    
Projects in Progress 19,500   $ 19,500    
Convertible Debt 14,300,000   14,300,000    
Fulfillment Center [Member]          
Significant Accounting Policies [Line Items]          
Payments To Acquire of Inventory     33,000    
Genetic Test Revenue [Member]          
Significant Accounting Policies [Line Items]          
Breakage Revenue 39,000 $ 86,000 167,000 $ 242,000  
Customer Payment [Member]          
Significant Accounting Policies [Line Items]          
Deferred revenue 300,000   300,000    
Kits Components [Member]          
Significant Accounting Policies [Line Items]          
Deferred revenue 2,700,000   2,700,000    
Distributors [Member]          
Significant Accounting Policies [Line Items]          
Deferred revenue $ 2,400,000   $ 2,400,000    
XML 26 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 27 R7.htm IDEA: XBRL DOCUMENT v3.3.0.814
Basis of Presentation
 9 Months Ended
Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation
Note 1—Basis of Presentation
 
Interleukin Genetics, Inc. (“the Company”) develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive or therapeutic measures. The Company’s principal operations and markets are located in the United States.
 
The accompanying condensed financial statements include the accounts of the Company as of September 30, 2015 and December 31, 2014 and for the three and nine months ended September 30, 2015 and 2014.
 
The financial statements have been prepared by the Company in accordance with accounting principles generally accepted in the United States of America for interim financial reporting. Accordingly, they do not include all of the information and notes required by generally accepted accounting principles for complete financial statements. These unaudited condensed financial statements, which, in the opinion of management, reflect all adjustments (including normal recurring adjustments) necessary for a fair presentation, should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2014. Operating results are not necessarily indicative of the results that may be expected for any future interim period or for the entire 2015 fiscal year.
 
For information regarding our critical accounting policies and estimates, please refer to “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2014 and Note 3 to our condensed financial statements contained herein.
XML 28 R3.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED BALANCE SHEETS [Parenthetical] - $ / shares
Sep. 30, 2015
Dec. 31, 2014
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 450,000,000 300,000,000
Common stock, shares issued 172,841,047 172,683,342
Common stock, shares outstanding 172,841,047 172,683,342
XML 29 R17.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2015
Significant Accounting Policies [Abstract]  
Management Estimates
Management Estimates
 
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates. The Company’s most critical accounting policies are more fully discussed in these notes to the financial statements.
Revenue Recognition
Revenue Recognition
 
Revenue from genetic testing services is recognized when there is persuasive evidence of an arrangement, service has been rendered, the sales price is determinable and collectability is reasonably assured. Service is deemed to be rendered when the results have been reported to the individual who ordered the test. To the extent that tests have been prepaid but results have not yet been reported, recognition of all related revenue is deferred. As of September 30, 2015 and December 31, 2014, the Company had deferred genetic test revenue of $2.9 million and $3.2 million, respectively. Included in deferred revenue at September 30, 2015 is $2.7 million for test kits that are still outstanding one year or longer after initial kit sale, of which $0.3 million was sold directly to consumers (credit card payments) and $2.4 million was sold to distributors for the promotional bundle. Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs).
 
The Company recognizes breakage revenue related to genetic test kits utilizing the remote method. Under the remote method, breakage revenue should be recognized when the likelihood of the customer exercising rights of redemption becomes remote. The term remote requires statistical analysis of customer redemption patterns for all tests sold and returned. The Company analyzed redemption patterns from 2009 through 2014 and determined the period of time after which the likelihood of test redemption was remote was three years after the sale of a genetic test kit. Included in genetic test revenue in the three and nine months ended September 30, 2015 is $39,000 and $167,000, respectively, of breakage revenue related to unredeemed genetic test kits sold in the first, second and third quarters of 2012, compared to breakage revenue included in genetic test revenue in the three and nine months ended September 30, 2014 of $86,000 and $242,000, respectively, related to unredeemed genetic test kits sold in the first, second and third quarters of 2011. The Company expects to continue to recognize breakage revenue on a quarterly basis based on the historical analysis.
Sales Commissions
Sales Commission
 
On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. (“Alticor”). Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to our e-commerce site. The Company accounts for sales commissions due to Amway Global under the Merchant Network and Channel Partner Agreement in accordance with SEC Staff Accounting Bulletin (“SAB”) 104. Commissions are recorded as an expense at the time they become due which is at the point of sale. The cost of commissions was $70,000 and $59,000 for the three months ended September 30, 2015 and 2014, respectively, and $239,000 and $160,000 for the nine months ended September 30, 2015 and 2014, respectively.
Accounts Receivable
Accounts Receivable
 
Accounts receivable is stated at estimated net realizable value, which is generally the invoiced amount less any estimated discount related to payment terms. The Company offers its commercial genetic test customers a 2% cash discount if payment is made by bank wire transfer within 10 days of the invoice date. No accounts receivable reserve is required at September 30, 2015 as all accounts receivable are expected to be collected.
Inventory
Inventory
 
Inventory is carried at lower of cost (first-in, first-out method) or market and no inventory reserve is deemed necessary at September 30, 2015. As the Company does not manufacture any products, no overhead costs are included in inventory. The Company has contracted with a fulfillment provider to supply its PerioPredict® genetic tests kits to dental offices. The agreement with the fulfillment provider requires them to purchase and fulfill all materials related to the PerioPredict® test and Body Key™ genetic test kits, with the Company’s approval. The Company reimburses the fulfillment provider for materials and pays fulfillment charges when the product is shipped. During the nine months ended September 30, 2015, the Company made a onetime purchase of $33,000 of inventory related to its PerioPredict® test from our fulfillment provider, which is held at our fulfillment center. The balance of our inventory is related to our Inherent Health® brand and is stored at a separate facility. When a kit is sold, the corresponding cost of the kit is recorded as deferred cost of goods sold and removed from inventory. Any kit components remaining at the fulfillment center are reflected in inventory with a corresponding offset to accounts payable.
 
Inventory consisted of the following:
 
 
 
September 30, 2015
 
December 31, 2014
 
 
 
 
 
 
 
Raw materials
 
$
142,351
 
$
163,239
 
Finished goods
 
 
16,742
 
 
8,336
 
Total inventory, net
 
$
159,093
 
$
171,575
 
Stock-Based Compensation
Stock-Based Compensation
 
The Company accounts for stock-based compensation expense in accordance with FASB ASC 718, Compensation – Stock Compensation. The standard addresses all forms of share-based payment (SBP) awards, including shares issued under employee stock purchase plans, stock options, restricted stock and stock appreciation rights. We expense SBP awards within compensation cost for SBP transactions measured at fair value. Compensation cost for the portion of awards for which the requisite service has not been rendered that are outstanding as of the effective date shall be recognized as the requisite service is rendered on or after the effective date. The compensation cost for that portion of awards shall be based on the grant-date fair value of those awards as calculated under the Black-Scholes option pricing model. Common stock purchased pursuant to our employee stock purchase plan will be expensed based upon the fair market value in excess of purchase price.
Income Taxes
Income Taxes
 
The Company accounts for income taxes in accordance with FASB ASC 740, Income Taxes, which requires the recognition of taxes payable or refundable for the current year and deferred tax liabilities and assets for the future tax consequences of events that have been recognized in the financial statements or tax returns. The measurement of current and deferred tax liabilities and assets is based on provisions of the enacted tax law; the effects of future changes in tax laws or rates are not anticipated. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized.
 
Significant management judgment is required in determining the Company’s provision (benefit) for income taxes, its deferred tax assets and liabilities and any valuation allowance recorded against deferred tax assets. The Company has recorded a full valuation allowance against its deferred tax assets of approximately $33.4 million as of September 30, 2015, due to uncertainties related to its ability to utilize these assets. The valuation allowance is based on management’s estimates of taxable income by jurisdiction in which the Company operates and the period over which the deferred tax assets will be recoverable. In the event that actual results differ from these estimates or management adjusts these estimates in future periods, the Company may need to adjust its valuation allowance, which could materially impact its financial position and results of operations.
 
As a result of the Company’s change in its capital structure during the quarters ending June 30, 2013 and December 23, 2014, the Company may have undergone an IRC section 382 ownership change which would limit its ability to realize the benefit of its tax attributes (i.e., federal/state net operating losses and research and development credits) during their respective carry forward periods. Furthermore, pursuant to the change in capital structure, the Company realized cancellation of indebtedness income under IRC section 108(e)(8), which reduced the Company’s federal net operating loss carry-forward pursuant to IRC section 108(b)(2)(A), due to the fact that the Company’s liabilities exceeded the fair market value of its assets. Accordingly, the Company had a reduction in its deferred tax asset and a corresponding reduction in its valuation allowance for the quarter ending June 30, 2013. The cancellation of indebtedness income resulted from a shareholder’s conversion of debt of approximately $14.3 million into common stock of the Company prior to an additional investment by an unrelated investor.
 
The Company reviews its recognition threshold and measurement process for recording in the financial statements uncertain tax positions taken or expected to be taken in a tax return. The Company reviews all material tax positions for all years open to statute to determine whether it is more likely than not that the positions taken would be sustained based on the technical merits of those positions. The Company did not recognize any adjustments for uncertain tax positions as of and during the nine months ended September 30, 2015.
Research and Development
Research and Development
 
Research and development costs are expensed as incurred.
Basic and Diluted Net Loss per Common Share
Basic and Diluted Net Loss per Common Share
 
The Company applies the provisions of FASB ASC 260, Earnings per Share, which establishes standards for computing and presenting earnings per share. Basic and diluted net loss per share was determined by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is the same as basic net loss per share for all the periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the loss in each period. Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:
 
 
 
As of September 30,
 
 
 
2015
 
2014
 
Options outstanding
 
 
22,258,659
 
 
4,810,675
 
Warrants outstanding
 
 
88,301,079
 
 
37,269,125
 
Total
 
 
110,559,738
 
 
42,079,800
 
Fair Value of Financial Instruments
Fair Value of Financial Instruments
 
The Company, using available market information, has determined the estimated fair values of financial instruments. The stated values of cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to the short-term nature of these instruments. The fair value of warrants is calculated using the Black-Scholes pricing model.
Cash and Cash Equivalents
Cash and Cash Equivalents
 
The Company maintains its cash and cash equivalents with domestic financial institutions that the Company believes to be of high credit standing. The Company believes that, as of September 30, 2015, its concentration of credit risk related to cash and cash equivalents was not significant. Cash and cash equivalents are available on demand and are generally in excess of FDIC insurance limits.
Fixed Assets
Fixed Assets
 
Fixed assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization are provided using the straight-line method over estimated useful lives of three to five years. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the remaining term of the lease.
 
Assets that have not yet been placed in service, have the costs incurred presented as part of Projects in Progress. Once the asset has been placed in service, the related costs are transferred to the appropriate category and depreciation commences. For the nine months ended September 30, 2015 there is $19,500 in the Projects in Progress account, all of which is laboratory equipment.
Segment Reporting
Segment Reporting
 
As of September 30, 2015 and 2014, the Company has one segment, the genetic test business. The Company develops genetic tests for sale into the emerging personalized health market and performs testing services that can help individuals improve and maintain their health through preventive measures. The Company’s principal operations and markets are located in the United States.
Recent Accounting Pronouncements
Recent Accounting Pronouncements
 
FASB ASU 2015-03 - Interest - Imputation of Interest (Subtopic 835-30): Simplifying the Presentation of Debt Issuance Costs.
 
In April 2015, the FASB issued ASU No. 2015-03, which requires that debt issuance costs be reported in the balance sheet as a direct deduction from the face amount of the related liability, consistent with the presentation of debt discounts.  Prior to the amendments, debt issuance costs were presented as a deferred charge (i.e., an asset) on the balance sheet.  Further, the amendments require the amortization of debt issuance costs to be reported as interest expense. Similarly, debt issuance costs and any discount or premium are considered in the aggregate when determining the effective interest rate on the debt. The amendments are effective for public business entities for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The amendments must be applied retrospectively. All entities have the option of adopting the new requirements as of an earlier date for financial statements that have not been previously issued. The Company does not expect this ASU to have a material impact on its consolidated financial statements.
 
FASB ASC 606 ASU 2014-09 - Revenue from contracts with customers.
 
In May 2014, the FASB issued amended guidance on contracts with customers to transfer goods or services or contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards (e.g., insurance contracts or lease contracts). The guidance requires an entity to recognize revenue on contracts with customers to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance requires that an entity depict the consideration by applying the following five steps:
 
⋅
Identify the contract(s) with a customer.
⋅
Identify the performance obligations in the contract.
⋅
Determine the transaction price.
⋅
Allocate the transaction price to the performance obligations in the contract.
⋅
Recognize revenue when (or as) the entity satisfies a performance obligation.
 
The amendments in this ASU are effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is not permitted. This amendment is to be either retrospectively adopted to each prior reporting period presented or retrospectively with the cumulative effect of initially applying this ASU recognized at the date of initial application.
 
In April 2015, the FASB voted to defer the required implementation date of ASU 2014-09 to December 2017. Public companies may elect to adopt the standard along the original timeline. We are evaluating the impact of the adoption of this guidance to determine whether or not it has a material impact on the Company's financial statements.
 
FASB ASC 606 ASU 2014-15 - Presentation of Financial Statements—Going Concern (Subtopic 205-40); Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern.
 
In August 2014, the FASB issued ASU No. 2014-15, which applies should a company be facing probable liquidation within one year of the issuance of the financial statements, but is not actually in liquidation at the time of issuance.  The applicable basis for presentation remains as a going concern, but if liquidation within one year is probable, then certain disclosures must be included in the financial statement presentation.  ASU 2014-15 is effective for annual and interim periods beginning after December 15, 2016, with early adoption permitted. We are evaluating the impact of ASU 2014-15 on our financial disclosures, but are not electing early adoption at this time.
XML 30 R1.htm IDEA: XBRL DOCUMENT v3.3.0.814
Document And Entity Information - shares
 9 Months Ended
Sep. 30, 2015
Nov. 11, 2015
Document Information [Line Items]    
Document Type 10-Q  
Amendment Flag false  
Document Period End Date Sep. 30, 2015  
Document Fiscal Year Focus 2015  
Document Fiscal Period Focus Q3  
Entity Registrant Name INTERLEUKIN GENETICS INC  
Entity Central Index Key 0001037649  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol ILIU  
Entity Common Stock, Shares Outstanding   172,887,221
XML 31 R18.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2015
Significant Accounting Policies [Abstract]  
Inventory
Inventory consisted of the following:
 
 
 
September 30, 2015
 
December 31, 2014
 
 
 
 
 
 
 
Raw materials
 
$
142,351
 
$
163,239
 
Finished goods
 
 
16,742
 
 
8,336
 
Total inventory, net
 
$
159,093
 
$
171,575
 
Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share
Potential common stock equivalents excluded from the calculation of diluted net loss per share are as follows:
 
 
 
As of September 30,
 
 
 
2015
 
2014
 
Options outstanding
 
 
22,258,659
 
 
4,810,675
 
Warrants outstanding
 
 
88,301,079
 
 
37,269,125
 
Total
 
 
110,559,738
 
 
42,079,800
 
ZIP 32 0001144204-15-064837-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001144204-15-064837-xbrl.zip M4$L#!!0````(`/N);$=P2[?WL,X``'Q@"@`1`!P`:6QI=2TR,#$U,#DS,"YX M;6Q55`D``YH/15::#T56=7@+``$$)0X```0Y`0``[%UI;^,ZEOT^P/P'=[Z[ M(FJU"E75R%:%H"N5($EW/\Q@$"@2X[!+EO*T)'$/YK\/*7FA9(E:+,643>"] ME&V1XN7AX;V7E]N7O[[/W-$K#$+D>U^/P"?I:`0]VW>0-_UZ]/?[[^/)T>BO MW_[S/[[\93P>_8`>#*P(.J/'^>CW3PY^0Y2\X9/MST;C\;*<4RO$ M9>#W_'%Z^W,D?P*+9^^/@8L^D[\C++87?D8NBK\>/4?1R^?C8_)*Y$ZQC!&R MDU<>$P$D4\&52M.[R/N=24_>]KI*&J"@A?BDX_N/JYYW]#&?6&'EA9'EV1A;$D#V?'H6^ M*@.#E2--L)E]EM/_:B8)X%*X3VIZG_>KQX M2-I#&4M@K(!5MC@(,.'*\BV>DHQJ-J,#47$>_*`@.7RWGXO3DR<)4;(9D/<* MPZ@X2_JLH#:>A9E7G"=Y1+*`;)80V<49\(.BY-%+4)(>/RG($(?CJ66]K/(\ M6>%CTIZ+!P55?W<9K/GC)T7E.`H89,%/CW"W'8V^$/I_#A-BW\*G4=(=/D?S M%_CU*$2S%Y>P-OGM.8!/7X](MQXO^^ZG]Q"3[!B_*-4.9[X7P?=H=`?M""N= M1#/@(E+=8"\>(DSB&PD\X/\(%^Y]R7Q0I.1S*M(J!_0B%,T7OZU^10[Y_0G! M8)2(#3/57$)^=OFWHV\2[K>28NBJ^>4XGWE9U'&NK(P$+S!`OI.7`/?F(,(Z M%GY;DED"R_>LGRU?157'H3*98T5:%^XLLM`B484O?UI@N'AW%;!`?E#`H0&+ M[9L"^@16HQBK#1%8K0VP6G^,-?9(%1@\J0)CCQC;'-C^&'L27GN#8VKJA$8% ME%L^Z1J9H5"-0D;K#1D@+3JC@NVRM+#+RD`0RG1&90RDQITQR=2+75X!JU+` M#J53YLQ'"V#5WH`E?1F`!P`&VY?Q>`N`GK37>3;OZ_@[!$&<4AB`7<1[M;XI='%GS&N M&4[UXGOX:WCRCL(/!CJOQ."4"+8J;_'`P8*\O[C(1E%:D9&S1.7KT2+"\;FB M6LMD&Z!\.2XL8EWGXR+9.&!'+0Z<.`XBK+'<&PLYE]Z9]8(BRQ5\6"9C`K3? MW+B%D84\Z%Q8@8>\:2A(L4Q6C,R>L:$X<"JL!F=68R@A8HI"PN@,P^@,D%K" M9O%JLP9!IDS\6I@ZGDT=;W-+Q102IFZ`IFX8U!*F;A"FCC,R96<4A8GCS,1] M_-RI&(X-Q4;M@AO"R/!J9':PRD)8"WZM17_K27(<$-9B<-;BP[@AK,4`K$5_ M;)"T]6"Z^?DA(. M@DT-3$XK*RP6EC=HTMZG$,[J1;Y* MI""X*5BR,Y9\6"Q;*`7.FKL_6Y#KW7]#4;@>U-,M?F7]RP_.XC#R9S`8>!2C MJ"Y):Q=5?P_[-SV7O4#AQIKG7<&#:/'"^N]WDY^C,`K08QSYP>'U\,W*[UEC M%Q]"\_`C/0KP'H;1+7R%7@SIIC_S/1O7)+#(C/TM"G^?SD^A9S_/K&#@@[_J MFB6T*(-G1T,`SL[?*5EZ+3@U,$[QM`*[^!0RP:E!<8JW`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`A@F#7+B.0D8 M=S9*F\>@UZ1$UONL!E34IWTN.Z:P.Q('TEM]%&2J;];1P6K M!L@J2OGDZ-''#2,@N6%$23\+F@R')AGE`]IP:H"LHI1/CAY] M'`HO)X?"IS21!4V&0Y.,\I';'"*?9.I-^0A6#9%5E/+)T:-_Y?,=!2%&PL.# MSB"T`K0,U1.H,C\GTRN"5+V1JHE$Z9Q.OG66Y\:5M*C0DOW:X(<[B$MRZO8E MT0]Z[@>ES2$Z0L\=X?X9!:(?\-(/REI#=(.D&TCK*V?QY[0;*,+1&8[WG+N- ME@0/&]]&BS-])+N$T\T)%_?5Z>:L&V36L(!%-]`$L0>J9-NN>0$?ZLDFP%U9 MP6\8(6]ZV(1B8"'<0,9"9,$AGCG$Z[I>[.SASTMG3W"(9PXI;5;[)IEZUT,K M6R;T$-\<:JF'>K=EV17C@D,\2`LF7XLRQL&?\<4MIP*,TD\\ZA9C$S MP;@#"''M,=G%5/*NV<[;[/%>TUU,&.^8[9S-$?-*]NSTA7"&>7:&.9ND2+8& MK`?C%[,7UY]#6')U7O;QFX=[Y3-ZN7$M[^+N^N8+,.[GR+KMKTNQGXQ*+/S=Q8#];(23H"!8UJ6RBNRJPW&\BW03H%:LX7%T[ M.<.%YL]=_!@B!UG!G)SA-K*'?8]O?/`82"`(E%V(3D("CPW8\#P0":`6M$#H,`>/PO M")`AP`J1/2-`R22Q<`=Y&,\N&,#I=!PI?EP9<= M,'^$*\R!*\PS?W)#J#/?"V.7S'ZE:!RNYYQ."!;"<1B#*$$%KJC`O1+1'H"1 MKI]9J-J0?*%9<^9:87C]M'A\'=RBZ7,T;-8PJD1;'0J*G2@/A9P&!XP^E(=& M+:$2%.",`OGU2,V/F(9G?C6\J8# MOSB@RB0Q(2LG61M1*#27/V4PWY56FV";]H%QY27$)U/\9]FQ"P=8"ZVP#XY1 M>972;?X,4(1[5+181;"(5Q9]_*RE^O`=>99G(\M=C#!R*PPC7UQ44^.BFBQ6.Z-5 MB]-CDDRRTI.;(N@T*#IES%6&%WV&WDD9IP8+NT:(*%U&/>(IIM@ MKN.(T-A91=T/GE0EN.QNH,W5+:/%7$K&FC_*1]F'QZ(-1`1_&/RIM4WM@-G$ MS=:S07`K.^@7=FX(=DYMPZ4/.*,QRR5AYWBU<\/@C[!S0[1SO'&K>.I4V+DA MV#G.)DY+N"3L'*]V;AC\$79NB':.5VZ)\=SP[!QO9^X7CE&46^_[)F`U]\G:U%>KXHJ^X[F?3O M;P5T>;.3';B'V.39>N]9,E$1OWWEO'\08*+]S=#;SO<2JUO8T!-6:4ZT' MOVBUJ2W?A(+PRXD3>4EXXT$&0DURJB8-ZA#UVJPQQG(O5UFIE)K$GW4Z#)DN M$`P@M74ON3!@^=,P"9.>TY^M`S7F*JCT[JBBME$P.)/.(U7V7Q=U2:W]UH'[ M16P2.\9D%Z0?F_GS;:9DQ7\/6CF%.]".IF]6?,?KO]HN>VV9#^04Z3"6_@* MO1C^@IG#)XO"WZ?S4^C9SS,K&/C!,]4U6^F[(GBZ5:E-]I:G M@\)\H^\THLJ/1U&\@4%T$=%%Q#X,MA5YG(8W@3_S":B6BS\ZL1V=QI[C0OQE M&E@ST74.INO4)8.P.BRK([J4Z%)#Z5*\6:GB>*APY`ZQZW#BR`TC>BJZB.@B M(F+&MB+",1-=9RB.&6=69W$8J`+:S]4-E^G\SWSE#_Y45L3I>`\0Q8$3QT&+ MSF,AY]([LUY0E/4^#IL/3(#VFQNW,+*0!YT+*_"0-Q7[E;^M#541,OO,!H4X M7BT=J_LW_[]@X%][,+DI-F.8B1E//(O%KT.?'V_CPG3I2J4[Z@L`7:YI+FV) MG;!7&1)[D\VB@KR[)^]&0^P9=\N'ONTX+!AYJ".^LCO/`A@F37;B.6?/"#[= MV2AM0/OZ"?_)7@Q[0)?4U`5&L"NY1$):WQ.*/R]M;0+OB. M@A#C[J%7&(16@&!([1JB?]Y?^C&0Z]#"%H"YN*&IN`%V1'9L7Z465YOB3$H? M&WX[);N@[T%R:.-ZW/?2&VZWNCMWN/3B_'I!`"_XR)?GTM M&')1C^[G+P.?\RFM4$F"';LCH(T[@C.!7JXY91T94^?\H^'19DAGP/'DN4K: M.GJ(/P,CC0!1!ECSB-QW`V!BK; M@")6UXO5]4-97;_[#2NQA]+^%#Y;` M__>[\Y*7H]!796!\QBG:O_L!5_CAC@B8*R69Y(/Y5B!9?\4SB'GM!_F.45LT M&O#\&PL*/(>>/T,>N\@JJ/-E;KYT^92J>0T,7^(-Z+(BD02UVN?+7\;C"S`-HAE:O^)L` MOEC(N7A_P8X.;,H8LX(Q0))E,)%T;5)3!NRK8O\FFI,S"%=B%N"I5*AX&5-551U MHFPC;GYG.>[:\2Q.QM&8N"2V6C_BP+8$8R!C-E6`LL+ M)%-2P%;R)J`_^ZX#@S!=/%VE=APOJH*WE[0,@PK7/L-AZVQI+XWO8?![!P^1BT\>X5M2%2, MY,2DQ2LLC@%??4G85F1BJ!-`&WZJC$;%ES44VTY,#$V2]6*+NA&)7JO>9F%R MM4+Y&_)$I31_OISFI`<5RW(:EL^`HL)O-V1`8U%6_ID? M1M=/BZ?-06#K7456@)+1-51A;20IAT-C:U]%P\[.I*8D/P(_).L:GO*^:0U$ MM`J?&KO4"B4'551S*1AH5,V`*AJMWQA2W,(06H%-ID?/,5JNG\2`%[,*S=&I M"*@`8&9'&XS"NY"4@6#%U*8J`[6MI'?0=4FT%WHPL%RNJM^#_S9&18)>3$YQB7-318*PR<_@&FZ>^L=AE?(\P,4S9=M@^UT]BUI M6.P*1L^^LR9X"\7(-B!C69(U#638\F&5X0_')V@C$:@VU5FPOV"T9;.!]&Q?3&1A_+%-=&%@8T;,.Y MR5.F+,O9H1L8)&O<3ZT0V60HA]PX@DYSI'(FE%H]3\DI8SFE3Q*EBBODZ$9L M!JCZAXC]3T@.%8#.R2M6$5/X*R9;0:Z?DJS7<43V;I/%4%LW`FVF%]LOJ&I< M_OJ^",H#2:4\TW;2]5I'1HM-:M11EC5U(IMRUW5D!W,+=SYGA6?;;%,&.J@? M]JXG33F4DZK%6:ILTCS9/MQ=C="D8BI'4_2F\>X&26)#2/Q->`@3UJ,R>:H5!"M([$U\"C(I(' M@";1JR!:AN)K0,(>ITU,3:86[[6*Q-=`@ST24W"K`*.6%$WBVS7`J5"^QL0T M))JT/47BJQ$TV8I9U_6)8K:4M%4PNQI#4;22^!I`5.^5P;S.55F'O M"I$8@+$-BH8MO*Z9;40J'8#6P*DB"*AIAJG2@Z1.(O$UP&+;F[%J2+)*]X7N M(O$U0&,;'5F6Z9!&I['X:N2`Q#8TJM9]-+X:,B!5V!(-&Y.,7%N$X^N`U"`F MU4D\O@Y$%8$IC)$TH11$YP'Y.KA5+L<=5DB^3K.P3LT`VVQRV/SQF0BTVO5 M.8K-UVDSM48E95D#FFZ`KBO9:->+DA.\8@PH:TK&5>]X'Y/2[M[I;!4J@I`R M'@29/=9@ZUN3L[6I6&<(S,E$4V@2=5ZA]E?]9FM2,3S%G<;05(U>.5^C*DG? MHOI&W^0R:W5L59T8]"E3&V)N;7H[J$O%F02]>0T=]Y"*0PWZJT9'_:+B`(2& M;E-CA[(+(M5>9=FQZ!T3B3U.[Z\:71&IZ:";68V$$)=A&$/G/`ZP6#?)N9?) M1L'T/&\(DS0W<6`_6R&Y;\MK[BE5G-`@&]K&3N6F0GU8S;KH2A7F7LH;>G[! MZ+AS5FQB,%1Z[3OGT'35X=FC?^EC\$A]F]*W?)0WDSF`H\0S,TUMDC^$H7F% MFO#D%WQ+GK2([50%S[Y?0/GGG(WZ#0RH!O3"]TP#B>H4H@G

$4V3,N_A;8_]9*W M%!QN4F?(4''@##EY6J5/4NRY`IP`QC)#;#]1UX!A'AY@73N@%8<`20<.<+<6 ML^*DHP/5`;V,,BN.<3H\7G=MW"M.I#IT@#M6'.PQR(':PEX\^(J#Q';(ZT8' M6.:/TF>/2TS%D">=3R]WZZA4Q)AE6?O_]OYTN6TD:1B%_T_$W`..W^EW[`B( M)L'=GND(25Y:S]B6CJ3N_I[SQP$211%C$.!@DV;"_,PB$HEKI6]'3+Z4)=.$`%4=>*OG!Y'9\+2;\H5'2EFLBM7_2\ M,OUB$S@*89)U\L/F"]17PK&.(A533WED:/-@PJI6J[>99D\M:"\0%2TD M5I6]%HN2#VSJP_/)_L&:.Z5,;(OM7-'+%#SMGF(,+'GW\Y>Y).:WHH==HU^O MJX76&RQ3YL:F[AHEPV7K+>X*W?H,[CH`^/_?^6N M&O.W.597=+UK=.MJ^=_F*]H93,LV8U7"5[_?[W5W"Y4Q%+78;K%,5FGTZ\OY8%U M5K53V);MSXKZ)NP846_O'KK,6*DM-FFY'NT81J^Y#DN+!12UXF6H7Y&/W6YV MVYU&T6O.S*+:`M$K^L6"P]]MK5AU9A$%+GP)OE?UUP,2,0I?>&:@U>;H7M$A M[PSHNMM=2MF9)12UYF687J%@NVW#:"Q54"O6C&-WS6!\XWLX!]RZF/T.IM*5 M&]?3G\,Z'OFZZEB\GD+W`NXR_9OA=)N];K-1J>Q*W!! MG$GO;`B^G\\6SD/=8B=7#-=HU-4DJ/574C@,R[9G103<,-1Q"]O#L&!7>07R M+KAL15^/S.8\;WE[`7;9)J[0_IE=+!9821/7HSA)R72'#-N!;;-O*P:ZIM)% ME[VZ@&4NP?B*+H/;KM'WAHQ95*)\OW[M1+8, M/"M<\W1R:U'KW#/\R_9SN961J5S9%?P+&/.3[<(;=B`D5_1<['?437_>XO8" MZK(-7C$')KW!Q<**CP)"P/]#_?AH.B@0^.EVUES=8A-75(JU&_U.HZ-.K-M@ M.3L`9=DFK6J0TF]B*X%=@G(.&^_[,]C/5=/Z,L7V*[I4=MLM\*X:JY:>>7U! M:UZ([Q5U6)UZJZF*@*W6G!R1?/+\YYUOK&AVV6OTZ[EG,YD7;Q,GWGRQ*_I= MGO6Z]:7!RODU%+CN)4RXHNEENV]TGKMLWIH(#\FV6-[&C; M.(.ION9"-N6.99A9N^1Y;<[`9L_"<$WU+PGX8>:5>^^#&8/OGUMP6RRX"0MN M@UU/G[<-KHW1TB7!TMKS0]H`4G5L%0W%U$I8)<@!>PG6)*P MG+C,8-;U7N@J`_2J1+HZ_2\7V-5`S"ERQPS`)12I`=?^+?8*BHF+#2.?6Y>F MXZ#Y*:X+Q(5Y\YP37,B+\8]M=G^-601-H]OK]-3RVV<"M!9^/OYD_M`.&-%6 M_&/\C,9.L=+?DB>V@F3GY`)6K-'DB5RQI#A_@/\H:&IMCB:COD;A-NC&?K^K MLE(YB6=G.%JK=QV14J.N-J\KA)2>(7L!(;$1HB`';#]"`O[Q?.UC+.M,>]9$ M\D'KJBA!O+V%LR=LK)$D.<]0^[%8=@AU:TL66=<"R8_@J4/KU]KL/P"\R&=? M/--5H<3GA.(Y][,IRP%P2=#FK$U;FK8V5B]X/F5O$%ZY0>A'O+LU]T%N86?( M*K(`-1BD-!^6!0S:SP!1M2*G47KKFKAU]7XJ&7'=Y>Y3.6X/_1I%WD:K;[2- M50*^3'IP>W3T#JGSEB8AI.D]L^PE`2=D4Z.?8=,5N08K%Q)'%].^O;&L'2\N MI&D4O!!%`OS+#H/$=OANDE$2G"=&N]-=N.';V[\)GY`P1M?LY.[L2^ M[S@V)K2']RBS^6WJ\L$N0^$M[#([^'$QNV#N<#PQ_1SMWU@>R&KV"9*\I6X` M1GXM0:%@K&H$TRT"CMSA@L7"L?Q4IMT^[M;W>H@O+&BXZW1 MW,/REB!O12?;1F>CO26JQ',W4!!TOH*&\18X,Y;8Y`;9Y(9@@>S+4BN9RP/# MD58\MWZVEIS]%#DCVW'P(9<,;7W.U_CP^$'\AWE&7M&AMME,^'C9.O,&$-$/ MM^;35P#8M^&)ZYN**QK.-EI&LYV9.S3WMBV7M,AH7-%#MM%I&LW^MDOZA+/A MQLSZ['G6)FA:45[7Z;:,G"6EWK;MFA;B:<6`R6:SL^F20#4],C_$"6_SP82E M^%FB$="0:[2RUF?F57,'C"X\%V<+V(\L<2$__APZD<4L/E=F,HU",9DN.VCB M?(("8`M)LTYO]4:]W>YWF^J9?1&KW2<*EFB`=9J8@M'1[??4[3PZ#*0%.X7> MKJ?X'-54>^8"+F;Y#YA7#JE&JXOB+B`9>ZE1@T>.=!$`.0S"C=4([_6:]080 M^A$C/.V7')S*US@5:/4:]4YJ!.EQX_R@1+Y&BX=FU^CT&\:N$2Y-VD^>K[@+ M:\5HSB=/YNRSXPUD&+YLZ!*&(C5G1^Z&Q"3=S#\VW/YPF_W[S0'F[A%#?[ MKWZ]Z=0_2)\Q^\1E9X=?X';DF M;R#RQ1FJ@D[I"#!3CFZ#BYGZRSR^5[0QS=+,AX<%K+`G/*P(QK2:^T/$ M`KFV)T0LSYYM-O9/$(?!PXIF_L:S.&,N,)T<7C>*U-3?Z2L5'WP$4)SV^,4; M\K8Y\PAHK8H$II+8E@!4`/!;:9;G`-]>"7QO;\!G=G[PL!U]/P<=RS(U"!V- MUJ%HX1#HZ"Y!1P/1T=PY-IYE.#X']MY*SNCO#?B]BX7^2N`;A]KY`_!!JOEG MOEC8O8I80`N'0$=C%3J:6Z+C.9EZ121GM9>="A:9J2>O%7V==I]FV5YNYO72 M5E[.\E*^)OSNVVY@#ZG.,=6.\;T\CZ;9RP2]LJO;>/T%HWY%P]$LO2P& M@&15W,CI"Q8,!]@9XY;TR/\RT[]_\C8/X'66:>86SVJI=X2H7/7Z#=8Z]MD6 MX<;.,FV[V6IQ`5GBH`O/70LO,QTA1S?/3%O1%K3?26UY[DN?L[(EQ^HKNH!F MQ'!A*UMG9U?U]NSM=FG+D+9">36WP-KU:&0/F1\LZ6;<4I`&GSLB-7MLL]'' MGVQ()V/B,45$]5;T[6QVTH(J#X#TX4)LR5Z/+CPW`DL".1!\"-.???+\&(;L MDL'\A@O9LDEXL#J_,GT+9X>$'PF0_S*Y2=*G_WY.?)[)I;N&FE) MC9;1:AM&=EI!L6C8&-/!1N_XDV$Q$+/.'T&%/K!4S="!=V"#`N"VFE"P1PPM MYGZBF'OO@OTQ9WCNB^6[*].8C5R>3RU](83)&(=2P-I<`FM;F(O8CGIM.`XG MX>K$7]Q`J7^_@379%J.^H82^NZ$-?]F`NAS\W=NA0^G;EOUH6Y'IY*!JG2R= M3-I]"<3:BE<(ML1.2NN+-$&=NT-U>QT11K'#=(>8_2`C=P_FYLW-OW:0?2W] MYP_>%I47ERX*QNZ-R)<=UM'I5'964M%P[U]^R)X_#>KYPW/X&SM`[3J#N;-= M@$Y9@.P2UVL5A/-#M\Z+D!_[(O*5AYQS%N?1"Y#X4,.@0PV.6Z-XW/;6<*VR MY3NG+$!VBNNUG"@>_&B]!`&R@,@_V7X`2'?!*_$#$T+SX;5K+ M5=N_N#G(7A2`W>]W#-YDK;NAF:59QZ43!'O*L*Y-\2OWSFVF9HH<8#(YCXE4#[Z#ZV: ME^6YGJYJWA_CSE-1UHOO%`+ABF9#K20)=]EZ MMP1L0?I[(8"MZ%?4V2U@W40+PV>IA0L!;'D6EB@Q7ALPR9KWOOG('!QQB$F- MH6F[RM6+=RWI.50,<"MZ\:45WM(U%P%@.L&T$`"7IW"UG@'@_HR?)NG@NE$@ M4:\QE"';`O9%F#L[0/5:DQZXA7/D'JQX,SH/S$HWBM\ANC?S>U.;TUQSOL0< M&Q2,G6/?@6<$D9OU-3IL=3K5%NPL=-RLK]-RJW68'3A`<*$`H=]<9\Q&)]NR M]27HUQV@>JW9'F6*(-SXHEDZM7WCQ'\>A6//QWJ^M7M[-NMK'$MTY@=_+'OY M\J7>F/ZUSXMRJ3!TR?"Y14M>*Z#/:X3KC46K7K2.^;KP>(K;,["\1A972\Q7 M2;517?CN)JU%7AR@N M>_F2A5Z:4SN4&?ZG"&L9Y22<]5??6*OZH=YO]SKU=N[JUUO1 M3D'Z_G$R=;P98POZ4*9_?G+!E!C;4QPY_O'N^@8+D!TO@'>!R,0OYV5T8PT; MKVW`94:W?QQ(NHG\X1@T`\);+*K6,,::K8ZQ@!?*@*CG#^QJ-M:PG]KU1J_? M:N;+L#+@(:?#Z/H#1)N--:H/YB<^E1(#5%B\+1K6'K%;=BQ\\B)_6R1TU@G7 M==KM;K.\8D&B`5S1;=&P3D)]JV5TC&:^);89&OC=A30?C!BNX\L"&D^ M31#B0N65'W].;=Z'[L.:0Z,*D:0X=;!N-,X:QAE:O&LN;Q?0/%,(=@B05GD` M>9;\ZB(TC>Y9O7.&QY>'A^8YHJ='6U,_J[?/&MU2`/,,J=&7P/3.ZIOOS&Y\ M@$O/#2('@_T^-+C_1E1?C'ZEYHWGOS(%PC5@8R.%>I]=;I?L//ON[0*P< MQ"B*3P\3DD0:MBTF.O.*#O[7KM*394%A=I,*LR4Z%!&UML#__M6X^FLQ>(5Q;G-+OK0;P(BN<=OO:^@UH@0)]#T]^_VBYFX*8:)>&!?@Y" MUHG`/>M8]]QQL/DWL_)3#3;)A(VQS(BN6+Y>P@Z%@;[!M9A\0IR*^)?W4>V MN6K@T#/(MWB^S2Q]10O<`I8^)YWXV<`2@FM]_V2[X/'8IB.,\4QD8XT,K-8: M)Y5+/#)UI<6FQA0"W%J=R>;*6[=(I]E)Q6:&3/NY]3\%8&EE%[%]E?ZFI/@G MT_8)YTGBQ:[)9<581:6^:\DB=^^=[D+AK&%1]?K=5,)&L4ZJ8@VF4XNY<+E: M[)0M&%/!HPA>$8TWFZTUSD?!WNSWNPOW%$G-'(+>W/?UFL^',1?736TJ)&==;)LZ5E`8\5[#K)TPK/Z<;36)Y\Q=0S56H(C M'V3\:CKR2]K0O-.EA`A`W17O6`3,%8"6<'Q,,RT[*)_?B; MO=9R-.2#LPDB/J#!QUSK@&A8%L`#5JBOAP(5D"P"Y"IQ4`>)AJ6I;05,\VJN M&,(D9Y*ML\`L,#(1^X*Y;&33/?FN]%JSFGA.O/*Z;7=Q>?S-:#>:7868UP9B MM]"3^43J8U\KVWP0#*T:&UWN]$N`@'15!/H"*'^Y<==H=#JE M@[IHNN\N-_1:W6816N^YK1(4&NLW M_FANTEBK&#A*@[Z%%+C!P7:V<_Q1HV^1Q%^(J'6*;PVCW>NT=T-FNQ'YVX]Q M6H2G[OK\6)()*L6\=F."6N.@O%GO=/M%TM/<>@]I4S4S"%GG:+S7:]7;)V=3 M+9ZQW5QG^E,##.[=]1`KGT6U#%T;#'`Z[`S<@YL$B_BPMU8Q,A\FDQWL<]0F MP98*,$N!Z]OTIX6^E0HPBZ@U$D9;O0:HP`)'O:Z6]Q@"X6E5'R(?+N,T.K&6;M8;Q60Q813'N)\\?,1L3##!`F)1Q/B-P2BK*@;0GM]->Q2(U&O5FDW"X><:LL.DG).PK]96>X+#$3-C+M"P6K ME$A=1IKKFZZ'1RH7KEN_.B-_=TVNZUNU<6G#86`K+WJ7$>[Z4>R2H'=O@KU@ M.MX@WKU/O7_L*%]&VVMU^R[<(2X5RC>)$V?1MX8'TC5`]15H;>T\3/S\8X$Y$UFT<_-@ASK=@_B/\G+^*;QX5DS!>\!C<>R%6)":_7WI!^,T+_YM=_W@B.[`HFZ/E:.'LE9,S-YLW@W]_,R7SB>VN=N4.]7E$#0A;!5QH$8L^V#9"W M1@J.T6JVV\>!O*W&U229B\^CPS7R=CJ-;KW;*M`D*F)0S8Z0N547IN?MP#K= MO>KUMM$Q2C8KZ-E;T!4SK]HTL]-H%$'/:YPL-.>:^IP$-EL*00^L=T_$ MSY0>:SA<((>-_LEIPV?C'4]7;8M=CZAWV_H87Z<+6P-0GJH4VA?*!ZM?,`0*+U6>9I="/V/(Z;@NQ%RI=_UBK M46!UP8:8*.=&%$OMZQ][-WZXTEV*,>MLV=(R]?;Y6(05/SZO(9M+\W+)56C*5FV.5CJ7$H6CH"1FRM M%&,;JDJ+V>\^>,,(K53L1+=Q]E@+Q\\UZF?_[S_>9I^EON,MX\]K;)5],WGOFUW%) M].Y^G=FAKPL.9765D-7Q'1G*AY2[U&7`4(0 M2\CN9I.!EYWLUFRWC^\E9UC,U?XQK56.NL<0EY;K2ZK#:(WL()LSY<.A%+NK9 M&WC>T&;!/>#FPEES&%@&;%"?_]<)WUOVHQ:$,X?]\]77\]O/5]_>:?5I"/_^ M?*]]NOYV_TYKX-_W]H0%VC?VI-UZ$]/5^1>Z=@=6WDA[]7\?PO=:YG&77SZ> MW[X;>.&8/^GLT_G7JR__^R[SJ/?TV]W5__>1O^I]O`S;Y?].PU>:Z0`>_OD* MW1'FT^OP;6_A=;M^=?S\@7SK"'`MWY1Y`EW]S0O9_S4GT_?_I]&IOV^(C^W& M^PLSL`/-&VDJ"1`<^,@8J$&YP4M`V^/2[S_^_^[/KKY]^(@46:^U;?>]MHQ0 M_AT%H3V:O5H7*.KK[[#H!SSG,W-9:`^!NJ_<84U[S0'N&4;]?3AFTL:-OVV\ M?P,BXY$YWC30'OB]6LB",-!&GJ\%X,QKMAMZ&MX,'.X_H-8$0RQ`84S)W6-F M.N%80R>>A1HH+/P9;IX$]""\/N`U`?#%V`PU$`=PDS.%!\L)2H%F3W!^)*/[ M)R`:43SB2VU?OB`<^U[T,-:F/@870ALNAA5B,8`Y91&N>\),%#Q!3;N?![71 M?1_`O3;(JZGI:-Y43%4)Q"MQ]?`9#%0Q"XO.PE,D2QM)[03W2_4$FSIT(HO1SII<)Y%44YA#,^F;.S8- M22MKS;JNH1(B2OG`AN+;!GW;HF]'G!212!DG8E#K3`.S*QP'&H,E68L>B,_8 M/5D5B?-EA'2$Y)-+)V,3Y,N`,1?ES13$@J4-9BDJ@3'O2`/YH@5I[APD+)A+1$XV2G5[HBS/EZ&*FG9.;X:/SDS' M1\TTR]-<+XSI&]XGR=IV41KS9L!$F1Z^S6=@_`FP(Z8>E`#B9/,M!AL2.'#4."RK1PD_DN MO>;@XBI=A!%Q-(Q\S`)3KWNCN<"U06#Z,P(!$&R"8IDJEHRN!6,O<@`=#)YA MTA;!TO\=N7QJ&.UON(A:$K2B/F*@+\4^Q%N=IXW.71=TGXA`:?"23P"#8GS5 MS_X5"Y89,WTA1Z0$2JZ4HJBF77.U!N`#;)$C-!H2AL2`[ M30IZ8LX0#4P,B^$H`XH?15A-&Q/FE/O MM"%SG&!J#@%'=!_^/34M2_P=/]^//UGQ8M2/?O(17X-_)<&$?8<*4KT]/GMP M"9W[^6[RK.>$%=IE#2L$X&F]TWHH(;1&HP9R8>=1B\W]"RT=.S"2V,$7&VP- M8/39"X@7K'SBFM>DWR7_*(/F49QK,),#LA-\FP$?@A'$0NE:@VP&C@Q@&8&- M%K+-O2]&F:&Q-S_O%*6\=W@!?ZAX%*B&O^5B4,"M_3T#^=_UOP?(CW\7^,E@ MNE-KIO$[L1T'U[>.(M!)$Q2\GGIK^8+6\2MUDGV^/8AH&T!)F>2L1).(LC4T MBX&HM"6Y8H_@R7A1@%0-K[.Y4\UG M[P;Y3Y6C>57;\`U8MI$?1&!U()>0+YH"!RP:2POBP<*:B(2F'TBA`'23'S$/ M8BIG?FIADBDUMR3$(`=6W!:/"E675X.7T`L77Z[/KQ>9_>$!C?V0'+PB.5QK M-?4N2)A>JYMF*WZ\B:\;\CT/:,_!G234#%GAPJ9>,[JM=GH5H'KX2DA>/E"- MZ]3WAHQ9Q2N/AJ'7ZW7\-[4(KL`R)&(Z@8?!"9K@K3V)$:9(3U-)[=%42NJ= M;5[3T+N]CM[KM=?;/!>4.Z\$/\@>YO*Q'/^:YI,8Y?)G"GQ@O&C(LXJ4I[#@%W'.C92 MM\<"/.BQV*0SFM*D6Z+,D@'S:ZJRUDY46>L9JBS17ZWGZ:\$J$KEVB M17[#?G3`&/=L.'8]QWN8B3@[KL*?>CR^) M%1SU`%&U0%`5^1;D0`>Q."`3CXZQ0/AQE3""7_BY&8HU]A\\(!#*\MH%_PL# M+MJ7JXOK6^T6KWC-#WSQ/A#LP)Q`5_5?WH#V!$W>P\^Q[T;I*OQD;='C=`R/ M\./=Y,CP3Q0.=R'L>*C]CQ?YKNGH("*X[J#7Z>)\5P!"2W\"U.'I'3_^Y.>[ M2&43C*FG`;/LT0CN1!(9L/`)#[N#"#;=I^-HL5R@#WY("']/33^TAY%C^CP" ME99"VGF8&XNB\T5:&@!9J+;H9^CF%Q+-INM&DQV1CDT:DKUOY%O30F2ROBJ@WNF'>A%N9M>0.0 MS.(\D(LG?'!:))(^I5"-('I8FP\8!'QX)%L#*61CY-I(\`/,L@YMGO[`LR8P M5&T&`2:$>7B@C]3OB@`V&&J8BH!P@ND&]!;.LA%K84R9N#+*"R`KRF'6`Z6L MT2.?T&0!UN/-H!<^6BQ#QW7^&S,@X$E#^`&SXU`4\#8+M+E`9B[+)"ND,936 M23:O(1"R@.L!3C((_6AD.S;)@5Q3$(P2[-U;N/UGZ*V^H;>-YMK&_&$M0#U' M3](A.:&+G_:B;%=0+.T_3C69+[,F7TB2`OB]LOK*#8IZ]>7UE^O;=]H`G.$? MV1.SE%A;-_,,A$`TH9,2(XWKR/KF,0Z;'#AS!2#C[\!,P_P`D``4[A#TB,JR&8(H$Q&:#*+!= M%@!9YN^JMC"[+INLADF72EH7ST+"9C$B,2F)QWE1"")`Y"W9J`VD.%1@JVVW M-R+CB5@7EA;YL<*$U8L#2'B1S-S41?Z?R,*#Q5ALBNSL4E*)`-Q]X`B>>B$C M-:/YO#@:WS**A+Q-TI$7X9(V*9I2R@HB0N9;6]Y4UHVWQ>%44<&,-M-AD@%Q/=E8!E#8/AK2+@$^"P*8`B():OIG* MTDWMT:8PB6`#*E9`WX4@$9>G2#8*;57T%0U!*OB:K*0`243Z`)<[-(,QRD.0 MOUA+D:2TY@N2I&X##%^/HDG."$$'^=7)L21.1Q7BD+G+";Z'\/U6S8RV-^\!9BG^;U523_`Q.16(`02.QC2*'1RF'$<9^ MN4N$=)[V@%R*4,!M/*\-<$`!U^Z-!44?P]\&P2,"_ID M'?@$BTR>P-/GM`\:%Q@#0:`+PMJ:.9M'DL"Y3@)EMB[T&PNO7#2^OBR>H]"Z M]Q;5=[>6],T[:[_ZM=/,].-/O2^[F`]L`+\&H4]=.SZP8.C;4YYJ^H?IDV[` MP!JO6DRM%=:GKM5H\HI<$9-%CUDMQOWBN0_HC.'[L,]+3@UN]]6O56BQ\-!B M0@>;;/5R,A$=*N\9%B?NEBAZ"E%40<."@X:+:$/=WU2JN`ROT!0XAK_O>/O[ MKWZ]:=3_5PC:^=?/M0_84:5\NUZEM*\TR8!\8$>W3'-O)FGN=^@4^F2V*?N9 M5ZPR;TNDUW#(^J@-L;',]-X_4/'S[4TRA0L+7Z=0D!1&*75)S3;Y M<'N\#V^+AUEC1;6@;!QE+U;2H4=4;+&OJ,0-%#^,W"+S!TM*\$C_41Q8#'(D MJ\D$*VL82E7,33QNC@69^*X:S\6_K=C>%\N2$5`J,N1-G\$EI>$-Z7MXB6F`]R(#)4E]O(19J14J5*E1SH@IB9T0BVJ]J M8HAJ?J>>PRB>]=&^A$YVMO2=$W_J2.=(%BVIB>2LVB,HU=K'QBB#G-FK/8V9 MRWLAX`_8+R@"]_P1(Q:V16$!.D52@_RZ?!9/-$-WUZ?#<6;Q8`0V(PK$(3^% M,(6'*;,EAQZE3\BP)2W(Q#Y%`X?R*#`QI*:)^<3\"?!B*_;-^;OBI,2YB`R8OXPWQ7S!2NOE(H9I0W(X?MCPU MIR2H$.,FGM+FTG-%)2ODV[8`^VBWT=D6@2`@'B,+@=_X"GU3R5H*EC@(`%@78A MTBFTS[X73;4O7RY3[=O.+SZGRSU0?,HT+?(G'&!/S]=Y!8>5)&N17`IXQA9U MQDD7'31KS1C<=-B1#^S1%$O%J?8/O!<+%=CI/#),=KKJXOKX$V5"%4B4-2CO]@$``T.VO<'T$TL+*6: M$@>#L2XA(N+'\XD#2'D3$P9N'>BPW^.4S]0/^OP[U"9.<\8(^+,_F&.//2\. M8(-G%WH@:602(1W3(-$+/]5BW-_&ZC]O0FVS<`$B'P;CR&)%L1./3B!R$'F7 M2M.;^$W*0Z=F",]PN3!!31E#12YN#IFS\[Q% M]"3P23G1NDP)X6DR-NC6_T0@M5'`\@010Z<^;Y1]B/9Q]M7V+K:O5;@YV>OL M8?N,EK%R^W:X58VT=%`RA^($44J!$.)P?B\I)TX\%.R!`1V9TY1?S>,K&=M8 M(Y@2:2LT\,YB7SNK:"YB@26+H.PL<$4S?JBWATT=WJK@4AGLL*,,+EV[VO4P M],@]ZNADN2PMG?S*T*F!9WYCX9/G_R"Y>`G?N,S1;GC>JU(31"Z/DAU*2LE*6 MDUI,@'E?"].0KUP,JL%C?J.NV'26MV7:ZL`W>29'NN^WM!M1';$SK+?!25K: M$P/8P=Q[M$W`Q'@&YB,XDS]D!T3E2KPL8['*1LNRIWA`=3Q<>`24W@&/26$A MJ?+:<,=SVO+>?;S$8[?12#V*OX@--M3_9]#MHWZ>>V`"&'.F4L46QC$U54 M`L/I7`K"6RJ/H7SQD+^ECF+1TD(E%&Z3$W[YB4FD+(WV"#9?V3\I%)TX\\_ M4:*2>5$H3ES>X`&R,NG)]:A5'7^F M(LY$?#,I4; M.7ZD8U6QH/FV'-05V21)*6ML(F=D.PX)?%'YZO."M^D4*RK@^455B::];'YB MCP6M+N^C,<(L&KYD,QV^H%APWCKC,R>X8I)NSX$CB?@MI#A02?LVSME2]'/A M);#XU@O/FFG_8C.9%=]\/Q_EUA.X3O&T[4.2BKI>N^UT_2%V-,"4"PH%)*?P!9]M M-)OS3B56,RK\&&]UD71,VTC'C!CWR=L'Q9`<,X`7B\P46AJ04\&YQA7*J&BN+D(7G=@^=9JB8>M%PFUBA`[!YK"QPWC.:!XJ6E3 M?HF()\VC5D2J1MP03,E%*?O2JP<)%#"*3L969FZ/IC(;>_M0^CNV^V0&#HM3 M%'@Q'VS1N^/'W_Y(04O#@I#\>?7A_C?\N?Y+L@.\/%N\[.+Z]L/'V[.+Z_O[ MZZ]8(?=3HY$V[S7QRY>/G^Y3W\]A!__EB!.OZ_5^B6^_O/[RY?SF#M:(+IHY M#=A[[?J/C[>?OES_^4Y[M*GQ17SU_?5-WAINKS[_IBYBK4IQ#JLO`?WM(W]( MPYC^5'ZWY.^$O/,O5Y\!-"Y/)!'?_^\76#X7K^D=H<@WMJ5XTGS:$DUTN/@_ M5-==GV.#]QJ`?G]U>?Y%O@JV&7Q^<>&?8HVM.H!$U?+_?-5I*ELGB^P7#U,0 M=?!'`ERC`-A`\8;L#(D!=>"3;TYCNI%4+5:L-1+**@8CVV&@JV(`4("L`>L' MZ6+,H2,VO93RR[JNC!P"8ZPB@A,G@MSQARD::+U8&A#=/BII7W[@BF#T`\.F MVBDY`F4QZ"LX_-CP4.UQM<<'$=8.&X7;8.'B_/)?GV^O?__V`5`Q'#(V&NU+ M?M^:3TF(;HNM/RS($]NRT$/;&\>7?(=SP/W;%E!2Q44^F#?G'SY-#K\[`W6H;>;#>.;I\KLJ[(>AE9=YJZT>P?W3[OD*Q+HKM']+]]Z>Y/ MMFL'8ZQ;P9.+0Y'#UC#O1QHC%.7D&"59E]9L5:U6L5;%6P:S5;>CM;KO0*I5T=M@+X]I#85(U MP))A&=K8?>K&GZ93GPUM#B)O7E;3_F0Q MLF!-8DFR:C&%4TI'1ZSC=53?R*=`!MJ$F=0T%;/,1Z;M\S+16@IKR>V\KX$? M-R;E;\1?DJ9B5+%";2347J^N%Z;[O2:M+-4FEF9<7`(G#"F$;S[`@?$G=T-QQ[VS1#3'K$++N)DXEG,X2TJXJFX MDI*LU$PZ:M*QA.3B82N";"P!`\U,I#QT7+JH_>(0B!G$`9\@$S\,&_16#=`K M[;U%$00U3+DW?QY\4$:EL?>\]PMM`9L318A$L5SOM^J*WI^C)?I65J:IE9/9 MCMK\3:+V"?6#SW!F(?TE]=PP\JD,C7HJ\]Z:HK@+[IZ;M2$F:LB;1Q'5M>*5 M6.P#2\&&Z"1$:9Z;:(RKMAV/U5K<&C!G1@D^'I[)FX:*4E*APN7<5KGN=9>L M-@*DZC[>ETBJ89?7TM(#S*?WB@ZE:P2@V+WI@6^>N)+6*D;!^;S3.6@I&P>0 MA=ENI[R$#KM`H-+A:MC$BB@B`>IL:$6HU\,@#9(`012ZBM85?(!VP.=[4(M3 M;'$!V@_7(!O!T[!(J^HQ7")0U'E:RIB+U9.[:!!-[I/E`Q>M M$BW33+/O9JV5--5?,!M`ERW9XM':!&.FH%B9#\N[-S,Q'D>%*&_5JE19,'LV MF7O$)3+O9<-W9C"#???M``N9\<&VJW@8<8<9FH,L-D9M=_R8ZG*Y-,S.VIUZ`==]O`B90X.UV/$DZ4H2E@D4%8!C6?0Y MZF].6YFAUBFNYY8"%:MC9RAS:H=DXO@1;P6BC`B+FR`S'ASXG\AE4GXUT[-- MC&;>;!-D)S*QR--^P`D98`9B+,<>V*' M65&HSIH6>D4.F289$_(1$K`=K^T:J^G:B%G8:^LM67+4F$MP'D#E>#SNQ#D3 MC$UX-[?='IGC37F]/TW("-XHV+%]I4\@GWB-JNV)AFC(D6J?(A\']*`EI*XX'J-G`UH'H"UH>(.0W#RHH>*X4>^]9F]>]]XD MECE:<]9"$A'8RL$3A_,LAE.!*/O&P9O7QIO7YV]B/NU5]SX$Y."ZP4NUAF)^R8'&BIR_)U.3V1Q[CL7\-"M[+NC.0#P)GY-CC!3I3C9:BT;,4.?@H1HA M2XL@C%AYU/7'=-5)]9B4$H3$8WS0-79NYQ80_\GSJ]88>;%\GSW:[(FW]U.= M:VS^&HQEOQ/5-06JH#CBB-QMP2M+G=W8,B46D38,RM@?C**ZF9YX_'N,'RA. MF62R1#0$\>5*BQ)9($+A_%N!MB($G&NN(,A+#F^#FNQ&9;3*I)9!S*!*'24G# M4&Q`'DNHQ1R2LW`[$*/@<,0BO2.?CADO3?IAZ. MU44K/;58/`<`1YC,6ARY`9><$6HIL2-Q^&D%F,-@PF9*4'8G4&Y6KY;]%&UL M910YS@B1?O1B1-._@>@6&%2]`C<`Y:"]`KNI9H'UJEE@8>5&[>[QM]_9:=G# M),U(=AMISZ#@/$H1XH^3S@B:"+Y4<3JME7,7SI\#SFU3G=#/5.JKY.!6_'$(_FCIO49=[W2WL2%/ECU*8E+LKG=1GDGQI^EC35\I M;(HRMC*JFGT5A)!C;/:5(SE[/;U9;^CU[L$LBXI+*BXI.YL-XV`& M1AFYI"0&QGYC%M06KS(SJV9=^T?8R_#E&N#)M=M]O=OL56Q6L5G%9CL*F1AH M].L],:CX97'9[EK8[2Z9N:2]\8XTQ_7(8 M#NR$#N(>>7A## ML>>'9[AZS36I,IQG!%-GP,P2TQW7GF3@UDYW6PMD2G.ZVUJZS=IR:;D3F7PL M!%C5D2R2J9>2(^C#QX0C*DE:1D)6JT8FV/@&&^R(=A0+1!OO0V9Y$Y2@PXRX MM,-(5/9F.@MH`^;8[)$%HD`9A-,87`+1SD&3ITKI.M[D'GB:OJ1_#RW8;VJ_T32/J'!LMO(ZN[3!';]K)"U9T?1%M&[Q&:HB6CW:O.(2!U]> M]>8J$2CGHN5DW+X3E>>,B>[64W`M>'M"T8M:YQ=1G1\5L,N"]:3R$57\U/2I MY/'&]_Y-K37A"?#Y`9N2U[1K:H,94PPZ=HO>QDF)LU52,4\MOV6[(=$L$STP M\'W0`QO"?QX\?R9J[A5NPS)&ZEQ:TSX)0EVG*0A>R`M#B^W_T]?;(LH8.T^B M@4P>XJ3;J5/5*7J&5-,+JP+KQ0.;"4%&XX8:#%362!G8]\BLD3O&>Y/>,FH4 M+S+$RF>2E&B']]"',-=A(N$VWR,0A2DV!@SX3O(?T8M!/R\$_:T-T*@@.9QJ MM\1;DP2I:\5H"Y,:F0I!"_:"_X!Z?;SN1/X M(!HHP66ZT#7@F,%-SA0[MF%;@,AT`FF1\%Y;PI,5S0'%"\"D\2)P.4&F8UM3 MM&M$4ZXT/)FVN:"E["FXMTF#4/$.7"[7*8XW%'W2",S?71O_ND-;K_+L2L%I M1R9+;QF&,JB/8L1;:8`B=SWL6%8=2^QF"M7::Q#XW@_81/(J MP*Z>0Y1-09C7F;CDR#I)K_[*U7N"37A1N,I424#TZ$+@C%#W8A]A2UXR!`?()NAQMU31N8P[OPOG&;I M_\A>KC.=AC#8`39GX9%?.3'J]#L>F_\!D6V#L18H>W1O9]#$%N;H"T./TBB(A*> MS.+D^`.!<&J@)KA5=%6K(8_:CNEC&]N\1\@N^!)3&,``<"=V-"&[@%#-9R^) M_30?P!U[0$?S:P5E.V]!PP,,?H[7PJ5-Q$&NF:4S?"2(NQ)W&G(C%7B_?@5!\X MM[@)]FT?,-&1"MLZA[XG6S4[,V5?S\$OC1<:!PK$_"?LQVGA9]F-$[-?^'X+ M)(B>G=AR"E[D\TE9'-Z<=JKID`4/(&`_5"\*,%Q/?)RQ<3W&#P=XHU5X`OC. MR.E`1O0@,VFB*OK.>ZX\EZ!,(G[6G+.:*J9U*!U^J77J':G+6V?U/BCP6W0. M(L:E*NQ=Z)M#>>@U!+QXX,-4BG@[NMN%)OYJSA175M7#)(;@_Q\BFP]0HB!> M_H:21A.10>W!0R&'WJMT.ZG)G;Q3=AB/KP?)XWINPMH\WJ]KD4OA?2XFD_NI MP9V4H*#@AN!9T@0*:J"`2N@<'CRU1LNKF)88VL#92** M5=&M7S9$]@69K\")Q?`!5=[8F/;T7E4X0EK_`1L0.VFAA'Y;.10<)*' M@;E^Y'H:[DPFE8@UD4# MWDHQ-M%YMSG\BTY%P(B:'J#UW,'$]S,;PGVY^O;Q+"YD:;1_2?6=RV2Y7@(L M`]_6`R"Z,W*==O6:TU2OD*M7O.$"V^PHSN6A+P7=,.H&UDEA0;E+QH5:TA.!S MR#6SX1DNT'/VW%`UW\+`R]UL,O"<15$6'MOKUQL;)`-OCMG-47EX_&55JX72 M<3238I%4Q.O@#5<29BSD5UBO:R955Z*E$BV5:'F)HD6<]7`#?0"K%F*G MZ/#VF23\'.3RD\OUL75"B9R94W72).+\>?[XWW1=/JE=Y.'&Q_:K3OL[>-B$ M(WGX--(%9_YTB)-^=$W[B$D29)]M5*>HDW_XPXP444V""*DJ%*-@YJI0(]Y91'H#4^ M*:-B'4J^H$2,^"X5V-V?X!_I:?VA,K$>/4$YE&TD,J'H\(]*EQQ*O.!T*K=5 MS0*`&Y-QZO5&MZ;=\)2:(66#H%C%>>K,H4P0CY.J*+7BI[<`D"<.#3W?!K;# MV;J`+*S`JFE_\OE53,RO%A?*M!%1$64EN2]$E?$Q9N[<72!^9#>;E\3D)J,H MJ=Y_#ZI,E'+D9>1GHC3:VME<0FC2H.0NWC$!;[OQ_K.'='2)1="^J^2;&O7V M6:O^YKWVP0Z&CA>(]A&_R^''E&]E#KR(3L0_DOF0RH`_YXF#2';P=*#6B/%, MOM0;2Y,14R(*V8?TBQXPPRX_`49)1$62DHFHJAXF]X\D@J*$(<2ZR(]^ MQ\,@=,V98\Y`3+X;85'W^[5&"R8!"NZS9F($BG.5]JW^\38*SAY,<_KN+NE% MD52#W'C``<#"]^QG>.%XPQ^__O4O?_V+IOU#WH5#5H/K4>:.&?]O?!>%HN"/ M6S8"-[K>^`[_H"%U[]7[WYMU^OQ*LRW8(XQS6=];[<:K7S/",19HZ*#)UGU\ MB^;\7_Z%KMWAEFJK_.N=&F<>]YK<343+K,Y.:7VY15B5$7M)QXQDQ2RR5J"K'C5M(C!GYGTT5%A"22 M)\`U0S/)8IPD!`.VV<3\D?18$*4)H$$G4Z4?C\E=7^X.R;J'"6]'ANGSHD^% MF]2+V.)1JN:C:>N2P2Y\ARC-"-2YS/$] M0C_6M',R,>"'('(H!1\-'H3,HRF4P831&U^+ZSXD':G[H`U!8Y*!NHI#! MI/PF'LYTCG`?$5-1$,0;&9!JY(FQB["P*A9W--IJ/;V3U58X7!ZL/:33CWQ[ MBU)71EG5U7,%53E5V)V),BW9SK*HK^.JDB@\)J*"@9[7S!Y]QA4DJ M^7SR9,[@@?ZTIFO6V\%;\ZWX[K,#_I^CO9:JP*B_5W^(OVZ\?P,:3`NB06!; MMNG/2%$[H"S`@;MRA[7T(_@/ZMT86?31SPVY?L#HLURDGEY,@`)<14%*3UVY MV&8&'O,;-3L@HRV:2@PCML_H\SO>4UJE]FY+F&;1E"ADX"/N`)!T.P?9/@%K MVM@9=M_8@`[*/E'VP1,C&>@@QW;_8'@H->H7(F7I8OJXEZHLE5$0%UV MA"Z0+5!36(A<2P1T-]QQ+$6!U_D\ADK[?_?Q$NVKT4@MM+\`+0Y0NZF=NSN_ M4'<-R+154^0<-P+PR,"W1)VK*RV55%@#/F"8!8#D#5[C+CSBHJEG\]I=1`;' M%5::1LV*BRTFU"WKM>SW800G86^I-V??TE<2T7MQE:U4DK:EH!E%Y_R MZ,4OU6CFK+7PMX">68R1M7I+Y2-D37/RR&S+-:W$K'%Y&[=?#IYO3S8K>_*` M74/.I;I(]O3`%N:1-D*I+,YEU*4T;`?-G'3L3!I8@ED$5V'[*KJ*VJWKB3)/ M@CH45'&$ M5*.NI`377)Z9M:EB3&WM+[PI5HRH*Z'N1WY\1"$:HPY MU@=H<#D._7V::G2Q/LQJSBL7VZ1Y?@%QF%:E-P^I9.*=+*FZW.QX8:G./.[S MA:-4G#%U\2DCOF]S2>QX3[Q;!+FPKT>V'X1G-K`S_X09)[P7]1O,7E+:/[H> M:@#Q3$7,6^C*H_;%5OH8;,D5]S7M/!4F25KW`'*B$68?8+]J^&'J>]A#"R0+ MO!';5H^9J;8*5H_VXP6E53$F6\F$?KA0U$:/(F=D.XXX^Z=^W-0S*X@PSY`4 M]PT>5=S@A()A^)Q@33I&\\,.1=L.-\26E:-1T@;#3`>_Z"PB;YU*EPPV(4LD MPD!+P,]?Q"VD4&6.6:#:+=3*KB#@R)3!MUYXUDS[%YO)=*=F&G""6T_@R@N0 M49-GL-32^^S*(_("#FX^0$5&G!)7ZDZ*MHE[+>YD%/!V;-U0CTB(#Q4:DV@VYT,2E/2:\&.\U472,6TC M'R@Z^`) MH]34`GYHS#.L,)^NIOV)Q&(B[=+%GF/IHD#(QVB.1P-1XO@?_B(N50.-23L] M<1UO@H-/HV7X;`*2S>*H5838.=`4/@YSOX"HN%DLV^Z+:.0\:D6<<\0-Y)1< MC/M"I%8/$@C;M(?>W-RK3<=+G6X:7Y'LFVXCFVAFV?31B@_C92NC_?UY5WAQV\%^../&Z7N^7^/;+ZR]?SF_N8(WHNIK3@+W7KO_X M>/OIR_6?[[1'.[!I&NNFA7EK>*.B`$\"NLF0G,=UDY_\J@W.+PV):%'MK>.+[D.YP#[M^V@-+'F9?Y8&9Z@;3D`>3A0:_/P]YH&7JSW3BZ M?:[(NB+K963=:>I&LW]T^[Q#LBZ)[A[1__:ENS_9KAV,Y2R!0Y'#UC#O1P_3 MG^+VRUA8M;4ER%(5#=R'L MZAGMH*9NX3SQEZ*,Z(57W2[NK$';.*!M'"K;&+>HR.F-$?>E[39ZNA9C5Z4" MB<4VR%:BE'D:H7MX/G[2&=FR?!9@Q076D&"/-*K[#%!8B$7*(M+7=QZ,&"%U(Y@G@-KM07+4GGGRO;F>0# M"PN"2<+T*5'TC;FPC&!&>Z& M8P_;S`#S7&ZG"1&](+,CIUQ0N2W$Q[G6PR_2;+E,'! M`,F!F2U![/MP^QU-X(AZ#5(M.9\-(+KF)X\E'Z>F)81F"4+#YD..)#2ZBOH! MQB-A+.RY`SM@DY4?7ZV,30#S=:A8N&`)6]@I:,#[%3TQ]'E0=#\RWWQ@FAM1 M7;KTT0+9C3"VD%6O0FG++&=#?5B\<)LC/3`G-%-D0,#F7$?S$,">3AX;)(.? M=.F=)).=N/,4(EY-)[U8]&#`WN9MNK&4$Q\$LEA],J_:QX_A1X?I-3 M]F[FE'U9\6!5YU_10%7G?\JIHGGR_UH,2%*8 MD=:?1Y%AZ$:[IW?:5R<&M^.,0_-'2>XVZWNEN8T.>+'N4Q*3870U2GDGQ MI^ECBDHI;(HREB1517L%(>08B_9R)&>OIS?K#;W>/9AE47%)Q25EYY)F5SAB_7`$^NW>[KW6:O8K.*S2HV MVU'(Q$"C7^^)@2,OB\MV5XI:U)/G'OR":EQ7)&QG\[L_F;;_!U;Q7(\^V:[I MXD3&*S<(_0A3P[U/V0I6;R)FK*+\_Q097(?/A54R>36 MM2B@O.I'TW9(O(@".]O%.E-*E-6I1E+)EJ;,X7@4:U)12'G.HY@.[(0.XH)6 MO"&YEF:A8J8V?5`R=_7\T:,X*"HS%(E/*?M):U&+&Y6\Y&#L^>$9KEYS31IE MQ_.=J8PWL\1T>>23#$O;Z=+(0"9LITLCTS61*W3!TNQ;^ MW\=D6Y]?P],OJW1_$34\EY)?Z8.RL96<+[F1.4 M[\.,,+?#B&?^4/&Y.FMQP!R;/;)`#(0&T3D&=TP;XI3#4),G>NE!DLD]\#1= M%-?G#77D4[NISMF/*S?$HWT[^*$.)UP"F*CS#P"5]L@>@ERO:9<++Z?RCU@I MPCLM-I&#"O&W9&)YJ@C]TX>K2\15Y%-C",>>P.I/1A6L)=6SJN#&]Z;,#V=8 MH!["W7@GE7\^6QMTZI4V.*3]CZ2GG0,#]P5C7=T?A&?%XQ=%V27A:0N%HV0J>E302RHK7^S M(5V&GQ^P`U--NT:MGE`,.L:+WL9)B;-5TN:!^AN)`<3"/R4/%GQ']&"'\)\' M'#_+&T4HW(9%KLREV>2?!*&N,Q,;+^1EPX4.O6[T]79VZ+7-V_3D(4ZZ[3K5 M)*-G+0=3@WWE@56'(#-I&)R,O;2NZ3/7!I`]X%6WC!H\N0_\\N?;2XW*7CID M;T"^JUJ\K24UFEZ4"LEW.DG\8F63GG)S4=Q[+K9RHYWD/Z(GB+YR"!:&-D"S MAS2%ZNJ*CC]!ZEK1:1!\*)"40A6`1>,_H.4!8B/P7(`*39HQ,QWPRD5DEEI@ M,)^W`<0'47\_KG6$-@3G%FYRIO!@:FL1F4X@;2:Z7T8#\*6V+U\`1I<7@=L. M6N>1-Q63'?C2\'`"Z!F-[GL*>KI#>VJ"6(=5F3Q`P-^!R^5:#^05Z4&A(GYW M;?SK#JW1T_&.UY+:65$/M'_.=2/>X7LN?!PR);+Z?*EO5%+_H(W:,'"E)9NL MI7>YI$J@Y)[STD[!ZT

+.BWTGFG]6;VIEVA66I*,GA(S8=B@..\0^O[Z)! MZ$U!BO>:[;-F_]8)% M/9`HO8'IT`7!F*$6!\6H6?"0(3[`BJCC;=*G:`3N)`8U0&3(`(3T)1W;'-B. M'^C8ZD<$)!&%D3?O::!]`3 M\UG:48;E,^'(#L>F_\"TUW:-U<#%<[EW_$:VGTU!KJ[@4^2C>ZIG5B#Q*[Y6 M(DP2GLSB^*E#C'#JH"BX5;15K"&/VH[I.[-\^'AL?Q9C"H-!`.[$CB9DP1"J M>=->L9_F`[BV#^BT/XV9&Y^/2QF0M/*-U^+CQ0(GN`9N5"EP4Q_(^#XT#Z?1 M`-1_;%9J:):%V'D-?QS!6L'NHN@8(``,1WH[;R?\`?0.V;1(UYRZ$49:C#V) M>X*)ALR\$;#ZP+G%32*T;YGH_68!ND/?"Z9\L.JOW08'?HAL3,2Y5T6[VS:$\XAP"7CSPMBI%O!W=[4(3?S5G MBM.MZF$20SCP-+)YQWT*B.9O*&DT$67E$U)1EL<.,K63E'?*MO'Q]2!Y7,]- M6)N?G>A:Y-)1"1>3R?W42E)*4%!P0_"!\1D>JC6EB>5K5GNHZ'B*H8UMC90)J)8G2&(<:MYS1=DO@(G%@.;-9P#=PK,80=RF&P*57B> M'C\!)QZXTB0AH>NSD4.!7AY2Y_J1ZVFX,^FY+];,I:U4UO2EP[4I^PD&A/O` MQ'8@BN<6LP@GO%%_C!@%R/2*!KQI:6RB\[Z.^!>=,($1-3U`D\>#B>]GME[\ M5(-"*X$[2 MR"C5>U(I@HN3Y66A0(P)W![YI4""TEVR7C/:ZA5RE>IW'"#;?859A;2EX#LF M/?=:23`C-WW_4"M:0O`YY)K9\&P(*6?/#57S+3R4NIM-!IZ3?P(EX@Z]?KVQ M0=K]YIC=')6'QU]6M5HH'4(T2%C'4O)48J82,Y68J<3,!F+F@RP^2MQ7/B-NO6%?E42I M)$HE42J)HF;^.#PG)5^@R%.QRJ*IY$]I5E3)GQ.2/[=SX7LZ17Z-8YN"-VK< M'`=^!B,\2C47R*-BQ$_1X>TS2?@YR.4GE^MCZX123C.GZJ1)Q/GS_/&_Z;J1 MZ8C,!I$72L?VJT[[.^KPYX5G_G2(DWYT3?N(21)R^!FI1)L?ET_1!`]#?IR. M@\`D%#24C)_JV'3PE4D-X`?^O."!#P>CS)/LJY7T$F_^&7&"BRA60A0EX\ML MU\918$[JE$>@51W*S(^&**,@N4L%=O4C.D;!`4JQ-SIC&',D$\3JJB;$V.7W<\ M<6CH^3:P'1`,MDC":C8:7E1;C**DI3^]Z#*1"E'7D9^)DJCK9W-)80FS7+NXAT3\+8;[S][ M2$>76/+NNTJ^J5%OG[7J;]YK'^Q@Z'B!:&7R.UZ'V?R4;V4.O(A.Q#^2^9#* MU3_GB8-(=O!TH-:(\4R^U!M+DQ%3(@K9A_2+'C##+C\!1DE$19*2B:AR#FLP M]B+'PJ.\N+D"II"2;O6]`3F6COT?%#M$@L("P%H63/:3@BK.B11_YPD671M$ MH30)0!Q%L@F"^GRA9U%,DIX5SU5S/^_'3)VPBH-,>3Y.*H&5U^(&G$H?B$J' MG$K%.D9+X;*#&'["J:L)5J$\3\Y"268CMYB2#,\<\%.K4\%1^1W>FFO&Y>5? MKF'(D>7#N%4F-8EBBZW20.K*4/I$:B*E@@:.4'P4Y4:B0A0C=M47FR)?$K?V M9"IW-BW"F:O7'(Z9%3GL>G3E8N64Y\\NL;38#>_Q9<\IWFE6Q3MED=!B9^.L M>RL6DS*7K)H2O`$H!YT2G!H2W*N&!!?6?+W3K`:&+H7M*(9%IC"0F@;96#X- M`;>O^_2LX_-CP4.UQ MM<<'$=;E&..QD?R^-9_B(X=@BZT_]BD31P7N-L3_MRV@+/%TE<6@U^=A;[0, MO=EN'-T^5V1=D?4RLNXT=:-9C1DOG^[>W<#+/-W]R7;M8"R+N0]%#F6<>EG- MABT((<WFQV*@XIG4VQWW@`C4[6;'G\K<.R MPLK0K$:\;N^!59-=CM;CL_J;BP(<(OB&L/ MAT+=N),-OXC@TCG_JN?OS)>-AT&1.H<2R/Y\*UB$%U@"`3&Y#T=)839&4C8]PS^!W, M:WXH]#\$=+[S7J>J>[C0UYLNQ1$I-B=UDN>2;%GZ;OFQBQ+8%- M4<:DERHMK""$'&-:6([D[/7T9KVAU[L'LRPJ+JFXI.QO-XR#&1AE MY)*2&!C[C5E0`F5E9E9I7?M'V,OPY1K@R;7;?;W;[%5L5K%9Q68["ID8:/3K MO7K]!7+9[I(=BWKRW(-?9!9E4=F0V7S+6^;@U/<;TP]G]\FXF"!IQ?R<1,IV M61,I`_N_[)W6PY1`K=&HU=6A#04\?I,DP\%"ALFRV#>89Y+)1:6%>EF*Y,U!VG3=Z9V,SZJ^F/QQK1KW>U-7&]]0='[M#8S]G MG.V@#7S/1.7CPR8_V$-XJV-3.VOJH!RP1^9C%^;1R(;O0YP%S_NWGCNA/?1\ M[0QHGD_XFPUSH6S@4A M]A+&QTPB>-<9]:;&1M($&;:%MF!QCC>E%M/F@\^8O,&QA\P-J#^T_)J#XWLS MTZ&.[YX+:/!_,%J>[UG1$+MTTYP+')E`M^!,^B2\K3F>B;VUI^:,OQ%6P`\^%N"O7>UZ&'HT%:.#C<;K_31S M48H,M4+'H1C:5P:4:L(SO['PR?-_$,ES!D\T)_6 M=,UZ.WAKOA7??7:\`7#B:SF$>5+O"M`,42%,#4:X- M5I5^NBU.`7`]$<#`1]3`.A^8RV"E&@B:$-_L>]'#6+.Q-.`,JP8`HR"9&(`6 M,NW1-@'0\6S*?,=V?\CY[&6[DLDMLV-6TK#?C?BK0QNW6]+LS_F.(1 MW$)?@G60V9<`N2/4=A!0^@\VU:`R%H;02X.EMD6/Z`@^+0#4C]8GX*9<^8#S73` MLI7`=%@@:-7VXSGR09HFV<\IJ#"X4%V@]\2G^J1H58#SMJ`?^`;L-[.P8$/`NTB`H,&/WP&F3C5 MOGRY3*N"B\\9#>`F1INB`71MZIA#-'HB5$X!SF<"[Q0),@1XD&:G8`_]M+&; M(1AG?VO6FAH8=PX68(DF_L+2^9-A!`HFS082FWM!TAK3LOXB%PD!@IUT\N M`O'ZZN(Z>%/3KKF-FEH\CC@A4/6")4NMG98J\H5/`*W/A@P$@Q7+%MQ3A/'! M-R<[D'*U7OY:E->WY.MKVGD@IM]XKK!WU27&FR.NY[+?]7#^W<@1DUIP)VF> MC=PXE%PV=KP()04\@960C!_C,^_@$UH(U9E@^O1L8VM&&9C!.:$RZ6T+X+P8[F7)(7")6AD-S MX)D#'.W+Z$&P.O*&?'HXG[B)\U[`,H35VB,PU&(>!R`BWQ64#F]"H46"@N_! M`![Y`[4@2`MGAF.+XAEN@01S8(I16T!4^+:0CW&,-]@.:.O1?+M23/$<^A`( M*=9.:>?9<=ON'Z$IR1)\P;BMOPU/S M_`23=?,(2#!,(!EW-^3@)8.B'(P'D%63`]+\DH]>];]H]_DH%WV=,M$X(1I+ MO?XO%'QBZIN#7'*/N:BVK+NO3L_E5S(:(1\(;HD#,@&?#L>LYWL-,53X$E,.B'[:;F3-=N(Q`J)MUXYT6(Y!'(5E-[C;+P'F66' MGF^S0$5GC4#742:9FF,./)"\.*O*8@'0"D$#Y@F_1LI"=/903./!3D:T<80$ M&$>4L4&);KI;B%E4&!2&G'$1C[-]"3#4!7)&H;R";DPTRB@>Q3<5>F%JAA2, M3(;Q"I.;1B!R.WR>(FE&JAN/\D5%C-0TPN5AG#5(&C!(:3RR?5BCB*+0>#_3 MB37/@JT"HUY,GU7BL`0?VL;_$[E,V'OW&$FB67ZZ0",LB&`W(W!@`:XAA8I] MAJ><-!W0LFS!-6"\\N"P'`\8N0YR&%BJJ&C)U'``,I_OIQBW3#%IG,SG`&K# M?*F[I:70R1@)ECD+Q/AFP9TF^'^PH`#M6T1P3?L0^3$-47R&;.TU`A$%>S/[ M"<:TFG-OR<91D$)@4\&$T/FA@G`>BH6VL0]HC?S8',U+-BB%$T#\<8,_\1 MGJ7$W^,_`A!+Q[BC!;;`4Z;]9WA5(FET_69 MD`I%1I%8A9@$XHE@L!H5NOWM[C(= M%4*'&"PXYHR((.'Z`1N;\)>7!`S@8S:^`Y?&62)DR-UC,HCBJJ,Y.>%2#"\& M2@PI*@(O^.8]T' M3,^D3!45[`\?OF:#8;R#Y-AST/1++S@4;;!W*HXW(,C**-A`)%.3T2(19 M.0BCQ^70@SQX]!FF6BK$F8LRP3HY$5B*@&%BM(URG2B+AQ#YN9*4,`@*;LIK M7""@@P/(TQL%G)EM>P,L['`,@8_J>'CL'^1!HKS\G?;:?*.1(H:5B-Q+&;2E MG88OB8\'0($C.\1,`U>BG$KS7\,$=98636&[ M";[7Q$JT'?A27<-XHNU21%&+\834@O))E:7R59840C=P?\KE3LZ(0=Z`\L!S M+A03()ME5(!-IHXW8PG>4GHV0:OR=9+W0^%:!FJ)MS-%!+P>O,&P@S^TN0S! M-*$X\.K,SC`:#&J;B@L0+6P$BPS)P9^88$W:_^4DXD8DHE$+Q&^C[>#;96KY MX&>X/O&LD73B!.!8,^2'06P,P!)IX0IX#BS?@XGY@^U0)IB/INWP1K6>@U8U MO)(S6%KU82)#2GZ`T/>ETO*D.)%*,0LLC[4H#(WN+`^=#^+\GGF387%]S%S0 M1$2Q^2$YX0Z>[MAJV\YT2/%UXPUG"4H'B^CT_,FWPQ"$6[)N6&S$$8!(T;77 MQAN4ZZFH^(`!N8ES>;`0_@WF)Z4VF^X//YJ&PQFF$`!VP=[$SX[]G\BV1(]F M7V`S`#)T3'%`PO"L(J"3EM?--S+V0V?\I'A<(+)A1`%ZGUAY$8UE`_@KL5A% M@LH*"IY,A4`D/,K(\S;(@0GFK9:)&6=UJ(=*<]3!;6IAB%H,#\GPZY@KDO?A M7R0%Q=_YDC"(3_+04&;_B>BLS?*F4O*3REET+]`J5Z)2^.J917"U`DM]9"`D M@`6$K4[0P]=8V,?M`A4:>+.)N<\HXH22%]H8'TLZ72K"H"8-5#Q=@)\PY2H2 M"+:Y$!/IJB*?*AC:F+N*N1S`T2;'MC/#)R\"D_R=/%6#*R<3AB1^(I<7XIH. M)<$)XD?BCXP_6CXPI52'O-\_07"Q]B:E.U?PQG4I25)V%%3[SD=8*;E#)ERT"E!D/@-N!S5,=+M5$ M)WHGN<7]N9<)4:KGGP;7;,,0RF]_/!P]?R46.`GSU M(@Q>S-1?SG_:P??[)^__8[YW[;)[-"MN>#"&/PP7^M`+WW#-!O>.;T&I6JVR,@`TY_*76W&_T% MP/"E9EGQ`QN$A=3>=NLOM/8V912=->JU!E;.YYA%&O_M^46J6)>KM9-R7-Q# M\,^"T(]0W>RS"+99M/'S[747_`7]#`]U/!)VYASF=Z@)WH4]YTL24*M4R6DB@?F4_Q>,Y;T-"F6NH!A4MB MRQQ,=E,;P2]48(3UZ%@.CNF)'--@$VA?J\)H33?1ZY'T`5 M]5_>@'$/;DX//U,T*PDWQ+YEWN,HTN\S#.TE*2I_8HCX+H0=#K7_`:/$Q:-% M]A.C&@%_'2>1&!!:NDP8-2TD0IYZB,)AXD6PBA1@EHV.*$/R&+#PB3'AHO@\ M5L67RWB!+(^FTI%2A.$5.FI.^QS:>9B;)T@1:5H:`%GHH64_0S>_T%@NTP6G M<$>D8P=Q(1%5[=CD!(:S,TIA?=UJO^&8<;"ZE^KU@TSUVL@>A8CIUXV\:['T MWZ7>!&)/^5@QOHT8*`31_KI9?R,V,N_^J6^[>.SG<`]>/"@36\UN+E,:#%!L MD6+Z(87^9G$L4$E&0VR\H;,E.L85M\;DU:JU?U$OI1#=MQ%C]IA-RC M(=F`&8&0E44FK^)$9!7*WX;>ZAMZVVBFZ8+F[@6BZT6'JG$@HMKRQ,Y\+']LU MH,H">Z@]FDX4G]UF>$27=;Y##&%:_*35LH,AV3LB_NY(_PC,(#!A_HNY)(_* MX:*JJC@GB-B.VXX]",!5U)[$BLMT:]!UZ*X%HB! M52=+0L55$Q:./4M?!O0Y"=1%]EOD)IB+D0O:R!O:=$08ZQC"-!IZQ6*H-U\# M6],ND5"SF,BT&\DI9T$\Y21'%K[H1B-G6POGGV8KCW_4Y+V:]@W(>%AN9#5[ M^ZB(R=F1#*Y.\A1E0?PU&Z:]Q)8OU/TL.'>M2TK!>0"KU&;%=$[L-EYH]'9I M8&RCB&QBV'22T*RR;\0S0W7G]ABG+0;,@S1'+"8<>SVEXSP0F5^P;K8LH=>U MU[\,]?E+/\EHK.J_8Y4N+,:FV,H(/4KD,*5HFZ9YBC`$KUP?8L"59QQX,4'0 MN-AA;\)\)0R`BCB)B#A0N-0G#GR0A>`I+(Z$XO0Y=)*?PM?+56 ML<$V->>]NU8L_`Z,?ZQ^Q+P<'L+R\&)9,?XEP;V.'@`&XF3FG?L`,O.-:'@B MP5:I.9VY'=O%^3K^S!S\GQULN M;1?.SCXS1Z.P"5`N>6MZ-T:HYQT`@;_^2X^V-K!NR)10%?4FH`-;O\0]13\"C/.PH5K M1Q%EP*#UXZ,IPJ.?:+FBS2[:H9M4SB0//X&#(T<U\[QGPNWYH%W@`X`^8&?&"X>G4LUW1+G)1J?KEV&8C95G7 MY/_R4RU3FS!92[#H_@O/]"ECX@.XO4-PEH.:]C$^;J%RCZ]^O*YT-1Y?'S]Y M_P`7_8NY8(F.M3OXZ/GNA(8\8+H_!V'94GE]YW)0;_!AEAP8P9]VEQ19B,>] M'#EWDI&J;/=%);E#H<-,&\#$;<=,*>F]!Z"<^3E9.I4GFN*?Q0+3 MTHU66S>,;IH*DC2>18T[4^D]66UQS5>?2EO=5PI0VVC/4S3!PY>)9V74)5,N M@+Y4H?$R>O0-3SL00'&.?:3LU*#P#3%R:)["'V)#TDOK<*^?K\-TU2R$HB-J MO>:JA5%(%OMF6B9OURWJ[ZEOW*.<1A$J;3U%!P!+N!BR.4(@B^J=)-;*\M*1PMM+Y98GW&BBM(O0"EUEQ6=W/M4\STO M3>P?\9KW(K>53H+Q>M[((Y-4YT9J2R./9(:.:4]2'5[&2<8VFF:A.`9Z;;\1 M,]#088[3>^/\VH8A(U8R]"WT-[5QL.%NT4$C#L%/L-U!TB2#]V'ATCY^6"I) M..X9._#0Z;9'J31@.V[+Z+FBFR)/5>;C9[!=%A\]@VD$ON>(+'BA\%>@6>>I MM\H,M(@&LV$O`CZHS7P"0SP`[#G$OW/&CCU!>/F)R*/L[S%@4C7,)QL?(S>< M$&-?)YV=$JBPX;E1K_>6-;QR5>;.%.2#EY4\3/A8.H6%UG..=-%ZAT+FO-4S MLH#.FZ*(*7OBA#1Y$3\.E"/:J(TU&I13GSW:7A3DKS<^2$V\R=3A(K5^GVN2 MI9Q:\EY7<74]C9T[& M@E%G"WP+L0S9WYRR9MYZ?NP/H74-WXH^+J)6`M,>P?Y7:B#RH@&)2;X*3;@V M1>)/XW9M=/PD6_OD-352N2'6@9Y/W0.P5=K`L3&.*2>@)&=<-,\NCBA,TOWP M?4Q&R)2)/(UMP-R"79XWHY2%(9])OU-V)1O;DX+W73?ZG>RNXQ:*'E-*PJYC MCQ"O020T*BS?CB95G+=,H-RG&KHEAAERKZK0TY3&9?V0S#,R:`_8%_PV,2%VP9MQ4E0>`ZSU(N"G5#0QL36#_*>F%H;PY%ZE/`4E M7T!3Z-#4$.1E`Y_@S8&_1A*T&&AR?1,4\PRH%>K6Z\X)1DDD=[VX]C[ M`G_QY>B'DXR/7\E0%L^:5/:;;&)1]`A_BJ4GI+H*3"R+?20Q0;=3'BWI'_,!`SK:Q$ZS**4(4\GXYS'P$ MH"3IS(U#,F:C_FS.U-6H$K)IP1S9ZAR6(5>>%N0PI!?Y%4,>%RA7:@\:"AT= M4EV6GBN;K5)QI5[P!F1/XHH?XF%L+E9DE6HE5XX(E*O4R.3F(<6*H><.4]Y4 ML.S)$F]V^_U2R9C\XWC.FNID27$9L2(QIII!4'C.0/X:>7@:_7ZQVG3'(Y(M MV60!I8.ZEQ!M7(%W])QX6D+E?TR7][BG)A59H2)SG/8B5>K/=^]%OW^Q5C$G M=^Z[B`9,SN^,#??%?^@3*:12*L,MHN/N'AKDY"I8\YH_(:R MSXM2_93#)6J$*8;9\Z,I^`T'`RG5\`J`CF<]I`"DM`M,KQ@HNVG)A-CX8473 M54Y:"V'M/'K`0[U6MCE"T6BC3*&UD">1PCER*29YBI$::FH5/E\]MUW8=:(= M^FIOLYUA+O0RB-L"7?&A:+$(:BVHAYZ33)CZA8D.8QO;6RK"==]&]O,C@OOR MVXT-O'9*#<"@ENT&(>B[N(MOHCEJ=LMP81*;>#D> MR!&`,A;J^]3Y]C&M37)%/FF+'!1>]90W0*FR2HL*CLMQIXB+SH, M,`\6DWR5)-TD+U?-R94!GLP@%B7X,A^*HR@2;V@C:)A&<\IB<"6;E>#F\S=% M%O'$M'@E";TI[5^X"WD\^'VXG4Z.%[RA_CT[/)Q032:C< M*6FU29TVX5EWHI'>!Q::MA-LT2K:>/5KU0>T1'U`Y;#'C?8]VV!6LYY$:_(_9Z&YBR.WZ'(I>. MDU34*1W[+F;))>+1YUC;3?_Y@_=AN+4?QF$`:F>(4YL?V()IO4UE6F_S.R$K M/BQ<%U??/Z$O>:Z&C)(AL*FO^5.3)#0V/\RDH M9&F<1Q?M5]7G=OMPQ'$$'C=:99$'(3'$RV>$J1U_BPU7TM#0)0'+:?OIR_><[#?LJP-/6BD'R ME_ORS;]]O/K\&UKGQO2G\KLE?R=HSK]@N8`CGW"DP?*O;]]I_X?[,'-$]UX#4.ZO+L^_R%0 M*`[[SU?M_B\IE/;#%I6\QJUT]\UV\PMZO: MY6/?Y1S]_!&;]LU>[-96NOEH@#L!RUF(BOOKFUPYL1CT%>+YV/!0[7&UQ\<, MV]9[7#G(NU'"#AN%VV#AXOSR7Y]OKW__]@%0,1PR-AKM2R_?R41E<6+!4S_5 MDP]Q%B+F0=%D&?GYT;0=4[:+H&SF+8CGL$B;V);EL#W*B9+32-'@^IC%E@_O MS?F'#U??/I_=BE7(I*K#XZ`^CX2VH3<;#=WH]H]NSRL2/QB)EP/>''(^XOVM MR'G'UMS);F])#+P1_>]0!MXH&54OX^9*O<]'.>V)DCNU&UGU>^.8[J%(:6M\ M':>DV!UY'(]MMT,GI?`QMJM7AE-?XX3Q/7N17N0KE!K=, M^N^X8G=UO='KZZUFX^CVO"+QE>#^[053=KW6J->;1[?-):)JN=U?/GZ"-1B= M\FQWCO67*'#J%F54\JQ\1N!^HWO/-0(?P>[#4*#CF;S!=L"&D6^'LZ1M5N5H ME!O<$S(+]QLJ,?16W]#;QL'T9T7A+\4JW"]A']8J/`6J?J95N-^88-8J;%4[ M7SJKL.RAP:05`YF%0\\-(H>&6V6&8WTPW9'GPX=SZ]$./#^H7)!R@WM"YN%^ M8ROJ0/9CVO"*OH_,.-QWR-!H5U3]8D*&B6+O'=8X+./.E\0XW&_(\%JI[7B2 MAJ*89V2[?.(BCD^MO(AR@WM"AMU^PR.M9E=OM'M'M^$5?1^98;?OJ)_1;;6/ M;IM+1-5'%?7C>IK/CZU2E\MGU.TWXK?"J/MJSL0;!A&-%XB_%T-M[!.^`AMXI4/511?!04S=H[)Q1A6W+9^>5 M*G@W;^>=1P]1$![4U"NCDY"`NUG?Q)*3S/X13,:6FTW* M`^[QFXM57/"XJ/JHXH)"X?C+B1YNC:)<:[&N]]L]O5.O.*3DX)8I@%X.>$O9-:8BYQW: MA$<,[^G;@_L-(.;9@R)^2*V=U9&793((R^A05$'$*HB8-@LS`V8K/BDMN$=J M%NZ7GH]X?_=.SMO/P*C:"99L@TMB&!X^4)@=@%X%#LO&/GN-BG6KP.%&*,IK M-=UHZMU^7^^T#U9?57'(25N(5>"PK.1/Y[?O8'?' M:;QF7O$^B["OY[>?KP!/==OE_XJ7T?-M^=HY$+)+2V-,+I+^B!^20DH!2R,WV-)ZK6T#T>2!HYF._>#^\]6_HR"T1[-7:P.U"WSO>M'7//^3YPIC M#B@.=+GT)E/3G6DD>RA)-/3H![PDF>]RGN[R$U]PY6(BJ><'.C820H,_Q*9" M3V-[.$X]'XRAN'FDS:CST/Q#,$45OY5IJMJ-Z$%^(WN0U^#B%9?H\^_%WI4/ M`,$#7NB-"F4]K0466Z.M]T1,+Z8*Z2.--#L,,MV50LW$_NI#6LW?BER.DLT5 MKV0*?A>M1LQA]((`WNZ!W+2"PA?0,+`K3MP91RZBIMW/;[?I!!XXC4-FH],8 MTT-N>ZIHBG_N=">;AM[M=?1>K[UH)].[Z&KL)_.'-JSN`)NI8#1&V!/#L4V3 M";.P=Y<9)Y5#OH`1P,&&\U2R(NF'C;`!0DU]!G2HQ!5;D1A#7B1&85CS[?_ M"Y2<3S`U#22PFGZ7D<%<4_:,1O=]P!\Q!N'%_$#Y03.GP+F/C,LT$'<6"64A M3?,>=,E\T!+V4##,E3OT_*GGFSBB%>^+`=H0&FT$QEBQV]=HUW-E1^%DVZPO M>!$'51?Z"S%M6R*<95KL/Q$B<1XS]+/C:%,OA,VPE3`9(0KN`Q7E,*440]65 MJQ3>/)>C),?W@3+UX9(LF[N6-C8?X8,&*GV"^Q:P1^9J,V:"S*5MPW=:^![X M,$-R-]/D7INWU8[-0EMB=AX9*)\PF`K;CK%5T#+"2K)!F@,Y!.80.9D+DGA4 M"RA)_&^L6H=F,$:BG#*X@3A?B"]SXD5P(3(\"I:?]H3KC4+56+>7PVI(IGEK MQN]1MHU&MH-*+`'B*<\LV*E!8.A&OZW7>\8Z]H!.9MUA;0+M-:)4RG^C_IX+ ME1C%YX1B*4CBZQKOWRAR9M'E.7)"\^8UVLAS'.^))H,G.DSH+1"-2&KS:C1/ MT*G%RTA@4LM\&[1K8+3,%M'>H%;*+G M/=?]5\_QX8JU&1>;=Q^TQ.K-!R;H9Z6!1O0RB@5)L%5P(Z&&)E!LR`5[O&B$&1I M!!LX8+"]W%7P7,8!,%T7U+,?F/Y,+W9OV^EM_65.5JN>+J)/CP5\XF"VZZOO MT[;#ACD*A1O)?L)^!J@%Q*N26_A%$ELI8H#'@15/09``$]BHQ$;"F=BB?(SPT3=/9E!2@]R)08, M'(+$!,06RC]&*]]")`P-R$X%-Q9-`1`@2O?Q$6.20U*[+FQE^`96[2N>E.NY M9_-V`1@1\)G'Q_!!X1B02`N`IS'.D(`!%U$QG\M`J"H4'%L3Q,R,=P-I8&M8ZF8!WVMA5%Y^O%0 M$?DMMG0/#OB2S5406DBXK@K$E0@4#,3%03B?.30>A>3A.L$XW&@'V`0]I@B, M#2?AL2P/%6M:-7KSFAXP0580V4_'$(KK@100\WE728&<&%AK@QC8/%[F#>:E MCYP/(0G3N8HD[201HS`:2V%C7HZ_EO2P=/??+-Q^T$XJ);G)*0SF"`C:J&F? M\JEM\V7`FX>F,XRXG(H"I#0BYSA`:[O3*`PX^5U@:.#L;@A$!SB;>!9SWAT_ M>>R/TK4T+`C)GUN__AX^^G+]9_OM$<[L.%IK[0AG,3&M66VY/4:VPT`J)QY0@*0. MZP=V-^;0(1W,!"W@`2M_@$@\ZQ]LKLWNY$*.R/SE&"3E[FIY\R3EQY\8VP=/ MP+%'!Y./92SG+2.X92HN.ZH6&]T$"Q1`/;V=KPS$[<3>H^>8H>W8X>SH-.!Q M"K^3J*P]M/6WF7G7[-6.;X!K9=\5(N@^V)@6YEK:S&:.=71Z[SAEW"D:>)O* MN#VWJS^]K7Z6?%M67K['$YJ7>OA8ZKSUO$5?\W/'H>/1@:`\?UPC>TM?=AB> M''X7G0O9KF7*;T3NDK[]^7S12YQ/I2Q_WL[:#1RT@W1PV`DHM^S!#D)1^WJ+ M"C%(DB&/';C#[-.NQ=65B^G>+N.9,7&^ZDI1Y:U,DJ4TQU2FK*DM)9!%V;*+ M\J=6M<3@"?:4GTYI9",;TP'A*V4-00APT2/ACT]@M&AW9PU:"."UU0;Q/:,$ MJ#E8>9Y\DA@?F`Y)Q]?V&[4D/IL[M23%5T*YX$ZJJ7=F,LDDDP()][ZVE[\Z M[P&+1#C/U)*(1,3)LH^%N&,#/S+]F=;A.?M<>]@A[8+%AHZ)N\#+).Q'2L_Y M:OJP8\T&OZ'\$KU$EENGG'^\?,2B.T7Z+5NT7Y`6U@ M1H[^AJ6]P&7W;#AV/<=[F&F?J*80GY-TJ,@FL8.'O@ M^;[WQ`HNG6G7,NFT<3K]`G651D`:6Z)J4Z**X!/"*4AR;P/Y2VXJOLG+LG90 M`-_J&WK;R*2[ESS]/HNI3'H]EEZ^;M3?K)5A?X2,O?[:BR25%/AYNU!X6NS< M"TXHX;6,]%=EN%89KF6(:N=EN%;YJV79X2H]82/.KO)7JQ2%P^9G[3=%P:@U M#C;[J,I0J#)0JP2%(Y1PY8`W+^&JKE59IN44;566Z M=E-GNH\6VP>HT MV@&VFS/MQS5T_U`M6^R M=6H2J4YZH%EL$&J6'6!OLU!I'/M\;!;?7#6G'UKA",W;MC1"=9X>8BI=:U-( MU`:F0ZQ0>$.XG'$,*[(@5O]!:I$.?@>X\3X=TLH#.U1`[_BI+UUSYI@S+PK? MC>R?S'J_UN$N-[+C3U:\3/6CGWR4ZNH?;Z/@[,$TI^_N,$=%M%3[2*D'W[R0 M?0!L.UX0^>R>_0PO'+CFU[_^Y:]_T;1_R!LQ\^`/E%L7LPN^)7=CQL+/OA=- M887Q?=28&?ZX9:-_OKJI-[[#/TC)]UZ]_[U9I\_?XXQ&2FB4H@_/_;X2_4869P` MM`RIZ/P+'1@0"$;C%D+5^LQY=RR:M(NNF-R3XSE^7/<4<:>GCSSC0AZ4;7GBV*OOY,3Q&.O%]WU* M&--]=2Q8'0M6QX(KCP6K0[^R['`5TZD._8[&YSG%N$ZY:XJJLO`RR;KJV.[4 M)=Q)1'7*`6]5%EZ9<=717-D$7&7"567AE0U7'?#::]+GX@L!>X]6O-]W_S0%O MP3+7`0OCD9]\QJY$-/(6S]O6`:^8$T?CE1:Y-G_3-/+9*QS98`,3!?]\U7KU M:[U6-QK=Y1#G0;#)AOX16_![AKVY!/;FJU\;-:/166^STR!L`KQ4[WL&O;4$ M]#IL^WI@JXO?"0L7`VP;V+91?P;?R@6<`Z@TNN8Z"H/0=%%8IN$X#ZY=6'^3 MP_)]D="Y=,P@N!Z)GZ]]>FK.RCO*-OU^]T'=I3.`JFV0LDH`6[;0PH#*EZNY MFR/@I`+Q'/"ZB\$#(NQO#5I2>GX]0LI@;D`S+VYY5X5++PB#.YQJ<&$&S+HQ M9[C68*.$CPPDO<(3-PK*(0CL_[)W6@\3'[1&HU:WW4(?OS25(@A]SWV0]L&J MQ(IO7L@24[@G/K8;[XEZSFBK-'4WM7.DB`M9<)#I2U.01!LTN-A MD\Q9]'*/@P8.V0CDI9/(L6=/5S10B8E*3%1BHL0F8\G3>/*L2`K9:AZ=K&@/ MO"APP!YLEYKQ>B.<*VQ[!\MFJ3+V#B8Y_U:J')=2-5@SV@V]V3V^'AP54U1, ML;NN@_6>WNPTCXY**J:HF&)G3-'J-_1&__C*^BJFJ)AB9TS1;/7T=FN;6,3) M,D5)?,_=I5@O]#U%4HBI9`BI`W.X^_GN4+1255,FDX%:Y[[5?YXN<$MD]@[=#AJ M(U'8-XYNKRO2KDA[`RW?;AS?GEJLZ5RPYN1=_;TK?>Z!Q? MS["7Z:/M]WSLE@6A;U/O1*J?ILD.K#H,*SNX91*%Y8"WBD\=,;@5.5?D?$+@ M5N1TC'(?AGV<3!UOQIAPLZ:1/QR;`=.FCNE6GGD>N)M5 MQ+Z`R-1F"#F=V%6]UZLXI.*0BD,6\R&JY*H:QE6QH@FRPO(C:$9<'(P6U1L2Q=# M;[JO5J%AK\ZF710T2H@?+:3IRO3L=!V7+USYGY$_\D+U.LEI[ MZ:G*3].U-#^;9JR4@QX38`?9DW4'$D4P]!^M,/9[J=P%8^]4Q[%E?S+,25>UVM7<[D*B[RVBLX>*Q-PN^J/7YJ! M2HWG#U2J=KC:X=/Y+#]P)3'?<>B)5??E$JE/&PPD:[KLB@S\9GCJH\V[/'Q^.@R(JKJ^XON+Z MBNLK@ZXRZ(X5ME.6W:R(\_F3^T`U9M8ZE@JWBQXL67MXV5\7,TP%5Q MZU7_AR)?9+V>6*F5_$-K]L9BY)Q?7NZN[S+++K M*`Q"T\4L1UT;L`?;=3%SUAN)J:1;4,/)EN27$=PR1.>/I!_%MBCJYW6K:!M- MO5^O.E:4'-QJZ/D>N:)>:U9-CDH.;J4O#L$9;;W7:^GU=J4O2@YNI2_VJB]: MU5?DO5O1W=RFQ/1D:;O$+MI^ MSPW3+AH3J7O5<6')P3TA.;@['.3(08&#=N/XMKRB\(K"U]+TU6EVV<&M:+N2 MWA6%5Q1>2>\C]M/V>Y1VFVU\>W!7K8QN?1G!/2%1N->0U>&5?47A%86?JK*O M:+NB[4IZ5Q1>47@EO4_>5=OOD=JEZ0Z9PZRW'W].;;\Z2ZOF1>\`(4N$:"DP MDB,P7[=[NM'IO:GXH>*':G[Z(J/"Z%7\4?%'I2]`7S1THU'7F]UVI3(JEJA4 M1E5]=W`_M!2QB)7M7YAK';[Q2QE#%-6\Y7TAK,0QO@(+GPU#-\"I[;2KJ>85 MEU53S8ON*F`8%5M5;%4IK]WP5TOO@7?=Z59U81635;KK=#KBE)&M2N*3[_<< M6,Q!,($'2N*3ES%<:VXSI[IBK--GK$I_%<)A76Q);AS,+:^8K#S446FOPK57MU$Q M5KYC_C9$5S7^<^2YH<1%"LJ_WQ.8WP#,6P3S[_K?`W!K1W^?`X5618_&A\5_ MJ(N!S_(EEU\^GM^^@UT?I]&:>=W[++YHHZZ^??CX#=!2K[5M0/S7\]O/5X"Z MNNWR?\5B\B'+KCB-N[VMO=FN-7'_\Q:OF8[]X/[SU;^C(+1'LQBS*V%1(3B: M56O*%I3HDW8>:G=L&K+)@/E:LZYK1KW1UK5PS'RF/9F!9DZGOO?3GI@A!39@;QDV;X>D6@`R`:I=PK>G..%9Z M1J/[/A`EZ5/'=(/:]M0K#VNI2KU.GSUFKG3Z9O!?/`V$<%EK9L7W8& M2D;.%"UE\[6KG4K0U2M8\\!E1DH/W#KX!$U M,=R(C]`^3J:.-V-,US[8H+Y#SR?Y<^FY0>2`M`FUC_^)['"F7;DXG-%^9-H- M:%GM-3Y!/MJHOZ>'X2_Q=XWW;VK:O7P/W60ZCO<4:"./*W([""(L5403(IJB M=5"DN:+U]%XGQUXQ+G)C].UP#:UB0DV6S3!KPK%@:&WFFV]O14.]!02<.5#*BQUR$K3 M$9X1L\/(!^(!T!@6FP+L\*0E"*NW!"D`D87,G]@N68;P3J2\4:ABEB./2!86 MZF7)OZ9]B'Q4AGB#:[M,@Z6'8W'$B0>>:`/E6\N2:^(U%HKUCM[HUO5NJY?& M>I!J=9M+1L#C_Q.!X6XT!R-[^RW0J/N&P+RHTB^,9V(+0D,=4Y M4!6YIB20IK[M`+L+*OSJU[1+TQ\P,R)G7`H7R?+P-!"IPS'RWPX4'K@,1JNM M&V(`3`Y=7N%X98=%/VPW)4S2]!HB^\CV;MH49SGCS84&$^JU1EL<,<3K!,'- MU\JMBZ'C!2C>XP70E^I*LSL`!L@QVE:,.T7/%+J6U`K0XI/T_F0[CH;1'LTDXC?:O\BU2)I, M[R#\%S'%KT:T)7:*4:OWFCFWXU^.":^PS!G^RLSA6`NBX9`%`5JKW"8@C47F M!5@UH"IMBXQ@('6XW6<3T\;F\]P6ME"I264BWH!`("U:H$\V#3`5%;8NJ_PM M7I-UY^L?]$0$3"(AJ9M@\FM_^#A1J8 MEE',(7FOR\I&O(Z_&(F!$VQZ"?`604J`Q`?F,A^]`LX(8*7Y8`>`J3UC)EAN M//P93>$-0\"*[49>!,8=\Q]AU37M-QL>#0`D;L7$_#=\$=>9;IK-(J-2Z7-WMBFV5XKP0=FHXG#GV/[TASRY\PC4P-=PES+]#4`SB># MZ&EL#\<,%1-H7<<#$W)!:"58&%11#BT2Y$K$%FWZMKMZMY[Q'0HWL/M]O9W9 M*6%UZGCZ,D7E^<@<'O":\Y_`#L=\%F:=@?+US0>64-G._*ELC`\P4O`KC+3; MDT4$T)'#`TMST*?(&EWCHH$W=@Y\,_.*V%O-H@'^BASR%LC.4@ZVV4_\7/SF M-_6&T=\Q`EIZMUE?LOTK;+75?^!G2@#2!IX/"N"?K^JOY,(IS>A=HU[_Y;U& MUYPYY@R\VWSWK_2,"P=3,TA8)WNP[^G:)KRO^/G^_$G*UZF^M%//LI< MI'^\C8*S!].D$8W"%%7*#0NS$I8!3__N6O?]&T?\C'W8'0M2(G\S!\RB?/GWO.N9(4<>[`\^CJZU%R8?8I MP<4,=>(]`A(O@KP,^..6C?[YZJ;>^`[_H`"_]^K][\TZ?7ZEV180BPD[:WUO M]?JO?LW8$;'NGX9:W`J3TXJ6H2J=?Z&#S@#:TEX5:98LS;$Z-L/MGG)H2(/D MY<2`9C:#Q&(=>72F]*Y4;D6)O"$MO5VX67]>?;C_#7]6*^6XP,G/6*TGI9?B M%][]5?E>P4[J!?$=E]=?OIS?W,&RAK!CYC1@[[7K/S[>?OIR_><[[=$.;,H@ M53-,YU\K\E[C']82=\\H=<2#7N9ODVY:?%UCN^CFSV4"K@C8P.@*V1D2`WOG M>D^^.8WI9LTV9-MC9#L,=!4,&,U?7B%KP/I!H+3GT'$_]F4\"G'RE;R0Y.^/ MZ(XD?\9^2?(5."@5D9PXD7P#![6BD>UHY/F%\67"0Z4M3D$0;-('0Y43C88J M)XSY;FG@VQP'#1RR5]%+)Y%MBHLK,7%:-%")B8I$*C'Q4GLIY5F1=TH:`\]L M"+0!>[!=%P/]56.E(P'W@'WJCKC8?2W,Y#0@,]H-O=FMNK64'-R**?;)%(UZ M3V]VJHD))0>W8HI],D6KW]`;_>[144G%%!53[(PIFJV>WFY5?;C*YWON;K;. M0M]3)(6D>J-829(F=S_?'8I6RMCSN8S@EFG6=3G@S9%[1[R_%3E7Y'Q"^UN1 MFMFV:Y[[5?YXN<$MD]@[=#AJ(U'8 M/]BXPXJT*]+>AY9O-XYOSRL2KTA\K7/E=E=O5>?*90>WHN]MZ5MO=#I'M]TO MTT?;[_G8;;89.C8J9=5A6-G!+9,H+`>\57SJB,&MR+DBYQ,"MR+GBIQ/"-R* MG"MR+KVC993[,"QNO1G/2!$M#64[V,HSSX"[647L"XA,;8:0TXE=U7N]BD,J M#JDX9"&'R%$6%8=4'%)Q2$XU4-SDM^*0BD,J#LDI(HU;5%<;DL70V^W#];2I6*M\E!' MQ5I%-X;IZYW6P7*P*]8J#W54K%4L:W7:#;W;.YCW7+%6>:BC8JV"F]2T6WJK MU:A8*]_M3N9(:?/WR,4_Z!PGD=GA[+D#K_KU:N#5!@.O MXG>NG'"%LREI;A4U+2*"MUAHVDYZ8K%FBHW<_72KPF$\Z1%7R;\<4^)UO78U M[ZJPB&:KZ*RL,@&WJ[[SI1E4U'C^H*)JAZL=/LT=/JU14Y6@WH*-2S<@9&M& M7S!&+O[C>(;(5$2P2R*HQL14XK[TP)W`U,2M)SW5ET]Z.F4\G*#AOBLR^)-A M-%^=(WO^^'`<%%%Q?<7U%==77%\9=)5!=ZRPG;+L/G7AO/5&?OS)_*$=L&H; M2P5;Q8L5+[Z\;:R,GZ,!KHI;K^)FRI_:IH]]MQRQ1;9=10&H>EBEJ.N#=B#[;J8.>N-Q+3/+:CA9$O=RPAN M&:+S1]+G85L4]?.Z0+2-IMZO5YT@2@YN-4Q\CUQ1KS6KYD$E![?2%X?@C+;> MZ[7T>KO2%R4'M](7>]47K6J4U$L?MI/GE*H#40,^$76KFI:3K?XN([AE:GY_ MZ.8'FTC!1E?O]IMZW>@>W997%%Y1^%IZOE'1=LG!K6A[2^G=[.KUP\4!*_*N MR'NWHKNY38GIR=)VB5VT_9X;IETT)E+WJN/"DH-[0G)P=SC(D8,"!^W&\6UY M1>$5A:^EZ:O3[+*#6]%V);TK"J\HO)+>1^RG[?OOQY]3VJ[.T:@[S#A"R1(B6`B,Y`O-UNZ<;G=Z;BA\J?JCFDB\R*HQ> MQ1\5?U3Z`O1%0S<:=;W9;5%\)*'.,KL/#9,'0#G-I.NYH67G%9-2V\Z*X"AE&Q5<56E?+:#7^U]!YX MUYUN51=6,5FENTZG(TX9V:HD/OE^SX'%'`03>*`D/GD9PS6'E;@[::.EKKA, M&"MQP'-K-.8(WZ9>[W3U_N&<\HK-RD,?IV#9E(J[ZK7F-G.J*\8Z?<:J]%W4;%6/E.^9O0W15DS]3]\C'(HKP,M@=WV+^ M/U_!*N1,'5S,NT:]_LM[C:XY<\R9%X7O1O9/9KU_I0V9@R-KAK;[0/?AWU/3 MLL3?\?/]^),E/[U5/_K)1[GB?[R-@K,'TYR^NQN.F14Y['I$PXXNS(!9E]YD MRMS`Q"9'Y\/0?K3#V3W>>L]^AA>.-_SQZU__\M>_:-H_Y%,N/1>'X?ATRZT= M_/A@!T/'"R(_N4<;>FX(?]RRT3]?W=0;W^$?H]YHWWOU_O=FG3Z_TFSKGZ\^ MF?!2ZWNKWWCUJ]@CB;2OY[>?KV"/8>.U.*V=$X)V3^3T#" MA_HS#7=.,UU+2^TGD0X^/::C^)TIHM\SX*O@S;!T"H""ETVR[^K;AX](BW6D MBO=:D:#7&T`]X_LL*:=!QAJNV/3D$T&S->:=5U#9M2U M4'EO@-)(&]F/;/F;:WC'!$-YIJ,%$4CQ@)ZO/(OO3,]H=-^O`N/)=AP`>4KQ M0!F#7UFV2B!$2-#+PC/ M0*LPE&H@E&0#=*?#98!J->9]N`SN-*'I;NFBPP$+,B&8Q=)64\(4Z='P0;` MI<#:7N0/\?&/INV@EJYI5VF"M3PTL[P0,3'T'N&N)2@!"9'%"+Y-B)TETL8Q M(Q>P#TP#_V'^HSWD3YOZGA4-0^15$#],L$Z,*Y(R'%U34%#`N2`W4$X%0`7$ MQ?`6'][N1@PQ/4,>AV5'0\`L7,8<>P+H`CSOGO-V3<+K6A./1'1P8<6L,,4B.RG/0$J`"[*?9GT.?Z>`?/O M^M\#M`__/N=8<*.IU4XA\Q=Z:[%OZ*7?H"-/3[F&# M;TYJFD+:KNV6A;+[.Z?LQHNC[#QIT6P?F/Z6*Y,C#5RL$W+(ABGNHD'`_A/! M;1\!R6'PG-B$4<4FBHM-I$,3C7H2FTBV3.-[=N+1B(.8=OP^C""/"Z65G=O+ M!#/2;:!/OOHU[6[HA:%VY\Y`8NOH1$V8 M#V;#Y=AF<$$@5O%_'E"S/T#?5!?NEC:!Q:"FREB(N`JH[8*-1/\.HO+ M7[!H;)=BC5IG&\US9&IHH4J9#Y%/)G:(NQ68K+7)M?N7O=Q]>:3\#^YUK._]\%?H1>Z6]?=9K&\;W)BF^5N:UK4U?>\NM MF%LV],"+1Q5]XSGV4-@E MQ\X2?;ZSI>]#GQY=W$A2$_E*,G2)84D*X%9';?T%#/8F0(X8C`SPG M"2(SP"@^>[0MD(X,]9OI@E[S31"7*#YU^2R*^`X8/,!'!]YG%E?'W$V;^G@) M/-1B0FTF9P^.`QZ@.;`=.YSQ!9F!YU+DUPS0<0']>B=>0D]03C7DN^*EHT<9 M.6'`P\AB/5//#_DM>(7MPO;95@2>X=/8TTB#,G[(@?BI:??\.A##%,K%H#2/ MYR;/G,)#3=L"ES),OQ'CR3,6IM^L2R0C3Q,.'0>^$3 MH>P#&XIO&[H(B(2IT+L5/RFU\_&KX-%_*U*.&;5TT$2;V(Z#H.)J"WU3LV;D MOBD=2:AI5^[0B2QN=,6XD.##?N9@%O!?,%*Z^4C!*#YMQP^,^1-YH:$(G`E4 MX24E^)KG,J`ET\=XON,!P_F:.<*#$!LI"<@7'D#\19&3I[$]'!<+0KW6S`?A M"7@]\!R@,QLH.P1.!=Y*S@Q?T^EBJ`U-W]*F)AGCP9OBJ<&HM5:L#Y8%!GCH MV\"H>`)%N!^S5'B(AX5JV@5[L%T7$0]$DQ`($(?!#ZD>3/@!_H%OP.,XYZ>@ M%U%@N_CAL^]%4^W+ETOMM8Q$&?7W2ES*:+Q_HY/X!$?#L8'Y<=O.'6!/#_R2 MJ6/BVDM8$V<,F-(H.GCCT$,U\`9SZT?Z0*_+!1P4)!L(B-$/DH"$0+_"- M,P-^PF?%;U(>.C5#>(;+A0EJ3XD9\GHH8) MQ(.DP<8%07:_TVHUU[(0)_S\R;C\M0YVBE:]S7X\A356#84KGT:G._>6G`.- M90P5N;@Y9,[.\Q;14YRTX0=D:H.DMT1*C@VZ]3\12&T4L/`BU%,ZI1"8OK"/ MLZ^V=[%]K<+-R5YG#]MGM(R5V[?#K6JDI0/[B:\-A!D%FAPV`S['XG!^+]&Z ME@\%>V!@HL0:8)ZJR`C3QB#0/#\ETD[SS&ME5$V&X4!91>\HH3?XW7V$[6/6 M+=]B_N5G<&MQOU-!N(82A(//C29]_IZ)<'XEGH@"7%#FI_O9E)W_M(-,W*ZC M!`\#>OTK$/9#,/"O5KKP44^H^W:RY[[E@O/W,Y\=TO9LDE-]Q* M/W\"DYW^\P:\`H+ MS%CXE9D\1PM->@QXD,CCH1#2C#K:OQ@$D4EJ9-2`/Q"(\P;X83"+V5F\X5&$ M6RS8JYH2'"]N8U*4?>-[_T8IX!$WVM_KA]![V5AV0HOU5[\V^NV8$N=? MDZ6\#VP07KG@=D6X=`'!/<.$G;+KYAB,6W0"X8WPV2"ZWO-^C&<2:` M_RB@M#8'!7#^+%#PE,-SZ=E<4IQ'8('[9%ZO>\K1KC=6"ZIF7?Q/3418^.[" M!-4UEQ@D_Y`P%9EKTIQ,>H#Y])Y_234R=(T` M%%,M'_CFB2MIK3XO;?#Y@1!(>7MH3WFJ2#;PYEMPH?9H.A%I#XPH>4]$`N0` M8D8_%0>D0!(@B!,M)I<9[%(X(R[)J7+AO3L_9:%+2]F1,X^D*RHKJ5+-,` MN>81*2=A)HY'T*.:?^!\:5!R%S`2NGLY3Y8/7+1*C%%FSD2:M59R]KBP?L_B MP94(7N*'\`Z"48GUT/&(.(_&ZRC(C5$QAL5/"D1YJU:E2K*9JJK ML#"*"UZ>M,8/)(IHM&&)PWY;8D&P1JN4)Y$2V@`ZQR# M*.\K25@F4(XQT^8<]3>GK645#-Q20$:@4C]S:H=DXOC1D/C"2JIAXE@QXXD` M_Q.Y3,JO9CH%Q&CFI8`@.Y&)%>$9W`,F$H`9<'5[B7%IXH=FS\!R9WC)V)[* MM7'.>B+.POK!,"L*A?E`[Q)Z!4&F/`:4,2$_:8?M>&W76$W71@R+.)VW9,D! MAX>2\P`JQ\-Z2LS>O>V\2RYS79RXB$8&M'#QQ.,]B.!6(LF\_9S"+)8+'1DVKXHLB5YS.2.2TUX3DX+K!2/3+*)2"8'6NJR M?%W.#0P0Z3[NK,>)?NZ^/&TKW0[!,;D,PW7U.EO(F1A61HK.Y/'BL>?`KJ19 MV7-!=P;B2?B<'&.DT+/&UJ),'+!>\,@(8VWP(@P,9;09.'E*DZESCF6DPECD`JFL*5$&90B-R MMP6O+'5V8\N46$3:,"AC?X#'C-7==%P89T'R[S%^H#C)64^3+QOS%:31E'FZ M3&?@"0$@?UQ\/"X+)#IE4LE4!,S-H#)[>XF_*85-=OE/,MI9;_ M^'11B'EE-Z,;YN,78/HW%H2C6THXNO7]?/`0W"3)93<\H^R"4LQN>%&F>D8B MSCBQ9'5V[YMN8)(Z""YFZB]X:/(=#U$"<0S\C:4.8^=6?3&[8.YPC!HMY\!% M+>D`+_QTE+$+;C9AV4G^\4$&E=TU(OOMI6=W M1MMHMUO)JM=>2=$@I*@A`T)G^?%CO=]I&0<$89WSE>Y2$#KM1K?7+P$(RW9A M^2%PL]UJM1H%@*!T5T.3Y6)VZ8`=^)RSK7Y9S[:6EM40-/-GWK<`*'0M3OTJ8456;$142V:M\FNY>.2 M>[R%[F:SOF`W89G*3B^I=?WER_G-';R$.@A.`_9>N_[CX^VG+]=_OM/P-`N>MI9+](P!,6B] M,W^;)KW%3X-IYW0>WKC3=5F!*Z*+]]/8#MD9$@-[YWI/OCE-=Z/>'M[MX.NJ M\`&`2,BP.A<]QRRPMT(J5-MXU-MX%_KV#U9M8JE@2VU@^\2`*\LHM3+AH=*4 M6XC8!:,=E%F%QR*$P;!.,"(M[&K73WS7;["E2+7+Q[[+.?KYX\^I[<]>[-96 MNOEH@#L!RWGK8<\KQ/.QX:':XVJ/CQFVK?>X MTJJ>?(BS$%&I3_-6Y&TMBX(WH?XRSR`F5\<=Y-.IR$'@ M#6U*(J?64DD'`6SA._7M1\PIG\KNA96K4&YPRZ3_CBMV5]<;O;[>:C:.;L\K M$E\)[M]>,&77:XUZO7ETVUPBJI;;_>7C)UB#T2G/=N=8?YD60$8ES\IG!.XW MNO=<(Q#;OV$HT/%,WC`M8,/(Q]9/INS>7CD:Y0;WA,S"_89*#+W5-_2V<3#] M65'X2[$*]TO8A[4*3X&JGVD5[CCK4BC*V M`X7Y:+HCSX)*&(J8"\E$CU$<;!\M67D2YP3TA MPVZ_X9%6LZLWVKVCV_"*OH_,L-MWU,_HMMI'M\TEHNJCBOIQ/=VGOIE5ZG+Y MC+K]1OQ6&'5?S1G-1='C^=3RF\H=*#>X)V3E[3?.8=3U3KNM=YL'$XX5B;\4 M0V_O$;P#&GJG0-5'%<%#3=WH4O"N"MN6S\XK5?!NWLX[CQYPLNHA3;TR.@D) MN)OU32PYR>P?(:<2/6FT]);1T8WFP61LN=FD/.`>O[E8Q06/BZJ/*BXH%'[_ ML`9C&;>])`;C?@.#]QX.NY:Y?SF]8.(F,&:8,Y"IZS6X&^G.CAUBC* MM1;K>K_=TSOUBD-*#FZ9`NCE@+>476,J/2CBA]3: M61UY62:#L(P.115$K(*(:;,P,V"VXI/2@GND9N%^Z?F(]W?OY+S]#(RJG6#) M-K@DAN'A`X79`>A5X+!L[+/7J%BW"AQNA**\5M.-IM[M]_5.^V#U516'G+2% M6`4.RTK.!5F(5>CP\!NL6HAO0QR!EOR9ND<^%E%$D](&GF\Q_Y^O8!4"8;28 M=XUZ_9?W&EUSYI@SL+S>C>R?S'K_"NC&P7&,0[#"Z#[\>VI:EO@[?KX??[+D MI[?J1S_Y*%?\C[=1_0PO'/C[U[_^ MY:]_^?`=VJ>__#6J->;;_'GMWCA*W%].)O"]?!RYEK, M>O4K/?SMW-/A^W^\Q4?9[_"_M(K_/U!+`P04````"`#[B6Q'QFNY21L(``"E M:P``%0`<`&EL:74M,C`Q-3`Y,S!?8V%L+GAM;%54"0`#F@]%5IH/159U>`L` M`00E#@``!#D!``#E76UOVS80_CY@_T%S/RNVDW9K@F2%\U8$2!HC3H8!PU#0 M$FUSI4F/I&)[P_[[2-ER+%FBZ-BISLFGIND=]=P]=\?CZ:7'GR9#ZCUB(0EG M)[7F7J/F81;PD+#^2>WA_M+_6/,^_?KC#\<_^;[W&3,LD,*AUYUZYTBA>X&" M;S+1]YI[S;U#S_RP[W_AC_Y^H_G!^Z-Q!L;D26V@U.BH7C?RDZZ@>USTZ_N-QD$] M$:S-)(\FDJ2DQP>);+/^^\UU)QC@(?()DPJQX$G++).GUSP\/*S'_ZI%)3F2 ML?XU#Y"*756*RRN4,'_S$S'?_,K7#CMH[DUD6-,^\+QCP2F^PSTO!G"DIB-\ M4I-D.*(&>/R[@<"]DQJA)(K=W#@\:!C]=YUH.$1B>MOKD#XC/1(@IEI!P".F M-*=M3DE`L*QYY@H/=U70/?$/H99R%F$H>GB!J. M.@.,U1I0B_2W`,W-"R;&PHCBV]X5>\1,<3$]QPH1NFUW6RZT31XZ.C_Q4*\O M;WNW(Y/Z.O2?0TC10B\%]@S)P27EXTVQ+JVS@!H@&D0TMN!:`TM!QA.%]3)A M`MJL_-RPC0N!OA[E0>H:U)0@+M)^F5\BKC,])+MQL8FDWT=H5#?^JF.J9/*; MV(-^HSFO.>_FO_[:DC).F-G*%'4QC:_W-2N0.*,*>&>1$)J=4I0+N26P2]RU M1!HW$D&RI/YQA;AT!9]+U*7)5K.:3W3,)/H]P8?Y?IM?D%OQ1E)?FH_,LD@G M-!:/B[\C\HBHR9.6.D-"3'5]^@W1"%N8 M<=0'PU@FUK+$.9H#F-#YUB+O<(`U_JZIPM1T>&TDE-YH')+-=85=(=79H'Q: M]V'2^@6KYW"YK+:[!"Y;D<_:`036%KV>S\!X""VV!1XB$ M%Y.1:]K8U<#05B**<3Z1)?AF8$:[\4DH)$9,7WF/!P32JW5SD4=/'UN9@#>G&[5`(LY M=LZ"TK)8(`^>J`+&1&\V.1@TV%1!2.&37N<*J#>H?&-/@`(@JAM M.%(@#R#B\YQ>V)^ET0,^NRX07Q)&I(YQ4T>=",HH[!I#&?C.>__W+$UEH]\* M2H]V[173`/$UE[8PRH/5@(;%FS'=$`2`-;1';"U<2@H`T99PS1*2@@Z8B#NL M.X((V]+N200`!3F!DW7]$U[`?N\@BN4IV;S4%\,[3P92: MV7W\2"S5^%OAT,QEE#'\$9>SZ+K`+M'I:A/@C:LUY$*1?V*WF(EY^K:-[>&) M$L5=XK',%L#WJ;YPQM,[1GDJ6G0`L`9@0F%Q$.!4?C)LACGQ1LDM@GP5`(%0 M&MIY=PSRK0&\L28@R]-V17(W.7F.HX+9;_D/2;2R(V7H"@9'$YWCVIVU0L-8R%?4>6!E\;<$?B2;N M=/J@B;ABB[:K%>@NF,0/$>?LXO9;DALM#"#9GA,&*VW(AFX`O.MM?G.ZPBJZ MA:#/H7I'[H:=XY'``9DY7I]XEXY.%AZM6J^65:O5@$\2K?"O:-9(7W+AR+!% MY]7R:[$9\,B@,T`"G^I])SSC0]/DE5%;I/!J>2TR&/!K'-F>XHJMOA=D/[T/\ MI^S.I_H7H%3/7W\[QSTL!$Y>@].]Z=)[(&O%@-N";R@XW!R2'S4?@49-4O#: M:/KL/F*A^X9B8<7V?-H/P3:0(L+A-4%=0LES6H85];?%_8KY16,=F/PG):S\ MJ38'W3?$_(KM!;2#&.<5.&5V*_4%9OC."P,(F!>]X* MM'L$+GQGWQ(FZRP"("2VDRXK'SM8PPGEMP:JZQP+O'-)&&+!"Q03YX4!1,X+ M%A-G-P`>2BVP+#K@:`]NVD1%'!R#<;NBG1VC:XB.P!/'S)3 MMG*ZBA1VBJLB(P"?[*XYZ]]C,3S'7>7T*;TB!5A$%>Y0!>@!I]):;6E)(PJ` MF;7ZNSQ)P%3I$]B0LQATZ_"=2L6/^!U!+`P04````"`#[B6Q'Y'*R*ZH\``"[W`,`%0`< M`&EL:74M,C`Q-3`Y,S!?9&5F+GAM;%54"0`#F@]%5IH/159U>`L``00E#@`` M!#D!``#M?6MSV[C2YO>MVO^0S?LY$\NWV%-G]BT[ME.NXT0JQY/9LUM;+%J$ M99Y0I(<7QSIO[7_?!BG)E(@&0!(0FI/S9<:Q`;*??D!<&GWYVW^^S*,WSRS- MPB3^[>WHE[VW;U@\38(PGOWV]O>[JWO?GQX\_N4^C7Y)TMG[_;V]@_>KAF^KEK^^9.%&ZQ\'J[:C]__K M\\W7Z2.;^^_".,O]>/K:BS]&U&]T>GKZOOPK-,W"7[.R_TTR]?-254JYWJ`M M^+_>K9J]X[]Z!PH[&/WRD@5KN:!-D*]?4W_`T?OJCV]!76_>_"U-(G;+'MZ4 MLOZ:+Y[8;V^S9@OKN.'))V7`-^^X<_]_?9Z`VD8S6`(Y.&T9.P];_)>_I3W(&1/,3\F<<#B MC`7G?L2I^_K(6)[I"XCU-R&:_Q3F?O0U3Z;?[_S[B+412]#7@$@WX9]%&``- M9P'\%SCPHQHA%RSWPTA?2+VG&1#[:S&?^^EB_/`UG,7A0SCU841-ITD!0RJ> M39(HG(8LXQ]Q4$1L_'`=/\.82])%6T2]7[0SL),DAS>'?O0QF<^3N!PHET#' MLQ_![[/+EVE4!"RX2I/Y1S^:%E')R?CA(HP*F*._L/PFR;()2[\^^BFSHR<[ M,NY,Q4:^$0.O,@#XED5\99[X:;Z`93G._"E_@QF(G1YN;>H',6!P/7(9_18@ MM!YF1.CY/,SYDIC!F@AOY<,`-E6FQEO7YQM>[\Z*_#%)PW^QX#K+"A:`++B!#-K7K_7&`!Z'0<%J')Q&V;?JVEP M"J]-*SE,0.S\`I/KWE/\?1#.WR_;O/>CZ*U2/8A]:&7>X8:AHU)KY=/ZB@0_ M`TK`^"Y@#WX1Y08%%#S;H+C)W`]C.](N']U;V/(Y[^9L?L]2DY)N/K>OF(\@ M43HM[MF[M0H,"BM\>E^1XR0_,_HMK1ZX%@Q&;!B7D]X-/&[C1>PE9S"K!ZM7 M<8GZF4-+BRV\-$JF&V^*N%DY28682CP9F_XR2Y[?!RP$7*-#_@.?6@_?[8V6 MEN/_@%]YJ[?77@JPV#4L2=GJZ9%_SZ+RG9ZJBW?XJJD=BUV:1/5%+IM[!QOB MOE)[EFX*#L-K]>CE2&LUIS^DR5Q?@5(_G4*YWT8F)=1N8[!U\!F_(?7OT<)+&J_O84EG?4C[\'/[DM-%-F[F>\_ M<0:/WK,HSU:_*1?W&I7+7WOK/=#'R,]6>[>SEU`T!)5]O-'HZ-@BKY)94=T5;7S,0?UP2)1V);@E25=O8O90A&):3H8,DU> M8Z-FDZ[-#:=EOEZAB7G;\9)V!X]5+&.\"8A^<&B3#=$6U=0Z5@,@UOG1;G1^ M!L($7*"KR)\A2M]HPX4^&IK610C$:C_>[5"?L#1,8-<;7,#GK!CS&VTY")M+ MO-7!+T(BIN/#;NFX"K.I'_V#^>D5_$:U_=]JS8%87W]M]*%=AQ-*/(-,L2>6?R49+CF!_:'3@.!`F>I[0=9FX2WWN M+OUU,;]/(H2#C39<:IN62BO:%R%`]+ZC$_9RTGSU_%DZ`Q4Y=_'FPLK7#4E' MCF]PIW%M6`AMRX,P@'V_>2EBZZH$<D0F^=K4ENYG["G9AIW#YWU;?E^H?M2<)9EL'R> MW?,3_327+`6;#;UCA]:+3HN"0'XKUPY]J5B>'[49V6KO?7!HQY#H6D:*"(*5 MNXD>UZ=^]LC]>>%_M4BEL_RCGZ8+V"27WO6R&U6=_MX'A]8.-25B"O616;G? MZ/&Y5=%6V2V;,A#[GON9K0.60K92@>P#U'N"]\&AU:0KK6VP6;DC,4GL%Y9W M8?.UF_?!H>G%'(5;@*Q*HW\SXX-+ATY:4!P,[E272<$3!*M"%%R*D*(L.C<,C'Q M%_PXKF^3V.S@G1"P1BA4+S=)"/`@7#FS1H"H:<&")DPY7>(^W@D!.T57QB20 MD+M:9Y:+"_;`0+K@ECVSN-#XP,0=O!,"MHM.=$GP(%PYLV"T^K)$XX^`+:,3 M1P@6A!]G5HV;))[=L73.LWUH':W$';PC"MA\5P*"U MIS"P(ZPP(=0X,UA($O')[H_Q7MX)`5.A`>94$!$BG1DW.AVO99HA8"\T0*," M(<*B.\>.5\]GI0_'5E/OA(#54*%N_%-K($&8<>>?L4XK-O'#X#I>9H6LR2X[ MB2D[>Z<$C(Z=V-/$AO#IS/AQR].DQ2RX]-,89O8,3I;%O"A]2N#4$DY#V;RI M[NR=DC!(=N!3$QO"IS,#B2BW8HMUSSLE<"SHQ!>"!7&H=F8+4:WE/2X!O%," MAX5.W&DA0Y@<[3S4J5GL88!A3J>G@XMS^G"\\YQP*@5B4U%3;CJA3E1RP7TX MMFE][Q,551*FH%8,YR^6!>Z#U=!"$TG@2JTCQRD$SU\L!1Q@HA&%98$LLO%9 M6!&5\T7]+XJI4?\AH`NJ$:22N;(M/F*!7W4AE1]FLS%L$*QNQ[4GS[8TJ,FL M`R06$6:`-%JSJ4WV5-.K,R/C>HZICG\\K7\2EU<0FIM-43]`;-.V87O#B4,B M%NBU):CR*Q2V!V16'0G:;SUQ_8N)D\`B%N%EC#!:,Z=YYE3S99?8L&9A%?X; M;Q+YTU+XLQG\9U4>C.=L^+QA@*O1H]4/8!"XEY9\&YN4M,!D+A0,H>2&FPK3 MU>OE-(C:>J,]E]D,N^E>`H1:O!?W!,J7GD`\B[5BKR!J#FJP:?"PM$7`D5`+ M\-J65+G4B#L`.*MW_-J;`USS>DS5X5`+X3+(%:U]@3G2E/L!=UY0ZYK75172 M16E?NV,O^7DD=]%0]/3L;LL[!QC);F,T$%$+&5N7ACU?U!,J?DJ3XBGD#J]J M(G4?X5'8$+9CM!4T>`7\/EQ2F-'!13+7^/CA8\I`JBM_RJ_A M%S<:=\K2?GR+Z&SR$TFFNFI&^W`DKFZ==52,K%ER.'0NH^WFW1SMD=G.*QC9 MI!'%,J@LG*,]MR8\5(M-93?E'E0B3I"8QAZ[A\K)WO6*OER5;0'I`CAM;K;L M34AZP(A=X`J7S]*>I3[+*KH"7JMQ(?H6""DA^B0VP1&[V+5,)HWITS:K]"]\ M#569M6EGMS_+*I`1N^_M7\/4:HB(D4JS>)Y=!`^Q*UX#'-&:(0V29>-6E[(; MS&ADTR]MA[,CCHY:6E`S'A:CD4U+E"F7F)(`,7,26-0NDXTQ1G3:-$:=6Y9R8@^7/G)*#&B75;\L4 MVUF92P)9P(3M`,(PC282-';NBWL0@DYP2$OOQ&I$@GHQDBA7P4(=@)U[WQWS M0&.),4&(;.C`,Y?I<]?Q."`_!8_:[O1H M(J26\--$M,C)L4TG@!UXR>'V#B;E(V4WBQ_+5JM&02TH@/$`Z^@5K$H:#6O+-+RR_CJ?) M'"3-9*O/1CMOM$]@QR!:<&ZT?-,%8*@ET;2=%'4T(I%5NBN#N@BIY=ZL[W(+ MKASXQZ.?LNPZRPH67,>U7:^F\4CU&%`$@734W:ENCU6>IM,IZ7"$G+()2TL$ M>@1O=(&5GD3!(`-D"G`AQ#ESP:A)^S&!_1F(4X;*586S63!N_[FJGP/K$0$3 MHA&*=<$BO+M.B+BT)(S3VW#VF%^^P%DXS%@Y;M=_S)9_S482_CL]#U1#8=_; M>1ST`(V,!W>E6410UHL1FQ9I5;3)CR(6G"^V4;4=&?I/!G4->CDP`A\9+!UG>5J4K@4LFZ9A*=WXX9N?AMPD=@L;U7,_D]K[VCR&*WG0`Z$#6(1V M9R:G30@3?U%FSF&I-(0=[\11#OJ(IH2&$.C,P6:2)E/&@NP*E,#/%CRKP_BA M7MU-0J2Z,T<]Z(.8-D2$6&!WG#$Z/.9]/2F?D``XA4_B#/Y.=R/0? MPL.-![V#;PT5(;R#\4SA#'#Y\A2FC`\WE3/`:TLN(X$*0.WID.-!0M3W=IU4 MYFLQG_OI`K9KX2P.'\(I2+NLYAS<D2A;Q0WVL&).YT&0/O"W?Y9M8BK/4O M^>Z;C;V1N[WE6IIE@5A54AEA>P!@,PVQ-*$,ID[Q3"01_Z=)('-`)E9.PL8F M?2B.826/.7`;[(9JL:GLIMS#2AYS0"1(K8?*R2:/67^UM_Z/S[!]@]-TI+7@ MU=L#0@(WOAT7CR808FEBUI)>@4XSV"E]2I)`BZ.-#H"-@,6X(TD"),3ROZQ% M_<)DEH!Z,\!!P(;3D9&U_-),+=1.&I,$'IV'&V5O>1#KLQ^Q\APUC0IX,S=B M?/2C*?<9*,V,%V%4P-D60'.GD-6]I+M#RAF`"+A,X3-[M81OB)_,GXI\*?[* M$6(EN,[1QM0KO-&1.X>*]<&R)QIE)4BC+_)&AS9M$M(CF%G:D4M@"]KZ:4Y\ MAW2*!%F@4>.H>(B>[ZD>%0_=%EI#M:@ZMQSB58W):IKP45%/Y62/BCT_\O.% M^`&*P!:+;P5MTZGP:WTNW9E"B1V?Q>+R*#)EV(>J*^"E47_8.J=MAM*V?H@= MU"V/!QKKSP`&!N%I]F,CA3`R)6%+7YMS\0%HA^VF,BT?.\[ZU MXD7#6G@TN*I$1P2K$AUIE,@Y&EQ5HB,BV1MZJ)RLM?#6CV>JI#7K-H#$>0K= M'A,/@H>8(:R43GE@JK4"%#2*"&WI5:+\NN#$[$Z=U$]C?NK#`V$SC]&2/L?. M2_H8F,`4^(C9@'H7C3DF7]CGN%6MF.._8&&?X^$4]FE+%MW"/I_]?R;IQR++ MDSE+53>TS<8`SGE8@H'9$`-&K7I/E1%S0UKEIX;V`8@TJOA@VA=SIQD*Y>OHQ&EZN[76.8S%7?`?+<1]F>1K>%]!>H?!F2Q"1P!UJ>W5C2.Q4 MV.E3%2SFX?/+K%AA]OU\<<[BZ>/<3U6G4U57`.P\'[2!;9D>3&H%>II2KV16 M'XL470$PC?HN>LSHLBH"2:URCV56:>WJ;-.KW.J92QGRJ?(JN..92]@SBPO< M,BMM[XTH5'31^W8$BZ(VES,Y+.L5=+;> MC-?U0QN#H#9#D31*+$HUJ-9V'8;URCEF]$UC03"G>&61`7.G^ZLB>@BCJ#3= MEE+(9WRD.0CML':4:A0+5"_%8:[H#:+T._^E2FHEF]LW&H%@SH-R^L[J`D#F M"M:H-"V?6;::@7!N(U@P?Y; M)0>MK98`RV'6C9Y>JU),U*K'\%SOW,0Y#S,^1K.S.+AB3.I?(>X!\!SF1C5$ MF12;N0(SV-V&GSU>A%DI.<_5B5YK;+7S1B<.#[@F?+S%B,R5?D$4?IXR_[L_ M8_C\)&H&PKG>7O94MQ"0N9HK6/G+-/DGF^;9=0P_S5(FK%:%M/1&>R?#G5[D MH,S53,$47]T89G?)V?3/(DSK.5Q1"B1]>/Y:JU:%'9"AAD>NI$D"`J9Y"(<: M12;SK99\F#F,I#.T-(M!R>N,["[>[9:5E$'`()L_-%[5_ZR<'T'@5KILWU2)K^2TT'LKOM MA/&GB:L[=>X=WH^H3=)1B,,*M#MUZ_Z-:K&I[*;-QKRZ"_8L!!(B-@TX1<)4LII2/J5)\526.8K]ZI4WT51^=ZS]`,!%P'<9 M^UH$MHV6R(P%#&),W<\43*P:@#P$W);;:'I3II,2&_=1:U!3'=>@-+U:?4=!V$N4`[B[JFL0*;4KK2 M!]?*?>2'H!3.>A\#;,)4K(U.+J$(&5QVYI/X!*(UA>24.1QC[.-J'*_9U;;T%UPNW75@"'0+"]QB>$W)AN(S$7]&:(D.(^ M8W\6`.J2>Z_32N7LS50"M=<\)PU-I5S)MH'(%JUINFGSI)1 MH,U:'92YP#NBO-%:YTP3J`Q8<);R9^46>)6D-2]P"8OB#M[^B$#$<5 M`-=A*$/OB4H'G+G@0TO92&#X\5_X,S:2$"GK!D"M6CCLLJA&9BZL46?1F43^ M5'/)J9J"D`3.N/T7G#H::F&**W2P(;D/*T<&&#=9"&*5_R@=6:IP2]E7U.8Q MH`@"?A]=OZKV2.7AC;L+I0`Q`SZ5!^=^Y,/4\/61L3R;^"G,"8^\K>\D=.+5 M>J01,-%L[.T?.=L^K*51!D%L-`21;>[KI"$.F`*1TZ9`[I\E;&'_B,[=E8"& M3<)0`(,*2MBW6DBK6U!"J<6FLIMR#RHH`22F80KKH7*R00G MM6&KU@UP.DQH88BR!AYI,,$NSY#S>9B7MQAG<0`G2IYN@,5&:\Z:&5DW"3^C MU^33.5[BG;Q3=Y=G#:E4QTUQ!V__V-FQ4Z58\6?4>1HC)T9]30NCY42-@8YW5:VEBM0K>PZ#&.G/:OJIC&CF-/[[F+`KV,X M?%1IL^5E"3::@8PV#UXV)Q8A$MOQV[67JA+B;S7T]NT6WM`M/B!0FERY=?%M M!W7W4R^AR:.7GNF66=UUZIY]]ZGUV\].77%2J]+:-]G+ON-,_5UY4+-9!TBM M4*L!UFC,H[N@ST:M5D-&]L>0/5R^L&F1A\]L_/`03B4%8#1Z`5P"]X_85X28 MV%5PS,6[DXM`LYK%WO+*)P5%+8+><+R2W>S2_>/,3AK)(S5!48N/-\X;K67/ M-('*I<[9??*6V.J(:E%[@$@@[D;Q"6G15L=#+>3]+LRCLCI`$#Z'0>%'BM5- MV!Z@#?!Z3`,2M7CXAJA_A/ECN0/C^^?'\.DN45SZ='R2=W)*(\N(A"Q-=G6` M4HN<=\H[K55T%P-`&<%MLFH0XU$K<?CAZ"O,62`.'(Q41\16_0$6@2BN M3A^CP,C:#K7UPKJE")_]]#OCRXX6;Y(N(#0!UU135"F!6H^Y/XOC\)FEF9]R M_SC)35JC(0@XP'V-#(OU./N-]\IO?`1-04@"B6,1W:FT7(=@O=9N?SW36-;- M*%RY8)OSBK@*TRS?$$-1Q!MI[YTZ3Q:+CEZ!XN4PK(>P?V73)`Y:J!WM``*[ M3A';1N\*'.8"V;$,O8]AVD;O6'L0UW6RV#9JE\,P5RK7S/'P[(>?!AI7$QOM M`#N9E/GMC38"*.;JZ1JR@O(8DG,_8\''9/X$*JC29Z:I#RC+X(WSQ6N;95JJ M$MZR8;BG[A'+,A\RY,719 M7!R6TWSQ>PQ/YF[)L+:&?K02Z6L!RR7\6`7ZR0J/MW@*0".0:;`=5YUARBLM M[_YK6QK*LOKL(OG81,V]DP\$[(C=OC4<#T*4.V<3U4*`K0/C$D/V"1KFV75< MI6G\E(*Z^JS"[=\&:B407-]MF%A3!S+*W+G&=-YN")'^P<+98\Z",SC>^C-V M^<)GR(Q-4G%B5`=2``T$\@=8&I6FU82,5G?^/QS+52$1+)[]:PVV5^+?_#9U=0]BU'G;TF@[:QOLG>!ZHEX!"T MXP5.K1!DK)ES^/KLOX3S8O[ZWO'#>1(7V3BNIO"O?N2G"VQ-T^L-4`9W\F\- M#V'*G%?74IB--75I]4/W'+(^(/;@CC2:H!`N#-H_FR."+RW5>("-SCJD#+=] M:C_!.QFJW;,E1(0U<\Y@XZ&&\^OXW\P/[W[D6!B[@;-[PGQS#,Y4<;&\*/,_/@7>H_L^@L#B[CG*4Y MJ*J4W(7_.4Y=/':EY^N//3&C!Y=Y<.=Z/4P(#^:R!=4E M>,UDVYX1K"_',;A3;UMT2!J^#N82S!FW?.OO\7-I)UXF@*A^6=Y6AGEY5&JS)4A(P-%+6\M2%+9S>"_?>Y44BJ0FC88@'P'K="7P66\POS8$`0D8G+MI>0L$M8S9E_.G*%DP5N[0QS]BEO+4-SQL M[_+K>'(19MQ`4:0L.U_P7RKVP1V>!FH9H+V@,U!JN;?E0/C_U=LRS4>``FB8 M'3J3UV4L;..GEK5[QP.`UE;=X4A0)K=U9@391%'*I=S@HWT`*@%7F7:?J`ZY M#8CF-]T^*=/KH9XR++M],*;J!\`1<8/KPHX^28CKP,`C]=/'5CYCF MO0O6!R"2*8O5PLHHAT,N[_>KD#RKQ?BA5MU#G6!$V=D[&+DMN*5)"\*E)CYJ M&<)W0"JM78]%=I6[&F=1=Y,T?(99"=:$:3DU*;J MJR2]*G(X*''G*AZ!*[OK;OLL4"$!&VL[5Z&.(,TE\C;JQ+"T98[3,J1P(X!U M_<=L^==L)..^R_-`-02LORWY[P[47+IP44GUL'3?Y"/@8/DSY_Z@QGWU6^^Z M_!\'O)+S\N4I3,M`U`M0A6B^UNL),`FX*.OQV0J2]=SCV*RR=FD=%WF6^W$` MJPJ^GNH_PSNU>QXQRE0W<-;SF&,BU21ILXKV?B;`IK!QZL^I/EAYRG0W_NCG ML/?^_G7Z"+_//B&&&TYD_SS"GOR,U=M:YO M>,]F-=LUM#M4%-U5]/-.#P@8AB7?AL#2HH?)G'\^0LD-MQNFJ]?+:1"UY3?$ M9`-[,-U+@%!SB+])XAFWPUZP^WQ5)TDRBXF:@QJ<%Y[KNE'`\5!S7-^65+G@ MB#O`9V_U<]+>(N":UV.J#H>:2[E!KFCM#LR1IMP5.+-CK*^CSK*LF%?IS6_# M[/M5RM@U3S[(LOQ6[!'0]A%P!'7HZM/E$J<;0FJ>Z"+I>2K)*9SY[V"XMJ2V MWA4`._3>,4UI$QDU%W69U-^2R,]!)?FBP_0@Q&MX[5!LBPXA+0RNG_S84&A6'%YT)7_94PZ/2T MW00D=NL&@VJQJ>RFW%;\(BQJFL;TWT/EJFG>791Y<9^Q/PM^D?S,,R.HKY:0 M'H"2^.V29,LK@T3,GT$@JSH;`-8'$!)Q1)$QH$U:'90Y)P:BO-&8$VT1J+QW M040+]NK`J#E6 M6.&/UB1J@T@;"?WDF72Y\]J!5BK=6DM>0XM`:5'E5R&P*Z!@K.?>T_><%/@5 M@HP$4B#V5/@F&&K^"SS3'T_`H]@=U)L!:.=5.;IN")HXJ'DAK"14+AN;#0$, MC>H;30W+F:B+3\U1H`<7M%;M[J3034MW%N=A$$9EU?*O;%JDH%B67;Y,HR)@ MP17H@/M8%WEY[3]^N/33.(QGV82E91:,\X7X`8J)T.);O8.CP=[(6E>+N=QZ M-D>?UF2AZ@J`:5SX6B>US5C:U@^U1'^6!P2M]83PR%`M6.Y2`MH)K3TXLNGW MO1LW'AR8G91^KD,U#XZLNB48BJTM"1`S)X%E+I4?,<9HS<#FJ5-.G,[":&IY M[)2YIQMM`1J!G)F2#P8QF8IQR!/R[9Z:NS#G>9ROXX"[A!=^I%C+A.T!FDV[ MJM4U3`((XOPMB/IZ$?+5/BRPK*RCN`X`2*&77ZW`2W M+PJ8B.^Y,UO2SA/;'1%/!8HOMVU1(E0[LQ+U3I)FMW:'E*&`(I`VB#L6Q%3(T*`T$$FM4FG?$&' M@[TRP_$@1#FSOQC+07-HU1+3,U_0(7KM((.#<.7,(&.0*UI+ECG2E`M4!PL- M5.,F4=6:;30$00GX&LI&ON#79.:SO^`. MY=KU8=6=.`("MW7:GY)@#=3!AS#CSK[AQS/5\6O=AF,8K,O)-@J$"6*BWXU@(+.K:/`AD1WAP%R0$SV)IRH)R M"9SXZ3@M'<*",F/CRLU60I#>`[R#8X?%"CIE`NP"$&'77=C1ANQ5S=:S(G], MTO!?K_DPE:QN=P2P#NO7&F13#`QAT9FUHN;!UX)"22^`Z?`>JA=_2E1(6C-G M-HF:P!UF5XW>`)MROG9-,N7H$%+=I479'H7RHN\ZW0`HY1SMK;[)!BR$/W[8%8(XI6?8+9NR\)D%X[AFI]&S&:J?`ZJ@G*9=QG`'G`CESNPA=4M< MP54$_R@'*Z]3SX+K]HPK'P.*L)IP;#>$:\)$^#:8TI6E4Q;G_HRM,VADER_P MRS"3)217=/,./@SM8*(/"^'$7$X6A11G#_ER&:_@G3T]I M+:(0'A%574!HR@5CE%R@D!`>W)EG1%F]EO,XFZ3AM#:]+_^:C2038:?G@6H< M)CCK=WSLCA=)HD[!`:447,/"@W7A]VU#-=(I,"<'F5(><-H: M^*2($,+?5N*9 MVA(E[PB;V-%0-^9:R!`>G;DHK4IW3_Q0MB>O-P,D+AWV>G$DP($PXLZM"$2[ MCO\>QL%*6.G7M-V8HQJJ$1=%@W#DS"K%Y^7K.,O3@G_QO\?^/$ES[B;#S6E) M$Z-=$%AY2-6]J6WNRL$'6)4W;8RLH6XU)2OM^",9F&O+AV^?M/ MY3ZL2[%J@V?UQF5'\ZQXOGU6O)&4P#;W<.]PSYVU?XA?7ERU-8A3?M8MU3OALT3B!_W_"60DW%(N8Z=T;A MGK!K`236SQ*-=X%*"23_']Y8112)C$UGCK(&%?L'XVY!+#A[9JD_8QONWESI M#[NTS&@*`Z0X].$9G-6FE5:1H>[6Q=B^'MR/;^]PY#``UO6P<_H15*I'1KZ[ M0/G.5VA"&X2MT6]."J!AR,9X-U^`:?4C7P'=BR:5`E88G7\(K00!,OY:EP$4 MOH4.#""?@[G,#=U!;1F(^HYSA]*`JO]:EPP]!KMS&I`1/]B+,Z7YR=&QH)=< M0-5?Z_*$P&'!`"'(M^/NBL^<.W= MC7:`R*:UD!WHU:I93[N.E8!MTQ9F ME1:&YHT^C-%%8QDA,\Q4BY*[XD9+415K4KT9X+$9YDQO26J"-^;Q;99$Y=?> M&)A671&U5X&F@N5$U,4GYF?=@PI:4V9W3E1S71?'8>2*]G+^%"4+QJH\JLN\ MU%PB>5E<13?O\("`OY=HL`LN)+6PF/.218BX^Y'A$*I<#H*C#G?V6-9O7I%^L#$*V&.VIOC:44:+-6!T7.B\@T;[3VT:8)5.ZN'4:M^WDY MX52I!OELE,3EO;YBMI7U`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`X)-.\\4=?.V9/RT7FO-%_2\* M5T[]AX#BZ/C2"R@5D]\6GY4T*V8X5OK\-1L#)AI.\6UI4)-9!V@E8XM3TFBX MY>R"/0O)7S`OJ?D/?_$I2N[]2.ZRTV@(U-Q9ZJ(CE#FD*O1)9N4ZIN@)>M\78VQ&C2ZH( M)+%<(I9)I;45LMZ7QERF,=A M42MZV("Y]$;U9VS4YINL=0.@%`R:K[LS>"I`%W.`G6`+/QPQAV M#U7J^F':%=TY"W:U*Q[;-%FTMRNBRXE(;CIV1:KNI M-]JS.NWTV?Z@JP0"@EJ&Y,UMM?ZYPCO\0.!$@2A9ZPA1(2!F;BM=0/5)$34' M7`2\V5C1LBD[.VI7EXX>EB-)C=*T=(*$0?M9J MX1``(&:2*ITP)VGR$,KFIEHK0$$AC*H5#0WQJ9F9E@:*>+8,E]'96:%]`"*% M"*16#"G`F,ND:VKMR!CHX_$L#B[@XXZ2IS+_D3*:3-H/H!+8&2N8P%8;)2YS MF7@-[999!,^71B4P<8M1S"#:!MED.` M1"#;6B>N$"S4)D4];E M:-+86RK[`F0"AHEVS&F"HI;@][H,1N8H*Z%AZF8I_$9"']8%`!*P8VCR("91 M#HU:CMZ5=.K=Y%9+@$/`V-&3*0$B:BEY481=)D>`2,`TTHLT!39JZ7A?U^`K MT,/')`:Y"Q#]U>'CG#TD*:O:W?DO+/L93JORXGUG^F`2O MLXUL9[-#*8"&P=EV=JX>#&KW(\#`*5/;+<'@G((&(+:\=T' MJ3R/LV-7W#)CW&,2@4Q9M8@/T27W:&]XH?ZG-H_^;5UR2P4BUPX"N7\:E]Q3 MFZ?^7BZYG(9-PE``PW+)/;5Z9N_FDGO:"%D4RSTLE]S30\(NN7HJ)^N2:ZD, MW*E-:X/A^:@%)&*>NX8*@YU:-0Z8*N5VBEY[2F`1<^TU1AB-"=$>E>M/H!4@(V@-:,:6`B MYD]\R]/WQ2Q8&:R4M(D[P`&1@&=(:[YD8*CY'`LL,;)MXG9C`$7@AKJM:4&, M@II[<96SNV;GDS&SW18@$7#R:$F,&`0UG^%NUT-'>P2\`MKQ(0!@SL,723Q6 MVYW4\]-)O-5TNGE'(YJ.:@+MZ^.AYJB+%&8K:P1]83_*OW0H>K?9'U3FT/=! MGQS)VJ,'D9J?[UGPSV+I8'&7(%O2/WR>K#JO`$IWZ2V?Y1VY]!'NRWI'N-1\ MB66#%ZV[V/%[1Y\'>G;H9V'S^U=`IN:13*?HZ9'+!**61H0>:&J>SCH3G;@X M\"V#DU@6YJN:7)46EI6U>`-5'4G;KP:%.[3V[6(%ZJ\=N5^W8Y^3CW[V>!4E M/P:9_>W(816DCJXF1P3HP.;Y^(^5[LE#"&` M0;F:'!U8-+ MWV'"NX[7@;%GL#EY!B6S3!3KH1-]:N0%H$.B=E=\03*)G)B/2T?;^0&!<">3 MK&C9VP]0(Z`S"]#&,8*?`>)I&+$-N>\232UI3`$V7@=Z)1`]97\PV=,=,1^> M"_:4LFE8U1*,@WJ&$\G0DO0"E`0BN>SQ)QXO2H60FFK MU-@\Z#_$.SHDX&:VZP'15C_4W*.:\I]-ITD!Z@/EL?!98:W4Z0[`";B-M"5* MEVX,+S5_*QW):^7[0JF/2?N'@5((>-+M;A"(T%-+[-C$P=-_Q/"VMNS7^@%4 M`GM`6T0W@%+S'FN*/$G9DQ\&%^R!I2D+5@F,XJ#,+J],XMGM@:`<`@9#6Z-` M7P/4W,_PJ6OB+SJO]C?AU'895W?Z@[` M"9C^++(LQ$O-;ZPI^6HV4I>"4/8%R`1L=[8H%H*EY@/6S[1M[4(0E$4@]F\G METB]M40N/Z<84Y7RS^)=<\L7>$='!.Q(1NZ:.R&GEA<4]CLKC\?IGT68,D`) MHN<+[D'+LTGRZ+^GI=\6-C3T'P)*(&`M,DFH>,BTU0BU1)S]-&1M%@%E$;`S MV1\^)K1$,&.H"--5&/OQU.("U?(%H#P"%BXC"U0GY-22FZYFTF5"1!X%`J`8 MKQ(`J? MN3E.?%NK"J`R]0I0((%3]`X&D5%]R3.N#FU1LK88@;((N%_8'UPFM(0,*6=& M6@X(/@7^/[[)?_8C/@=7(6';YBK)`&KS&%`$`;M-NSU+>WP(T>X2HPD1G,&( M3M,%#%15-*96?^_H>'#VDA;`$$Z=&6:_%D]/5;R:'ZV"(:_CAR2=5TZ?ZE.( MYA,`/H&3;,L@P#;0$&:=V4=7!5)X.*_T]N2U&0"A@(MM!8KJ1[9HJ)QO9OOG-*BHG-!L#-IM[*AO3CPH,L2#R33&_^'.F M3+V/=?&.[49X:)=+P%2O0]0V'&)!XX;IHC'QF>>-;)&$FR2>P1E[SH6_@Y+':)T*<4,0E,!5IFS@;ZI=AH):>*_X;IYC MO5MB;>T(4>_LG7P@X*S9P;JC"XU:%.\FU`N63=.PE&[\\,U/PS+RU,_+DL;Z MYRWY8T`1!.ZA>EOP=$!2"]#=1+"ZH^%"E\;^8`+[-7[K,],WQ`DH@<)O5 MFVDU1&I!NYOR+YWR^$2D_PW7.P%(`O=1O7EL0J(63?LQ\K-L_+`L.C!.;WFA M\75]<38MTLHSR8\B[KJT;)FC-!>TBAY[5>R]?GL*4\9D*._4T6WHG M)P2./2T(D>*@%C^[V@0LT=#7/7)D!!+VZ0E^WY>Q@' M*V%EMM!&8XZ*0'Q7%^,GAD4>[+<[=\XR&+%10^F,KZ>SJA"1N(4[%\^^E8E. MCIR=3KM6)CJQ&FC?MC)1J4#Q)TP!QRQ-R^4THW`K0/J`6FWON/C6, M2L(4U(KA6/'[[&T'*H547E8W&P,FJ_MM;9\"A=:E9IP&'BL>HTXYHN5,8)`L MLKZF:XP\F#!?\"U!$I>!()JSH:@?(+9Y/+(](^*0B/FA;@FJ_.B$[0$9#7\K M#?V+B9/`(N:):HPPHA.E,>8L^*(BEM=QY==0Y%GNQT$8S^0N6$ASD)E`D@#) MAR"PNDJA&/,M1=1>KH^?2BNO7.&-AMX)A:#]=JI&0!CS"D64C%;OEJMYO M[_F+N;6L5,S_!U!+`P04````"`#[B6Q'LC;88@).``"R700`%0`<`&EL:74M M,C`Q-3`Y,S!?;&%B+GAM;%54"0`#F@]%5IH/159U>`L``00E#@``!#D!``#M M?>MSY#:2Y_>+N/\!Y[F8L".D?K@].V//[&Z47KV*4;<4DNRY/8P2*J8`(>7L!9 M5$7W113_4C;\X/V;]V^^!^2';X\_YT_'W[Y[_P?P\[L//WSW[0_?O?\/\']N M/OU?<'YW#X[!\_/SFP2W4-$6WL3Y%AP?D^^D*/OE(2HAP()EY3]_]5A5NQ_> MOB7T7QZ*]$U>;-Y^^^[=A[<-X5>,\HI1/W]H:-^__5^?KN[B1[B-CE%6 M5E$6'[A(,R*^]]]___U;^E=,6J(?2LI_E<=11;M**Q>04I!_'3=DQ^17Q[C# M/KQ_\Z5,OL)]`,!?BCR%MW`-J``_5"\[^,]?E6B[2XG@]'>/!5R+I4B+XBWA M?YO!#1DL\H7OR1?>_Q/YPN_J7U]%#S#]"A#*'V\OI0I]WVNK9GJ+I70EYPTL M4)Z<9^,$'G*[E_RNBHIJ@NQ=?I?2W^=5E(Z2N\OI4N+/<%P_'_B<]B]VFG!< M_W8XYY:XXJ6U[E2N-U/R[RLL0T\Z^*6"60*31C["K?"KM''JCZF+),WF<:_! ME#CGO.CKBU*TIQ/1N^\_O*,:D=_\_2R/]UN85:L,.X<*52^7V3HOMM2YKQY* M,BU534-4?-K\WRUX&^T;_7NB%K#,]T4,K71GO=J7*7JPD0G/>9B33.TP._[Q M[JM_:=@`Y@.,$70XP<\-[W_\A7U_H-2JZ`]!5,2-A/A'C58UQ=LXQQ/RKCKN M*;@N\JUUG]>BY-8=TQTL$U35.E%]2AB_V>1/;Q.(L%[OOR,_$,1]=_SN?3VK M_P[_JI6D(\!]]'"PSP[,U.3.D*616@JF'H(HM4?XF'1]@QCS?K<%R3HJ'ZCH M^_)X$T4[@I0_O(5I53:_H4ZJ`YGZUW_'\W\%B4"G:526U^N[*H]_67U!I0`W M!CS.P&,B_Q!!E`3D:T")L/?!9!ZA8SP$#7XL^]\=B%9QG.^Q^\LV-WF*8@1+ MQ21GPN0<1DH-ACBZ0YL,K5$5PS)LP+WW,M7,&H*$&5!N"0@GZU9U]@D+*+C?;J/BA7IKM:[^;E6.5@W?`.>5V36.NTV\$BO53C!3@.OR M+!)__#%/$SSPY[_N4?7R.:],)A4=HX=328TF'`JC':JBM#V9#&>:,!L4_HC2 M?$1\`\QN#K!H(Q#8F?G!+B]@S(!PA^CTI^C9L[10SV#2E]_I3&W9NGI-[0FBSQR>$&G0; M!*L"[R(WD*UJ0II-Y@'#T`;F1$*`AG'2E=IDCIK<T++ES@,&U=K_O6 MT9PFT58!;18P(VH:#F:FF[]?C'S&*W(4:N,8[2E,+,/A:3@J?R$[MQ]QWQ55 MA/#^S>B.78/&0FQR`C5+O,DOV&&TO3+/ZJ._0D-\C MO5$:27R%?P=A8U;\P9VM3;ES%WB*1.7U>A"T\,+^W\1AF#;@W&48:S;$(&4D M,2L'UB,6J/("?J[_&XSG&*WEIRB+V$(1G)<5VN*54P!F9@?'H:&-P:++:(@G MF.WA+8SS38:(+S"W,@->#Y$/>GWX&`#*`SI,K6D%LEN;22W_MF2,-SZ2P0IL MCN^`2_*.M#S_0K9]T':V,F[!SZVOD6["RT_&"6K6QJ8",ZWQ.MY%*=XQ=OC] MFY$LLK5M@5H8\$>,\S4)9)K*_]F.@'F7"S'5(R[G-3B?`OOHR\VDYJ,Q<.D M)I6>GQ`(*<"TX>Y,ZCPJ,I1M MRAM8T$G0?%;1 MEF"'M21G6'@A2QOS;U2&\!L:E!7VW!G3182*GZ)T#Z_7%RB+LAA%Z6565@7- M/*/?:AGR.S'W3U%ZD,GH6LF,W_VEDJ%>_/N*DJV:Z`\=UM"FM-D5]&]E5ECD M;I7L@>C.RFZ*'*\:JA=R\D&3[6$)Z>K5W-#,FW!N:Q;:#='8L![14\"*`K-E M#S?V:(+&%^@+7DRNRA*&8'*VP!Q:W3A4.CS$AQLBS2W?0C`^TC.':V&PJ^K_D8Z%\M!>I^'8X=08/\)D MG^)=:7OS?KHO"OP3S>AK-#L:-^%^@C37CIM`:E9RVG*(":FY`64/9A^9Q_B=-]`I,+W#/DZGQ?L9OS M]?"$ULXHY_N81_.=L<=4AM[]##A\!S0?`N1+H/,IPB2X^`C/,2S8@3=Y12(Z MHK2]#Z'Y?[JG9FW_K6G_16F\3UG_Y6OQU4H@=RK+V:S<>RUCL!ZR\7=.NF_R M$FGJAMBQ^\O1K]:*#_FJV?JW-@UG4(_`;09.FL[?>-0\`%)62T1&Z`]DLOHA M!SAY+QJB[ETI/F8H%&):3>8*;J+TG%:TD10#$5(YK1W#RS@<Y# MT:W=`C'*/EUJN-GWSO)MA#+)6/=)G`[T0#HN>J8>7T;@>81%/=D=7GDW>G#J M5RB#E_A'HV(_'6)_SKTKL<+!$S)`Z3SG*9Q9;"^3$X<2Z00E@8C#0D3T5M"D M^-"`T'W!H:&DW',\2J!=Y+H!LE[:N[OS^SO_H!4#@"MQI!A]UV"MS]F,,X(N+[<$P`ECL.+T[.0LV8_`!U<7*3E=EQ]:S=J70$ M'N`&9>0PD1S+,E$6U?-0<]REEA#_5J.?_WA'B62I`>\=YZ;R+B4CT7^BC+0/`3KT M;`8#>#PM@JLTC0Z'59?/7>`N0DG]-%L_]4CH/3QD$):K70VJV<-X?BN=VS9O#,-90ECJQ5X51;<#2Q8H;J[647='703R%5"RV MS`W!Y9ZFPKV+\/Z*N1@L"HL@1=GF8YXGSRCE!J^WQC1A][`',M**WVLT;*"9 MW4BP\=M^;CS#-?5(RQJL7!/:->K M$GKGMB^3>P@?2E?;.3A0^K1H.]%#6<`J@3)$O`%*7&_%M'LP;YLOQ:XKD,V6 M=)<5"CC[0RS>5OF"WQ6*'E!*7^W@U2!?V]@@3,J\"><0MM"."V4_L-+]EJA< M]^(15H:))Z:H>;DZN;RZO+\\OP.KSV?@[O[Z]*__=GUU=GY[]_O?_>G;]W_\ M,S@[O[@\O;SW;TBV8!V:VCBD>C%&\RA%%9-/@].'_'5-+*R@12LU&M'3`U,` MX8MZ+"FL(Y!`QN8"]B9Z(;>OYA$!0P9OL0"=7>;:YA\7V##Y41@?X,@;W M2)=)SJ$=$QYC+[L%A/0('.[IFGWAIZBJ\^)X/B6R40G<-RH%@'PEBCCT&T#( MBX\W<^Y^O;K:G0?BOJ5^6RNJ)W]MX*A]ENG.,WH4JGT6RI%Z*;P]D%948;O- MZT:)_'I=[-^_>O26"1`N@#)0\QWUDCMZ/4^:J!B)&#_&BL6,S[^MF&./.VNR!)[+ZI)5 MA#*8-,DI5W&\W^[I\\@SN$8Q4FU83)@]U)8TT(C/=\Z8#CEB.VR@YO-;6'*$ M5ET=$I4.+JW(''%\14D[N+G,<3:\35=8C8C80XXS@<3",MC]L`^?NR`CF=EF MJ.R0-I$34UN@C M[3R5Z>3E-(W*TBZ'O(338T)XF2[2[.[YNMZ_/KP`RE5GT`VENHJ]:JMV>WH$ M+@\[2%(@N7C"_Z@WEUCQN+,9#L"(S``I3Y!N@$8?YD6RLL.LI&G93_.RNLA9 M0O:3J"1)05[(BZ!54>`A9'5@5BD5BR9Q/Q`.6RE/Z+NB$=58G,KCT16X[7=5 M^8AN&X`T`K`LK)3!,?T(J,4!77F.P$$BTDJ7GFNQ!"T!@49$^)"!'T;,_&R4!(*O"*GJW@A-\(5VS7H M:4*%ZH"LPH:)U9G$K>(8PH&:CI@B@4H^WM M!AB&7>TR9"`CDU@!$U1=1#&Y('[158-1\'@()Y#+SP<79&PU2JE!0QY.Q1CM M8/!W^D8CX1=.DA(S>I8@P"0K/B/#DNMF MX1T.?N3]S<7$:#K;0XTE=H-!EO1Y1G?WZKE.P^>O\I)$#ZX8%[O2.]`%,]\9 MC8BTM)%^.-QA:R"+U@5)Z)UC22:W#D,!N2)EUP_!8]#O7B)K/]$`2-6@\TLM*>PTSX^%'&G(G",+5%)4D67%<'SA_IG@N0/'22S MW]+\S&5%#\W%4ZF$SMU!E41.41IO1N!]CE1V;7LRI>]7=^[L,ZPNLSC?0E+V M7.'*!G3.W=A0SB$(2#)%1D`+N/L,YC(1-5U01A,'.TU&E_Y4"-"A+U6@T^%6 M)6HC0S[OB4.O[R)*%AESF=T745:2"YAZ#1`^L%PS<%BN$-9'?L9G@=L/C$YE!Z#0XI.<#T M#(=!`4XX$`IP*4;!"Y!.\ZQ$"2SH/2PKN@.3:WMO:-*.3\@9Z:G!8:\-T#0" M\G#=H?GH*B!K.[3.SZC_%I'`HNJZN$6;Q^K\"RQB5$)J:>T?R_JOY7O],;9M M>[Y.NJWU%A^&8X#7Q"`O`*4F*158:[7S/="4+9'7-?)<77!7%>B76DO/CY9G MTJ@=)]@,X8X.X0[/GV48\^JUUPPKA.6G(:I2E,3EZ&YFV9<":)B\^3)V;=RNQQXJ1O8P%BH M7UG&@=R*^HQM7MY0`K*4?2\M+2CO>`^HN4(9O*S@5N5"1<3^\-*56`H6\#,A M`Y3.ZZ60I=AGJ(S3O-P7T$`#+U#G`"/%N00M'D!^&SU_BO!PH2@UPGF?WA_4 M!W++88,)04L9!-PUHA.!MVJ!O:!;A!0IP.4P\8#Q"Y2A\A$FI$R2$<@'#/Y0 M/I1<#O.&DI8="P/G.N%;D3=RD;T@78@7*=058/'QT&R552A!Z9ZD[3HLS5FZ M2YA<8*U)X,V^JA_2-1E*FO-EW1IY[@]Y?)@V4T^I7N]V/]'=138?`>0KH/,9 MPM0F]FFO+\)9UB^#,_GCK_E!YC`!W#393U[$#6@"91?]JON4( MY@]]1M7C(9TU264-R%:='!RG>931C&8E<^8O(-H4$+)8\V`L6&@/0^M5&(/O M]8_QDL[DAF6^3P2RGAK5.TOM5$*Y"_+95>MA5^4CN\K_BG:\Y9B!2MZR[<"&YGI^B%++P MNZY+JA[Q&B=*8Y(WO'9+5"[\]ZQ^SA-2A-ZL%C>S.Q*9VX3L8'=HDZ$UBO'Z MJZY-BS]VDZSM*EF<.OESS-%GL.2WN0')^:>XT.C?M"'1WY^'`-_+=@CO6YGN0J4XB[ MT?%8:X]Z>E1^QEMZ&%&/>#"'VX(>%8ZZWZ."3]%_YL7I'B]ZMG@5IC%V$;%S M%`@E'H*!$H&6*AA'(._N(39T?>TP=T&TA=?KGCS::S0%C_NNEA%OV,L9HWV0N.CG',)/< M&5Y5..G!50^2"6@]0V55H(<]IM=@543I%JE"68>#W24*`J1S2^T,H')H]."I MPX7+]'A8J:RJ7_*C\I>3EQ.8Q8_;J/A%LXC7LWI(GJ?5AD]+UV$!A`>T+,&L M]DU'B<]99S-$/E'72*7/*ZQE#0!UG#9VJ`MFDV`Z3GKP MK&[A$\SV\J,G#;WC>AYRN;F:'HP4$%I0$XFZOU_%FYP^N:HMG1^XR(M9"V4$GK M\F1*@H;A0902"FZS*Y/[J"TJ2^R?RE667$"HK(3 M.X'')*"A`83(V[K+0-H;6)`#]6A#@XIB(GO2R)ZOL8_#OKG*0=R$>?E<99EV M?JM`@8G>^(Z$D2"['P2CA/4$NSHI8/0+'ESYVD9,YM:J>"F'X]I0++RJ,8*A M7EKV:H08U$,C=[V^`1'-&?P08?H8@O(1P@HD!*;@9$B*\#37_J.`<8X7T?\@ MSY0?84;?^*3H%YBBQSQ/2)OTU4\3#E;GXR9[B8*FTB44V);AEF4=>("D2$Z) M?[7-_=N(!*4]$U%"U$>^M),][EY8EJOXUSWN:=*MYZ@\`Y?U@ M7]_=*NC,?,B_BF/L*!N'^;'(][M+7T:59E%ZEL?IRUJ(!MXM=&\VXA27E M/_EJC=7>PG8D4*?8UL-&8SL'`L>VT9&, MP\3)QU"B%;@.[`^HN/>FW'B2T[>;(M\4T78K>^\LI71\DRF257P@VE)Y7TUI M>KE_F:7IXMG&61VT(*;U.=;2A0XWVMZ7.MK>5HSXS`N=^^?\?\,BO\[@!1Z< M^BMJ]ZQD<1R[HI2>BV-YS@$A!Y@>$(8&%)ZS"8Y0A68'-)/>75".'DK]`!U3 M',T"[WM,!RWQ+>+Q!7"A_$J$4XXP(6ZD#![-#^%B7(XG"/VOX0D&7XHF0%%_>=VU68V.(,<_E&,C.4E^(H4OE)TQ/7GR![NW]SUZ* M'A7&LOF=M^[V#R7\=8]Q>$[>L]WC[VGF+"F'>SQ(9>>PT5("2@H(;3#SE&8, M.-28#(!7!&GG)@5/""B2GQ^*<13,?*0="P,L^9V'!($I5P8E%M1LSC&ET8*+ M*11$(WE_+^56%Y=68H*QH:&8`\R=K=2)ZLJ+O.@$Q"NL1,;@W#ZDDG-!X34A MN"`I)G7/%MP8A+'PW65-70;HN$ECCQO#U-RHP-,4]$/H>ZM$CE5HJAY?`?G*/'> M.]4T`/L4NRM07MQ`_/_)Y[Q"L2@R7$;HV-X$DG*()32`$0%&Y=/.@I+8S+X, M1+Z'Q1:LB=2\[-[-2@;GODFIL>QPT5;D,81)20J^7&$YLA*2]XN*^<^8T_TR M3JL+CWW&P6HIU3ST_:SG67(&E=:6*CE=^)FACEL!VD#.8V[-P]O1]PH#4K/Y MSZG9UT*?3_,('#C\6HVE*NRHODGT^#'/L?5\AM7RZACM[QPIXS7)J5X%R(,FW5B(4N3_J/LVW#XB]L<`V5R(L&/T'?0+'4V.^SJ)4$4-9#:5B_JYH) MNM$ZKT=@AY5[(AS^S'LV=DB.3,?$D^W+K$1A\VH3\6CKEV6YM[/S MAL._C;>RF]@W(P[*MG7R]^T:*13P:@A]"&F-0(0?CP9PO:_**LH2E&ULK*#' MYM\4^EJ8V$.'(RBC,-*D;QFY3A6OYB$`F-9&I.AR9RA7.=D*TE3%,.,*I`M, M1,;@W#BDD@_!1`A!CS*<[%OJ[A\"R*3O)QR87L&HA#0:IR+G?JH,#$)2MP>F M8FFYP2=4X$"F#,QVH2H-`>?'7!G] M[06N!53R+[`QM&-8K[6#9\/I]8G+ZB.#Z_`N,]Q5Z@M?K-8H5 M]=6,N-SO.I4Z<%LU0@U:\VHX%(3IYM./;JX/:(FN?/>M"X0_P]JDAB[,LL04\HV4>IYAFTA-XYXF5R MV(ZLLN24[M/3\RXZ$R*I.YL3T[@_F M)'(/47.]HR$GV090CO((W%*WPQC\WFHNJ8/3\T45AKCC13V`)CT-RG%G52\_ M9@FD;_Y([8XH;3Z*'79*?CR#5812Z?;8MA77CXHL=10$_-,&`&T!')I@^`*X M$="T`NIF_#[PF:CP_2,$"?LKC0=M]-]3_>.#_DQE4A&MK!OU'A8Z"M"#ET/C MT3S!%/\6%4645315H#J3GXC2K4D)91VBJ":J`8K0D]FN-W#DP.&$)@ M2E#A[ICA?+M+\Q<(:5S2]7.&7=PCVMW@;CZ_N[XA]3K3O-SC03YY(;_4'%V- M:LWY$<4XG8?@:UJI(^[:=LBSO`Q\39KZ!GR.`JC\,<-8#P\+)@]T*`@G_]4F M%31O(C`L][0;`^`C]@__U\%C1],.N+*A](566LA6>T6FX/&,Q[[\.@"RLKTA MW)?9:%&'6I,7SL433.JSJTZX,@MD!OF.E8(EAUCMST\12DD4)TV!LZ&+&?_K M&&,LJHU+"L0)R^[>%YH7U\1JU8MP+9O;);E>"XVIM(D`F'?VOUJWU^B6E>Q> ME64>(_JD]6_DW;]/1?7[^]025W"XR5P1B:_*.,-N0ABR`IEWZ0=`5'XB4'WNZW!4(M!=J37ZTX1 M;'U*=0-F+Q4;M!IIX!7,IL9\>$1U'FS&QLL;S--HAZHH90OEVWJ=?)$7%_MJ M7T#R5#3*A+E")[3E\[6FL;[J]_%U,\U;SJ8ANE5@38&FK6"2`(Q6O:<=4JKE MZ:&G'8H5KS_'0-C6;DL8O]GD3V]1]@3+BECMA_IG8J\?.O;*?OOW2_H?LEJL MCZ;+\R\[Q)("G>'EN6AG9L=BD^!E4.S^=^W:/J9?505@6>956'<@-"]R=Q0TDY@%`"O,JN20)8"(E[ MESMF4G3ME,KDQ#D_YFD"BY)]0O8:7DWNN#ZY5&IN]=NA!,W@JY["NSF`&*?` M[W_WX?L_&VGA[,Q!@Y]^N743\+CS:A<1*FB:LA5>?6S9X31)S'I10'B951`/ M?G4K7@78-^'<$UIH-X0<8:US[768:8YD0-A!PP]NO2T19E"3D!VOB3ZHT:>0 MZN-R0K`%YG"J&(=*OX9'0N_C"B:D-(*EP?59@S"T@3:&!M9P`<+F\R9PA$JM M["E:!VI"(HB9F(X<7V&8S$]YBM<:*9Y.1\Q6LD:",B-.0UN#.C00Z)1EK&FK MTE-+&;:UB=%I8WPU[X):GT;+5XM\1 M3`/(56D+1QN#DV-QREM(4AR`)J/9=,ZWU!$L:A['[QS5\G.O&AMR0.D/!ZR! MQ`J8#$?_W9[Q6#B\;DNCLKQ>U\)<%S2\1A,EH.!Q?WVFD)^[)B.TX'K=((FD MQ:?TP40,:$>#NQXR&PK/>-*&"BBYPL"4-#A`@:I@`@4,1L4(67Y#`TA,%8E6 MT+BG/IG[$H1]*06S6A;6\PY1MW)E]Z1]ZG[XM=YD2.@-`E*?T0%!,#Y"W+TR M(/CU!%S&'1(#?`M3>F%$'F;T")@6*]8M^4^GI-65CY$Y$(,J!XP\(.B- M'$YM'B:;L9RP+[M`6921#!RD)-8^K2)%>CH=@]L=F4IR[I"BH04'XA">$-CH M4)E7@2SE]1"J+>1-,2/RQ+2D!5_&UM]S;0!#P6E#37C[79'C*7ND=J"P&U3AW\;FS4#O[ME MX2JEC>-YELAT$I4P.Y MM-WP#1=98\9N>KJ^\CYO'O9?KSM/\F33B9;-2RH_A1:2#'DEN,\/B1JPE^R^ M-`T@B>O,&OEVZH9H$V4$-(/:#);01CT=DK7IK$#(XL<"Q-)+L=()S#LPA(#[ M.?0(!>T*1`F1KH63P_P89!)Z&$Y"*R+GAD9ZG;P<2&ZB%QK\]1P5"?V_GV!) MBD"PC$:'19ABY;+0]]QGX5BHWX0YUD2KH,WW)OI MC/W#F6;=-EF#44YPHC33$IR\]`A[=NK_*>]BF.(L4#;]UN%<+'NF;(T,.@>YZN`6:Q*..7/ M:%*OP-.P'+3E]2$9[VV>IA=Y0?ZXA/?1?/#U>"1=S\WOI>HO@LXGP<_DHZ#^ MZNOT7:,Z4E+5[57X(2.;F\TW61CZ^LCS?^LU>ZFVO\3K!$,'=2QP M4$>-ASKJNJ@CP+ZXD&_:P0+ER5T5%95##R7MQ)[B#W"#LHRX:5*ZD0JZ:"^< M9TEP?4">02^MO6&(I'/=?X,S5=_;+CA)B5SMZYF?/M+S^\OLAL)^P]9UV1P0\)]M'YC MEA[J^0;84'H]/YA#K^9O9,G9+RKU-P MK`I$4@.9.JA)K7G()3Q&9[$!LI8`:ZKV+N#06*_L6QNO.[^9FCF@>3N@HR4S MU*6=D'FJY?G&%['Q3=CXLCTPJ8/7UYQSP[[CE:99-I_&>:)9OYYMWT5>K"$B M12K*598<\O&[V`D:?/O5;0Y-^G.Y_6+GZ[0F9>?[P2P&/73P*2F^DL+D+27_ M+6PIC52S^/V,X%NOSM&)^LO!KI9\;^'[&2=WQR;=UU/Y M-W0K8:W[;^560NICYO;2&@?S>KQRYWKE;Y!$)L-DA5$:;6"S\K[!BW)(X@/6 M+B.`C(5Y=7Y]5(^[B1QJY`&U0.WQ`J`B@8Y,K]M!SC(&G=[:O!ETU>MWI>,= MPX(WP*.\PF_.&?OWP+]=M^LR"$KC;G]3T5&6??Y?*&9J2L^XV+.XCO2=TA__ M?TKN3`^>YN%@)U_I@S!A?,=2$_"<4H0W"<_:QT-3_\CBE8YZ5NYDSIS'!R[: M.1:A7<'LTIR@!5C#):@Y87ZO93TO+.6R7M'+`5Y?3.$;4^/V:V5 M$R+]?&W;7/G:M(FT/NY10@)9@A^00`,E0^F>%D=1C:,=O;V**O#\ MB.)'/MJ2I78M013_ND,6/5Q9S"C M!WD][KP3'.;)<1M+\.I""P;DA M3B\L"2G^BJ:4]X#.?4&.@9Q;XD!.>[]C#%WX3+C?OG_/XQWY=XH.X? M45%!F)$OJ MZ*.OIP"120\*U](/9J=N#X*%=%NNCCU!'!2M:VH1>3]D<]:=5.M=TRF[@`Z, M%K7)V4HQ61ID((D=S[>[-'^!D`G:J("1H2P',[;%L%(\*G4W3Z+69#DX`DV# MC0MI/0QIT_/Q]&^^(Z8G?K3JAE;%Q>,^["6)+P;G-G[>LDXD&'Y`$$P""4!1*A.(6KOVU6O(\"YS37IF"=Y MQP1U*[:,,UBV6(&E)PAEV==5_?P+^5'E/$>T%=@23JSON(5:S[75C86[$C/3 MO*<35.D4SB)+@6&[I906P!ZL%A9/>"$G]E6?R;N9DC@=XI;*^[R*TN[?3_.R M^IQ7_PZK6QCGFPS]`R:'EAC3=?4(B_O'**N]FHGUNY?)GQ?QT/]R;\2$`;+U MU1%H)6+K*+Q^HD+U7141"U-6``L&#I(=]=IE_("*!XA\S9+,[^G=*Q@7_B;& M=EQ>A./RP(]+I1T7+U[:E\^2>GN_#NL5;+-9AMWFN&"UKQ[S@BBZQ$9:_JW7 MLU56]-?LA>";5.$DOK\^^#M\\)6&^L_1?U,[Z55L>76&.=NFULPJ7X$K$^[. M/Q9YJ;S'7>)KK\>=*?O,[>D>_>HK]6I6W=@D3Z.WH[^=TTHU:B9-@T/4("/4 MO`HWKW=:RYY>"CR60U%=%%0N8?2BK(HI5(:92#N?0DH_[WY'7./X]_7Z+P,<3)>UQ1:<3_"#%8H!A4L2>(G_UB6 MH$'C`GUAEYXXF0-83.XU!LL M%8O(AD2[>'1UQ&(N\P_AP%6WO%5CP1U\R8W5];J61H'=`9USX`[EY&-1RHI$ M.]^J_):;Z=](U'P=CHL58F`(6`4`W*&5'CW=%/D:J?QLC\HY4OLR\B>Y^*^` M_=GG`L!$RIU"2I?X%(SZ$)W2(7>Y$"@A5NQQE25GV$K2?$?.+?1QDAH^#TL$ MM1Z"[->4GB;6Z7"$$.4X29?DP.'?!HS0Q2\RC*'E\"0-IKC-#3G3*:(4B[9* MMBA#9!E4H2>H-QC3!MR?NYEJQAW',490_J,?LW\#L M8,F=](W`I,,4A]N\J-`_Z*W?]?HRJ_#HH(<4KLH25LJ\&4(M2P!7\V;VPB6RM#`6 MAX?_.TA\4+:I?9#*W`6T[H_]!?)R)^<-33,M>CU+-9&8':KFK=Q0*;?3XW\9 M/KBS?S4X/"+:X.A5P>,?X8J#31[IRQ_+FMUQC5*B@7T`![5:%&GQ[_OHMA6( MA4I=`N MP0,/8P48W*'W4)7.<%9'3WT1=8 M?D)97J#JI7$#JRSIMW+^ZQ[_^1.L'O/D,.6IM@Q.I?`45N^JCR6A^G3+0#C! M00!PD``P$1H?0H4`C13M0I'>IW`-,ED`$P9TI/&YD?+;Z;1S'EB7UGZL(I_P M[\(\&+SXP84':W?M5K'HM9L_@1E4AQ)).3RY*Y'L$M>"2=M%1TWL>^UMJD'] M%X#A%J2=2A$DMBD-?!PFBHJ*#%MT>0.+YKTGBDEP"$KWE3I3KX[3?=(EK2Y< M"IZ:@SP$/I0*0S$+7&)LGA,66>MT4"!A-""#%4AI]![6,F:U&>BS<9I>.\G3 M-"K8'^EO`\BT;8A*+F&/#21=U@VH7RQ>KVGBN,<\3?".C,V$!GM@0WX/-0', M].(3WS>/44DNZ@YGLT`-Z8VJU>#Q*=ZM1\YA"%"2(+*(B]*;".&UV&FT0WB] MKGT_K^%S'P"DT8.+,VGI`6$XOLQ`S;)T!3*SN)F)ZB!3=9R&SYA@C8N>,0>: MRYCN*D(93)JY1FLN,@8/4=P2R?F09T8(VN51"'9A+/XJCO?;?4KV'^`,KZUC M%%+"##5^^'!M/7@<)]4JK_=56>'U)99'M6CA:?TDM!K(*TPL5((.T4(@W['J M+E545#JHF\A]$N%_QE!?(631UIJ-I\W7B(ME!==A`%0 MCB!V4C8#H[C6THR*PR!C6!%9;HK\"24P.7GYL81X)'X##D^V#E\XD@0U!A("O51/ MG:[N_@U<7%W_[0YK^\O/'\'J]/[RI\O[R_.[$**F9[4A+K1Z M`0/RM),DI9RR&*4DV>DAO/$^-]3/P-LL\SF_^]'Y>DVU9;W/0?LAFBR_&P:- M_]CW6".FA(_'>OV@[DL:/X=^06+*8].">N?E.`H.H_4`` MKFQ)Q57=N[@SN\*`C5@TD2[H)3!3>2LGEW.FH=1A"ODO-TFQUZ'VN M1B:J$6G5<&F/!K@:FI4QJ'PL`B[RPM`V%#P>IV->?E4ZIE#F/CNI21*I-(\R M>A%+HP[BO,03&[&.BY_(7Y_9F6<`KPBTR))/.DI8^:ZXIXL0$C`$4O=.%BLD M*%T78KTYV>%P71LM-B[4[NC\=UDEG$<320W!K!";Q^=P!<3"G$'VW\ML%`=?;U MD!IBPT#,L,,2FK7IM&%_#=*(!(#2VXL433Y-XZ:`NP@E9W`-BP(F32:=+*%Y M@[2IQL(\;(KG.%?KZ-5X;R.NMVA[O(:QH;Z*7T?O$EC<`(^;U,;+7=G%:\_D]'1JC M5JO!3J5!&$O-`=C,5Y9"I'DVGV*/_2R*'E"*QFP!.?8PC(C7RM2.""?HL`9H M2GKE&CW"2?!O@STC@U("SZ=--3.GOIJE`6\`UL3K8V1*[=(Q@%J88Y1JY0^F M0*8QU/3VH\39:PF@55C6U(9?6<"L`+[S!L70>[0="B+(W7$@OUE?#./O+SS^=W[V:./N15F3H M62:9D#L/@[?ES3O5^-<]*B#6`PM7O9#7:R2=,$F>1XO6*KR(32/./865AGRQ MQYP%+`'Y]`XQR+SM4SQBTWM MKVY*7W0J#W`?,*U;>OL`U';$*]@'6!K&O+-U8$[B`F51%B^X#[#^0"A.P[YG M+)U'^X$0]@%37MM.[ZGA+N#B\O/J\^EKV06,M"%#OS+)@-SO`NJ\V9?U`XY3 M\G[#8-TO9O.VTI=H(5W;YW5:=-!P`,H2QEK>5)DZS=FN27.&M5I#FI`FEBOC M8S&OPIAL^:X'F$-;*?(8PH16UVD$PO+15*4_9@DL+O$OL(D_D<`1\7,#LOE0 MVM5LGW!O@_/U#@]QUC0KKM7:*BEJP)(*T_9!^P&Z,V^KC`S>$-'-^V+K>I/Y MV$5/T3!F&'2.IKG-B7,AB]C2:UGZ+[;D?W5+_467^`&>#TSK%GH^L.MTR[KM MC%=P1F!I'/.NY7TY"B(R=F'D/^10\RE*R!Z?ICU166+(7R?=MY1QHS[]`1[:]&_*8^`[--SQV'7X M;G^_VZ5TAQ:E33:_RVR=%UN6><,@2:-I"^Y?]AOKQCTS[W`>4C>"#G,@IV@S MJ9B@,D[S.::(P.;05P9F8)5NZQ_1BDNHQ?945S25YF9:AJE\Q# M5&I/2CX`M2Y!3?[N-]!4*2E@PKT6 MZ!O5W)7EV3'M+=3K+=&&,8`9;2XS$BT]Y[.A"96M/N;X2Z>D,XKL\)E[^*4Z MPF"RU446K M^0;"6XO(U]^?>@:KY;%7JW MK^WNRDQ&*_+[W_WIV_=__#,]K*Q>`EA!CBE+'UHM^L[C87+KROX^KR$%C#:L&JF:8>##3$S&P!^,5)=O!CS>@:2Z[1$@:?G[ M-L-(K?%:A&<#THLJ2P"Y+&WW4%F%H<@8/!2TDTC.Y\E[J&PB0-Q6@%-U/U_\ M3=_WOJ!CXCZE')[!HW(Z''J\!RJ,U.$RPW"AH00!Q)%KL*,&?A!.\]"=]YJ\ MWD)J+XCG9>:FV/@1)OL4DI"QJSS;'.-)?`N&^,%&0/@#\9^2D1!A2#D,OO"S M^H)4$2$B8L_HJ276N!D\T6*ZX$#2[6XU1OB^=GCWBXV/V!Z1Z!Y_3`,2,;G[ M.UZQU-R];L^S'`%"&@Q:5#W/76UJN]V74_D<;>%9OHV0ND*UC,6S@^E)KW$S M1X!0@Y\9?0``T@V$VNG(1L$=D"XB5-"S]Y.7DR@E+_'O'B&L/A;Y?H>RC@# M@4]Y@F5?E>5^NV,9LZH<^V_B_E`&0:=S\-KQ;\'4D+9%\]`ZQT%YPM.`:]J[ MU_NJK*(LP9_X!+,KPZI8R>.BP(-&>O'#0FWGO=8&3?$]P-'?N/ M=,S5CD9`Z-;%B"05(YD1^71VPZ2[^2YY+#[OC[L5DSI M)LR!)+P=:*1.T-JFLN6N1OW/W MV&3P/&QQ?:IKQO.]AU9+[5U(IP4"U*8-0!H!M!7_:!TSLNI+$YMA]87@)CT5 M$>NN(LGE;V!!DAI'&_/H$74CGM&KT5"+W39)&FG@"+`FP*&-T)!K,J)JW)H/ MIR_4UKG]R61@[F7[3)Y1.=!`B\*:'E"&T"`G&@XUQ.1CX0Y2U^LUBF%1&AX* MB4\V44T9`07@EOF<^Q`?936^*&?]6\Z2T*0>Q6R./XFG$*MLFP?I;<0;1_V14G% MN;?4%VCC<%W**]<*4PH2VW)U4C]>5>X]-F0*\=@!MJ3>%Z M#4A;H&T,-*WYO#N;2?M;N,,BTECQZI'4^*&=4?0Z@V08WM6=@0T_)9V!VL[8 MU8V_\7RX-P7^O>.^Z=B?8,2?HB]HN]\>=A?7ZY,\VY?7&1/K+DJC0I10RHK; MK:$:ZS0$9\W8V5D28Z2\X!I/8PRLC-VG+4Y6<,A1/*2I>;RX=9G\,E_77V@U M#`&X;U-%VB4373%M:[7Z2Z8ZW9#W19$)QD3>V@!@[@N+U')HKC6%U-[*C/1E MEE8;J$C!FH%$\[`5`UZ3GW^!\9[4FI3Z2YL6W'I/ M*]VX"V_Q@I@T4"^'Z0[VT(9/]SJ7IMW%,3E@J9?&='L*VS9\>UQ[S/;\[UC` M3CLWPNT59520Q*_BYZLR0N.ZAZ=XH;Q0.!$G(4 MF26GCPBN[V*$_X76**[O$M1!:N;\CEVHN5Y\Q%#-RNH?$&9PX`8UN_^'"1-4 M/"O>@+_F1;:-LA#>*+6`ZBEYS-$$N2TY*$!QV`H>E@Q'H>YU@;R^'4IJ\#:D<@IW<[[`JYNMZOP<#LZZ?\MH48ID3 M"S`H&!R_/E5(SD5(4-HP\:`=@?YC0[/NGX"(^T=4V`!"3N\6#PJYNW)#(LR.G=8D$AM^!HEI'6N5*N=;E2 MW!RF66B`^G=PJ%7HB2K4W,GY/C#38:F';#,@>;N:N"9%;\SO)FIRWY<3C=3Z MVPE*&=SU1*_7-?<3@B[W%;'_8Q9M\Z)"_X`)29F:[S-=.F<-K^?X?;$^VC#^ M#AMH^/Q#S'BHU$']VG'R!;XKE,'+"EJ\%>EP>`9:5W9M:E-"#"AU>C\B,AL!7=+3F8^+?L*8W!?P*H\R]4Y0 M0.AVV2^2=#CR-0T@1*%L^J0]W%L3:[IWRN5`OMWF&\D[LOJL`=1C9+"/+AW1%)"O('GWOFB:I?5MUM=+\+R&^+)]P)=5]T^L'W MOGJ,\?;OET9;[@(NI_.MV[K/+_+B8D\\7Y,.P]8%F;49ADLRU-_&177S;39M MTF`JUFJ;1\5;\,/,?2%R83V_A?U8T>T'U"22>34>;63/B#T'9N`XC!VCO-USNT=J[*9:!SW_K.9%2& MZSOS(7$9CD$R/.?R`'89H8<0C(&DXCS;>0C1Z>K>Y0,NY%WK,C.R81IN'8.' M#,B&2;=MTVR[V?8:B]\ZQ6=4/?8/G:(D0612CU*PPT(^DL>>!7.;45GF,:+Y M1BE?/_/XKNZ274"9Q\T0R:=[GB?/N&25?;V#142VYE<0=VY)GIC>0I+F]-]A M5-P_Y[*EMI[/=34SK1Y\M:F:!3`>]FJZ(&"YS`#A`YC1;^6LZ4H]M$JA#+P0 MI:KGW/<)K2GJ!G6U;""WF$U@5ND%DPEG2'91ZV)F&;<]RR"LX=J&J6("ZR"L M8=M'%X$6%L+#S]TJ[+Z(GG#_9W%4CI:?; MO1Y'$TGM?S5B-#+#18G%L#C,65ULH@S]@WJ-TSPK\Q0E+"UKEMRP.\V(U1NX M0%F4X<5C2C.X$]'+U4-9%5&L"KR>J7WW6;%GZA?.F7;:/0*]EBG@NVV3G"UM MZ^#0//BY^4``"_-9`<0EZYX?/:_$M$B\>YJ7^P*22FQHDY$D!GC#MXII&#R> MKFYP>^1BT*10N7M17I?!CNOM16S[(`JKI7@0!ARD`8TX+NJP&Q96#&``:!D< MTK/=[[UR%SG!$V MCU+U=F_GI._J2:&L6;E/J[82N":KCH3:=?BI1&8^L+0A!(PFA`@-8^E;P%;Y MX82Y?P0].&<^Q'_2@^;XH'ZTP1MLNKEC!])1MLX+_,,J>4)E7@1C%&HX#@(? M]5AT&-*(,GB]/BU@@JJ+*,82JF-"#/G+DA\YAJT49BM+C$9KEU383NA_>3I.6[CAJ[FA$D^X+,9^3OF)R\6L?_VL$" MY8GO@W$Y\@?9$]6P=QA^P*K%E!=Y\2-98CX7B'2G_N1;Q^@^'$&G"6?PVVQTN"MYBZ%QB3247&9_15G29#I1HHLG]H`H@<0\BE!RC+)C0M;6 MFPT!.;+>YM&B[FJ'(9>0A,[`9(6W4-$&]JK/=6+VR-%3O,J2,Y3N,;4"16,; M=!^F.59S;K]8-P3JEIHRB-=U&<3>6TK:'#WZK!OT>ZHY?R=$=2=(GU(>D0OV MN@\2UA[X&C64W_@WXVDFP47"SF`/,U2\PG_YH#YC$E'ZJ7C5DU5Z.D.H0CA7 M,I*:"AO:2:@<&\(J5S)@3*IR]4):-8['-6%R7>=*K0%?Z.J%(=O(O"/R3ZN M3O99DD)ZU!5MU1.J10..2S98:,85G;]W_\UG\^1U7']H=;U:L3!O5\ MNTOS%_:>O_Z"VH$H&-P.M$KRX9`?:$%G],-P`]H1Z.'`L/NGO'[95Z3RU/6: MKO-374Y/*;GC=RY2J;G01D9)%MAL]NX4D/N<+WCG[2,N M9P5A/28OFA+0;1]T/@`>7D"7KOX(H!\X8O\!]8?J!`7^U]P+0&NX7E\,5S,5 M/;ZK"EC%CZP0[/H^*C:PHO^0GH:8,?LK=:S22%WEN.9LJAVO`6-F_PZEOK&- M>H*PC%ZQX[)6N"YZO`854[C]=^<@9=T&X@=QI&(#86GY8T/\SF5J]&[J/C^! M/XGOT+4<'HUJ*+O&DMB%W7T.3B#U^L%8CTX/K#I95[1V5',' M9DLZY$JMR@RV\]S1:W*3^L]&:I39TB;?J(_;;E4NRSFR5W9WSR6,WVSRI[<) M1&3C_!WY@6#@N\Y^&?_J[V>U<9-:+(+AYTF_!T0`K^C*^S+[O`J.G)IR[VA M4]YYEIQ%E;'DHK]2H&2$X)T&+F#0,^Q;VMLC0%5V]-"(N4!E'*4FT MWE9*)QB+!91>IDE\,M?H2CL44'K`0R\O!(TU(2`4@), M&@(>)+W-`T+9U4LAXG1?%+TI3+WRE),[Q85":B[0CY'VEAEAK$%U7=]%B%F_ M+^LV+E`*BU/\T8TX5EI*Z<%E#&65.`Q*!AJZ$+R%L)-Y7Z'HX:5`<%]$Y(G1 MW&UP*$C'5:)3+Q24 MC#Y6#6I-9$N(3C7+(T$9RQ!\A,D8"987Q@,TI;02;?E'6I\!)KF-V"\_ MDJ6N\-&O,:?C0DLFN@A#I4K0<(&:K4%2S>BU7)%KM9S=S9B#KU_"R!)Y[B(? M/Z$,;??R=Q<2.N?1AT,YN>>*[.\!W.$I>W88NJ?H5H<8B+Z88:!/YQX#`SGY M)ZM?##`P64RCM&+SR.H4KR(4<'B50V#I4^A+DI%P2^>=*T7>/#V+E[-HB?32 MX^@.?2"IY4S'0G0L+1\(K`'3"/_^%_QO_"_\`XGOIBK^/U!+`P04````"`#[ MB6Q'0>=MM=)```!U2`0`%0`<`&EL:74M,C`Q-3`Y,S!?<')E+GAM;%54"0`# MF@]%5IH/159U>`L``00E#@``!#D!``#M?6U3W,BRYO>-V/_@]?WL,4T#AA/G M[`TPX"`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`:\YN&TI.$]+_)>WLI[Z&3+ M;MZRB"O2Q$_S!6A1G/E3WG:FWT6\!0O=.V?W^16H2EI*P:!7M8H6.O,QF<_# MO&P/^/B8`"$Q?'D:,H..21NQT4G_*3+\;]&JCEH5NE"WQ<040YT\, MM((KQ6D*"C)CAESJM&6ARU=Q4(#"+&[#[/N2FBFTG1J.6'DK-B1;W&?LSP(: MO7@VE&.MII7NS.=^NKAY^!K.XO`AG/HP6TVG25$J]B2)0J[:Z_^:=-:LW9U! MN?/O(_M`UJU:G@%,.RNJ:V7FC`,8MRPX\R.^ZG]]9,Q$<['Z.YFHC`G7;M%" M]Z_#/XLP@(W!:0#_PG?\J+)%.&>Y'T;Z7==K;6=#C>\5@R)B-P]7,9^QDG1A MBJCUAW8X1>;PY="/^`XAB4LMN@`ZGOV(Z\S%SVE4!"RX3)/Y1S^:%E')R1@5L/_ZPO+K),LF+/WZZ*>L&SEUT\>=B=C*&+'PJ0[W[58@-FK<_F[?"A:3 M-KL](UB!T[1]R_N*TR)_3-+P7RRXRK*"!="76Y:Q])D%Y=#.;AXJ4X0QR-9? ML@SW+/*GWV&1@,:RSTG`HKL$OL32>1BS2S],O_E1`8O''SY?Y/.L#=Z&G^IL MDP:3`"C;(^^Q;Z2G&HW95DHK`TRWP9WL/<4EC)>LEM_9'=2;I_+7Y1C/TW`* MJU#Y^T^-QI75C^Y$"'9V*.T^T[$IQ0K$QA^P.4]^S6&75,KSYN'FB2V_WN14 MBS7456=+!8$5)F!IQK?O^:)EIT4-=M7YCW[V>!DE/]H*NM*.A:Z>^5D(C4Y@ M0P+-&]H,A95M&@<:6`!V>"RS??:J=/VI(M)KZ.D&!O833K-P7%VCX)]H=R-3 M7AK!9Z-DNO&EB%]7):E*7/PWGNP#I_<9OZC+UPU%_CV+RN8][;K>_JM\=+NZ MDDEY?9:QZ6^SY/E]P,+WT/L#_@.'@K[+BGOC MC>Y6"3U--[ONI]-UX_!CCJ MR*![R=-RI7K[)DEA\OS'V]';-P#Q@:4I"ZZ7$D(AE/TOQ=B.T0<_NR];+;)W M,]]_XK0>OF=1GJU_4ZIIA=_5K[V7^?1CY&?K=>#T9Y@)2%;6\4:CPR.79*L8 MV^17%X^8Y_U>\5R%=I[,_3"6$%POS"7QP26SNER)&48!B:D=.Z"VQ:0,RR*[ M`JF(QJRJBG?0G_&J@T5,Z$$/"+V#9A4$\B*@N&.*G&VP@/-6@2"FZI`P5:>` M(.`H+B-_AG"U488C/>P?62(,8K:."+.UQCUA:9C`OB\XAZ5#,<(VRG+D%+L'@99E,_^@_FIY?P&]52MU6:HW>Z?6G'I!B-F,OCWG"YU$]] M-BOEN02.^\YG'8^8T1/"C"Y/T[=L%O)#=)Q_\>?8%"LJRG&?](]'"13$)K!' MGL./I?4]NHH#]O.?;"$E<:LL0#_8ZRN+8BP(C2YL.[HT?BS2=&.MD.]XL.)< M`*/^D:F`@_#IPH9C-BPOPXBE'P'(+$GE@W*C)(>]WS\6<20(@90M-7>ISX-_ MOB[F]TF$4+=1AD-U:BMO1IH(`T(793O,:CEX]41:.2<5.8]SX@CE:Z*D(A=* M#VTVVL`0MMN8O_KJ[$D0CH(RN`^U8ZE'73?SF4+>JM]_RYM`^JG-8 ML*,D*U)V!\R=167TDC%`02O>OM.IU(@2\:6%*5A+UY$Y2S-V[6HD;D?].1B` MO`NO,M88=N(*WM'HP-5HV^R1SLA":@`(I_9K'1&+1X\4D*6A\LS2^\3A8)%% MHCH8.)+N&(TGHW:\_6-7HTRKGSJ#SZPA;]^IR:PY2\C=O#GX0:QT&P';#D9K MW>/S2Y+K#$]Y16\\Q1TS&XK:;7ACI_85`S+$P\X,Z"!&G$86`A?;S1>1 MEW%0+_U:;?\_)EF>E0?OLN<3?[&<*C6VI:T:]L;N=J^Z'3^K=EQKE]NN9<^M M,X=%8I$]LP7Q#&*FD*8`<6$3@G[PW='OT(\T]T/8(S$M@Y"LGK?E$K'3G7-% MH+R3IOME=77/K8.`/@/8KE@3XD".LK7,-BYVQ%M]T-D+(U6\H]&>LVWP5I^T MMKU8'0#B]#983]#(%E<.:A`KE6&2)0>C2I!90SVN\$K>@;.!M0KRV^K;8OFO MSBC3:\!SZW^A28%XR!D@[&SAF.D,H=F"Y]9/I)5.F$"T%)[E7C-@!+#PN4P: M9S(U8)4\M^XD+><$*2I+`5SN*7_)0Z=/.%;%.R!A=VI$MQ23I1`P]V2_6L6J M=K.7M#17Y6$^?&:3R(]7:B\[C9FWYATXC51JI2)-X5H*2:.P@P2,R9S=^3]- M)@MQ%>^`1*!VP\E"@LE2[)K[R8)GOP-A/H)NG\,&.4J>N!U]8S,DW14H:WL' M)&R?#;<'>O`L1;^YUX8+/XU!1"\Y5?5G`$5-[X"$GT@C+="!9BE:SKT&5))" M7H:Q'T]#'H_TX@.IG!&TZGN'3D.T6FF#/D!;X7?NE8(G-^-7C_"?2GYF`TN" M3GWOL+^F1GV`MH+YW"O%)$V>6)HO^$ZX3&8%P,OU45\O=)OP#OMK=C3":"LT MD,(QXBN;<9BW["E)FUQ0:-7W#OMK?-0':"O@D():?&$_*M)*DQA^G++*VJFO M(:9->8?]M50VPFHK\K$/U\JK5U`&<*F\E;9PEU-V_>&252Q[*5VM65NS"8]& M"C\%#_DA,0R;4J=6@&J^.AD M=;:P;B]W,7Q[G\1EU('FVBVJ!^(A85%OL'[C<.ADA6YQ`;^)3CFRA>5!'+1F M<)PSY,8=1^4V:33RR,XD\I>VV%,XG^;KQQ1Y7K?/;'[/4@&!6O4`,@DKF82/ M30(-4+G-&(T0>IW$,_[F*4_# MQ-]\4*RW1XHCB MR:(^NA0(AG`)=IIE3"LUUF9![XC$F1\A1LRB`,%@`M:7V%8NE-IL;I7W/I`P MO`IXDA$J`F'I'LL]K^*HJ-/\HY^F"SC:E*<>F8^*3GWO`XVP,91.,?WZV`83 M:KYR?DZY4[NU#MA:>VFE>U8+W@<3EMJE*F*`;3,1Y'?07EC?1A-=JW@<2 MKBWMZ=^"-)@8\Y>H"0`HX;A:S/M`PM_4E-,:A.'$A$]2]N2'P2H9AGK$"LM[ M'TA8FDQIQ;$,)[Q[0R:ZFW'O`PG+D_'46\-@Z]8M3W(_HAFF+Y]\9=6\#R2N M6;2/6DHLP[ELNP(:XED(FX>E=`#A,C@,CA2?DB3X$4:BYU]-JGL?2-B_M-G7 MQM35W=KNM>`F?V3I"FT23Y5SN+"\]X&$E4R;9QR$K2=AW1.[A*=A?Q]&97PNK#GU>$0-0Z=N$]XQ"1N8D4';"!NB%<9&,`H) M4"K`]4W>>"7OF(2QRXA.I4:(,"(ZT&.;U\1?<#./OK5KLX)W3,+.I:!-;NP2 M($)X[J&="T"F!?2V)B`YU>(ZWC$)"UA3MB6@$'>/'MK$SE?=73TUH69;7,$[ M)F$5:T2U!!'"QB,K[E:1%5J'9W$%[Y#& M):2-?9D$(,)[+S,35D2E-YQ!!-1V8!;VWDM4"+'FQC#G`UKRIKO,]P2OY1V3 M,'];8%T%$E$"8\,9A='=R``CDRH)*[@%)5!@1'2@ER^;<'U/XA*PTO=LJZAW M3,(:KB`+'^8U+`BOO32IG09!N`0R\7I=%K,B]*/#LZFX324OE&NK.R=$#&U-]`%372(+O30 M`%>7DM%:[U%)DM2`:P0-$K]C;FMSOJU7[7Q:7*MY-'*C->)="QNB!>:6N"TM MV'%>>`[N?ONIOE.>Q&:VS(SO+A_P>9A-HR0K4G;S4.W=RJ/[8Y+E69F1N>S_ MQ%\L#V'J$TF[AKVM;">[G(M?DAY4N\W[>YFDKZ\NKGI<9?$T*KM5)K06/\]8 MHCXK_;L:)*K?87^\T1Z)K:0%+4*6'7=2'=`;[I4$(4))G$[S\!DF\P;*;M(@ MR)7$9G<'VFHNED$DS[\.85,0\)W%RS'Q*GY(TGGYC7-^7HC,ED\DL=ZG!`X< M'Y-XRE)97@VT+,A\[&ZG&7/%`T;#_-*?\MW50I50`ZW#T^JY'%,*"6.;2BF: M7R6MQFB/R+V\E(U-"E$LV.2KY.4+W;0\BS(=)35>I-I`H(ABN/RXQ&)`[)C0:[ M`M4040`32*2M@6K MFAAM);^@X-UDXSF^8QI)^)O=!Z*`;*6^<'L9:.EE/I`@B<&-TZ5'[P8<6[DN M[$[0WT`,11=#8BM)!;W[>(W'3J3UN(!([*&: M3;H:T*PEL7`>^/2%Y5?Q-)F#?F:-]&A.N!E5BD@5P;"6H<#J>NXYI M'(W([J;TB-?%:"VKA?,17CUR%'S]6OFP9U=95K#@*JX<031-DZIF0(0DC)3- MU<0B`P)DMK)=4.'[8Q)G(6!8 MQ66A*W;BF;HPK651(."/]_*]G23WH:SQ_SB)TNG8<;* M,?+RQVSUUVPD49M&[8$\:9PC&ZM/"]BVLF_04Z.7999-BW29-="/(A:<+;9% M8:I0^BV#C'N^9ED1@*VT'DZ5C)MWKN(L3XO2J81ETS1\6@8-?_/3L'PT#7;] M9WXFM2F;-,.9Z;G^-(!K*U$((6U9!0;S5);ZNE&MQ$73\X.R$IRMU"!.>9^D MR92Q(+L$R?&CG1_SQ;>:QU3"O[HR%U7/3\+:(!%]Z)>OWJ;67\4Y`[YR/N65 MWN(!G`&GG+Z9[$BLWP@/\^SY6<@8+*(GN[*S*OQ_+GX^A2GCJJWR_WDMR8&1 M"%0R9U&."*&JC1_>CA,_%?.YGRY@ZQO.XO`AG/)GW98/2H3Q;))$(<]@^YK< MX^45SB8)+2QEJ*QU3^>=<[22-QJ/7$VF+])ZBIH%C*>.'^#O8%X*W_XS/LBM/0C[2XK98'F9#PNL#84G!;AV(IGP4A M>B_#.,Q@,\E?B]7B=Z,"2(7$S49#@@58+"6Q(,2P_"WL:C&0``D38$,V7Q!8 M2ECA.`.PUD%PDD#3>;B1])X'DC_[$2O/Q_PQ:!9P4]A'/YIRMZ'2-'X>1D7. M`A`9=R=;^PD,Z`QYL.?,0^'E;'X*?0NXH,-G]GJ3M<%),G\J\A4G:P>O-1NJ MPZ?=#X'(2%B$5*0B_@T=R.*7.>X>D#!7=$&AQCGY`'_IC3#3QN?D`Z![F>-G0ES"-DRQ1AYX*@R5$Y5 M%81$PE;4N1Z8J-^V>(:17]&.9`""6-3&VH%@&Q9*YQ;G%I.C#HW"+8^X8UH.+'T9O>R)3E+F4%[ MK[.G*BP2;Z4`=A.CW,MAAB"90@&O!*2\EQ>*07023@-;'$A(:S: M[V'8RZP^4'/D]&1L850JL/WU3`VL.$7) M'$Z=BC%<+PR"<'K-:V'P8J"&\!;-,G_J!D+EX$7K@%A(G#4QPL3T*N"X?8P& ML1BL.[J**)9GD106!G`DKBX5TA>8!21P'+\S@Y#USS#/7M]%DG,E*@O82-P? MFE.%HW'\G@SV.$&8Y6EX7T!Y!4_UDH"+Q%6@.4L8ED&\&U,^NQWGJ]128?;] M;''&XNGCW$]5!Q)559"2TV.FA:V-'L1!/"E3A[H&JCZM**J"E$CDI]!C4U<3 M1!AIOBGS:7E%=<=3)K!G%A>XM4A:WAO1>#]&CPO!3"X'1O/-F-D2W1+<4G:VW5]K0CMU7^-GC>9B5F'E60_2J8JN<-SHF?O4OI4V" MB<+3*`A99RGSO_LSAL^IHF(`R_V!H2550DB.WR3!'OE,D_]DTSR[BN&G&8@: MW?[42WJCO>,^SX9R6+;>%.E@9*VN++.[Y'3Z9Q&FU629*'V2.CS#J'MK2ELB MU0"'\>Y'`JC2/(1-O"(E]E9)KM?$C9Q:FQX]AM.,PM*Q\^F_AIOJB\ M6$,M``;MICH,1E45ULEC9R>$EW#%LR(#+S M1?4OJA@=[49`<,22AS4?M4W1#R+LIX),Z:)3+PR"()$RW90ZM0)4\;D-%D*. MN7`^`&U?:_VG-"F>RB=-8G_9S^MH*K^3UFX`A$#"-1:C1W#<-<3F-C0((_A^ MIB!P70!`D/"*-2%HL^]N8WBP"U%^#U#:O?SY'`MO14H"+!+1D3;61RE$M_$Y M6LS)?0M$90$:`=,M(G$E.54,)`-K[GXD_YNER4W,+I,B7?5;/M=)JGC036)D M51D0T*4$8RO$IEW*-R5[=U".&=)7KP.0"1A>F_&'H;$5>=,)@:?S'_[B4Y3< M^Y%B@[%=$,`1N`DQH0J!,(BHFZMXFLS92RSU-?\2YT%^QI?4`MF0.,W9/-0K MX0XB[@9!J3S12^N!?$A$&BLI-&*^BLUQI(U%]RUUPMS74H"=1%2R!D'(?8:NRP*R$B8/=JO ML%4\MD*<2)R'8,MW'RY]-$!'LQ"PE/]3NO0LP#Q#%=QEJ=%>40@YOK/>\PB. M]IL:JKBAJ1<&09`X.V@.-!60(?C`;V+3>K,6J^(='9!9`$5TZ9"[C68(3V5< M)_$L9^F<(]6X6!45!V&0L*P;#EPP]A&IQRXX@K>"8WK4IPL/7*K:$BZ MU'\#(<"._#KQ\2>>Q04!%`F'>IG(!78;!,<07K78G(BN->ZOD1H@$A*FF%9; MHBTT;OWN[=^A7&59X<=3=O/`!\#=:@!H7J.(*WO';K,*:_&HOD21@7/\5$87 MX_R<9=,T+"'=/'SSTY`/$YYQZ\S/#(Y"\F9`>@2M$5JJ80[3\2L=72A)&6O) M\Z,#TM*_,WB]8=)6$5DC(#D2M["M%40-BO@QI$.,+JJ;X__#3UX_PFO0UGC_F7@N]_;QY>7W?_Z$<1"\X6JW+9JJ#T MN9AV+8.,2=P!-U`<*\@'$?`@E,3%3Y@WPXQ-TI#OQ;;A2UT]FK0'\B1X:&FN M27IX:;YNLN[LQ<^G,&5\,L7,"O62WO$Q";N"`8]2)(.(A5COB@`<=U!3'#4% MI;UC&DG%&HQ.%`W-AU"@NVD89^'TFQ\5E8D#&X%8>1!)WW;T&G@^S/DS0/_\6"=39U[0.:H"[(J:_;;4UL MCI]RL3O`)WXH\XRO%N,YH_NZ_Q7@L!7ZX-9>#WBNXG^&<;!&*+//UPIS49"X M!6UBD,?0V(ID<.;T6D;!Y4N'USCXF)09P5G,\X$3M?M' M3L\FJ.3K!-6[[=:C%K$)7#,_8Z_3B2QSIJ`H`"-Q:-`?.W(D;EUD]2B2I\@4 M%@9P3@\`5+N_+WNC>*`2`2>4`,1X\0!JE[F MWBKH[7]PGZA4*&@Y(=7>N_4JM;-OW_53"?LTG!7T1V13C$/P:FW[(,(^#0<# M4^K4"E#%-P3OUH^/(7NX^,FF11X^LYN'AW"Z?LQ>9IS`:X%H2%A$,=(09P`5 M(%L^K.Y3;%E,L.CVP=SF,[H4T"`<42VG473[)J06;=I,5S$-PJMT"Z,Z!ZZH M/,B#A/E509@6RU5$@W`DO0OSJ'RJ-@B?PZ#P(\6$+2P/\NB9,58#SB`\.6OX M_@CSQW+_PO>JC^'37:(PYC9LR3L^(7$FDQ"LJ1$Z.&EZ;4Y`Y&'`[1!Q4.Y" MO\*8@+[##E2U&S>J#S(@<21K1)W`,F.&VY8_:`=)4\O.?_;3[XQ/B5J<2ZH` M7!+>"[9H5D*EZ0]Z&L=PCDPS/^4>"A*[=:T@H.K9,BW#X=CS4X<=N?E:4!20 MN7\6#9&WBIDJ`L>.FP@WEV&:Y1M]EL^%6'GOA,![:*CL!3S)@3CVL,1>&&33 M)`X,V$(K`$KWSY^9T*5`XMB5$GNT[C%,3>C"R@-&]R^@F;`E!]*!>^3N3Y&G M/_PTT+#F;I0#@9&(^S(W"@A@.$[7;,F:]P@"._,S%GQ,YCS68D5%ZH-H2K?$ ML\5KF57D="F,5XG$P23R8ZT4;EU\SCMQFYQ1HB*(_;`S(0PB+W5M<%YK9#G" M*X%D2)B:S><<%29;N:7=7Q*67F*@T[>VZ<1?JJB#2$;AX3P M;&Q-ZN@UE^2)I?GB]QAZQ1W]>$2['ZWA?"U`R7T>4A06G ML*+Z,[:1Q:63PX]Q+X`[F@[I=I39MJ"0@)X=OY=G4=?OU3/!/2*[;RP#6;WD MN.)%E3.QY<]YQS0\P%IH;R<20=34L97W-(X+/[IEX?R^@(,DAW.9I"M@-P_7 MX0.[BK,BY?E:)RF;AX7P)-^X+9`-S0.^^C30'"ZB"OVR(;?=M*QF!56 MBP114KC)?_OF"L'&;F%E)T;W4[(Z@+6'9T1-6`B%CL.8!=K'%\VE[L'.[R4D##>4:[?@ M'??72&X($B';L5/FS5/Y*FP\*XW[&4?`+W>NXO]@?GKW(\$H5M7S1GLTGFYI MP*PF-H10QWZ<\LY#5=$63;,F!][7I54;'4)KOVS)=ZG_S*+3.+C@2>]R/XPK MJX\L6$96CPNHQ[F,Y>7_Z"S&:&5O M-*+AG]1R(58!1/AU;)S<0%":4N^2,_9-G*9348,#[:$91P\50M^N#(H:]+UF MWC0G$JO+P??0R&&*#R'7<<:Z95=_CY_+"X]5!HWE+\L+O->DK36_?F5-`'[0 MU].M-CJ$UC:&J!WGV?6?PAQT-D^FWT^+_#%)>;)O_K@?"TI?N(RESVOL-P_< M7RJ)R]+N,NZ6GW],(I!U=O%G$>:++TFNDV)77M';WPK$VRDDT+"7YS>E$*H% MH.LER+1"Z>G5H.<`4:7>P.B`6$DNDB"P%K6(H=)+KMGZ. M:SD7JJ(NZH5!$"1,2`JFQ/1B<-RFY;4\D7U0#PD;$L- M1C`.QVV&7SML;Z%3#F1A>1`'"=.1!F=BLB6HW.8(MD/RZG$J9:*LC7+>V&T\ MN08W8C(%*"QE%.XD?&75W=)*+0].KI<$="0 M5HJ>_U>]O=5L`J1&XO3:F/`F^K,-?Q")@S#9DL,@]-/% M5S]BFK9HK`Z(A\2MGH$E2PYE$!F%*\AX1IJ;A\KC%^J40,K*WGA$PA:BH!+A M7Q.>XW3!=A1ADH;/,#!@.IN6HT.YEHLK<(\Q$K[+NN2)J9>"HYPB.(FS(N(> M"\L>*[(#"TL#RH,>4ZA&9BL1,(DE>KV:76MDVJH7!@&2L(,VN%[:PN`X?["E MJ^%7+YFU?TWI/[/VIKE,TLLBAV,I][/AD<6RFV/3MD".).RM&,/(C7(SF+92 M&E.8`U:7ZBO#YDU:ACYNQ.>^_#%;_34;R32G27L@5A+&8$/M:0[55IYE6RG\ MUJ\]AZ7S(=>>\>IGKC?CBMXL?^M=E?_AHEHCO/CY%*8E8><@1-&N0:\F"(B6 M_5>J"T:@;&5K[N2N#9L+7[PR;XH\R_TX@'T1OB?4;\,[(7*ZT^.Y&3Q;*9]W MRG@%AH76;(#(:1X?V&J$/UU8VZ>V5P)U#]QF<>[]_G3["[[//2<"BN^2< M0??F(,U+/TR_^5%161G=>70OKWXU/+@W"X(R?+`V!NL^S)@OMJPX=(F&E5P@ M*,&HD:+XRP][VR5V/'+_$(R4,L5A6PSH+V_LV!OOT]H"B9F2GGYJ<(;@C;WK M1^O';E/5-QWAI@B'X+K=]LGZDWT2+BRFU*D5H(IO".[;W41DG+@-.VZ]EN.@ M+'E[#R`NXV2?EJ\"SIF8;`DJ2\[BEI,%K"]:3V<5`QR4.U"\::NHYYV,26S/ M)'P(#E=ZJ.BZE%]SZT.Z[K><05%9?D]+XEK2C#8)%$O>Y4YGUNLDGG$;T#F[ MSS5>CQ,5!]$Y-7(T73MQ+(/P_]Z&IUPTQ15@6B(Q:G&V]-BMHG'LJJUMJR*1[`9QB&Y:(N0\^1]4SC3W\&<9J@8U:H@+*<>';85HH[- ME@>W^U<897B_)1%0%H'H&LP4XD9`?!1M(*U50X32EGIJWO[AR/G-FK3!&Z'),Y:^N)56*4KJ.BX M#ZQ]*@,6N4+!)%MIY.@X` MNDPM$:`&CNTB`-/I'AB5?)V@>K>'<(W?-KYE_Y"6)S(ZQE08AG#Q7G&UA&W% M35IB#)J'B-13+DV,$MW\NZ/JQ7$2V?;UPS">@JP M70OD0R)_1&/BQ8`L7<@3)'SI;V]"]K(&R(6$FVQ+HJM@+%W($R19'FZB4PTD M1,L1HQG=-40=W=T[3`'_\HK!5?R0I/-EV%3_X@*V[JC6I#H>4[R71.=3%`(=[_NN#*OCL5-+#2IYA6&U[/80 M_.1Y1C3V9\%]RY^Y75+MT(G4`)$0]NF4[&%D<-PZR7?&L#JC'U8'Q$+B&")E M39OH*B9+1W$*F]7--#:*X8S6\<9NT[\U'=`*0$-PP1="U#V=B&J!:$BX$2BX M,R"\BLNQ<[[\P04>SS/6>G&A4I(_"DKBADLI>\$Q!85#T\E>/PI-$*$%P$A< M2+7D:1/.(%SJ><)NGDY4L3Q6BX&DG)+9=$6L8[#E^DZ"0>7"MUD0)$#BZK#. MBIR]:N\'D7/\%`[401@5>?C,OK)ID89YR+*+G].H"%AP"0+C$9?%DIB;APL_ MC<-XEJU](+!7X4>*25I8'N1!,0!..3E+ MP-A*>4Z+W#_"_+',@L;#_![#I[M$<9?9L"60(0F3D(1@38W0P6DK4;I=F]Y+ MC-KJ@1C9X][R"H"2A#6A$3D"HY\"*(TLZ#U-#>K6A[GI0F"*T%8:=*>K0^O< MH#2>SC+E3JT!57P(T_VR0B[?^TCP)]+$!4$")&Y,,6[$3(HP("SVRSAG)2G= M02^MMS@6A-E^6*!N'7<0[7;R"%(F77B>J]Z%I!0$7" MJ4$F<\&6&<&!L-,OHY;=IY]/#BAF$M-R$94`0HCNEZVKZP>@1WLG-,S76-1C0R@FW3(2%MH^<(;?TR'WT.XW!>S)7$ M;93C`B"1":Q.BI@\4>\1^OIE$_KL_]2CKUJ."X#$FJA-GZ#W"'V[,@;M)L\Y M0.U59(LF((2['J8)FJS[VS1'F%X#WOB(HL5OFU?QZ#6!B&A&#W,+;:(V2!HF MKPABHC@C--$$,31$`W;Z2A#5G''C(XI/-NIQK\2%$&]LG")%?$=9(\='%`^^ MQHH@QX>D`#$V49%2"&MYYL9'%"W4#>>"&C"$>V-KEGON*W8_[J@4`I"2HULV M9>$S"V[BBB%0SW*M;@>$2#&MC)YV-$"*J$N_+&A5"W'!3[KP/Y7?J0KW8X2YF9`0OT[([8'C*A$O]S#3J.R<3@B MEW&*?L8"'N/"8"+CP/BC/G$F.S[H-0`2Z^_VT00BHA2[\BQ39.JX2R9%.GT$ M!#4)KO,PFT9)5@@/^:HJ@)1B#)8! MA2@HA+Y^>9D)L].L5B@V2<-I9>%:_34;26;K1NV!/"EF=]$\^S='C&B0L860 M0DA/Y?!2@M8P#&)5N-M"?^W""E1(7ME^17#:>TQD_*&_YW4I)H3G?KFO[<#P M?]R_0[TQ/D07>F;-XWCNM\\FIWQAFY7>FV>+UR(3?U%F0__AIT'YSS>6Y6$\ M6RY_KZ=BV>K0Q?>`C_Y9$G8@$41#^^7Z)]R)O5A27[(;??2CB`5GB^U-F>FN M5K]E[V34OW.L5>R(?O7+-W$-[30.EMCT;CUEU;P3DL\EZ&F&&AA">[\LF),T MF3(69#P)&]_A\9>Y;QYXI-K=*E)-ZORDJ@R2ZN\66!<>H@C]BH==+:G999+^ M'@.`'WSFBV=J$[:\(AP,1_T][FIA0^CO5RZYJSAG0$P^\4/92;=:#."3S`^H M1ZT`"4)DOVR>',]5_,\P#M8(I6-WNS`717_OFE`\"+7]BJ7E*\Y5G.5IP2>E MWV-_GJ0Y=\GDQONDB&5,*^MR0?5WMZ8+#WE:J8V!/HI8"DAV3,W$)=V^E MOMXLE;>$+SU:99CYF&30Y^V3?:;QMFJ[AKWCK6"=75J;UKE.L1=;Q06ARR1" M,&T('C$""?#^]:KK]M.:QS3".45D*6@50_GK/=<8!$$CC86<*:D1K0;'[7NN MED>NU<3JQS0B>AN,8!P.G3=@76=4/Z:1B%>#,S'9$E1N'XY%G+INROY4[+/R M##1(<0!(X@E*B?0WZ5*#L?20;#L/'%GL_2>-Q[1K!;UCM^'5S8A"8%AZ";83 MBB[F3U&R8&SI!+!R]>3/1LD)4U0#W"1.,6;T:8&R]-8K@3"X]=)Q+`:GQPYF[BGCRPH2A]=H?Y6 MN5TY5)UM.U0IC9*VO@&"(G%0LD$WLJS8%14=4VC&IK_-DN?W`0NY:UKEN5T5IR2;_Q-(P@6.XG^:]5NZE#>$JGI1X.M3LS0\!%S3,5+U3:Y$< M25QBV+)\)]/ORU#7\R(%L2YQ+D-@*]:P=:(;:5RP>6,@3QI^(+O7RX:R:GOG M49Q/S` M0OX,&;\3N?CY%"ZS.^YBQ59^&]BB<!`_ M"T[AD.G/V$8*,T[7PR[MQ)J=`3I)>*3VQH9L)%=DF!A?Y9&P6NQ&ANY'AW

!C:-3J!L60D?&34&`=C#N[.QM'(T>P!D#>T6WH"(\=(^$A(4>NW>:E% MJYX&0;@$>14#!_._,M^)&@:=.'8VZ_4J/O5@1.+^S0;=R"QD5U2_2GSJP3Z- M2RB[[&VJ"(I[^/&I!_M.[T=0R=<)JG=["/&I2\6$KRAR[&V4`_@TK/%=#DH) M\B&DWVLNL5>!Q`'/RO3%GS-E]KXN/@=DD+!T"S3$]GV-2@AN M:$3#UJ')F!R&K:@?MX>DXCYC?Q8@LXMG^$?CG(S4`"6FX1ZPBXVJ5`:V(F:H MZ87Z!(S5`;G0N.Z6T:;-=!63K;"/`;Y*<3#^=0ZN&I*P%>@P@!<$I+$K")(;'F#VST$G\Y25NHN M,D77"WD'!R2VWIW.QQAL6R[*'9&(SJ.B8G#Z&#F=/S$ARZC8Z+HMA]4NS((E MI'6O=0R"@@H:V48ZB-H96S`I)#/9P'KS(X:1\!@^<;`7 M7V\F6][N6\-R*:WU+V7I?"Q^!2@@X?/3L8):EQBBM,:F6`)S99'19=!/88]`2)IW"'M8->P:ZDBPZ.';WK(9XZJ2"]^\A]E"F[< M%@B3QE66R]D9E0NB9#W,0O,B`)8^PYHC%O>7)'YF&1][7++979+[4?7O/);F M2Y+_!\MOV329Q>&_6.4ER&6EF_R1I7>/?KP:W#K*NNL^`;G]#KHT5'HW\D4& MSX[SSCC>PBQ3CZZW>*=%_IBD7(1=;%*P;P$=-&QQ1+29S'Z'+J;0B3@/F4X2$FD][^!PW]W%US_J-@.!H MF+0%=(J)-\5&)X.'':50.C77"X,@2!B%3:E3*T`5G]MD()@/Y?R'O_@4)?=^ M)/?6JQ4$4"2L/)BX1>Z48@P$7FO'V+F?91-`G"S[!C\&Q30_*^(@@A-%,DO] MN8(UW0;XEI*$C=J$3D-P0TB!L;%WY9N3L\49BZ>/3`J"-=XU0NMZJJ("02`2=Z9.HJ@@BCVVP:EHY3?L2R6_;,XH)]8;B' MO;2\=W!$(I9%CS;D?(4#Z^< ME/T9&YG,W)5J(!P:QDR$-LUYNH:HNRP>NS4Y`M*`^_4$+P+*;AYNGMCJ=0(7 MIL6K&'K'7OJC851$:@!3!\[G15-SXA$)"X-4HGJ&Q",\;0+AK*\-4_L>D3B3 MBBC8)`OM/!WK7F?Y>8^= MTL;C!6X>5N"DQI1*.9`!">\2LZ52`,&2=KB#:=/2Q:!X1#PEYCQJX"CJV$M^Y'ZRV0`8)\/(V# M5U@,AD3B_*%C$5E:<3I/TCS\5\G0S<,5$32V4MH2VN$M M;[&NY=&8@M+>P3$)@U;#7=TV$%NI;=TS^R6)DTV4*QW6V,,KZX*P2!B\S%C7 MA&4K,Z[[B?NJS,O`Y;.$"PL5`Z+D_@'B*B`:$O8Q30[%"B`'9RL'+P7>E[C4 MN_:MDB`($D:TEBP+,+7.V'NR)#=F,^[+3G-J;S*E@WA(&-U:4:Y`9RTGKO-5 M_76_<@D2_)C$@+@`T*]N:&?L(4G9LMR=_Y-EG\,X2<-\L1X6<&[=;&7Y+,!G MEC\FP>L,*=L'[K`70&`/K88[%Y"UK+A$-!Q$LAK!9RQF\AL$I`8(AH3ML8GF M(&!:)Z&EM(BQ7.O,N5$.Q$#"?&AX[JA#L):9U?EXO?#3&&:V;,+2=0Z*<,I- MYF%4Y/($P?*:("@2!D(SKK5`V4H\2L$5:BLYSD8B-/Y89.['`0A$7RV:-0B" M)6%F--.6-EAM)18E&591)EE]3"+`E"TW/B["*UYZ).J0AAU-J[YW<#)R=NO7 M-/3BA(0QR$"^R(V>`-8O$XAQ0L+4(Z)@DRRT\[]`(,:)4]L,*ODZ0?5N#RH0 MP^XSL">T3!KHR#.`,X1(#4M/N9[0,CO@G"$G&!S5,+*MM'K)]83$F53"D9A4 M!,E@@CA>4SY._#"XBC_Z3V$NR7^E50]D1.),:E)2+ M*WB'>R3\6(RYEL&Q%1'BG.2V`;&'>[3<5?1W7%L8!A,<(C#PR!C=+@S2H'5Z MW>()8U6,PU;$R-/R0R1<3,P8%4"@$.Z!I!6M;/"K:6XE1FJ=:M[AB-;"*65.']%PHC.01VW+ M5PZ_L!_E7QH\&;Q9'X3MU&*E3ZQDW=4#V3IJ@Y"+Q6GPG\7*2^@N0_0;6!`6YUI"-A::`CIF05]+;OA3(.V!PPY=?CIB;5J,!A/ MG%_T&#HD'HYIS8.H6!77/14TOXH?XN&8EHFQ0L$F66CGA^^'>#AV>B6#2KY. M4+W;@_)#;'K_/:9U6XJ.,16&(;@9?F$Y7QPF:?(<)*=P MW'H.^:.DHL!1G?0=5CX``B=[:S=&WYRQB=V2NZ/[4V;#6]LQ"3=EFXQJW?2. MT6N@'MI>-PPRW)H23\.(;2"^2S3EJS'U=/$Y8(2$1W7WBMB=]"RY>U((.#UG MT.=IN&0_#JJI^"2**:D%$B(15-X=^V)M4XID,.ZCKY*]3%)-A4'K>*.]`Q*[ MZ5WKBTHBEGQ3*:(I.&M>SHSF<5$%[*`.0Y M6_ZW(J[539?>>WR:C7B'!R1LG+M6)E,)#2QWYZ72:%"!X$#L+GQ4F+YYF+XFJGN5.J!F$CLFKM2DQK4(7D2U^%.4O;DA\'Y"LDZ5V<[SYB+2&.9T[M#_P_##WB' MAR3LC5;\/QIAM^6W3&%]A/WA.BIC^F<1I@PD!+#S!8\0XLGFN2-^^<"A1+'T M&P$!DK`KVE0'L<*9RJ1UIGY")[=VTNUL!@-!D[!(=J]\-N34^E$!Z@OK91C[ M\;3#A=7P`R!V$I90*PMK(^S67C]P?K18S_ZK!-0\-A?$P?BS[K+Y358-1$3" M8F63*:4-.B#KV\#%;+@H8 M@/P__#CU[$=\W5BF"-@V9TJ4SZ09$"$)ZYS9+LT<(:(DYFE!B"K)*8RC-%W` M\%#E]M"J[QT>]=`J9@`-T0=CLS^5C)6[T@H2YJYNM`*W6O4U-4?Q]!25.E*O1?(EB:?PXZMY-`X$&^KS,)M&25:D3&,B:-LTB)J$ M2YOYRM$>-:)@QI9GUR\8\N<9LYN'2:5A%ZF`;M*9'Z]"LN!0F"51&*R#^ZI] MNWE8<>1'KVF,-%3=2OO>:&\K)JHO$JIH<1Q\#6=Q^!!.^17?T@./9V.$]J:@ M[W>@16<`XWM7PFS0%2YW$N=9FUHDGIP!P/C!520M_:>$ M^Z;!*L%2V;8:+>L=?M@SGRTT.O/*LVRTZE2#+CH]^REDMSE&]`$-1)V_%O.Y MGRYN'J1CV<5R7>^%3GX-M)(WTK^UBJ#G/TLAUJJ``.5+K([0T\+9/7C;<4[/\'4$L#!!0````(`/N);$>ST"_5W@X``$:8```1`!P`:6QI M=2TR,#$U,#DS,"YXF?P'U)WI)#.599WOTM@]IR/;\L43G^5:NKPTD\E`)"2A1X(*`-I6 M._WO78"D1)$$2$D^'S[PRQU%8A?/X@$7BP4(O_W'4QB@!\(%C=C90>_PZ``1 MYD4^9;.S@P_CJ\ZW!^@?WWWYQ=L_=3KH'6&$8TE\-%FB2RSQF&/OH\CD4>^P M=WB"U,6KSFWTT'EUU'N#?CTZ/GW]ZO1U[S?TW[OW_T.#T1AUT./CXZ$/&J36 M<.A%(>IT5#W"FY,0(XGYC,A;'!*QP!XY.YA+N3CM=I4<#68`1%)/RW55+4*4!C1NIDZ7WRCZ>'P8\1D4 M.>IU?WY_,])8,\4!91\W2C]->)"5/^ZJQQ,L2%9;@J&ECT M_GP#BO-*J:4P94)BYJU!E$"G)O9.3DZZ^FE6-!:=&<:+5>$I%A-=-'V@&ZYS MU.L<]S(1+XJ9Y,M-&P7Q#F?10S=]J,2."V(QY]`)37+I4R7X>E/0)[1:!AY4 M%"=/WKRZO'I280]E#T3(:I'D684U#$//JI;1CY1(;U-$4*]:`!Y4%`<"Y')! M1"4U^DF%+4(NN*$2>%)1BT\6G'CJ[3?VKY,NYAZ/`@((/-DA3XL`,RPCOKR" MWZL&B1B+PVHEON1=A;@+A3I0BG#JK>3JA5(!\",(O<6,1>!@P#'IW^K.8D'9 M-$I_P@W5OT\5X#&((W7QX?[:YART<9>1%RL_TV?^@$DJE]>@E(>ZJ@-$H7VL M)5;59P!\,J6,:J"]HQXXQTP\?PFJ4*(+Y92][18U?/E%47TLB#]DW^EKH%"` M-BVK_$8JGQ:QRZXKV5;2PX$7!\9*4['N!ALYE3O2=!$QGS"HY!P'RN>-YH1( MD1!D>&:GYA7P,8*V(RDW%\/;R\'M:'")SOLW_=N+`1I]/QB,1RTIVY)RA\&E MR[DJBP,;0YL%[70=-Z0+_;JA];>6O@;TK1I6#*?#A8H*`4CQY3(4LM/VVDC; M:-P?#]X/;H&RX14:W@WN^^/KX6W[OFU+V$A&WL=Y%/@0MP_^B&%,L1!74=A. MX)N&!([&PXL?OA_>7`[N1W_Y\_')W]'@GQ^NQ[^T=&Y)YP46\ZL@>K2]?NLR M=O*^:4C>17_T/;JZ&?[4OGT6NLZQH-#X=SF3$XZJ'MB)^9L*!JGP@DC$G,`/ MK0)%4Y17TI)A)N.&@O?R5\YN_=/>\-\6&WXEV#:VN;%'<1ABOH3A@\X8G4)@ M!;,A3\_Y*9O=10'U*$D=5L.R=II.BC2E6M4;DM.+UHI1IKGET7M52D5T2A\;/G<)M_:]WT-&P>YG0N7 M1&(:%%*QMI)V'GN%=8N52KA>:\UOG4!?)8I;#O<>_-0^.#\.R'!ZS53(&/%E MGMY]E=B9+Z5*MADBLTK1<(I6U7[==HUG#'TE-`C%@4I@14Q[5[6*_(`#Y4@' M3UX0^\2_XE%XL39C.+VD02R)?TOD323$'>&C.>9D^U[U2>JW=\A2TFB[D#S% MBQ+`:?R0@XPRS&@*H%$.M:H@Q8T`.%+(T8)PI+&WO?KY>G7MB+:_&GL?*V>] M&O>Q=CS=V'5\OJ7"W'.\K:^2[E\JR+?BWY>Y&?2_#T8SF/./T/\:^%B(D/C-Y#2_`' MXNO(26V?6T>/&]U@7RWV#E'*_A622NLJ_XJ22G4WR:I%0M>K8@(O"2:%DFL# MP6T[R'F`O8\P583[XGWDDV`<00L2'E)&KC#E/^(@AGGK3UBEB*0P]9#=U-B[ M2%W>4=>)TDI1J&I%,D)^5B^2]!9GUJN+K$Q`=Q/AYW\TJZMADEK4['V+7_&;C%< M>E)MQ(?[[TICPW,JM'>8,8.5)]7VDN%O9.4 M\Y:-.DD[U.S1)6P[J6H[PZ["]FY02BW6[-!J.T!.H?I'O9[W9(KTZ0FGZL/T MLP-!PT6@3EW0]^:<3,\.U$$4G>RTB=_!Z,.G,,B*J!HLYSCHSE-LI[3B3$7Z M+;[]=`=0$BT(EY2(;@;^`'6?T3!@9%O#-DETTZP`3[8U"T1(X*Y%\`)L:U'A MG7E>NY+W+7]F`_S*G^F@;X%9$9>(59X48SK\)#EDYB;RM"J+B/K5R>0ZZE:G M]ZISW#M\$OZZ];LO'@74 M"$`FI*]V@%`^5D@/-HS,U/IF,\\5<+XAI=S7B7*;O6_VAM'0>>8@R&>IWGZX M4E-(>2V#M9(=$%J/V&K24S(9=;&#S[`?`M6H08I2^_)4?7[5=D@B=KLS&/O) M7[N/O%J7V:>F!^]I0/;3K_H3H8[\@_Z:A*7ZP+I3E51BLVM)0C6K.D`X+75V M('FL@E9="L)$&OEC+>?'V0=)C`:!VHR;E14Q"%,9JZ?O>!0OLDHHJ$\FSBKN M_;T92H.)[R+`JZ?!W"&3JE$93*C_..'%#?+EZ1PDN1=/R/6F:4W0&@R]B(6, MX(6ZPTMU]ST))X1GMB6'T9WZ48@I>UFV#+@,5OQ`I5!)N(BIK)LS1E3#,CD& MJCK1)(;QQAT+JD"9WOHD?S>&Z/^>/!`6$V>L,$,SV++:[7P!_Q'>?Z+B<[SO M/@5,ZO#8POM>":^9*9>Z^1W@Q(#+8,55'$RA(G4G*>],WS(B,U@RQD\7G/A4 MNM:I"L#JX#O3D4J(=AG2;RC3@^K+,U*RIRE.TX".Q5RM4"C!>YCE3T M`"6K[)GB0'RJH;R$R`#]G!/\$<](ZJ,WJ0AA$)68+Y\)?%)VDAR?>7;@Z1[4 MW*825(-)P"`1XCP6P)L06N.U9$;0*E!V_BH)< M@Y_'5(,>QE'GT.#1@_K+,HX;;`9N=_=B'*V"]?Q7 MI@7WHC\'?6&+:Q'66+;Z,'*])]WA^:P5M6UH2#[?O8S5`)#,)0M?^R0?X62= MI3AQ_"S4[@K+N%9V@KN"EV_$S&6[.ZHWG42PP\\=SRB4AS*D0K`9?O54ZP>FH145L MIBSE#"8R+L[M"\!,*WCK`6#C,!QG=E+5`FRP+VSM^L?D29X'N?$X[6LRN__" M#J<6I<&ZQ)4/8ZD&3_4G@IUY@XS(;&/N.[LJQBU81CZ.L0>'I0\\/:FX'58 MS?Z)JK]YC[DZ[\NU"*P,SKA"003UDRWP%W-*IB./PB^U,VLXA7\,]?,LZ)KT@F=61^K1&5,MG(A-P2<(<0,S110$B]BOIO&6+"9 M)LLPKW;4&#,TXRJR">H7CU1S.(IHA&VS\$2YA!G<3.934J,!4GPW(#D=+ MTIG9.8JY>=W>:4\C9SND!AJ@W=+DG&QVBB.$)%>Q:DE507)\@:M-T`S]5LN) M:O;H3)>NA]AX]=>EW?@V<,9,$%'5LIG>'2+.]<$?$,JS7PCFX\?H\X?Y]0AW M,DUM(''=N`2C<7>;VM[CW&I]-2RC]]0+X*LTGS-6F("9MXC]FWA2+=>HOH`IK3>Y&'4KB##55H(R9FZ4JY6QFM0:?J;,E^48QCOH>>'F>_T,[ M3N]"MN(V?Z:COLL(H^2['KCT8T^>Q\P/G/M,80NL=:N![J0!BHBL&_Z2D"J5 M<(87"S93Z`#Q+_6A@^K7TZ459B.R!@G=D>1$>O,D5SH=8SXC4O_8-P[:>Q[2 M$&43&_7\91R=DQ^)D&X95H#6P)KU>9P.VV4&61]6N#,EW&82J,W\H`^/(W[Z MUWJ2FWK5UXT]70U`*OO>=I/#A+2I_P=02P$"'@,4````"`#[B6Q'<$NW][#. M``!\8`H`$0`8```````!````I($`````:6QI=2TR,#$U,#DS,"YX;6Q55`4` M`YH/159U>`L``00E#@``!#D!``!02P$"'@,4````"`#[B6Q'QFNY21L(``"E M:P``%0`8```````!````I('[S@``:6QI=2TR,#$U,#DS,%]C86PN>&UL550% M``.:#T56=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`^XEL1^1RLBNJ/``` MN]P#`!4`&````````0```*2!9=<``&EL:74M,C`Q-3`Y,S!?9&5F+GAM;%54 M!0`#F@]%5G5X"P`!!"4.```$.0$``%!+`0(>`Q0````(`/N);$>R-MAB`DX` M`+)=!``5`!@```````$```"D@5X4`0!I;&EU+3(P,34P.3,P7VQA8BYX;6Q5 M5`4``YH/159U>`L``00E#@``!#D!``!02P$"'@,4````"`#[B6Q'0>=MM=)` M``!U2`0`%0`8```````!````I(&O8@$`:6QI=2TR,#$U,#DS,%]P&UL M550%``.:#T56=7@+``$$)0X```0Y`0``4$L!`AX#%`````@`^XEL1[/0+]7> M#@``1I@``!$`&````````0```*2!T*,!`&EL:74M,C`Q-3`Y,S`N>'-D550% K``.:#T56=7@+``$$)0X```0Y`0``4$L%!@`````&``8`&@(``/FR`0`````` ` end XML 33 R4.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED STATEMENTS OF OPERATIONS - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Revenue:        
Genetic testing $ 248,873 $ 439,400 $ 921,610 $ 1,342,947
Other 47,125 32,751 153,651 145,365
Total revenue 295,998 472,151 1,075,261 1,488,312
Cost of revenue 323,136 358,578 985,732 1,115,095
Gross profit (27,138) 113,573 89,529 373,217
Operating expenses:        
Research and development 411,902 242,142 978,970 666,839
Selling, general and administrative 1,413,702 1,305,583 4,631,718 4,338,245
Amortization of intangibles 19,414 23,525 58,242 70,575
Total operating expenses 1,845,018 1,571,250 5,668,930 5,075,659
Loss from operations (1,872,156) (1,457,677) (5,579,401) (4,702,442)
Other income (expense):        
Interest income 0 911 222 4,511
Interest expense (153,354) 0 (456,311) 0
Total other income (expense) (153,354) 911 (456,089) 4,511
Loss before income taxes (2,025,510) (1,456,766) (6,035,490) (4,697,931)
Benefit for income taxes 0 0 0 0
Net loss $ (2,025,510) $ (1,456,766) $ (6,035,490) $ (4,697,931)
Basic and diluted net loss per common share (in dollars per share) $ (0.01) $ (0.01) $ (0.03) $ (0.04)
Weighted average common shares outstanding, basic and diluted (in shares) 172,841,047 122,548,292 172,788,286 122,515,671

XML 34 R12.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and contingencies
 9 Months Ended
Sep. 30, 2015
Commitments and Contingencies [Abstract]  
Commitments and contingencies
Note 6—Commitments and contingencies
 
Operating Lease
 
The Company leases its office and laboratory space under a non-cancelable operating lease which was originally scheduled to expire on March 31, 2014. In May 2010, the Company completed a sublease of 6,011 square feet of underutilized office and laboratory space and on March 31, 2014, the sublease expired. On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies; and, c) set an initial base rent with an escalation of 2.06% of base rent in year two and another 2.06% in year three.
 
Rent expense, net of the benefit of the sublease in 2014, was $96,000 and $80,000 for the three months ended September 30, 2015 and 2014, respectively, and $268,000 and $230,000 for the nine months ended September 30, 2015 and 2014, respectively.
 
Off-Balance Sheet Arrangements
 
The Company has no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future material effect on its financial condition, results of operations or cash flows.
 
Employment Agreements
 
On April 6, 2015 the Company entered into an Executive Employment Agreement (the “Agreement”), pursuant to which Mark B. Carbeau was appointed as the Company’s Chief Executive Officer and a member of the Company’s Board of Directors. Effective upon Mr. Carbeau’s appointment, Dr. Kenneth S. Kornman resigned as Chief Executive Officer and remained as the Company’s President and Chief Scientific Officer.
 
Pursuant to the Agreement, Mr. Carbeau will receive an initial annual base salary of $365,000 per year and is eligible to receive an annual target bonus of 35% of his base salary, with a stretch bonus opportunity of 150% of the target bonus. Under the terms of the Agreement, Mr. Carbeau has been granted options to purchase up to 14,245,227 shares of Interleukin’s common stock (the “Options”) at an exercise price of $0.1525 per share (the closing price of the common stock on April 6, 2015). The Options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.
 
The Agreement provides that if Mr. Carbeau’s employment with the Company is terminated for any reason other than Cause (as defined in the Agreement) and on execution of a release of claims agreement, he will be entitled to (i) severance payments equal to 12 months of base salary and (ii) continuation of medical benefits for up to 12 months. In addition to the above, if termination is within one year following a Change of Control event and is for any reason other than Cause, all outstanding unvested equity awards held by Mr. Carbeau will immediately vest and be exercisable.
 
On November 12, 2008, the Company entered into an employment agreement with Dr. Kornman, its President and Chief Scientific Officer, for a three-year term, commencing on March 31, 2009, the date his previous employment agreement expired. Effective March 31, 2012, this agreement was extended through November 30, 2012, and was extended again on November 20, 2012 through November 30, 2015. Under this agreement, Dr. Kornman received an initial annual salary of $360,000 and is eligible to receive salary increases and/or annual bonuses solely at the discretion of the Board of Directors. Under the agreement, Dr. Kornman is entitled to participate in employee benefit plans that the Company provides or may establish for the benefit of its executive management generally. In addition, while Dr. Kornman remains employed by the Company, it will reimburse him $3,296 annually for payment of life insurance premiums.
 
The agreement is terminable immediately by the Company with cause or upon thirty days prior written notice without cause. The agreement is terminable by Dr. Kornman upon thirty days prior written notice. If the Company terminates Dr. Kornman without cause or Dr. Kornman terminates his employment with good reason, then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) twelve months. If the Company terminates Dr. Kornman in connection with a Cessation of the Company’s Business (as defined in the agreement), then, in addition to payment of any accrued, but unpaid compensation prior to the termination, the Company must continue to pay his base salary and to provide health insurance benefits until the earlier of (1) expiration of the agreement or (2) three months. The agreement also includes non-compete and non-solicitation provisions for a period of twelve months following the termination of Dr. Kornman’s employment.
 
In April 2010, Dr. Kornman was issued an option to purchase 30,000 shares of the Company’s common stock at an exercise price of $0.745 per share. The option vests as to 20% of the shares on each of the first five anniversaries of the date of grant.
 
In May 2011, Dr. Kornman was issued an option to purchase 100,000 shares of the Company’s common stock, exercisable at $0.46 per share. The option vests as to 25% of the shares on each of the first four anniversaries of the date of grant.
 
In December 2012, Dr. Kornman was issued an option to purchase 300,000 shares of the Company’s common stock, exercisable at $0.34 per share. The option vests as to 25%, 33% and 42% of the shares on each of the first three anniversaries of the date of grant.
 
In October 2013, Dr. Kornman was issued an option to purchase 2,250,000 shares of the Company’s common stock, at an exercise price of $0.3799 per share. The option vests as to 25% of the shares on the first anniversary of the grant date, and as to 2.08% of the remaining shares at the end of each month thereafter beginning on October 31, 2014.
 
In January 2015, Dr. Kornman was granted an option to purchase 2,030,000 shares of the Company’s common stock. This option has an exercise price of $0.26 per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.
 
On December 26, 2012, the Company entered into an employment agreement with Scott Snyder for the position of Chief Marketing Officer beginning on January 2, 2013. The agreement provides for a minimum annual base salary of $265,000. He is eligible for a bonus of up to 30% of his base salary, based on factors such as evaluation of individual performance, the Company’s financial performance, economic conditions generally, and the policy terms applicable to such bonus. Mr. Snyder is entitled to a maximum of $34,000 in expense reimbursement in calendar year 2013, and an additional $16,000 for the six months ending June 30, 2014, for travel and housing expenses from his residence to Interleukin’s offices. On July 23, 2013, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement and increase the aggregate amount of travel and lodging expenses that may be reimbursed to an aggregate of $60,000. On August 4, 2014, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement again and increase the aggregate amount of reimbursable travel and lodging expenses through December 2014 to $80,000. On January 9, 2015, the Compensation Committee agreed to amend Mr. Snyder’s employment agreement again to increase the amount of reimbursable travel and lodging expenses to include $40,000 for calendar year 2015. Upon hire, Mr. Snyder was granted an option to purchase 200,000 shares of the Company’s common stock at an exercise price of $0.29 per share. The option vests in three installments of 50,000, 66,000 and 84,000 shares on each of the first three anniversaries of the grant date.
 
In October 2013, Mr. Snyder was issued an option to purchase 675,000 shares of the Company’s common stock, at an exercise price of $0.3799 per share. The option vests as to 25% of the shares on the first anniversary of the grant date, and as to 2.08% of the remaining shares at the end of each month thereafter beginning on October 31, 2014
 
In January 2015, Mr. Snyder was granted an option to purchase 660,000 shares of the Company’s common stock at an exercise price of $0.26 per share. The option vests as to 1/48 of the shares at the beginning of each month beginning on February 1, 2015.
 
Mr. Snyder’s employment with the Company terminated effective November 13, 2015. The Company will pay Mr. Snyder any compensation that is earned but unpaid prior to termination, and an amount equal to six months of his base salary in effect at the time of the termination with such payment made in equal installments on the Company’s regularly-scheduled payment dates. Per Mr. Snyder’s employment agreement, 84,000 unvested shares related to the 200,000 shares granted on January 2, 2013 will become fully vested.
XML 35 R11.htm IDEA: XBRL DOCUMENT v3.3.0.814
Debt Instruments
 9 Months Ended
Sep. 30, 2015
Debt Disclosure [Abstract]  
Debt Instruments
Note 5—Debt Instruments
 
Venture Loan and Security Agreement
 
On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company borrowed $5.0 million. The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month. At September 30, 2015, the rate was 9.0% per annum. The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan, or $225,000, will be due and payable. The Company’s obligations under the Loan Agreement are secured by a first priority security interest in substantially all of its assets other than its intellectual property. The Company has also agreed not to pledge or otherwise encumber its intellectual property assets, subject to certain exceptions. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share, which the Company refers to herein as the Lender Warrants. The Lender Warrants have a term of ten (10) years.
 
Additionally, $89,000 in cash fees paid to the Lender and $261,000, the intrinsic value of the Lender Warrants, were recorded as a discount on the loan and amortized over the term of the loan. The final non-principal payment of $225,000 will be accrued as additional interest expense, using the effective interest method, over the term of the loan. As of September 30, 2015, the unamortized discount associated with the loan was $280,000. Cash interest expense for the three and nine months ending September 30, 2015 was $115,000 and $341,000, respectively. Non-cash interest expense for the three and nine months ending September 30, 2015 was $38,000 and $115,000, respectively.
XML 36 R23.htm IDEA: XBRL DOCUMENT v3.3.0.814
Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) - shares
 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents excluded from the calculation of diluted net loss per share 110,559,738 42,079,800
Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents excluded from the calculation of diluted net loss per share 22,258,659 4,810,675
Warrant [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potential common stock equivalents excluded from the calculation of diluted net loss per share 88,301,079 37,269,125
XML 37 R19.htm IDEA: XBRL DOCUMENT v3.3.0.814
Capital Stock (Tables)
 9 Months Ended
Sep. 30, 2015
Authorized, Issued and Reserved shares of common stock
As of September 30, 2015, the Company has 6,000,000 shares of preferred stock, par value $0.001 authorized and 450,000,000 shares of common stock, par value $0.001 authorized. On July 21, 2015, the Company’s shareholders’ approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. As of September 30, 2015 the Company had 172,841,047 shares of common stock outstanding and the following shares of common stock are reserved for issuance:
 
 
 
Reserved
 
Strike
 
 
 
 
 
for issuance
 
Price
 
Expiry
 
 
 
 
 
 
 
 
 
Shares reserved under outstanding stock options and options available for grant
 
 
52,311,279
 
 
 
 
 
 
Shares reserved for future issuance under the Employee Stock Purchase Plan
 
 
346,247
 
 
 
 
 
 
Warrants to purchase common stock associated with December 2014 private placement
 
 
50,189,431
 
$
0.1003
 
December 23, 2021
 
Warrants to purchase common stock associated with December 2014 venture loan and security agreement
 
 
2,492,523
 
$
0.1003
 
December 23, 2024
 
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors
 
 
100,000
 
$
0.2500
 
September 8, 2024
 
Outstanding warrants issued in June 2012
 
 
437,158
 
$
0.2745
 
June 29, 2017
 
Outstanding warrants issued in May 2013, vesting May 2013
 
 
20,655,737
 
$
0.2745
 
May 17, 2020
 
Outstanding warrants issued in May 2013, vesting August 2013
 
 
14,426,230
 
$
0.2745
 
August 9, 2020
 
Total common shares reserved for issuance at September 30, 2015
 
 
140,958,605
 
 
 
 
 
 
Total common shares issued and outstanding at September 30, 2015
 
 
172,841,047
 
 
 
 
 
 
Total common shares outstanding and reserved for issuance at September 30, 2015
 
 
313,799,652
 
 
 
 
 
 
Placement Agent Warrants 2014 [Member]  
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants
The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model:
 
 
 
December 23, 2014
 
Risk-free interest rate
 
 
1.98
%
Expected life
 
 
7 years
 
Expected volatility
 
 
138.4
%
Dividend yield
 
 
0
%
Lender Warrants [Member]  
Black-Scholes Pricing Model Assumptions to Determine Fair Value of Warrants
The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model:
 
 
 
December 23, 2014
 
Risk-free interest rate
 
 
2.17
%
Expected life
 
 
10 years
 
Expected volatility
 
 
121.6
%
Dividend yield
 
 
0
%
XML 38 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Industry Risk and Concentration
 9 Months Ended
Sep. 30, 2015
Risks and Uncertainties [Abstract]  
Industry Risk and Concentration
Note 9—Industry Risk and Concentration
 
The Company develops genetic risk assessment tests and performs research for its own benefit. As of September 30, 2015, the Company sells five genetic risk assessment tests. Commercial success of the Company’s genetic risk assessment tests will depend on their success as being deemed to be scientifically credible and cost-effective by consumers and the marketing success of the Company and its collaborative partners.
 
Research in the field of disease predisposing genes and genetic markers is intense and highly competitive. The Company has many competitors in the United States and abroad that have considerably greater financial, technical, marketing, and other resources available. If the Company does not discover disease predisposing genes or genetic markers and develop risk assessment tests and launch such services or products before its competitors, then the potential for significant revenues may be reduced or eliminated.
 
During the three months ended September 30, 2015 and 2014, approximately 45% and 48%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 14% and 30%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program. During the nine months ended September 30, 2015 and 2014, approximately 49% and 41%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 15% and 35%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program.
XML 39 R13.htm IDEA: XBRL DOCUMENT v3.3.0.814
Capital Stock
 9 Months Ended
Sep. 30, 2015
Capital Stock [Abstract]  
Capital Stock
Note 7—Capital Stock
 
Authorized Preferred and Common Stock
 
As of September 30, 2015, the Company has 6,000,000 shares of preferred stock, par value $0.001 authorized and 450,000,000 shares of common stock, par value $0.001 authorized. On July 21, 2015, the Company’s shareholders’ approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 300,000,000 to 450,000,000. As of September 30, 2015 the Company had 172,841,047 shares of common stock outstanding and the following shares of common stock are reserved for issuance:
 
 
 
Reserved
 
Strike
 
 
 
 
 
for issuance
 
Price
 
Expiry
 
 
 
 
 
 
 
 
 
Shares reserved under outstanding stock options and options available for grant
 
 
52,311,279
 
 
 
 
 
 
Shares reserved for future issuance under the Employee Stock Purchase Plan
 
 
346,247
 
 
 
 
 
 
Warrants to purchase common stock associated with December 2014 private placement
 
 
50,189,431
 
$
0.1003
 
December 23, 2021
 
Warrants to purchase common stock associated with December 2014 venture loan and security agreement
 
 
2,492,523
 
$
0.1003
 
December 23, 2024
 
Warrants to purchase common stock associated with September 2014 consulting agreement with Danforth Advisors
 
 
100,000
 
$
0.2500
 
September 8, 2024
 
Outstanding warrants issued in June 2012
 
 
437,158
 
$
0.2745
 
June 29, 2017
 
Outstanding warrants issued in May 2013, vesting May 2013
 
 
20,655,737
 
$
0.2745
 
May 17, 2020
 
Outstanding warrants issued in May 2013, vesting August 2013
 
 
14,426,230
 
$
0.2745
 
August 9, 2020
 
Total common shares reserved for issuance at September 30, 2015
 
 
140,958,605
 
 
 
 
 
 
Total common shares issued and outstanding at September 30, 2015
 
 
172,841,047
 
 
 
 
 
 
Total common shares outstanding and reserved for issuance at September 30, 2015
 
 
313,799,652
 
 
 
 
 
 
 
On May 17, 2013, the Company entered into the 2013 Purchase Agreement with the 2013 Investors, pursuant to which the Company sold securities to the 2013 Investors in the May 2013 Private Placement. In the May 2013 Private Placement, the Company sold an aggregate of 43,715,847 shares of its common stock at a price of $0.2745 per share for gross proceeds of $12,000,000. The 2013 Investors also received the 2013 Warrants to purchase up to an aggregate of 32,786,885 shares of common stock an exercise price of $0.2745 per share. The 2013 Warrants were immediately exercisable as to 63% of the shares issuable thereunder. The remaining 37% of the shares issuable under the 2013 Warrants were to become exercisable upon an increase in the number of authorized shares of common stock. On August 9, 2013, the Company’s shareholders’ approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 150,000,000 to 300,000,000 shares, which provided for adequate authorized shares for all potential common stock equivalents issued pursuant to the May 2013 Private Placement. The 2013 Warrants are all currently exercisable and have a term of seven years from the date they became exercisable.
 
For its services in this transaction, the placement agent received cash compensation in the amount of approximately $780,000 and the placement agent and an affiliate received warrants to purchase an aggregate of 2,295,082 shares of common stock, at an exercise price of $0.2745 per share (the “2013 Placement Agent Warrants”). The 2013 Placement Agent Warrants became exercisable on August 9, 2013, following shareholder approval of an increase in the Company’s authorized shares of common stock and expire August 9, 2020. The cash compensation and the fair value of the warrants were recorded as issuance costs resulting in a reduction to shareholders’ equity.
 
In September, 2014,  the Company issued warrants to  the Company’s financial consultant, Danforth Advisors, to purchase up to 100,000 shares of common stock at a price of $0.25 per share. The warrants have a ten year term and vest on a monthly basis over two years, provided that, if the Company terminates the agreement without cause before the one year anniversary, 50% of the warrants immediately vest, and the remaining 50% of the warrants immediately vest if the Company terminates the agreement without cause after the extension of the agreement after one year. The warrant will also become exercisable in full upon a change of control of the Company if the agreement is still in effect. The fair value of the warrants at issuance was recorded as equity totaling $24,000 and will be amortized to consulting fees over the remaining service requirement. The non-cash compensation expense for the three and nine months ended September 30, 2015 was $3,000 and $9,000 respectively.
 
On December 23, 2014, the Company entered into the 2014 Purchase Agreement with the 2014 Investors, pursuant to which it sold to the 2014 Investors in the December 2014 Private Placement an aggregate of 50,099,700 shares of common stock at a price of $0.1003 per share for gross proceeds of approximately $5.025 million. The 2014 Investors also received 2014 Warrants to purchase up to an aggregate of 50,099,700 shares of common stock at an exercise price of $0.1003 per share. The 2014 Warrants are all currently exercisable and have a term of seven years.
 
For services related to this transaction, the placement agent and legal counsel received an aggregate of $218,000 in cash fees and the placement agent and an affiliate received warrants to purchase an aggregate of 89,731 shares of common stock (the “2014 Placement Agent Warrants”). The cash fees and the fair value of the 2014 Placement Agent Warrants were recorded as equity issuance costs resulting in a reduction to shareholders’ equity.
 
The 2014 Warrants (and the 2014 Placement Agent Warrants) were recorded as equity at fair value on the date of issuance. Fair value of the 2014 Warrants (and the 2014 Placement Agent Warrants) was calculated using the following inputs in a Black-Scholes model:
 
 
 
December 23, 2014
 
Risk-free interest rate
 
 
1.98
%
Expected life
 
 
7 years
 
Expected volatility
 
 
138.4
%
Dividend yield
 
 
0
%
 
On the closing date of the December 2014 Private Placement, the fair value of the 2014 Warrants was $5.2 million, and the fair value of the 2014 Placement Agent Warrants was $9,000.
 
Registration Rights Agreement
 
In connection with the December 2014 Private Placement, on December 23, 2014, the Company also entered into a Registration Rights Agreement with the 2014 Investors and the placement agent, pursuant to which the Company was required to file a registration statement on Form S-1 within 45 days of December 23, 2014 to cover the resale of (i) the shares of common stock sold to the 2014 Investors and the shares of common stock underlying the 2014 Warrants and (ii) the shares of common stock underlying the 2014 Placement Agent Warrants. The Company filed the registration statement on February 6, 2015, and it was declared effective on March 31, 2015.
 
Venture Loan and Security Agreement
 
On December 23, 2014, the Company entered into the Loan Agreement with Horizon Technology Finance Corporation (the “Lender”) under which the Company has borrowed $5.0 million. In connection with the Loan Agreement, the Company issued to the Lender and its affiliates Lender Warrants to purchase a total of 2,492,523 shares of common stock at an exercise price of $0.1003 per share. The Lender Warrants have a term of ten (10) years.
 
The Lender Warrants were recorded as equity at fair value on the date of issuance. Fair value of the Lender Warrants was calculated using the following inputs in a Black-Scholes model:
 
 
 
December 23, 2014
 
Risk-free interest rate
 
 
2.17
%
Expected life
 
 
10 years
 
Expected volatility
 
 
121.6
%
Dividend yield
 
 
0
%
 
The fair value of the Lender Warrants at issuance was $261,000. Cash interest paid during the three and nine months ended September 30, 2015 totaled $115,000 and $353,000, respectively. Non-cash interest related to debt discounts recorded during the three and nine months ended September 30, 2015 totaled was $38,000 and $115,000, respectively, with a remaining debt discount balance of $280,000.
XML 40 R14.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation Arrangements
 9 Months Ended
Sep. 30, 2015
Stock-Based Compensation Arrangements [Abstract]  
Stock-Based Compensation Arrangements
Note 8—Stock-Based Compensation Arrangements
 
Total stock-based compensation is as follows:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
 
2015
 
2014
 
2015
 
2014
 
Stock option grants beginning of period
 
$
251,374
 
$
108,363
 
$
491,197
 
$
348,545
 
Stock-based arrangements during the period:
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock option grants
 
 
92
 
 
—
 
 
157,463
 
 
1,166
 
Restricted stock issued:
 
 
 
 
 
 
 
 
 
 
 
 
 
Employee stock purchase plan
 
 
1,088
 
 
1,279
 
 
3,129
 
 
4,730
 
 
 
$
252,554
 
$
109,642
 
$
651,789
 
$
354,441
 
 
Stock option and restricted stock grants
 
The following table details stock option activity:
 
 
 
Nine Months Ended
 
Nine Months Ended
 
 
 
September 30, 2015
 
September 30, 2014
 
 
 
 
 
Weighted Avg
 
 
 
Weighted Avg
 
 
 
 
 
Exercise
 
 
 
Exercise
 
 
 
Shares
 
Price
 
Shares
 
Price
 
Outstanding, beginning of period
 
 
4,523,900
 
$
0.39
 
 
5,884,050
 
$
0.43
 
Stock options granted
 
 
17,793,027
 
 
0.17
 
 
137,000
 
 
0.35
 
Stock options exercised
 
 
—
 
 
0.00
 
 
—
 
 
0.00
 
Restricted stock exercised
 
 
—
 
 
0.00
 
 
—
 
 
0.00
 
Canceled/Expired
 
 
(58,268)
 
 
0.28
 
 
(1,210,375)
 
 
0.43
 
Outstanding, end of period
 
 
22,258,659
 
$
0.22
 
 
4,810,675
 
$
0.43
 
Exercisable, end of period
 
 
3,067,959
 
$
0.34
 
 
723,925
 
$
0.71
 
 
                At September 30, 2015, there was approximately $2,700,000 of total unrecognized compensation related to non-vested share-based compensation arrangements granted under the Company’s stock plans.
 
Restricted Stock Awards
 
At September 30, 2015 and 2014, there were no outstanding restricted stock awards.
 
Stock Option Grants
 
On August 9, 2013, the Company’s shareholders’ approved the 2013 Employee, Director and Consultant Equity Incentive Plan (the “2013 Plan”). The 2013 Plan allows for the issuance of up to 8,860,000 additional shares of our common stock pursuant to awards granted under the 2013 Plan. Additionally, the 2013 plan allows for the issuance of up to a maximum of 2,435,500 additional shares of our common stock, pursuant to the cancellation, forfeiture, or expiry, of awards granted under the 2004 Plan and terminated on or after the 2013 plan approval on August 9, 2013. During the nine month period ended September 30, 2015, the Company granted 6,170,748 stock options under the 2013 Plan. On July 21, 2015, the Company’s stockholders approved an amendment to the 2013 Plan to increase the number of shares of common stock available for issuance thereunder by 30,000,000 shares. At September 30, 2015, the Company had an aggregate of 30,052,620 shares of common stock available for grant under the 2013 Plan.
 
Pursuant to his Employment Agreement on April 6, 2015, Mr. Carbeau was granted options to purchase up to 14,245,227 shares of Interleukin’s common stock at an exercise price of $0.1525 per share (the closing price of the common stock on April 6, 2015). Of those options, 2,622,948 were granted under the 2013 Plan and 11,622,279 were granted outside of the 2013 Plan. The options will vest as to 25% of the shares on April 6, 2016, and as to an additional 2.083% of the shares on the last day of each successive month thereafter, provided that he remains employed by Company on the vesting date.
 
It is the Company’s policy to grant stock options with an exercise price equal to the fair market value of the Company’s common stock at the grant date, and stock options to employees generally vest over four years based upon continuous service. Historically, the majority of the Company’s stock options have been granted in connection with the employee’s start date with the Company. In addition, the Company may grant stock options in recognition of promotion and/or performance.
 
Employee Stock Purchase Plan
 
Purchases made under the Company’s Employee Stock Purchase Plan are deemed to be compensatory because employees may purchase stock at a price equal to 85% of the fair market value of the Company’s common stock on either the first day or the last day of a calendar quarter, whichever is lower. During the nine months ended September 30, 2015 and 2014, employees purchased 157,705 and 99,585 shares, respectively, of common stock at a weighted-average purchase price of $0.10 and $0.28, respectively, while the weighted-average market value was $0.12 and $0.32 per share, respectively, resulting in compensation expense of $3,129 and $4,730, respectively.
XML 41 R16.htm IDEA: XBRL DOCUMENT v3.3.0.814
Subsequent Events
 9 Months Ended
Sep. 30, 2015
Subsequent Events [Abstract]  
Subsequent Event
Note 10—Subsequent Events
 
On November 13, 2015, the employment of Mr. Scott Snyder, formerly Chief Marketing Officer, terminated. Details of this event are disclosed in Note 6.
XML 42 R34.htm IDEA: XBRL DOCUMENT v3.3.0.814
Industry Risk and Concentration - Additional Information (Detail) - Sales Revenue, Net [Member]
 3 Months Ended 9 Months Ended
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Amway Global [Member]        
Sales Revenue Goods Net Percentage 45.00% 48.00% 49.00% 41.00%
ABG’s Promotional Product Bundle Program [Member]        
Sales Revenue Goods Net Percentage 14.00% 30.00% 15.00% 35.00%
XML 43 R21.htm IDEA: XBRL DOCUMENT v3.3.0.814
Liquidity - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 23, 2014
May. 17, 2013
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Line of Credit Facility [Line Items]              
Net Income Loss     $ (2,025,510) $ (1,456,766) $ (6,035,490) $ (4,697,931) $ 6,300,000
Accumulated deficit     $ (127,125,802)   $ (127,125,802)   $ (121,090,312)
Venture Loan [Member]              
Line of Credit Facility [Line Items]              
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.1003            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,492,523            
Debt Instrument, Description of Variable Rate Basis The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.            
Debt Instrument, Payment Terms The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable.            
Proceeds from Issuance of Long-term Debt $ 5,000,000            
Debt Instrument, Interest Rate, Stated Percentage 9.00%   9.00%   9.00%    
Warrants Expire Term 10 years            
December 2014 Private Placement [Member]              
Line of Credit Facility [Line Items]              
Sale of Stock, Number of Shares Issued in Transaction 50,099,700            
Sale of Stock, Price Per Share $ 0.1003            
Sale of Stock, Consideration Received on Transaction $ 5,025,000            
2013 Warrants [Member]              
Line of Credit Facility [Line Items]              
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 0.2745          
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   32,786,885          
Debt Instrument, Payment Terms   7 years          
2014 warrants [Member]              
Line of Credit Facility [Line Items]              
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.1003            
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 50,099,700            
Debt Instrument, Payment Terms 7 years            
Common Stock [Member]              
Line of Credit Facility [Line Items]              
Net Income Loss         $ 0 $ 0  
Sale of Stock, Consideration Received on Transaction   $ 12,000,000          
Common Stock [Member] | May 2013 Private Placement [Member]              
Line of Credit Facility [Line Items]              
Sale of Stock, Number of Shares Issued in Transaction   43,715,847          
Sale of Stock, Price Per Share   $ 0.2745          
Sale of Stock, Consideration Received on Transaction   $ 12,000,000          
XML 44 R26.htm IDEA: XBRL DOCUMENT v3.3.0.814
Debt Instruments - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Dec. 23, 2014
Sep. 30, 2015
Sep. 30, 2015
Sep. 30, 2014
Debt Instrument [Line Items]        
Interest Paid     $ 352,500 $ 0
Venture Loan [Member]        
Debt Instrument [Line Items]        
Proceeds from Issuance of Long-term Debt $ 5,000,000      
Debt Instrument, Description of Variable Rate Basis The loan bears interest at a floating rate equal to the One Month LIBOR Rate (with a floor of 0.50%) plus 8.50%. In the event that the One Month LIBOR Rate, as reported in the Wall Street Journal, exceeds 0.50%, the interest rate will be adjusted by an amount equal to the difference between such rates at the end of that particular month.      
Debt Instrument, Interest Rate, Stated Percentage 9.00% 9.00% 9.00%  
Debt Instrument, Payment Terms The loan is to be repaid in forty-five (45) monthly payments consisting of fifteen (15) monthly payments of only interest followed by thirty (30) equal monthly payments of principal and interest. In addition, at the end of the repayment term (or at early termination of the loan) a final payment equal to 4.5% of the loan will be due and payable.      
Class of Warrant or Right, Number of Securities Called by Warrants or Rights 2,492,523      
Class of Warrant or Right, Exercise Price of Warrants or Rights $ 0.1003      
Warrants Expire Term 10 years      
Interest Expense, Debt $ 89,000      
Intrinsic Value Of Warrants 261,000      
Interest Expense, Other $ 225,000      
Debt Instrument, Unamortized Discount   $ 280,000 $ 280,000  
Interest Paid   115,000 341,000  
Paid-in-Kind Interest   $ 38,000 $ 115,000  
XML 45 R5.htm IDEA: XBRL DOCUMENT v3.3.0.814
CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Balance at Dec. 31, 2013 $ 5,253,222 $ 122,449 $ 119,885,371 $ (114,754,598)
Balance (in shares) at Dec. 31, 2013   122,448,707    
Net loss (4,697,931) $ 0 0 (4,697,931)
Common stock issued:        
Employee stock purchase plan 27,557 $ 101 27,456 0
Employee stock purchase plan (in shares)   99,585    
Stock-based compensation expense 354,441 $ 0 354,441 0
Balance at Sep. 30, 2014 937,289 $ 122,550 120,267,268 (119,452,529)
Balance (in shares) at Sep. 30, 2014   122,548,292    
Balance at Dec. 31, 2013 5,253,222 $ 122,449 119,885,371 (114,754,598)
Balance (in shares) at Dec. 31, 2013   122,448,707    
Net loss 6,300,000      
Balance at Dec. 31, 2014 4,516,857 $ 172,686 125,434,483 (121,090,312)
Balance (in shares) at Dec. 31, 2014   172,683,342    
Net loss (6,035,490) $ 0 0 (6,035,490)
Common stock issued:        
Private Placement (7,100)   (7,100)  
Horizon Warrant 11,848   11,848  
Employee stock purchase plan 16,799 $ 157 16,642 0
Employee stock purchase plan (in shares)   157,705    
Stock-based compensation expense 651,791 $ 0 651,791 0
Balance at Sep. 30, 2015 $ (845,295) $ 172,843 $ 126,107,664 $ (127,125,802)
Balance (in shares) at Sep. 30, 2015   172,841,047    
XML 46 R10.htm IDEA: XBRL DOCUMENT v3.3.0.814
Related Party Transactions
 9 Months Ended
Sep. 30, 2015
Related Party Transactions [Abstract]  
Related Party Transactions
Note 4—Related Party Transactions
 
Since March 2003, the Company has maintained a broad strategic alliance with several affiliates of the Alticor Inc. family of companies, a related party. The alliance initially included an equity investment, a multi-year research and development agreement, a licensing agreement with royalties on marketed products, the deferment of outstanding loan repayment and the refinancing of bridge financing obligations.
 
On October 26, 2009, the Company entered into a Merchant Network and Channel Partner Agreement with Amway Corp., d/b/a/ Amway Global (“Amway Global”), a subsidiary of Alticor Inc. Pursuant to this Agreement, Amway Global sells the Company’s Inherent Health® brand of genetic tests through its e-commerce website via a hyperlink to the Company’s e-commerce site. The Company paid Amway Global $70,000 and $59,000 in commissions for the three months ended September 30, 2015 and 2014, respectively, and $239,000 and $160,000 in commissions for the nine months ended September 30, 2015 and 2014, respectively, representing a percentage of net sales to their customers. The Company expenses commissions owed to Amway Global in the month of sale to the customer.
 
Beginning in September 2012 and again in 2013, Access Business Group LLC (“ABG”), an affiliate of Alticor, placed purchase orders totaling approximately $3.3 million consisting of Weight Management test kits. The kits are included as part of a promotional bundle of products that Amway sold to their Individual Business Owners (IBOs). Of the $3.3 million in orders, $1.5 million was received for the 2013 program and $1.8 million for the 2014 program. As a component of the 2013 promotional program, and not reflective of actual product expiry, the kits were required to be redeemed by December 31, 2013. In February 2014, the Company removed the redemption date requirement for the 2013 promotional program, for which ABG paid the Company $519,000 as a retrospective increase in the product purchase price. All cash received related to the 2013 promotional program, including the $519,000, will be treated as deferred revenue until specific kits are returned for processing or the breakage analysis determines the probability of eventual redemption is remote. In October 2014, the Company received $250,000 as a retrospective increase in the product purchase price for unsold kits as consideration for extending the required redemption date of the 2014 promotional program to December 31, 2017. All cash received for these kits will be treated as deferred revenue until specific kits are returned for processing or on the final allowed redemption date of December 31, 2017.
 
On September 21, 2012, the Company entered into a License Agreement with Access Business Group International LLC (“ABGI”), an affiliate of Alticor. Pursuant to the License Agreement, the Company has granted ABGI and its affiliates a non-exclusive license to use the technology related to Interleukin’s Weight Management genetic test and to sell the Weight Management test in Europe, Russia and South Africa (the “Territories”). ABGI, or a laboratory designated by ABGI, will be responsible for processing the tests, and the Company will receive a royalty for each test sold, which royalty will increase if certain pending patent applications are issued. The License Agreement has an initial term of five years from the date of first commercial sale of the Weight Management test under the agreement which was June 2013. Thereafter, the term will automatically renew for additional one-year periods unless notice is delivered by either party at least 60 days prior to the anniversary date. During the three and nine months ended September 30, 2015, $39,000 and $143,000, respectively, was earned, compared to $31,000 and $129,000 in the same periods in 2014
 
In connection with the execution of the License Agreement, the Company and ABGI also entered into a Professional Services Agreement (the “PSA”) pursuant to which the Company has agreed to provide services to ABGI in connection with its sale and processing of the tests within the Territories. No fees were earned in the year ended December 31, 2014 or the nine months ended September 30, 2015 under the PSA.
 
For the three months ended September 30, 2015 and 2014, approximately 45% and 48%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 14% and 30%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program. For the nine months ended September 30, 2015 and 2014, approximately 49% and 41%, respectively, of the Company’s revenue came from sales through the Merchant Network and Channel Partner Agreement with Amway Global, and 15% and 35%, respectively, of the Company’s revenue came from sales through ABG’s promotional product bundle program.
 
On February 25, 2013, the Company entered into a Preferred Participation Agreement with Renaissance Health Services Corporation (“RHSC”), for itself and on behalf of certain of its affiliates and subsidiaries. This agreement was amended and restated on November 1, 2013. RHSC is a related party through its affiliation with Delta Dental of Michigan, Inc. (“DDMI”), a stockholder of the Company.  Pursuant to this agreement, as amended, affiliates of RHSC have agreed to reimburse the Company a fixed price for each PerioPredict® genetic test that the Company processes for a customer of affiliates of RHSC. In addition, if during the term of the agreement the Company offers the PerioPredict® test to any other person or party for a lower price, such lower price shall then be applicable to tests processed for a customer of such affiliates of RHSC for the remainder of the term of the agreement. RHSC and its affiliates will continue to receive the preferred pricing (or any lower market price during the term) only for so long as affiliates of RHSC continue to: (a) work to develop and to offer dental benefit plans that provide for use of the PerioPredict test and reimbursement of the test at the agreed upon price(each such plan, hereinafter referred to as a “Reimbursed Dental Plan”) for which a significant portion of employees of RHSC’s affiliates’ customers are eligible; and (b) exercise their commercially-reasonable best efforts to maximize the number of customers that offer a Reimbursed Dental Plan. In addition, under the terms of the amended agreement, the Company is no longer obligated to make the PerioPredict® test available solely to RHSC affiliates and not to any other third party or person. This amended agreement has a term of three years beginning February 25, 2013, unless terminated earlier  (1) upon the mutual written agreement of us and RHSC, (2) if either party becomes the subject of bankruptcy, insolvency, liquidation or other similar proceedings, or (3) in the event of an uncured breach of the amended agreement by either party.
 
The timing of any revenues that the Company may receive under the amended agreement with RHSC is dependent upon the timing of the offering of Reimbursed Dental Plans and the subsequent adoption of such Reimbursed Dental Plans by RHSC customers, the timing of which is very uncertain at this time and is dependent on a viable market developing for such plans. RHSC has informed us that it has presented the scientific data underlying Reimbursed Dental Plans to a number of customers and will make available Reimbursed Dental Plans as an alternative to a customer’s current plan for any customer that expresses an interest in such a plan. The Company may never receive significant revenues under this agreement.
XML 47 R27.htm IDEA: XBRL DOCUMENT v3.3.0.814
Commitments and contingencies - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Nov. 13, 2015
Apr. 06, 2015
Jan. 02, 2013
Jan. 31, 2015
Oct. 31, 2013
Jul. 31, 2013
Dec. 31, 2012
May. 31, 2011
Apr. 30, 2010
Sep. 30, 2015
Sep. 30, 2014
Sep. 30, 2015
Sep. 30, 2014
Dec. 31, 2014
Loss Contingencies [Line Items]                            
Operating Leases, Rent Expense                   $ 96,000 $ 80,000 $ 268,000 $ 230,000  
Property Under Commercial Lease And Sublease Details                       On February 7, 2014, the Company entered into the Second Amendment to Commercial Lease which, among other things a) extended the term of the lease from March 31, 2014 to March 31, 2017; b) reduced the 19,000 square feet, the amount of space under the master lease, by approximately 6,011 square feet, to approximately 13,000 square feet, which is the amount of space the Company currently occupies    
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross         675,000                  
Granted, Weighted Avg.Exercise Price                       $ 0.17 $ 0.35  
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price                   $ 0.34 $ 0.71 $ 0.34 $ 0.71  
Operating Leases Base rent In Year Two                       2.06%    
Operating Leases Base Rent In Year Three                       2.06%    
Dr. Kornman [Member]                            
Loss Contingencies [Line Items]                            
Officers' Compensation                       $ 360,000    
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross       2,030,000 2,250,000   300,000 100,000 30,000          
Granted, Weighted Avg.Exercise Price       $ 0.26 $ 0.3799                  
Annual Reimbursement For Payment Of Life Insurance Premiums                       3,296    
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price             $ 0.34 $ 0.46 $ 0.745          
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         2.08%     25.00% 20.00%          
Dr. Kornman [Member] | First Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         25.00%   25.00%              
Dr. Kornman [Member] | Second Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage             33.00%              
Dr. Kornman [Member] | Third Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage             42.00%              
Chief Marketing Officer [Member]                            
Loss Contingencies [Line Items]                            
Officers' Compensation             $ 265,000              
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross     200,000 660,000                    
Granted, Weighted Avg.Exercise Price     $ 0.29 $ 0.26                    
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         2.08%                  
Maximum Percentage Of Bonus On Annual Salary             30.00%              
Maximum Reimbursement Expenses           $ 60,000 $ 34,000           $ 16,000  
Travel and Entertainment Expense                       $ 40,000   $ 80,000
Chief Marketing Officer [Member] | First Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares     50,000                      
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage         25.00%                  
Chief Marketing Officer [Member] | Second Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares     66,000                      
Chief Marketing Officer [Member] | Third Anniversaries [Member]                            
Loss Contingencies [Line Items]                            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares     84,000                      
Subsequent Event [Member]                            
Loss Contingencies [Line Items]                            
Shares Unvested Related Shares Granted 84,000                          
Chief Executive Officer [Member]                            
Loss Contingencies [Line Items]                            
Officers' Compensation   $ 365,000                        
Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Grants In Period, Gross   14,245,227                        
Granted, Weighted Avg.Exercise Price   $ 0.1525                        
Percentage Of Bonus On Base Salary For Executives   35.00%                        
Percentage Of Stretch Bonus Of Target Bonus   150.00%                        
Percentage Of Shares To Be Vest   25.00%                        
Percentage Of Additional Shares To Be Vest   2.083%                        
XML 48 FilingSummary.xml IDEA: XBRL DOCUMENT 3.3.0.814 html 166 195 1 false 56 0 false 4 false false R1.htm 101 - Document - Document And Entity Information Sheet http://www.ilgenetics.com/role/DocumentAndEntityInformation Document And Entity Information Cover 1 false false R2.htm 102 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.ilgenetics.com/role/CondensedBalanceSheets CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 103 - Statement - CONDENSED BALANCE SHEETS [Parenthetical] Sheet http://www.ilgenetics.com/role/CondensedBalanceSheetsParenthetical CONDENSED BALANCE SHEETS [Parenthetical] Statements 3 false false R4.htm 104 - Statement - CONDENSED STATEMENTS OF OPERATIONS Sheet http://www.ilgenetics.com/role/CondensedStatementsOfOperations CONDENSED STATEMENTS OF OPERATIONS Statements 4 false false R5.htm 105 - Statement - CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Sheet http://www.ilgenetics.com/role/CondensedStatementsOfStockholdersEquity CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY Statements 5 false false R6.htm 106 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.ilgenetics.com/role/CondensedStatementsOfCashFlows CONDENSED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 107 - Disclosure - Basis of Presentation Sheet http://www.ilgenetics.com/role/BasisOfPresentation Basis of Presentation Notes 7 false false R8.htm 108 - Disclosure - Liquidity Sheet http://www.ilgenetics.com/role/Liquidity Liquidity Notes 8 false false R9.htm 109 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 110 - Disclosure - Related Party Transactions Sheet http://www.ilgenetics.com/role/RelatedPartyTransactions Related Party Transactions Notes 10 false false R11.htm 111 - Disclosure - Debt Instruments Sheet http://www.ilgenetics.com/role/DebtInstruments Debt Instruments Notes 11 false false R12.htm 112 - Disclosure - Commitments and contingencies Sheet http://www.ilgenetics.com/role/CommitmentsAndContingencies Commitments and contingencies Notes 12 false false R13.htm 113 - Disclosure - Capital Stock Sheet http://www.ilgenetics.com/role/CapitalStock Capital Stock Notes 13 false false R14.htm 114 - Disclosure - Stock-Based Compensation Arrangements Sheet http://www.ilgenetics.com/role/StockbasedCompensationArrangements Stock-Based Compensation Arrangements Notes 14 false false R15.htm 115 - Disclosure - Industry Risk and Concentration Sheet http://www.ilgenetics.com/role/IndustryRiskAndConcentration Industry Risk and Concentration Notes 15 false false R16.htm 116 - Disclosure - Subsequent Events Sheet http://www.ilgenetics.com/role/SubsequentEvents Subsequent Events Notes 16 false false R17.htm 117 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPolicies 17 false false R18.htm 118 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) Tables http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 119 - Disclosure - Capital Stock (Tables) Sheet http://www.ilgenetics.com/role/CapitalStockTables Capital Stock (Tables) Tables http://www.ilgenetics.com/role/CapitalStock 19 false false R20.htm 120 - Disclosure - Stock-Based Compensation Arrangements (Tables) Sheet http://www.ilgenetics.com/role/StockbasedCompensationArrangementsTables Stock-Based Compensation Arrangements (Tables) Tables http://www.ilgenetics.com/role/StockbasedCompensationArrangements 20 false false R21.htm 121 - Statement - Liquidity - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/LiquidityAdditionalInformationDetail Liquidity - Additional Information (Detail) Details 21 false false R22.htm 122 - Disclosure - Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesScheduleOfInventoryDetail Summary of Significant Accounting Policies (Schedule Of Inventory) (Detail) Details http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesTables 22 false false R23.htm 123 - Disclosure - Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesPotentialCommonStockEquivalentsExcludedFromCalculationOfDilutedNetLossPerShareDetail Summary of Significant Accounting Policies (Potential Common Stock Equivalents Excluded from Calculation of Diluted Net Loss per Share) (Detail) Details http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesTables 23 false false R24.htm 124 - Disclosure - Summary of Significant Accounting Policies- Additional Information (Detail) Sheet http://www.ilgenetics.com/role/SummaryOfSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies- Additional Information (Detail) Details 24 false false R25.htm 125 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 25 false false R26.htm 126 - Disclosure - Debt Instruments - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/DebtInstrumentsAdditionalInformationDetail Debt Instruments - Additional Information (Detail) Details 26 false false R27.htm 127 - Disclosure - Commitments and contingencies - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/CommitmentsAndContingenciesAdditionalInformationDetail Commitments and contingencies - Additional Information (Detail) Details 27 false false R28.htm 128 - Disclosure - Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail) Sheet http://www.ilgenetics.com/role/CapitalStockAuthorizedIssuedAndReservedSharesOfCommonStockDetail Capital Stock (Authorized, Issued and Reserved shares of common stock) (Detail) Details http://www.ilgenetics.com/role/CapitalStockTables 28 false false R29.htm 129 - Disclosure - Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail) Sheet http://www.ilgenetics.com/role/CapitalStockBlackScholesModelToDetermineFairValueOfWarrantsDetail Capital Stock (Black Scholes model to determine the fair value of the warrants) (Detail) Details http://www.ilgenetics.com/role/CapitalStockTables 29 false false R30.htm 130 - Disclosure - Capital Stock - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/CapitalStockAdditionalInformationDetail Capital Stock - Additional Information (Detail) Details 30 false false R31.htm 131 - Disclosure - Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) Sheet http://www.ilgenetics.com/role/StockbasedCompensationArrangementsStockbasedCompensationDetail Stock-Based Compensation Arrangements (Stock-Based Compensation) (Detail) Details http://www.ilgenetics.com/role/StockbasedCompensationArrangementsTables 31 false false R32.htm 132 - Disclosure - Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) Sheet http://www.ilgenetics.com/role/StockbasedCompensationArrangementsStockOptionAndRestrictedStockGrantsDetail Stock-Based Compensation Arrangements (Stock Option and Restricted Stock Grants) (Detail) Details http://www.ilgenetics.com/role/StockbasedCompensationArrangementsTables 32 false false R33.htm 133 - Disclosure - Stock-Based Compensation Arrangements - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/StockbasedCompensationArrangementsAdditionalInformationDetail Stock-Based Compensation Arrangements - Additional Information (Detail) Details 33 false false R34.htm 134 - Disclosure - Industry Risk and Concentration - Additional Information (Detail) Sheet http://www.ilgenetics.com/role/IndustryRiskAndConcentrationAdditionalInformationDetail Industry Risk and Concentration - Additional Information (Detail) Details 34 false false All Reports Book All Reports In ''CONDENSED BALANCE SHEETS'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED STATEMENTS OF OPERATIONS'', column(s) 13 are contained in other reports, so were removed by flow through suppression. In ''CONDENSED STATEMENTS OF CASH FLOWS'', column(s) 1, 2, 5 are contained in other reports, so were removed by flow through suppression. iliu-20150930.xml iliu-20150930_cal.xml iliu-20150930_def.xml iliu-20150930_lab.xml iliu-20150930_pre.xml iliu-20150930.xsd true true XML 49 R20.htm IDEA: XBRL DOCUMENT v3.3.0.814
Stock-Based Compensation Arrangements (Tables)
 9 Months Ended
Sep. 30, 2015
Stock-Based Compensation Arrangements [Abstract]  
Total Compensation Cost Recorded for Stock-Based Compensation
Total stock-based compensation is as follows:
 
 
 
Three Months Ended September 30,
 
Nine Months Ended September 30,
 
 
 
2015
 
2014
 
2015
 
2014
 
Stock option grants beginning of period
 
$
251,374
 
$
108,363
 
$
491,197
 
$
348,545
 
Stock-based arrangements during the period:
 
 
 
 
 
 
 
 
 
 
 
 
 
Stock option grants
 
 
92
 
 
—
 
 
157,463
 
 
1,166
 
Restricted stock issued:
 
 
 
 
 
 
 
 
 
 
 
 
 
Employee stock purchase plan
 
 
1,088
 
 
1,279
 
 
3,129
 
 
4,730
 
 
 
$
252,554
 
$
109,642
 
$
651,789
 
$
354,441
 
Schedule of Stock option activity
The following table details stock option activity:
 
 
 
Nine Months Ended
 
Nine Months Ended
 
 
 
September 30, 2015
 
September 30, 2014
 
 
 
 
 
Weighted Avg
 
 
 
Weighted Avg
 
 
 
 
 
Exercise
 
 
 
Exercise
 
 
 
Shares
 
Price
 
Shares
 
Price
 
Outstanding, beginning of period
 
 
4,523,900
 
$
0.39
 
 
5,884,050
 
$
0.43
 
Stock options granted
 
 
17,793,027
 
 
0.17
 
 
137,000
 
 
0.35
 
Stock options exercised
 
 
—
 
 
0.00
 
 
—
 
 
0.00
 
Restricted stock exercised
 
 
—
 
 
0.00
 
 
—
 
 
0.00
 
Canceled/Expired
 
 
(58,268)
 
 
0.28
 
 
(1,210,375)
 
 
0.43
 
Outstanding, end of period
 
 
22,258,659
 
$
0.22
 
 
4,810,675
 
$
0.43
 
Exercisable, end of period
 
 
3,067,959
 
$
0.34
 
 
723,925
 
$
0.71